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ABSTRACT 
Osteoarthritis (OA), characterised by progressive joint-wide pathology, is a major 
health problem accounting for 48% of people living with chronic pain. There are no 
treatments to slow OA progression and symptom managing therapies are at best 
moderately effective. This failure results from a poor understanding of the 
mechanisms that drive OA pain. Animal models are widely used to study OA pain 
molecular pathways, but pre-clinical findings fail to translate into effective 
therapeutics for patients. In part this may be because animal models have poorly 
defined phenotypes not mapped to specific sub-types of human OA.  
This research aimed to define the relationship between joint tissue pathology, pain 
behaviour and gene expression in the dorsal root ganglia (DRG), over time comparing 
models of post-traumatic OA (DMM) and inflammatory arthritis (AIA), and identify 
differences in what drives pain.  
DMM and AIA ultimately displayed similar hallmark histopathology of OA in late 
stage disease. However, each model had distinct temporal patterns of pathology; 
associations between articular cartilage, synovium and bone pathology; and risk 
factors for progression. Both models displayed sensitisation (tactile allodynia, 
mechanical and thermal hyperalgesia) and altered gait (reduced hindlimb weight 
bearing, changes in stride length). However, the severity and temporal pattern of 
occurrence were model-specific. At each phase of OA development, DRG gene 
expression changes were also model-specific. It was predominantly synovium and 
bone pathology that were significantly associated with altered DRG gene expression 
and pain behavior, but differentially in the two models. The DRG expression changes 
associated with altered pain behaviours were also model specific.   
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Combined these findings demonstrate that DMM and AIA are phenotypically unique 
models of OA, defined not only by initiating cause, but temporal pattern and inter-
dependence of joint pathology, pain characteristics, and molecular drivers. The results 
suggest that the mechanisms regulating joint pain are specific to the disease 
pathophysiology, and confirm the importance of mapping pre-clinical findings to 
specific human disease phenotypes. This challenges the current way animal models 
are used to investigate OA pain mechanisms and test therapeutics. 
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CHAPTER 1:  Introduction and literature review 
1.1 Osteoarthritis 
1.1.1 Prevalence and disease burden 
Arthritis is a general term used to describe a range of musculoskeletal conditions 
characterised by inflammation and/or damage of the joints. The most prevalent form 
of arthritis is osteoarthritis. Osteoarthritis (OA) is a complex progressive disease of 
joints that results in pain and reduced mobility. It is a major health problem world-
wide, with hip and knee OA ranked the 11
th
 highest contributor to global disability
(1). The global prevalence of radiographically confirmed knee OA is 3.8% (2). In the 
USA, 33.6% of adults aged 65 and older suffer from OA (3). In Australia, 15.3% of 
the population is affected by arthritis, and 58.9% of those affected have OA (4) . OA 
is not just a disease of the aged; approximately 64% of OA sufferers are in the 
working age population (15-64 years) (5). In a recent survey 68% of arthritis sufferers 
reported that their arthritis is badly managed, translating to persistent pain, disability, 
impact on work, family and finances (6). The persistent nature of OA means that 
sufferers live with the disease for a significant portion of their lives and typically 
develop a chronic pain state. In fact, OA is the major reported cause of chronic pain, 
accounting for 48% of those living with chronic pain (7). Chronic OA pain negatively 
impacts both physical and emotional function, leading to depression and reduced 
social participation (8). All of this results in a huge social and economic disease 
burden. 
The health system expenditure associated with arthritis exceeds expenditure on heart 
disease, depression, diabetes and asthma. In Australia it was estimated to be $4.2 
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billion in 2007, with OA accounting for over $1.9 billion (5); in the UK the disease 
burden cost was estimated at £3.2 billion in 2002 (9); and in the USA the total health 
expenditure attributable to joint replacements alone was estimated at US$42 billion in 
2009 (10). 
Despite the huge public health impact of this disease, there are still no effective 
therapies for treating or preventing OA. Based on the most recent systematic reviews 
of all randomised clinical trials, current therapy options for the management of hip 
and knee OA are at best mild to moderately effective and offer only short-term relief 
of symptoms (11). The exception to this is total joint replacement (TJR) surgery, 
which accounts in part for the huge financial burden of this disease. However, TJR is 
not an option when small joints are affected, and a significant proportion of patients 
that undergo TJR, especially of the knee joint, still report persistent pain (12). Yet, 
excluding TJR, no advances have been made in how we treat the pain of OA since the 
introduction of non-steroidal anti-inflammatory drugs (NSAID) at the turn of the last 
century. Current recommendations for non-surgical management of knee OA include 
biomechanical interventions, intra-articular corticosteroids, exercise, weight 
management, strength training and oral and topical NSAID (13). 
1.1.2 The pathophysiology of OA 
Joints are organs with a biomechanical function that comprise cartilage, subchondral 
bone, synovium, capsule, ligaments, tendons and muscles (figure 1.1). Each of these 
tissues is in part made up of extracellular matrices that determine their individual 
structure and biomechanical function. For example, the physical properties of articular 
cartilage are imparted by its extracellular matrix (ECM), which comprises a collagen 
fibre network that enmeshes large hydrophilic proteoglycans, the major one being 
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aggrecan, that provide resistance to mechanical compression and contribute to the low 
surface friction necessary for normal joint function (14). 
Figure 1.1. Schematic diagram of the knee joint 
Diagram depicts normal joint tissue components (left) compared to osteoarthritis 
(OA) joint tissue pathology (right). 
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All joint tissues are affected to a greater or lesser extent during the onset and 
progression of OA. In some tissues such as the articular cartilage the predominant 
change is progressive degradation and loss while in others like bone there is net tissue 
formation with resultant subchondral thickening and marginal osteophyte formation. 
OA is no longer thought of as a disease of individual joint tissues, the new paradigm 
is to consider that it is a failure of the “joint organ” (figure 1.1). Understanding what 
drives the pathology in different components of the joint, and how these interact and 
change with time and/or disease stage is critical to developing new approaches to 
manage, treat and ultimately cure OA. A great deal has been learned in the last 
decade, in large part through the development and study of genetically modified mice, 
about the molecular mechanisms underlying the pathological change. In the following 
sections I will summarise some of the key mechanisms that contribute to OA 
pathology in various joint tissues. 
1.1.3 Articular Cartilage 
Articular cartilage (AC) is comprised of chondrocytes enmeshed in a collagen rich 
extracellular matrix (ECM) bed. It is a complex tissue with unique properties that 
present numerous challenges in the face of damage and the need for repair, with little 
capacity for self-regeneration. AC is hypocellular, with chondrocytes making up only 
5 – 10% of the wet tissue weight (15). Chondrocytes are cytoplasmically isolated and 
rely on paracrine and autocrine communication (16). Yet chondrocytes are 
responsible for the production and maintenance of the ECM. AC is both aneural and 
avascular, relying on diffusion for metabolite and nutrient exchange (16).  
Cartilage ECM is made up primarily of collagen and proteoglycans, the most 
abundant by mass being aggrecan (15). Collagen is a major component of many 
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tissues including AC, bone, tendons, ligaments and muscle, but the specific subtypes 
and their fibrillar arrangement varies. Collagen is the most predominate protein in AC 
making up 30-40% of the tissue wet weight, the composite type II/IX/XI fibrils 
forming an oriented meshwork in the ECM, giving AC its tensile strength (17). 
Normal ECM in all tissues undergoes continuous remodelling. Matrix 
metalloproteinases (MMPs) are a family of more than 25 enzymes involved in normal 
tissue remodeling as well as many inflammatory and other pathological processes, 
associated with degeneration. These proteinases cleave ECM proteins and soluble 
messenger molecules such as cytokines and chemokines. The MMPs involved in 
articular cartilage degradation are the collagenases (MMP-1, MMP-8, MMP-13), 
gelatinases (MMP-2, MMP-9) and a distinct group of metalloproteinases belonging to 
the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) 
family – aggrecanase 1 and 2 (ADAMTS-4 and ADAMTS-5, respectively) (18). 
Understanding the role of MMP’s and ADAMTS in joint disease development has 
been a major focus of OA research.  
1.1.3.1 Aggrecan 
Aggrecan is a primary component of articular cartilage ECM. It is a large 
proteoglycan that consists of a protein core backbone substituted with many sulfated 
glycosaminoglycans. This imparts a high negative charge density that attracts water 
and when entrapped in the collagen network provides cartilage with the ability to 
resist compressive forces. The ADAMTS proteins are a family of zinc-dependent 
matrix metalloproteinase enzymes several of which cleave the aggrecan core protein 
with high efficiency at specific sites, in particular the interglobular domain whereby 
the entire glycosaminoglycan bearing region and load-bearing capacity is lost (19, 
20). It is evident in cartilage from all species including humans, that it is cleavage at 
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the ADAMTS-susceptible sites that is responsible for the majority of pathological 
aggrecan loss both in vitro and in vivo (20). 
The ADAMTS proteins are made up of an N-terminal pro-domain, a catalytic domain, 
a disintegrin domain, one or more thrombospondin (TS) motifs, a cysteine-rich 
domain and a spacer domain of variable length. The two principal aggrecanases, 
ADAMTS-4 (aggrecanase 1) and ADAMTS-5 (aggrecanase 2) have been cloned and 
characterised (21, 22). ADAMTS-4 is the shortest member of the family with only 
one TS motif, while ADAMTS-5 has two. Interest was initially focussed on 
ADAMTS-4 after researchers demonstrated its regulation by inflammatory cytokines 
in joint tissue (23, 24). However it has since been shown that ADAMTS-4 knockout 
(KO) mice demonstrate similar susceptibility to cartilage degradation in OA as wild 
type (WT) mice (25). In contrast, deletion or inactivation of ADAMTS-5 significantly 
reduces stimulated cartilage aggrecan loss in vitro and in inflammatory and OA 
models in vivo, indicating it is the principle aggrecanase in mouse cartilage (26, 27). 
Mice deficient in both ADAMTS-4 and ADAMTS-5 do not show any developmental 
abnormalities, and have similar cartilage protection as ADAMTS-5 KO mice in 
surgically induced OA (28). Exactly which of these two ADAMTS proteins is the 
major aggrecanase in human cartilage is still under investigation (29). Furthermore, 
studies in mice deficient in both ADAMTS-4 and ADAMTS-5 have demonstrated 
that other aggrecanases may also play a role under specific conditions (30).  
Interestingly, ADAMTS-4 and 5 differ with respect to gene regulation. ADAMTS-5 is 
expressed in human chondrocytes and synovial fibroblasts and is not reliant on 
induction, whereas ADAMTS-4 expression requires induction by pro-inflammatory 
cytokines (31). Differential regulation has similarly been seen in MMPs, where 
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induced transcription occurs for all but MMP-2 and 11, which are constitutively 
expressed (32, 33).  
In addition to its role in cartilage degradation through cleavage of aggrecan, 
ADAMTS-5 may serve other physiological functions even though some studies would 
suggest that ADAMTS-5 KO’s do not differ phenotypically from WT’s (28). More 
recently investigators have looked at the expression profile of ADAMTS-5 during 
embryogenesis and in adult tissue (34). In adult tissue, there is constitutive expression 
of ADAMTS-5 in smooth muscle cells, mesothelium, glomerular mesangial cells, and 
of particular interest with regard to OA in the dorsal root ganglia, and schwann cells 
of the peripheral and autonomic nervous system. The findings of this study suggest a 
wider physiological role for ADAMTS-5 than that of articular cartilage degradation 
and its intensely investigated role in the development of OA. The lack of evidence of 
any functional disturbances or abnormalities in ADAMTS-5 KO’s suggests that its 
absence during development in an unchallenged adult null mouse may be 
compensated by one of several related ADAMTS proteases that may function as less 
efficient proteoglycanases. 
1.1.3.2 Collagen 
The most abundant collagen type in AC is type II, making up 90-95% of the collagen 
mass and playing a critical role in maintaining its integrity, as has been demonstrated 
in transgenic mice (35). Like aggrecan, type II collagen degradation is a prominent 
feature of human OA cartilage. Degradation of type II collagen leads to damage of the 
collagen network and is a critical step in AC erosion in OA (36). It has been 
demonstrated that type II collagen can only withstand limited degradation before 
resulting in irreversible cartilage damage in murine models of arthritis (36). A 
generalised weakening of the collagenous network and subsequent swelling of AC 
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was initially demonstrated in humans and a number of animal models of OA (37-39). 
Subsequently, type II collagen degradation was characterised as a localised process in 
two murine models of spontaneous OA, occurring only in sites adjacent to focal areas 
of AC degeneration (40).   
MMPs play an important role in this process of collagen degradation. In vitro studies 
have demonstrated that cartilage collagenolysis relies on MMP activity (41). MMP-1, 
MMP-8 and MMP-13 are collagenases secreted by chondrocytes that have the 
capacity to cleave fibrillar collagens (type II/IX/XI) with resultant fragmentation of 
fibrils. Of these, MMP-13 has received the greatest attention due to its up regulation 
in human OA, greater efficiency at type II collagen cleavage (42) and a demonstrated 
primary role in the release of collagen from human OA cartilage (43).   
Much work has been done to characterise the exact role of the collagenases in AC 
degradation. Postnatal induced over expression of MMP-13 in mice leads to arthritis 
characterised by cartilage erosion (44). MMP-13 KO mice demonstrate abnormalities 
in cartilage absorption (45) and fracture healing (46). In a surgical model of OA, 
MMP-13 KO mice demonstrated chondroprotection that was not associated with any 
reduction in aggrecanolysis, changes in chondrocyte hypertrophy or osteophyte 
development (47), confirming that cartilage structural damage depends on MMP-13 
activity and suggesting MMP-13 inhibition as a potential therapeutic target for OA. 
In addition to the MMP’s other proteases, such as cathepsin K, have emerged as 
important contributors to the cartilage degradation process in OA and along with 
ADAMTS-5 and MMP-13 are considered major targets for development of future 
novel therapeutics for OA (48). The exact role these collagenolytic enzymes play in 
the complex process of AC degradation is still under investigation. In a preclinical 
anterior cruciate ligament transection (ACLT) model, inhibition of cathepsin K 
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resulted in protection of SCB integrity, protection against cartilage degradation and a 
reduction in osteophyte formation (49). There is also evidence cathepsin K degrades 
AC in naturally occurring equine OA (50). Cathepsin K KO mice are protected 
against cartilage degradation and SCB changes following surgically induced OA (51). 
More recently, increased expression and activation of cathepsin K has been identified 
in human OA cartilage using immunohistochemistry and PCR techniques (52). 
1.1.3.3 Tissue inhibitors of metalloproteinase 
Tissue inhibitors of metalloproteinases (TIMPs) are specific MMP inhibitors that are 
involved in the regulation of local MMP activities within tissues (53). Of the 4 
mammalian TIMPs, TIMP-3 not only inhibits MMPs but has also been shown to be 
effective at inhibiting aggrecanases (ADAMTS-4 and 5) (54). Consistent with this, 
TIMP-3 KO mice have increased spontaneous age-dependent aggrecan loss and OA-
like cartilage damage compared with WT mice (55).  
 
1.1.4 Subchondral bone 
In addition to articular cartilage changes, subchondral bone remodelling is a 
significant feature of OA joint pathology that is now recognised as playing an 
important role in disease progression and pain (56-58).  
Bone has the unique capacity to rapidly alter its structural organisation in response to 
changing mechanical forces, and this has been demonstrated in people with hand and 
knee OA (59). These alterations are not uniform across all periarticular bone, and 
occur in two phases – a destructive phase followed by a productive phase (60). The 
remodelling process commences with the activation of bone resorption that is 
mediated by osteoclasts. Osteoclasts are a highly specialised lineage of monocyte-
 10 
macrophages capable of removing mineralised bone matrix. Bone resorption is 
followed by bone formation that is mediated by osteoblasts. Under normal 
physiological settings, these two activities are coupled such that normal bone mass is 
maintained. Bone modelling occurs when these two processes are not coupled, 
resulting in a change in bone architecture and volume (increase or decrease), and a 
modification of the structural properties of cortical and trabecular bone. In addition, 
periarticular new bone formation can occur via endochondral ossification, where new 
bone replaces cartilaginous matrix. 
Periarticular bone comprises subchondral cortical bone, subchondral trabecular bone, 
and bone at the joint margins. While varying with disease stage and topographically 
within the joint, OA is typified by a general net increase in periarticular bone volume 
with subchondral cortical plate thickening, thinning of vertical trabeculae, a reduction 
in bone mineral content, focal increased remodelling and resorption, and the 
development of marginal osteophytes and enthesophytes (61). Imaging (radiography, 
DXA, MRI) of OA joints reveals various subchondral bone (SCB) changes including 
sclerosis, cyst formation, bone attrition, and bone marrow lesions (BML).  
Radiographically, SCB sclerosis appears as an increase in bone density beneath the 
weight-bearing joint surface. Bone attrition refers to the flattening of the SCB surface 
in areas of increased loading where remodelling is occurring. BML are a non-specific 
MRI feature that represents bone marrow necrosis, fibrosis and trabecular 
abnormalities. They appear to occur in areas of increased bone density (sclerosis) 
where there is excessive loading (62).  
A strong association exists between SCB attrition and BML in the same sub region, 
suggesting that increased bone stress, as indicated by the presence of BML, leads to 
increased SCB remodelling and subsequent development of bone attrition (63). 
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Importantly, in knee OA, articular cartilage loss is evident in areas of bone attrition 
(64), and the coupling of bone and cartilage turnover in OA may provide a key 
therapeutic target (61). SCB remodelling and the resolution of SCB cysts has been 
associated with an improvement in clinical outcomes in patients with advanced post-
traumatic OA (65). In a longitudinal multi-centre study of knee OA, enlargement of 
BML in patients with knee OA lead to an increased risk of cartilage loss in the 
associated region (66). Animal model studies have also linked SCB changes with 
disease progression. In mono-iodoacetate (MIA) induced OA, osteoclasts have been 
implicated in both SCB and calcified cartilage resorption, and early inhibition of 
osteoclast activity resulted in resolution of joint pathology and pain (67). 
 
1.1.5 Inflammation and the immune system 
OA was traditionally viewed as a non-inflammatory arthritis owing to the relatively 
small white cell populations observed in synovial fluid samples, compared to that 
seen in rheumatoid arthritis (68). This is despite early observations that synovial 
inflammation was a component of the disease (69). In the past few years the paradigm 
has shifted, and it is now widely accepted that inflammation not only exists as part of 
OA pathology and symptomology but plays a significant role in the pathogenesis (70) 
with evidence of a relationship between synovitis and the initiation (71) and 
progression of cartilage erosion (72). Both imaging and histological techniques have 
been used to characterise synovitis, and a number of studies have now identified a 
correlation between joint inflammation and disease symptoms such as pain (73, 74), 
and joint function measures such as walking and stair climbing (75). However, the 
exact pathogenic mechanisms involved in the development of synovitis and the 
relationship with other joint tissue changes is still under investigation (76). 
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A recent review has highlighted the prevalence of increased inflammatory cells in OA 
synovial tissues, including macrophages, T-cells and mast cells (77). Current evidence 
suggests that activation of the innate immune system is an essential driver of joint 
inflammation (especially synovitis) and a central feature of OA. A number of 
molecules released into the damaged joint can act as damage associated molecular 
patterns (DAMPs), activating the innate immune response via pattern-recognition 
receptors such as the toll-like receptors (TLRs) (78). These include ECM breakdown 
products, for example, hyaluronan (79) and fibronectin (80); as well as plasma 
DAMPs, for example, 1 microglobulin and 2 macroglobulin (81), that enter the 
joint subsequent to vascular leakage and exudation. These DAMPs have been shown 
to induce macrophage production of inflammatory cytokines and growth factors, 
implicated in both the inflammatory response and cartilage breakdown (81). Although 
a number of cell types within the joint are capable of responding to DAMPs 
(including chondrocytes), activation of synovial macrophages and the complement 
cascade (82), are thought to be the two main drivers for cytokine production, the 
development of synovitis and propagation of further cartilage damage (83). 
Cytokines (such as tumour necrosis factor (TNF)-, interleukin (IL)-1, and IL-6), and 
chemokines, such as chemokine ligand (CCL)3 (84), CCL18 (85), CCL19 (86), 
CCL20 (87), have all been implicated in the pathogenesis of OA (88). Interestingly, 
these cytokines also have demonstrated pro-algesic effects that could contribute to 
joint pain. The role of inflammatory cytokines and activation of the innate immune 
response in OA joint pain pathogenesis is currently under investigation (89). 
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1.1.6 OA phenotypes 
It is clear from the above summary that OA is a disease of the whole joint, and the 
degree of different tissue involvement and the predominant pathophysiological 
mechanisms that are active in any individual joint and/or patient may vary. The 
OARSI FDA OA Initiative defined OA as “a progressive disease of synovial joints 
that represents failed repair of joint damage that results from stresses that may be 
initiated by an abnormality in any of the synovial joint tissues, including articular 
cartilage, subchondral bone, ligaments, menisci, peri-articular muscles, peripheral 
nerves or synovium”, ultimately resulting in “the breakdown of cartilage and bone, 
leading to symptoms of pain, stiffness and functional disability” (90). This definition 
articulates the common end point of OA and our current understanding of the disease, 
but it does not reflect its complexity and the different forms that it can take. Both 
genetic (91, 92) and environmental factors such as age, gender, obesity, abnormal 
biomechanical loading (93) and joint injury can contribute to the development of OA 
(94-97). Each factor contributes differently to the pathobiological profile of the 
disease (98). OA can be localized to a single joint or generalized, and can be 
categorized on the basis of numerous disease characteristics including; etiology, 
pathophysiology, joint/s affected, stage of joint disease, presence of specific 
symptoms, and rate of progression.   
This concept of different subtypes or ‘OA phenotypes’ has been explored clinically 
(99) and epidemiologically (100), with a number of phenotype classifications 
proposed. For example, radiographic imaging can be used to identify clinically 
relevant OA phenotypes that may represent relevant subgroups for clinical trial 
selection (101), and distinct phenotypes of multi-joint and knee OA have been 
identified in population subgroups based on race and gender, which may influence 
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response to therapy (102-104). There is a move towards stratifying OA patients into 
sub-types based on different OA phenotypes, to improve clinical trial outcomes and 
develop a more mechanism based approach to treating OA (105, 106). However, 
clinicians and researchers are yet to reach consensus on which phenotype 
classifications are relevant for promoting the translation of preclinical research into 
effective therapeutics. 
 
1.1.7 OA therapeutic targets 
Synovial joints are organs, and therefore OA involves pathology in multiple tissues. 
Joint pathology changes include articular cartilage damage, subchondral bone 
sclerosis, joint hypervascularisation, synovial inflammation and fibrosis, osteophyte 
formation, meniscal and ligament degeneration and injury (70). However, articular 
cartilage degradation (including proteoglycan loss) remains a key feature of the 
structural changes that take place in the OA joint. For this reason much research has 
focused on articular cartilage and the role of chondrocytes in OA (41, 107-114). 
Significant progress has been made in our understanding of the pathogenesis of OA 
(115-121). Researchers believe this knowledge will enable the development of 
effective disease modifying compounds for the treatment of OA (122-127). This 
strategy for developing DMOADs is based on the theory that reducing structural joint 
damage (in particular, reversing articular cartilage degradation) will improve joint 
mobility and relieve the clinical symptom of pain. Consequently, many compounds 
that target specific components of OA pathology (SCB, AC, inflammation) have been 
developed and validated in pre-clinical OA models, and some have progressed to 
clinical trials (128). However, outcomes from the 13 published clinical trials 
conducted between 1999 and 2014 have been poor, and there are still no FDA 
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approved DMOADs (Table 1.1). Interestingly, the pre-clinical studies that informed 
these clinical trials all demonstrated some improvement in structural damage, but only 
one study reported on symptomatic outcomes (pain and weight bearing). 
This puts into questions the current approach for developing OA therapies.  The 
paradigm shift of thinking about OA as a failure of the joint organ that can manifest as 
multiple disease phenotypes has not been adopted into the way we use preclinical 
studies to inform selection of potential future therapeutics. For this to occur, 
consideration needs to be given to – (a) selecting animal models that replicate a 
human phenotype of the disease and allow longitudinal evaluation of disease initiation 
and progression; (b) identifying the tissues that play a role in disease symptomatology 
(pain and reduced mobility); and (c) mapping structural changes to clinical markers of 
the disease (pain, gait, weight bearing, mobility). This means that if our aim is to 
develop DMOADs that treat the disease, not just the pathology that develops in a 
particular joint tissue, joint structural changes can’t be studied in isolation of pain. 
The greatest obstacle to this approach is the complex relationship between joint 
structural pathology and pain, and the huge gaps in our current understanding of the 
pathophysiology of OA pain.  
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Table 1.1. Clinical DMOAD trials in knee osteoarthritis* 
Includes only placebo-controlled, peer-reviewed and published studies since 1999 
* Adapted from Malfait, A. M., & Little, C. B. (2015). On the predictive utility of animal models of osteoarthritis. Arthritis Res Ther, 17, 225. doi:10.1186/s13075-015-0747-6 
TRIAL 
 
TARGET DISEASE MODIFICATION SYMPTOMATIC OUTCOME 
(secondary endpoint) 
PRECLINICAL VALIDATION IN OA 
MODEL 
STRUCTURAL OUTCOME SYMPTOMATIC 
OUTCOME 
Oral salmon calcitonin 
(129) 
 
 
 
 
SCB JSW: No effect: 
biochemical markers (CTX-I & 
CTX-II) effect not significant 
WOMAC: no significant effect
  
Rat MNX and MNX/OVX (130) 
 
Dog ACLT (nasal delivery) (131) 
 
DMM in mice overexpressing 
salmon calcitonin (132) 
Joint protection, serum CTX-II  
 
Joint protection (no effect on 
osteophytes) 
OARSI score 7 weeks after DMM 
N/A 
 
N/A 
 
N/A 
Intra-articular rFGF18 
(133) 
Cartilage 
(anabolic) 
Primary endpoint not met ( 
cartilage loss in central medial 
femorotibial compartment 
MRI)  
WOMAC: improved Rat MMT (134) Increased thickness of the articular 
surface (medial tibial plateau).  
Degeneration scores  
N/A 
Strontium Ranelate (135) SCB JSW: fewer radiographic 
progressors  
Beneficial effects on symptoms 
at high dose only 
Dog ACLT (136) 
 
Rat MMT (137) 
 
Cartilage lesions, SCB thickening and 
Serum CTXII  
Cartilage degeneration   
SCB remodelling  
N/A 
 
N/A 
SD6010, Oral selective 
iNOS inhibitor (138) 
Cartilage JSW: no effect No effect on pain or function Dog ACLT (139, 140) 
 
Collagenase induced arthritis (Nos2 
null mice) (141) 
Rat MMT model (142) 
Cartilage lesions Osteophytes  
Synovitis  
Cartilage PG loss Cartilage lesions 
Osteophytes  
N/A 
N/A 
 
N/A 
 
Reversal of WBD & 
allodynia after 3 
hours  
Zoledronic acid(143) 
 
SCB Reduction in total BML area 
on MRI 
 
VAS pain scores   
But not KOOS 
Rat MIA (144) Rat MMT (145) 
a) prophylactic 
b) therapeutic (early or late 
intervention) 
 
Joint preservation 
Partial preservation, diminishes with 
late intervention 
 
Reversal of WBD  
Partial effect-
diminishing with 
late intervention 
Vitamin D3(146) 
 
SCB 
Cartilage 
MRI cartilage volume: no 
effect 
WOMAC: no effect  Rat pMNX (147) 
 
Osteochondrosis/OA in pigs (148) 
Inconclusive  
 
No effect: OA lesion incidence or 
severity  
N/A 
 
N/A 
Licofelone 
(5-LOX and COX inh) 
(149) 
Inflammation JSW: no effect WOMAC: pain improved Dog ACLT (150)  MRI cartilage volume  
Cartilage damage and osteophytes  
N/A 
Risedronate(151) 
 
Risedronate (152)   
 
Risedronate(153)   
SCB JSW: cartilage degradation and 
bone resorption markers  
JSW: no effect uCTXII  
 
Preserved integrity 
WOMAC  
 
WOMAC: no effect 
 
N/A 
DH guinea pig (154) – up to 24 wks 
NZW rabbits ACLT (155) 
 
OARSI score:  no effect, serum CTXII   
Loss of cartilage SCB damage 
serum CTXII    
 
N/A 
Broad-spectrum MMP 
inhibitor (156) 
Cartilage JSW: no effect No effect on pain Rat MIA (157) 
STR/Ort mice (158) 
Cartilage damage  
Cartilage & bone damage  
N/A 
N/A 
Doxycycline (159)  
 
Cartilage JSN: slowed in ipsilateral knee  No effect on pain Dog ACLT (160) 
 
DH guinea pig (161) 
DMM (mouse) (162) 
Femoral condyle damage  
Tibial plateau or osteophytes no effect  
Cartilage volume (MRI) loss  
Cartilage loss 
N/A 
 
N/A 
N/A 
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Clinically, a direct relationship between global joint pathology severity and pain 
intensity has not been demonstrated, and there is no established threshold of joint 
pathology at which pain starts to develop. There are however, specific joint tissue 
changes that occur with OA that are associated with pain. These include synovitis and 
bone marrow lesions (57, 74). But there is no established cause-effect relationship to 
assist investigations into how different tissues and processes lead to pain. 
This lack of association can in part be explained by the multitude of intrinsic patient 
factors, which determine an individual’s pain response. These include genetic (163, 
164), psychosocial (165), biomechanical (166) and comorbidity factors (97, 167). The 
other important consideration is that the relationship between joint pathology and pain 
is likely to be different for different OA phenotypes, and over the course of the 
disease. For example, following joint injury, inflammation may be the key driver of 
pain. As the inflammation resolves and joint disease progresses, other structural 
changes may take over and alter the characteristics of the pain response. In other 
words, early phase hypersensitisation may look very different to late phase 
hypersensitisation at a biomolecular level, but the measured pain outcome (eg 
allodynia) may look the same. A better understanding of pain mechanisms and the 
pathophysiological pathways involved in OA pain will bring clarity to the relationship 
between joint pathology and pain.  
In the next section I will review what is known about joint innervation and OA pain, 
focussing on the knee joint as a dynamic load-bearing joint, which is commonly 
affected by OA.  
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1.2 Sensory innervation of the knee joint 
1.2.1 Knee joint afferents 
Innervation of the rodent knee is derived from the femoral nerve, the sciatic nerve and 
the obturator nerve. The knee joint is innervated predominately by the medial articular 
nerve (MAN) and the posterior articular nerve (PAN). The PAN is the larger of the 
two nerves and originates from the tibial nerve branch of the sciatic (168). 
The cell bodies of the afferent neurons innervating the knee joint reside in the lumbar 
(L1-L5) dorsal root ganglia (DRG), with the majority in L3. In the rat 88% of knee 
joint afferents are located in L3 and L4 (169). However, knee afferents make up a 
very small percentage of the total DRG neuron cell bodies. 
Researchers have used different methods to identify and characterise the afferent 
innervation of the mouse knee joint. Ebinger (170) identified the number and 
distribution of nerve fibre size in the medial and posterior articular nerves of the 
mouse knee using electron light microscopy. However this histological study did not 
differentiate between sensory (nociceptor and mechanoreceptor fibres) and 
sympathetic neurons.  
Although the sub population of sensory neurons that innervate the knee joint and 
transmit nociceptive input to the spinal cord have been mapped and characterised 
(171-178), including the proteins and neuropeptides that are altered in animals with 
diseased joints, there is still no clear understanding of the disease mechanisms that 
drive and modulate these pain signals in the OA joint.  
Histological studies demonstrate that articular cartilage is avascular and aneural, so it 
is assumed that this tissue cannot be directly involved in the generation of pain. 
However, subchondral bone, periosteum, synovium, ligaments, and the joint capsule 
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are richly innervated with sensory neurons that have the capacity to transmit 
nociceptive stimuli.  
Sensory stimulation of normal joint tissues does not generate pain, as demonstrated by 
the ability to move a normal joint through a range of motions without any pain 
sensation. This suggests that, at least for movement-evoked knee pain, local and 
central mechanisms alter sensory signals in such a way that a previously benign 
stimulus (either sub-threshold or non-nociceptive) becomes painful. 
 
1.2.2 Nociceptors 
Nociceptors are specialised nerve endings that conduct noxious signals to the dorsal 
horn of the spinal cord. There are two main types of nociceptors, differentiated by the 
diameter of their afferent fibres and, the type and magnitude of stimulus required to 
activate them. High-threshold mechanoreceptors (HTM) are innervated by thinly 
myelinated, fast conducting (5-30m/s) A fibres that respond to intense mechanical 
stimulation. Polymodal nociceptors (PMN) are innervated by unmyelinated, slow 
conducting (0.5-2 m/s) C fibres that respond to intense mechanical stimulation, 
temperatures exceeding 42
O
C and irritant chemicals. It is thought that Afibres 
conduct sharp localised pain while C fibres conduct poorly localised, diffuse pain 
(179). A number of ion channels located in primary afferent nociceptors act as 
sensory transducers, and are responsible for the detection of physical stimuli. The 
most important of these are the poly-modal Transient Receptor Potential (TRP) 
channels (180). These channels are permeable to cations and structurally similar to the 
superfamily of voltage-gated channels, although not strictly voltage dependent. 
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1.2.3 Vanilloid 1 receptor 
Vanilloid 1 receptor (TRPV1) is a member of the TRP subfamily of cation channels. 
It is a polymodal receptor activated by three pain-producing stimuli, vanilloid 
compounds (eg capsaicin), moderate heat (temperatures > 42
O
C) and low pH (< 5.9). 
Its highest expression is in sensory neurons where it acts as a polymodal detector of 
noxious stimuli (181). Sensory neurons from TRPV1 KO mice do not respond to 
capsaicin and temperatures < 50
O
C in vitro. Mice lacking functional TRPV1 show 
normal physiological and behavioural responses to noxious mechanical stimuli, 
however they display an absence of thermal hypersensitivity in the setting of 
inflammatory pain models such as carrageenan (182). TRPV1 plays an important role 
in both chemical and thermal hyperalgesia, in models of acute inflammatory pain and 
neuropathic pain (183). A role in neuropathic pain is further supported by studies 
reporting increased levels of TRPV1 expression in uninjured DRG following 
peripheral nerve injury (184, 185). These studies suggest TRPV1 may play a role in 
the development and maintenance of chronic pain, beyond its thermoreceptor function 
and contribution to mechanical hyperalgesia. Interestingly, stimulation of the TRPV1 
receptor causes an acute neurogenic response that is characterised by vasodilation, 
plasma extravasation and hypersensitivity; however, there is significantly reduced 
blood flow in wild type mice compared to TRPV1 KO mice when capsaicin is 
injected directly into the knee joint (186).  
TRPV1 is implicated in arthritis pain but the exact mechanism/s by which it 
contributes to the pain of OA is not understood. TRPV1 participates in the 
development of chemical and thermal hyperalgesia in the acute phase, and mechanical 
hyperalgesia in the chronic phase, of adjuvant induced arthritis; via sensitisation of 
receptors by inflammatory mediators released in arthritic joints (187). Conversely, an 
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attenuation of inflammatory arthritis (both inflammation and pain) has been 
demonstrated in TRPV1 KO mice (188). TRPV1 receptors identified in human 
synovium provide a target for developing anti-TRPV1 therapeutics, and the efficacy 
of some of these has been demonstrated in MIA models of OA (189, 190). 
Intra articular injection of the axonal tracer Fast Blue and immunohistochemistry 
techniques have been used to identify the sub population of afferents from mice knee 
and ankle joints that express TRPV1, with 40% of these afferents expressing the 
receptor (191). Other investigators have also used Fast Blue to identify the cell bodies 
of sensory afferents from the rat knee joint, and investigated the expression of 
calcitonin gene-related peptide (CGRP) and TRPV1 receptors in this sub-population 
of DRG neurons (192). Using the antigen-induced arthritis (AIA) model in the rat to 
study the expression of TRPV1 in the lumbar DRG, investigators were unable to 
demonstrate any up regulation of TRPV1 expression (193), and the proportion of 
TRPV1 protein-positive lumbar DRG neurons did not increase in the course of acute 
and chronic AIA in the rat. However, it has been reported that TRPV1 receptor 
expression in small and medium-sized neurons in DRG is up-regulated during 
inflammation (194). Other studies have demonstrated an increase in TRPV1 protein-
positive neurons with acute inflammation, but not an increase in TRPV1 mRNA 
levels in DRG neurons (195, 196). In combination these findings support the 
suggestion that TRPV1 is one mechanism by which peripheral sensitisation develops 
following inflammation. 
A murine adjuvant induced arthritis model was used to investigate the role of 
extracellular-regulated kinase (ERK) and TRPV1 in primary afferent neurons (197). 
Preferential activation of ERK in TRPV1-positive neurons innervating the joint was 
demonstrated and TRPV1 KO mice showed reduced activation of ERK in the sensory 
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neurons. Changes in p-ERK expression in the sensory neurons correlated with 
changes in thermal and mechanical hyperalgesia. This study provides evidence that 
TRPV1 may contribute to the pain of inflammatory arthritis via an ERK-mediated 
pathway. 
The relationship between fibroblast-like synovial (FLS) cells and sensory neurons that 
innervate the knee joint has been investigated, using a co-culture system of FLS cells 
from AIA knee joints and DRG neurons (198). The proportion of DRG neurons 
expressing neurokinin-1 (NK1) receptor-like immunoreactivity was upregulated in the 
co-culture. Furthermore, the expression of TRPV1 was up regulated when DRG 
neurons were co-cultured with FLS cells from chronically inflamed joints.  
Changes in TRPV1 expression in DRG and the role of this receptor in sensitisation 
and OA pain have not been studied using a post-traumatic model of OA. 
 
1.2.4 Transient Receptor Potential Ankyrin-1 (TRPA1) 
TRPA1, the wasabi receptor, is another member of the transient receptor potential 
family of ion channels, and a sensor of pungent chemicals and environmental irritants 
such as mustard oil, garlic, cinnamon oil, clove oil and ginger (199, 200), and also 
plays a role in acute noxious mechanosensation and cold thermosensation (201, 202). 
It is specifically expressed in the inner ear (203), and trigeminal and DRG neurons, 
and is highly co-expressed with TRPV1 in small diameter peptidergic nociceptors. Its 
role in mechanical nociception remains controversial. TRPA1 has been shown to play 
a role in nociceptor excitability modulation and neurogenic inflammation at the site of 
tissue injury, and it may play a role in the transduction of high-threshold mechanical 
stimuli. TRPA1 KO mice demonstrate a higher mechanical threshold than wild type 
(WT) mice, and a deficiency in response to acute punctate cutaneous stimuli (202). A 
 23 
small molecule TRPA1 inhibitor (AP18) has been used to investigate the role of 
TRPA1 in pain sensitisation. AP18 reverses Complete Freund’s Adjuvant (CFA)-
induced mechanical hyperalgesia in mice (204). In this same study TRPA1 KO mice 
did not show significantly increased acute mechanical thresholds, however they did 
develop CFA-induced hyperalgesia that did not respond to AP18. These findings 
suggest TRPA1 plays a role in sensitisation, but that a compensatory mechanism may 
exist in TRPA1 KO mice. It is unclear what molecular or cellular compensation 
mechanisms may account for these observations. The findings also suggest that 
TRPA1 may be involved in the maintenance and not the induction of mechanical 
hyperalgesia. Although TRPA1 and TRPV1 are co-localised and appear to interact 
functionally, an up regulation of TRPV1 has not been demonstrated in TRPA1 KO 
mice.  
These studies all implicate TRPA1 in mechanical hyperalgesia, despite other 
investigators failing to demonstrate a difference in mechanical thresholds between 
TRPA1 KO and WT mice (200). Overall, there is strong evidence that TRPA1 
contributes to inflammatory pain, and can be activated by inflammatory mediators 
such as bradykinin (205). TRPA1 KO mice have an impaired response to bradykinin 
injection and reduced bradykinin-induced mechanical hyperalgesia (200, 202). 
However, further investigation is needed into any role it may play in chronic pain 
states such as OA. 
 
1.2.5 Transient Receptor Potential Vanilloid-2 (TRPV2) 
TRPV2 is a structural homologue of TRPV1 that is insensitive to capsaicin but is 
activated by high temperatures, > 52
O
C. (206). Interestingly, nociceptors lacking both 
TRPV1 and TRPV2 have normal heat responses (207). TRPV2 is widely expressed in 
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neuronal cells, with strong immunolabelling detected in medium-diameter DRG 
neurons associated with A-fibers (208). The broader distribution of TRPV2 
compared to TRPV1, in a diverse range of neurons and non-neuronal tissue, suggests 
that it may contribute to more than just nociceptive processing (209). TRPV2 KO 
mice are susceptible to perinatal death but mice that survive do not demonstrate 
abnormal thermal or mechanical nociception (210). However, there is evidence that 
TRPV2 does play a role in peripheral sensitisation in inflammatory models (211), and 
in the development of mechanical hyperalgesia (212). More recent studies have 
suggested a role for TRPV2 in maintaining cardiac function (213, 214) and 
controlling cell tumour proliferation (215). 
 
1.2.6 Transient Receptor Potential Vanilloid-4 (TRPV4) 
TRPV4 is a polymodal receptor activated by hypotonicity, shear stress, innocuous 
heat (threshold temperatures >27deg), low pH and arachidonic acid metabolites (216-
218). Although widely expressed, its distribution in cochlear hair cells, vibrissal 
Merkel cells, sensory ganglia, free nerve endings & cutaneous A & C fibre terminals, 
suggests a primary role as a mechanoreceptor (219). 
TRPV4 KO mice show impaired osmotic sensation and sensitivity to acid (220), an 
increase in mechanical nociceptive threshold and altered thermal selection behaviour, 
but normal response to low threshold mechanical stimuli (221). TRPV4 agonists 
promote release of substance P and CGRP from central projections in primary 
afferents in the spinal cord (222), providing evidence for a role in nociception. 
TRPV4 mediates mechanical hyperalgesia following exposure to inflammatory 
mediators (223, 224) suggesting a more specific role for TRPV4 in acute 
inflammatory pain. The role of TRPV4 in chronic pain has also been investigated 
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using a neuropathic pain model (225), where it was shown that reduced expression of 
TRPV4 abolished Taxol-induced mechanical hyperalgesia and attenuated hypotonic 
hyperalgesia. 
 
1.2.7 The dorsal root ganglia  
Joint afferents cannot be differentiated histologically or immunochemically from 
other afferent populations. In order to study cell bodies in the DRG that innervate the 
knee joint retrograde labeling techniques have been used to differentiate this sub-
group of neurons. Retrograde axonal tracing techniques, where by a dye is injected 
directly into the stifle joint, can identify the sub population of sensory afferents within 
the somata of DRG neurons which innervate the structures of the knee joint.  
Salo & Tatton (226) identified cells in the DRG which innervate the mouse knee joint 
using in vivo retrograde tracing with Fluoro-Gold. They determined the size, number 
and distribution of the neurons that innervate the knee joint structures, but did not 
characterise the cells using immunohistochemical techniques. Salo & Theriault (169) 
later used retrograde tracing with Fluoro-Gold in combination with 
immunohistochemistry to characterise the number, distribution and neuropeptide 
content of cell body neurons in the DRG that innervate the knee joint of the rat. 
Following from this, retrograde tracing with Fluoro-Gold in combination with 
immunohistochemistry (labeling for the neuropeptides CGRP and substance P) was 
used to demonstrate an age-related loss of mechanoreceptors in the mouse knee joint 
(227). 
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1.3 Chronic Pain  
Although OA is described in terms of structural and biological joint pathology, the 
magnitude of the disease burden is not linked to these joint changes, but rather to the 
clinical symptoms (228). The most significant of these is pain, and yet pain is the least 
well-understood manifestation of this disease (229). 
 
1.3.1 Sensitisation 
Pain starts with stimulation of specialised nerve endings (nociceptors) and the 
subsequent transmission of signals along afferent peripheral sensory nerves to the 
spinal cord. From the spinal cord this signal is then transmitted via a number of 
pathways to the higher brain centres for processing into what is perceived as pain 
(Figure 1.2). But pain is not simply the passive transport of sensory signalling via 
encoded action potentials from one neuroanatomical location to the next with the 
eventual processing of such signals in the thalamas and cortex. All along this pathway 
are opportunities for intrinsic and extrinsic factors to influence the nature, amplitude 
and perceived location and duration of the original ‘pain’ signal. This discovery of 
nervous system plasticity has changed our understanding of pain (230). 
The spinal gate theory proposed by Melzack and Wall in 1965 (231) and the 
subsequent discovery of inhibitory control systems such as endorphins, enkephalins, 
and transcutaneous nerve stimulation, were early demonstrations of pain signal 
modulation at the level of the spinal cord and brain (232-242). In addition, others 
observed the enhanced signalling of peripheral nociceptors following injury, leading 
to a localised zone of ‘primary hyperalgesia’ (243-247). At the same time, Mendell 
and Wall introduced the concept of ‘wind-up’ in the dorsal horn neurons, by 
demonstrating that an increase in nociceptor signal frequency resulted in increased 
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action potential amplitude (248). These phenomena have all contributed to our 
understanding of pain modulation and hypersensitivity, however they do not fully 
account for the tactile allodynia (249), secondary hyperalgesia or temporal summation 
of pain that is observed with chronic pain (250).  
The idea of ‘central sensitisation’ came into play as researchers discovered that the 
majority of synaptic input to sensory neurons is sub-threshold, and that increasing the 
strength of this input or reducing inhibition, can result in profound changes to the 
functional properties of neurons (251-253). But, central sensitisation goes beyond a 
phenomenon based on activity dependent signal plasticity. Central sensitisation occurs 
after the period of initial nociceptive transmission, remains autonomous, is sustained 
beyond the initiating signal, and amplifies the response to non-nociceptor signals as 
well as nociceptor signals that originate from distant sights. We now know that 
changes to microglia, astrocytes, gap junctions, membrane excitability and gene 
transcription at the level of the DRG and spinal cord all contribute to central 
sensitisation development and the chronic pain state (254-258). 
Recent evidence supports the theory that both peripheral and central sensitisation, as 
well as endogenous inhibitory mechanisms, contributes to the chronic pain of OA. 
Peripheral sensitisation is thought to be mediated by nerve growth factor (NGF) (259) 
and pro inflammatory cytokines released after cell injury, such as prostaglandins, 
bradykinin, and TNF(260). Central sensitisation may be mediated by other 
inflammatory neuropeptides such as CGRP, Substance P, glutamate and vasoactive 
intestinal peptide (VIP) (261-264). The endogenous opioid and cannabinoid systems 
are the main inhibitory mechanisms that play a role in dampening the pain signal in 
OA (265-267). 
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Figure 1.2. Schematic diagram of the Pain Pathway 
The Pain Pathway describes the neuronal network that links the sensory inflow 
generated in peripheral nociceptor terminals with the conscious awareness of a painful 
stimulus. Tissue injury and inflammation alters the chemical environment of both 
peripheral and central nociceptor terminals, and heightens the activation threshold of 
these specialised neurons. In addition, a number of endogenous inhibitory controls 
exist that act as inhibitory modulators. 
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1.3.2 OA pain in humans 
A number of pain assessment tools have been used to assess pain in OA patients 
(268), including mechanical and thermal thresholds, range of motion, weight bearing 
and gait analysis (269). Patient self-reporting questionnaires, such as the Visual 
Analogue Scale (VAS), the McGill Pain Questionnaire (MPQ), and the Western 
Ontario and McMaster Universities Index of OA (WOMAC) are also important 
clinical assessment tools (270). 
The development of chronic OA pain is considered a maladaptive process that is both 
initiated and driven by a number of pathological processes involved in OA (271, 272). 
For the majority of OA patients, peripheral mechanisms (including inflammation) are 
thought to play a major role in pain development. In a subgroup of these patients the 
pain mechanisms are more complex, resulting in a pain syndrome that does not 
directly correlate with the severity of joint pathology, and that is driven by central 
processing and neuropathic mechanisms (273-275). These patients respond poorly to 
conventional therapies such as potent analgesics and joint arthroplasty. 
Researchers have yet to unravel these complex molecular pathways and better define 
the intricate relationship that exists between OA joint pathology and pain. In a multi-
center study that looked at the relationship between knee OA and sensitisation, 
evidence of sensitisation, as measured by mechanical temporal summation (MS) and 
pressure pain threshold (PPT), was associated with OA related pain severity but not 
with radiographic OA (276). This finding suggests that intrinsic patient factors, not 
just joint pathology, determine an individual’s OA pain phenotype. The idea that 
patients with knee OA exhibit increased sensitivity to painful stimuli at distant body 
sights has been demonstrated in a number of clinical studies. When OA patients were 
stratified into high versus low symptom severity based on the WOMAC, individuals 
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in the high group were more sensitive to heat, cold and mechanical (both blunt 
pressure and punctuate) stimuli, compared to the low symptom group and controls 
(277). OA patients also demonstrate somatosensory abnormalities that manifest as 
tactile hypoaesthesia and pressure hyperalgesia (278, 279). The growing evidence for 
a ‘neuropathic’ OA phenotype (280-284) has encouraged the development of 
assessment tools aimed at identifying patients with signs of central sensitisation (285), 
with the aim of developing a more targeted pain management approach for these 
patients (286-288). 
 
1.3.3 Mechanisms of OA pain 
We know that OA involves global joint pathology that leads to chronic pain and 
immobility. Historically, it has been assumed that joint pathology drives the pain of 
OA so the focus has been on understanding the pathobiology of OA and identifying 
disease-modifying therapeutics that will re-establish a normal joint environment, and 
thus remove the trigger for development of chronic pain. However, the mechanisms 
that drive and modulate the pain of OA are poorly understood and the exact 
biomolecular links between different aspects of joint pathology and pain, and how this 
may change over the course of the disease are still not known.  
Evidence of a co-dependent relationship between joint pathology and OA pain has 
only really been investigated in the context of inflammatory arthritis models (56, 289-
291). Despite the associations that have now been identified using advanced imaging 
(292-294), there still remains discordance between structural joint pathology and pain 
severity in people with OA (295). This can in part be explained by the psychosocial, 
genetic and biomechanical factors, which are also important determinants of the pain 
phenotype, and ultimately make the identification of any causal effects between 
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specific joint pathologies and pain, a significant challenge. Further validation of this 
clinical observation can be found in a naturally occurring model of OA. The 
relationship between OA pain and joint pathology has been investigated in the Dunkin 
Hartley guinea pig, which develops spontaneous OA. In this model, both 
histopathological and micro-CT determinants of joint degeneration correlated well 
with aging but did not correlate with nociception as measured by electrophysiological 
recordings (296). 
In human OA, strong associations have now been identified between pain and bone 
marrow lesions (57, 297, 298), synovitis (74, 299), and joint effusion (300, 301); and 
weaker associations between cartilage damage and pain (75, 302, 303). But, we are 
yet to identify which processes and joint tissues drive the development of chronic 
pain, and therefore should be targeted when developing therapeutics. More recently, 
gene array studies using different animal models have identified thousands of 
differentially expressed genes (304), suggesting a number of biomolecular 
mechanisms are working in concert to produce OA pain. It is likely that local, 
inflammatory and neurogenic mechanisms, as well as psychosocial factors all 
contribute to the pain of OA (271, 305, 306). 
Identifying local (joint specific) and peripheral mechanisms that mediate OA pain will 
allow for a more targeted approach to developing future therapeutics that are less 
likely to result in unwanted side effects (307). This strategy has identified a number of 
TRP channels, including TRPV1, TRPV4 and TRPA1; and the proteinase activated 
receptors PAR-1, PAR-2 and PAR-4, as potential intra-articular targets. 
The endocannabinoid and endogenous opioid systems both play a significant role in 
immune modulation (308) via a number of mechanisms including T cell signalling 
(309); and pain modulation (including OA pain) (310), and are emerging as novel, 
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joint specific therapeutic targets for OA . The antinociceptive activity of cannabinoids 
has been demonstrated in a number of animal models of arthritis (311-313). Systemic 
use of opioids is an important part of managing OA pain, however these potent 
analgesics have significant side effects. Emerging evidence about the complex role 
that the endogenous opioid system plays in pain (314), at the organ level (266, 315), 
the DRG (316) and spinal cord (317), suggests a more targeted approach is required 
(318, 319). 
1.3.3.1 Inflammation 
It is well established in both human and animal model studies that inflammation, and 
in particular synovitis, contributes to joint pathology and pain (320). Early 
electrophysiological studies investigating the effects of intra articular kaolin were able 
to demonstrate that acute synovitis reduced the activation threshold of A and C fibre 
sensory afferent neurons (321). A number of joint cells, including chondrocytes and 
synovial cells, express and respond to cytokines and chemokines that can mediate and 
amplify nociceptive signally (322). Pro-inflammatory cytokines, including TNF, IL-
1, and IL-6, are released by joint cells as well as sensory neurons and glial cells in 
the DRG and microglial cells in the dorsal horn, and have been shown to play an 
important role in joint pain. 
TNF is a pro-inflammatory cytokine involved in the generation of hyperalgesia 
associated with both neuropathy and inflammatory processes. TNF can rapidly alter 
neuronal excitability, and it can also mediate long-term changes in sensory neuron 
excitability via transcriptional and protein expression effects. For example, chronic 
exposure to TNF significantly increases the proportion of DRG neurons expressing 
TRPV1 (323). TNF can act directly on sensory neurons or indirectly via downstream 
targets such as the chemokine, monocyte chemoattractant protein-1 (MCP-1/CCL2), 
which is up regulated in sensory neurons following neuronal injury (324). 
Interleukins are an important family of cytokines that are reported to produce both 
rapid and delayed neuronal effects. Interleukin-1 is not only pro-nociceptive, 
mediating hypersensitivity in inflammatory (260) and arthritis pain models (325), but 
has also been shown to play a role in articular cartilage degradation, proteoglycan loss 
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and synovitis, in inflammatory arthritis and mechanical instability models of OA (83, 
326-328). In vitro studies have demonstrated that interleukin-17 (IL-17) increases 
DRG expression of TRPV4, and an antibody against IL-17 reduces secondary 
mechanical hyperalgesia in AIA mice (329). The anti-inflammatory cytokine, 
interleukin-10 (IL-10) also plays an important role in inflammatory pain, Recently it 
has been demonstrated that IL-10 producing macrophages mediate resolution of 
inflammatory hyperalgesia (330). 
DRG neurons express a number of chemokine receptors (331) suggesting that 
chemotactic cytokines also play a role in pain. In particular MCP-1 and its receptor 
(CCR2) have been implicated in a number of pain models (332-338), including OA 
where increased MCP-1/CCR2 expression correlated with movement-evoked pain in 
a post-traumatic model of OA (339). MCP-1 has also been implicated in up-regulating 
the expression and function of TRPV1 and the voltage-gated sodium channels, 
Nav1.8 in vitro (340). The peripheral voltage gated sodium channels Nav1.7, Nav1.8 
and Nav1.9 are all expressed in sensory neurons, with Nav1.8 preferentially expressed 
in DRG and trigeminal ganglia (341). Maladaptive changes in these channels are 
pivotal in mediating a number of chronic pain states. Recently, Nav1.7 and Nav1.8 
have both been shown to play a role in OA pain pathways in the rat MIA model (342).  
Angiogenesis has also been investigated as a mediator of OA pain (343). 
Inflammation is a key driver of angiogenesis, and this has been demonstrated in the 
synovia (344) and at the osteochondral junction (345) in OA joints. 
1.3.3.2 Neuropathic mechanisms 
Theories of the neurogenic origins of joint pain are summarized in a review by 
McDougall (346). Nociceptors respond to algesic chemical substances such as 
bradykinin, prostaglandins, leukotrienes, IL-1 and serotonin; and chronic excitation of 
nociceptors is dependent in part on this response, termed neurogenic inflammation. 
The role of activation of ‘silent nociceptors’ has been demonstrated in the context of 
joint injury and inflammation, whereby afferent fibers which are quiescent in normal 
joints are activated (347) and begin transmission of nociceptive signals to the central 
nervous system. In addition, early studies demonstrated a reduction in the activation 
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threshold of both C and Aafferents in inflamed joints, mediated via inflammatory 
neuropeptides such as CGRP (348). 
Substances released as a consequence of articular cartilage degradation may 
themselves play an indirect algesic role by influencing the release of neuropeptides 
from sensory neurons at the level of the dorsal root ganglia, and subsequently 
enhancing the release of algesic substances in the periphery. Conversely, sensitisation, 
and the associated release of inflammatory mediators such as substance P and 
cytokines, may also further contribute to the degenerative processes occurring in OA 
joints. 
Proteinase activated receptors (PARs) are a recently identified group of G-protein-
coupled receptors that offer a potential mechanism for linking attenuation of joint 
disease with alleviation of pain (349, 350). PARs are activated by proteinases released 
into tissues during inflammation, and demonstrate both pro-inflammatory and anti-
inflammatory properties. Currently four members of this family of receptors have 
been identified, and three of them are implicated in peripheral nociception (PAR-1, 
PAR-2, PAR-4). PAR-1 is expressed in mouse DRG, and its anti-nociceptive effect 
has only been observed in association with inflammatory pain (351). PAR-2 has been 
localized to sensory neurons, and is considered to have a pro-nociceptive effect that is 
mediated via TRPV1 (352, 353) and TRPV4 (222). PAR-4 expression has been 
demonstrated in rat DRG (354). PAR-4 is also expressed in rat (355) and mouse knee 
joints, where a pro-inflammatory and pro-nociceptive role was observed in following 
intra-articular injection of a PAR-4 agonist (349, 356). This is in contrast to a 
previous study that showed co-localisation of PAR-4 with the inflammatory 
neuropeptides substance P and CGRP in the rat DRG, and demonstrated an anti-
nociceptive effect for PAR4 in response to thermal and mechanical stimulation (357). 
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VIP is another inflammatory mediator that may play a role in the link between joint 
degeneration and pain in OA. Injection of VIP into the knee joints of rats results in 
synovial hyperaemia and pain (358). Unilateral injection of VIP into normal rat knee 
joints was demonstrated to cause a shift in weight bearing away from the injected 
joint as determined by force plate capacitance testing, and a reduction in paw 
withdrawal threshold of the ipsilateral hindlimb (263). In the MIA model, injection 
into the affected knee joint of the antagonist VIP6-28, diminished hind limb changes 
in weight bearing and increased paw withdrawal threshold.  
Electrophysiological studies have demonstrated enhanced afferent firing from normal 
rat knee joints after injection of VIP during normal and hyper-rotation of the joint 
(359). This VIP mediated sensitization was effectively blocked by pre-administration 
of VIP6-28. Using the MIA arthritis model the role of VIP and its antagonist VIP6-28 
was further investigated. Rats with MIA induced arthritis had significantly reduced 
afferent firing during normal joint rotation and during hyper-rotation of the affected 
knee when treated with VIP6-28, suggesting that VIP is released into OA knee joints 
and may contribute to joint pain. However, the role of VIP in OA pain has not been 
investigated using a post-traumatic OA model. 
Researchers have also attempted to define the relationship between pathology and 
pain using nerve injury models. These studies may provide some direction for further 
investigation into the relationship between OA pain mechanisms and OA joint 
pathology. Neuropathic pain is thought to involve nerve injury-induced specific 
changes to the DRG and spinal cord, but there is now evidence that neuropathic pain 
and neuroinflammation share similar mechanisms. The role of MMP-2 and MMP-9 in 
the pathophysiology of neuropathic pain has been studied using a well-characterised 
nerve injury model, L5 spinal nerve ligation (SNL) (360). MMP-9 demonstrated a 
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rapid and transient up-regulation in injured DRG primary sensory neurons with 
concomitant activation of microglial and pain behaviour, consistent with an early 
phase of neuropathic pain. In contrast, MMP-2 demonstrated a delayed response to 
SNL in DRG satellite cells and spinal astrocytes, consistent with a late phase of 
neuropathic pain. The pro-inflammatory cytokines, TNF-and IL-1 are rapidly 
produced after tissue injury, and may play a role in the MMP-9 mediated initiation 
phase of neuropathic pain. Since both MMP-2 and MMP-9 are up regulated in human 
OA, the findings of this study highlight the importance of investigating the role of 
these metalloproteases in the pain of OA. 
Neuropathic pain mechanisms in OA have only been investigated in the MIA model. 
An increase in expression of activating transcription factor 3 (ATF-3) 
immunoreactivity in L5 DRG associated with early stage disease (day 8 and 14) and 
no change in L4 DRG was demonstrated in rats with MIA knee arthritis compared to 
controls (361). At day 8 this corresponded to reduced ipsilateral hind limb weight-
bearing and knee joint changes characterised by loss of proteoglycan, ghosting of 
chondrocytes, degeneration of subchondral bone plates with areas of bone loss and 
associated activation of osteoclasts and chondroclasts, and hyperplasia of synovial 
membranes associated with mononuclear inflammatory cell infiltrates. At day 14, 
increased ATF-3 in DRG also corresponded with reduced ipsilateral hind limb 
weight-bearing and, focal areas of pronounced ulceration of articular cartilage and 
superficial subchondral bone development within the affected joints. Since ATF-3 is 
described as a selective neuronal marker, specifically induced in sensory and motor 
neurons following nerve injury (362), these findings suggest an early phase 
neuropathy in the DRG innervating the affected MIA knee joints. However, the 
results of this study are difficult to interpret since retrograde axonal tracing studies 
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using fluoro-gold in the adult wistar rat have shown that 88% of knee joint afferents 
are in fact located in L3 and L4 DRG, with less than 10% residing in L5 (169). 
Pain related behaviours have been investigated and described in a number of OA 
models (363), however little attempt has been made to directly map these behaviours 
to specific joint histopathology changes or the mechanisms driving these changes.  
Fernihough et al investigated pain related behaviours in two OA models in the rat; 
partial medial meniscectomy and MIA injection (364). Histological evaluation of the 
knee joints in both models demonstrated progressive OA joint pathology development 
over a 28-day period. No comparison was made between the two models with respect 
to histological differences at time points before 28 days although the study did report 
on the initial period of acute inflammation and joint swelling seen with the MIA 
model up to day 7 post-injection. The study concluded that both OA models induced 
histological changes and pain related behaviours, (hyperalgesia, allodynia and 
reduced hind limb weight bearing) characteristic of human OA. However, response to 
pharmacological interventions (morphine, diclofenac, gabapentin and paracetamol) 
was only tested in the MIA treated animals because this model induced more robust 
and reproducible pain related behaviours. The investigators did not consider what 
impact the initial acute inflammatory response associated with the MIA model might 
have on later development of pain behaviour such as hyperalgesia and allodynia. 
Fast Blue Retrograde labelling was then used to identify cell bodies of primary 
sensory afferents from the knee joint of rats with MIA induced arthritis, and 
expression of CGRP and TRPV1 quantified in these labelled neurons (192). The 
majority of knee joint afferents were found to reside in the L4 DRG. Expression of 
CGRP and TRPV1 was greater in neurons innervating the knee joint than the general 
population of neurons across the whole DRG. L4 DRG of MIA mice showed an 
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increase in expression of both CGRP and TRPV1 compared to control mice, 
suggesting a potential role for CGRP and TRPV1 in the development of the pain 
behaviour associated with OA in the knee joint. 
The endogenous agonist for TRPA1, 4-hydroxy-2-nonenal (HNE), provides another 
example of how OA pathogenesis and OA pain mechanisms might share common 
pathways. HNE is a lipid peroxidation end product that is produced abundantly in OA 
articular tissue. HNE activates TRPA1, promoting acute pain, neuropeptide release 
and neurogenic inflammation (365). The formation of HNE is enhanced in 
synoviocytes from patients with OA (366-369). In addition, HNE induces 
transcriptional and post translational modifications of type II collagen and MMP-13 in 
human OA chondrocytes, contributing to cartilage ECM degradation (367). There is 
also evidence that HNE exerts a number of effects on human OA osteoblasts which 
alter their metabolic activity (366). 
 
1.3.4 Future therapies for OA pain 
Symptomatic OA therapies aimed at managing pain and improving mobility, are 
inadequate and not without side effects (370).  The options for OA sufferers are 
currently limited to non-steroidal anti-inflammatory drugs (NSAIDs), opioids, 
corticosteroids, visco-supplements (11), and a suite of nutriceuticals that have largely 
not been tested for efficacy or safety (371, 372). A number of new compounds that 
have demonstrated efficacy in animal models have failed to translate into safe and 
effective OA pain therapies for humans.  
NGF is one of the few novel therapeutic targets to emerge from pre-clinical research, 
which has lead to the development of an effective treatment for chronic OA pain that 
has entered Phase 3 trials. NGF was first identified as a trophic factor in sensory and 
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sympathetic neurons of the DRG (373). It is required in early embryonic development 
for sensory neuron maturation and survival, and plays a major role in the 
pathophysiology of inflammatory pain (374), including OA pain (375). NGF acts 
through two distinct types of cell-surface receptors, tropomyosin-related kinase A 
(TrkA) and p75. Peripheral sensory neurons, central nervous system neurons, as well 
as non-neuronal cells, such as macrophages and monocytes, all express TrkA. A 
number of mechanisms of action have been described for NGF. Following tissue 
injury and inflammation, pro-inflammatory cytokines are released by the damaged 
tissue and by activated immune cells. These cytokines stimulate the release of NGF 
from a range of cell types, which acts directly on peripheral sensory neurons via 
TrkA, to increase the excitability of these cells. In addition, activation of TrkA on 
non-neuronal cells results in the release of mediators that sensitise sensory neurons 
and alter the pain threshold (376). Up regulation of NGF in the knee joints of mice 
with surgically induced OA has previously been demonstrated immediately following 
surgery and in the chronic phase of disease development (264). More recently 
regulation of NGF by OA chondrocytes has been demonstrated in mice at the same 
time that OA-related pain develops (377).  
Despite the demonstrated efficacy of anti-NGF therapy in clinical trials, its 
contribution to OA pain, and the neurophysiological mechanisms involved, is still 
under investigation. Increased levels of NGF in synovial fluid (378), at the 
osteochondral junction (345) and in the synovium (379) of OA sufferers, suggests 
multiple mechanisms are involved, and this is supported by animal model studies that 
have investigated the role of NGF in knee OA pain. For example, it has been 
demonstrated that a greater proportion of DRG sensory neurons innervating the 
subchondral bone of the distal femur express TrkA compared to DRG that house 
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sensory afferents from the knee joint (380). More recently, the effect of increased 
knee joint NGF on local as well as remote evoked responses of spinal neurons has 
been studied to better understand the contribution of knee joint NGF to central 
(spinal) sensitisation (381). 
The complex nature of NGF’s role in mediating both inflammatory and neuropathic 
pain, has given rise to a number of potential applications for anti-NGF therapy (382). 
Targeting NGF has proven to be an effective strategy for tackling OA pain in pre-
clinical animal model studies (264) and in clinical trials (383-385). Phase 3 trials of a 
humanised anti-NGF antibody have show great promise in alleviating pain and 
improving mobility in OA sufferers (386-388), however, trials were temporarily 
suspended by the FDA from 2010 to 2012 due to an increased incidence of joint 
failure in trial participants. This was initially attributed to increased physical activity 
in the absence of joint pain leading to accelerated joint damage. Further investigation 
into possible mechanisms for this hypoalgesic effect, as well as the peripheral nerve 
safety of anti-NGF therapy, has been undertaken (389, 390).  
The story of NGF and its progression through the drug discovery cycle highlights the 
challenges of progressing pre-clinical research breakthroughs into effective clinical 
therapies. Many potential therapeutics fail the translation phase due to lack of efficacy 
or unforeseen side effects in the target species. The reasons for this are complex and 
reflect the gaps in our current understanding of OA pain (291). A major contributing 
factor has to be the poorly defined relationship between joint pathology and pain 
pathophysiology (272). A better understanding of this relationship would allow the 
classification of OA into phenotypes that reflect differences in clinical presentation as 
well as disease aetiology, and lead to the development of pain therapies that are 
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phenotype specific, and that can be trialled in a specific population of OA sufferers 
and at a specific stage of the disease (391).  
This targeted approach to developing and trialling OA pain therapies requires careful 
selection of pre-clinical animal models that best reflect the pathophysiology of a 
specific sub-class (phenotype) of the clinical disease. Yet, currently there is a 
mismatch between the animal models used to study OA joint disease and those used 
to investigate the mechanisms of OA pain. A review of animal models used to 
investigate OA joint structural damage as well as OA pain follows.  
  
 42 
1.4 Animal models of OA 
The use of animal models is a powerful pre-clinical tool that allows more detailed 
investigation of the observations and associations identified in clinical studies. 
Information learned from pre-clinical models can then be used to inform better design 
and conduct of clinical trials. Animal models have advanced our understanding of OA 
pathobiology and symptomatology (pain), and have led to the development of novel 
disease modifying OA drugs (DMOAD’s). However, despite their efficacy in vitro 
and in pre-clinical models, most DMOAD’s have failed to translate into effective and 
safe treatments for human OA (128). The reasons for this lack of translatability are 
complex and highlight the need for better animal model selection criteria that are 
based on more than our current understanding of pathophysiological mechanisms 
(392, 393). 
In the case of preclinical research into OA pain, the animal models used differ with 
respect to joint pathology, disease progression, pain behaviour and response to 
therapy; and often do not reflect the human disease. In addition, there is a lack of 
consistency in two important areas; (1) the pain assays used to investigate pain 
mechanisms and evaluate potential therapeutics, and (2) the scientific reporting 
standards. This is despite the availability of numerous guidelines and 
recommendations (394-396). 
Many animal models have been developed to study the pathophysiology of the 
different arthritic diseases, in particular OA. With over 20 induction methods and at 
least 10 different species represented in the literature (397), there is no shortage of 
options for investigating the phenotype and molecular pathways of OA pain. 
However, there is still no consensus on what constitutes an ideal animal model for OA 
research (398), in particular the study of OA pain (399). 
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An ideal animal model is one that induces a consistent and reproducible disease 
phenotype, which reflects the human disease with respect to etiology and pathology; 
and is progressive over a suitable time frame to allow the study of different stages of 
the disease pathophysiology while still allowing a reasonably high throughput. The 
ideal animal is inexpensive, easy to house, manage and handle; is not dissimilar 
physiologically from humans (ie a mammal); and is large enough to allow multiple 
outcome measures to be performed, including those that mimic observed clinical 
symptoms such as pain (400). Rodents fit these criteria and with the added advantage 
of enabling the investigation of specific biomolecular pathways through the 
development of genetically modified strains; the mouse, is an ideal experimental 
animal (401, 402).  
The knee joint is the most commonly utilized joint in animal models of OA. It is 
readily accessible for both intra-articular injection and surgical intervention. It is also 
a clinically relevant joint to study, since OA most commonly affects the large weight 
bearing joints such as the knees and hips (3) as well as the joints of the hand (305). 
Animal models used to study OA pain can be broadly categorized into four main 
types: 1) Spontaneous, 2) Intra-articular injection, 3) Joint Injury (surgical instability, 
enzymatic instability, non-surgical instability, excessive/abnormal loading), and 4) 
Genetic modification (399). Spontaneous models mimic both age (296) and obesity 
(403) associated OA. Intra-articular models utilize irritant substances such as 
carrageenan and MIA that when injected into the joint elicit a severe inflammatory 
reaction and/or cellular (chondrocyte) injury or death, and direct tissue damage. 
Surgical instability models rely on partial or complete transection of one or more 
ligament of the knee joint, with resultant joint instability, altered 
biomechanics/loading, tissue degeneration and pain (404-406). These models attempt 
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to mimic post-traumatic OA, the sub class of human OA patients that acquire the 
disease following injury to joint structures such as the menisci, the anterior cruciate 
and collateral ligaments (407). The Collagenase model is a unique instability model 
that relies on the enzymatic breakdown of ligamentous tissue rather than surgery (408, 
409). Joint-injury also includes models where excessive or abnormal loading leads to 
joint injury over time, such as treadmill running and sub-failure joint loading (410). 
Examples of genetic modification models that as a result of a specific molecular 
derangement spontaneously develop OA include IL1- over-expressing rats (411), 
and Collagen IXa-1 deficient mice (412).  
All of these models differ greatly with respect to disease etiology and time course, 
joint pathology and pain outcomes, which impacts on their response to therapeutic 
intervention including genetic modification (as a proof of concept “specific molecular 
therapy”) (399, 413). These differences highlight the need for researchers to report on 
model specific outcomes and mechanisms, because effects may not be applicable to 
all OA, rather they may inform specifically on different sub-types of human OA 
(391).   
The investigation of OA pathophysiology has been conducted using a range of these 
animal models, but more recently there has been a shift towards surgical models that 
mimic post-traumatic OA and better reflect the human disease with respect to etiology 
and joint pathology changes (407, 413). In contrast, OA pain mechanisms have 
largely been studied using intra-articular injection models (291, 414). In addition, 
findings from inflammatory arthritis models have also been used to better understand 
the role that inflammation may play in the initiation and modulation of pain signaling 
in OA (415, 416). This diverse use of animal models highlights the complexities that 
arise when attempting to extrapolate key findings from pre-clinical studies. As it is 
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still unclear whether the differences in disease etiology, disease progression and joint 
pathology, between the models we use to study OA, are relevant to our understanding 
of OA pain and whether this is contributing to the failure to translate. 
Three pre-clinical arthritis models that have been widely used to investigate structural 
and symptomatic pathophysiology and therapeutic interventions are discussed in 
greater detail below. Not all of these have typically been considered physiologically 
relevant models of OA, but in the context of the preceding discussion on disease 
definition and phenotypes all three models provide some insight into understanding 
OA pain. Importantly, the different findings from these models highlights the 
significant gaps in our current understanding of the relationship between joint 
pathology and pain, and how it changes with initiating cause and disease progression. 
 
1.4.1 Mono-iodoacetate (MIA) induced arthritis 
The MIA model (417) is perhaps the most widely used, particularly by 
pharmaceutical companies, to investigate joint structural damage (histopathology) 
(418), pain and potential therapeutic targets (419, 420). MIA is an inhibitor of 
glyceraldehyde-3-phosphate dehydrogenase activity. Following intra-articular 
injection it induces widespread (depending on dose) chondrocyte degeneration and 
necrosis as early as day 1, osteoclast and osteoblast proliferation in subchondral bone 
by day 7, fragmentation and collapse of bony trabeculae by day 28, and large areas of 
bony remodeling by day 56 (418). Histological changes at day 14 include extensive 
focal areas of full thickness cartilage damage with complete loss of cellular detail and 
some loss of proteoglycan matrix, as well as visible marginal changes related to the 
growth of osteophytes (421).  
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The pain phenotype of this model is well described (291). Movement provoked pain 
behaviours have been demonstrated using the knee-bend test and CatWalk™ device 
(422), as well as mechanical allodynia (364), thermal hyperalgesia (423), reduced 
hindlimb grip strength (290), and reduced weight bearing (424). This model has also 
been used to characterize site-specific and time-dependent changes in articular 
cartilage and synovial tissue gene expression that underlie cartilage injury (425). 
More recently, investigators have attempted to identify links between joint tissue 
pathology and the development of chronic pain using this model in the rat (426). 
However, in this study a systematic evaluation of joint histopathogy using an 
established scoring system such as the one developed by the OARSI Histology 
Initiative (427), was not performed. This prevents direct mapping of the reported pain 
behaviours to joint disease progression in specific tissues. This study also reported on 
altered gene expression of pro-inflammatory cytokines (IL-1, TNF) and the 
neuropeptides CGRP and substance P, in the DRG neurons of L5. The findings are 
difficult to interpret, as the authors do not include gene expression data for L3 lumbar 
DRG, where a significant proportion of the sensory neurons that innervate the knee 
joint reside (169).  
MIA-induced arthritis is usually described as a model of OA, largely because of the 
pathological features particularly in the later stages. However, it is clear that the 
initiating event with rapid widespread chondrocyte necrosis is not typically seen in 
any OA phenotype in patients.  Some features of the disease pathophysiology, such as 
the role of ADAMTS and MMPs in aggrecanolysis and collagenolysis respectively, 
do mimic events in human OA (428). Nevertheless, Barve et al (429) demonstrated 
that there is little transcriptional similarity between rat MIA and human OA cartilage, 
by characterizing the gene expression profile of diseased cartilage. They identified 
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less than 4% overlap between rat and human genes that were modulated in the same 
direction. Similarly, despite the prolific use of this model in pre-clinical OA pain 
studies, there is growing evidence that the disease mechanisms in MIA induced 
arthritis are different from those of human OA (128). The MIA model has been 
shown, depending on dose, to have a substantial component of neuropathic pain 
(361), that is likely to only be relevant in a subset of human OA patients (430-432). 
Fundamental differences in the underlying molecular pathophysiology of MIA and 
human OA, may in part explain the lack of translational progress with novel 
DMOAD’s that demonstrate efficacy when tested in this animal model.  
 
1.4.2 Surgical destabilisation of the medial meniscus (DMM) 
Models that surgically induce instability and/or altered joint biomechanics/loading 
have been widely used to investigate OA (407, 413, 433). These models mimic 
injuries to key intra-articular structures that are observed in patients and significantly 
increase the risk of later OA development (434). The knee joint is unique in that 
fibrocartilagenous menisci within the joint provide stability, proprioception and act as 
shock absorbers, dissipating the weight bearing load on the underlying cartilage. Loss 
of meniscal function (tears, maceration, excision) leads to accelerated OA in both 
humans and animals (435, 436).  
While different meniscal injury models have been used in a variety of species to 
induce OA, showing the universal importance of these structures to knee function, 
recent years have seen an explosion in use of the surgical destabilization of the medial 
meniscus (DMM) in mice (407). The DMM model involves transection of the medial 
menisco-tibial ligament, which acts as the anterior attachment of the medial meniscus 
to the tibial plateau (437). Loss of this ligament allows the meniscus to be displaced 
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laterally during ambulation, placing supra-physiological loading on the medial 
femoro-tibial cartilage and increased joint mobility. DMM produces a reliable and 
consistent, progressive disease state with all the structural features of OA that is 
amenable to evaluation of both the acute and chronic phases of OA, compared to 
more rapidly progressive models that rely on the injection of pro-inflammatory 
substances into the knee joint. The DMM model has been used to study the structural 
and biochemical changes associated with loss of articular cartilage and other joint 
pathology in mice (47, 407, 438, 439). In particular, this model has been used to show 
pathophysiological mechanisms linking changes in the expression of genes for matrix 
proteins, MMPs and aggrecanases (ADAMTS-4 and -5) in the meniscus and cartilage 
(25, 26) to the progression of the OA phenotype in mice. This model has also been 
used to study sex differences in OA, demonstrating that OA severity is greater in male 
mice than female mice following DMM surgery (440). 
More recently this model has been used to investigate pain mechanisms of OA (264, 
316, 363, 441). Although this model does not produce the same robust pain outcomes 
as the MIA model, it is viewed as perhaps a more clinically relevant model to study 
pain mechanisms since it represents a common biological trigger of human OA. A 
recently proposed scoring tool that assesses the translatability of early drug 
development projects, highlights the importance of this (442). Reliable biomarkers 
that transfer across from animals to humans, and preclinical studies that use animal 
models that reflect the disease in humans, have been identified as important 
translatability factors (443). Nevertheless, the surgery required for OA induction by 
DMM may introduce non-physiologic inflammation not seen with non-invasive joint 
injuries (444). As with all instability models, DMM is considered to particularly 
mimic the post-traumatic OA phenotype (407). However, unlike cruciate and other 
 49 
ligament failures, meniscal tears and degeneration have been associated with non-
traumatic spontaneous age-associated OA in patients (298, 445, 446), suggesting 
findings from DMM may have wider implications.  
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1.4.3 Antigen-induced Arthritis (AIA) Model 
The AIA model was originally developed as an animal model of rheumatoid arthritis 
in rabbits (447) and later modified and characterized in mice (448). The model 
involves immunization with methylated bovine serum albumin (mBSA) in complete 
Freund’s adjuvant, followed by intra articular injection of mBSA. There are strain 
differences in susceptibility with robust histological knee joint changes demonstrated 
in C57BL mice. This is a chronic arthritis model persisting for up to 24 weeks in both 
mice and rabbits (448). It is one of the most widely used models of inflammatory 
arthritis, exemplifying an exogenously triggered joint immune response that is both T-
cell and immune-complex driven (449). At the time points most commonly evaluated 
in AIA studies (usually up to 3-4 weeks), pathology is typified by profound synovitis 
with panus formation by 1 week that slowly resolved, progressive cartilage 
degradation and bone erosion (439, 450, 451).  
Although not defined as a model of OA, it is frequently used to study the pain 
mechanisms of arthritis and has shed some light on the role of inflammation and the 
immune system that may be relevant in OA pain. Researchers have used this model to 
demonstrate that inflammatory processes in peripheral tissues such as the knee joint 
drive macrophage infiltration into the DRG, which in turn correlates with pain related 
behaviour (452). This model has also been used to characterize the role of pro-
nociceptive cytokines such as IL-1, in the development of thermal hyperalgesia 
(453), and IL-17 in the development of inflammation evoked mechanical hyperalgesia 
(329), both features of chronic arthritic knee pain. The role of cytokines in OA 
pathogenesis (322) and OA pain mechanisms (320) are currently important areas of 
investigation. 
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1.5 Literature review summary and research aims 
OA is a disease of the entire joint that results in chronic pain and reduced mobility. 
There are currently no effective therapies for treating or preventing OA. Long-term 
management of symptoms relies primarily on analgesics that are at best moderately 
effective, and that have significant side effects when used chronically. 
OA is characterised by a pain state that is both initiated and driven by a number of 
joint specific and systemic pathological processes, with resultant peripheral and 
central sensitisation of the sensory nervous system. There is growing evidence of a 
co-dependent relationship between joint pathology and OA pain; and that local, 
inflammatory and neuropathic mechanisms all contribute to the OA pain phenotype. 
Using pre-clinical animal models, researchers have attempted to unravel the 
molecular pathways involved in OA pain, and better define the complex relationship 
that exists between joint pathology and pain. Although this has advanced our 
understanding of the pathophysiology of OA and chronic pain, it has not translated 
into effective therapeutics. A number of factors have been proposed that may be 
hindering the translatability of preclinical research in OA pain.  
 We are yet to identify which processes and joint tissues drive the development 
of chronic OA pain, and therefore should be targeted when developing 
therapeutics. 
 There are significant differences between animal model phenotypes with 
respect to joint pathology and disease progression, pain behaviour and 
response to therapy. 
 Human OA is not all the same, differing between individuals and over time; 
with genetic and environmental factors contributing to the pathobiological 
profile of disease that an individual may experience. This suggests that a more 
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phenotype-based approach to investigating and identifying future therapeutics 
needs to be adopted. Researchers need to report on model specific outcomes 
and mechanisms, and relate them back to a specific subtype of human OA. 
 The majority of OA pain studies, including those that are testing response to 
therapeutics, use animal models that don’t reflect the human disease with 
respect to aetiology, disease progression and joint histopathology.  
 There is a lack of standardisation of pain assays within the OA pain literature, 
making it difficult to collectively compare and interpret findings, and 
producing a plethora of conflicting pain study outcomes that bring us no closer 
to understanding pain mechanisms and identifying suitable therapeutic targets. 
To optimize the use of animal models and inform our understanding of OA pain, we 
need to know how different pain behaviours correlate with structural changes in 
different joint tissues. We also need to know if pain and its mechanistic pathways 
change over time as the disease progresses, and if disease mechanism matters when it 
comes to understanding OA pain. 
Which model we use to study OA is important to our understanding of the disease and 
its symptoms, and may determine our ability to translate this understanding into 
effective therapeutics that modify the disease and treat its primary symptom – pain. 
However, there is currently no consensus on the ideal animal model for OA research, 
but if OA pain and OA joint pathology do share common pathways, then the study of 
joint disease and joint pain should be carried out in animal models that are 
phenotypically similar. 
In this thesis I hypothesise that the mechanisms that drive osteoarthritis pain are 
specific to the pathophysiology of the disease, and differ between different OA 
phenotypes.  
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To date, no study has directly compared pain and joint structural change in parallel, 
longitudinally using two distinct animal models. Therefore, the aim of this research is 
to map the relationship between joint pathology, pain behaviour and peripheral 
sensory innervation, over time, comparing a post-traumatic model of OA and an 
antigen-induced inflammatory model of arthritis.  
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CHAPTER 2:  Methods 
The methods described in this chapter were used throughout this thesis. Any 
exceptions or variations have been noted in the relevant chapter/s. The reagents and 
equipment used (and the respective suppliers) are listed in Appendix A. Reagent 
preparation protocols are described in Appendix B. Scoring protocols are outlined in 
Appendix C. 
2.1 Murine models of arthritis: Destabilisation of the medial meniscus 
(DMM) and Antigen-induced arthritis (AIA) 
The C57BL/6 strain of mice is the most common strain used in arthritis research, and 
is also the background strain from which several knockout strains have been derived 
to study the role of specific genes identified to be involved in joint disease 
development and pain transmission. 
Male mice develop more severe OA following surgery than female mice (440), and 
young mice (8 weeks and younger) develop less severe disease than older mice (Little 
CB unpublished observation). Skeletal maturity in male C57BL/6 mice, defined as 
cessation of active endochondral ossification and plateauing of long bone growth 
(although the growth plates do not close), occurs at ~3 months of age (454). For these 
reasons 10-12 week old male C57BL/6 mice were used to induce arthritis using the 
DMM model. Since the AIA model requires an initial 3-week period for 
immunization before arthritis can be induced, 8-10 week old mice were used in this 
model. This ensured that both models could be studied in parallel using similar aged 
mice at the actual time of induction of joint disease.   
Mice were obtained from a C57BL/6 breeding colony maintained at the Kearns 
Facility in the Kolling Institute. This colony was established with animals sourced 
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from Animal Resources Centre (Canning Vale, Perth WA), which maintains a 
C57BL/6Jax colony (designated C57BL/6JArc). The Kearns Facility colony is 
refreshed with C57BL/6JArc breeding mice at least every second year to avoid 
genetic drift from the parent strain.  Male littermates are housed in groups (up to 5 per 
30x20x18cm cage) to enable timely surgical and subsequent analytical processes to be 
undertaken, and to avoid the stress associated with solitary caging. Cages are 
individually ventilated with filter lids, sterilized bedding, environmental enrichment, 
and maintained at 19-22°C, with a 12-hour light/dark cycle. Animals receive acidified 
water and complete pelleted food ad libitum. Animal housing, all procedures, and 
behaviour testing were conducted with the approval of the Royal North Shore Animal 
Care and Ethics Committee (Protocol numbers 0807-019A, 0911-014A & 1202-003). 
All animals were housed in the Kearns Facility at the Kolling Institute of Medical 
Research, St Leonard’s, NSW. 
 
2.1.1 Randomisation and blinding 
Disease induction (detailed in the following sections) was done such that in any given 
cage there was a mixture of sham, DMM and control (naïve) mice; or saline injected, 
mBSA injected and immunized control mice housed together. All animal cages were 
housed in the same room in the Kearns Facility. Animals within a given cage were 
allocated to treatment groups in one of two ways. In the case of sham/DMM, animals 
were randomly selected by one operator (Sanaa Zaki: SZ) who anaesthetized, ear 
notched and shaved the leg before passing the animal to a second person (Christopher 
Little: CL) that randomly assigned and performed the sham or DMM surgery keeping 
SZ blinded. For the saline/AIA model all mice were immunized by a single operator 
(SZ). Individual syringes containing identical appearing solutions of saline or mBSA 
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were prepared and then coded and randomly assigned (drawn from a hat) a specific 
mouse number. These coded/assigned syringes were then intra-articularly injected by 
a second (SZ). In this way behaviour testing (performed by a single operator SZ) was 
done blinded to treatment group within the sham/DMM and saline/AIA cohorts, 
although the skin ulceration and later scar-formation at immunization sites meant it 
was not possible to blind between the two arthritis models.  After sacrifice, samples 
from individual mice were randomly assigned a code before processing to enable 
histology scoring (done independently by 2 operators SZ and CL) to also be 
conducted blinded to arthritis model and time post-induction. 
The mixed housing described above was also done to address two additional potential 
sources of bias in pain behaviour outcomes. The first arises from operator bias if the 
operator knows that all cage mates have undergone the same intervention. The second 
arises from the complex effect that conspecifics can have on modulating pain 
behaviour. It has been demonstrated that mice recognize and respond to overt pain 
behaviours displayed by conspecifics (455). In both male and female mice these 
social cues may either enhance or decrease the pain response. For example, exposure 
to cage mates displaying acute pain behaviour results in an increased sensitivity to 
noxious stimuli in the observing mouse, and pain behaviour is enhanced after one 
week of housing with a cage mate exposed to a noxious stimulus (456). These 
findings suggest the existence of pain ‘empathy’ amongst cage mates that modulates 
the pain response.  In addition, male mice display reduced pain behaviour in the 
presence of unaffected stranger male mice, but not familiar male cage mates (457), 
and this response is testosterone dependent (458). It may represent a form of stress-
induced analgesia, since the opposite occurs when male mice are not completely 
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separated and allowed partial physical contact. The affected mice display hyperalgesia 
rather than analgesia (458).  
The use of mixed housing aimed to reduce any bias towards an enhanced or a reduced 
pain response resulting from social modulation of pain across different experimental 
cohorts.  
 
2.1.2 Anaesthesia 
All surgeries, sham surgeries, intradermal injections and intra articular injections were 
performed under general anaesthesia as described here.  
Food and water were not withheld prior to anaesthesia. Each mouse was weighed, 
anaesthetised, and ear notched for identification prior to surgery or injection. 
Anaesthesia was induced in a Perspex induction chamber containing Isoflurane 
(2.5%) in a gas mixture of oxygen and nitrous oxide delivered in a 1:2 ratio with flow 
rates set at 1 and 2 L/min respectively. Gases were delivered via an anaesthetic 
machine with an out of circuit vaporiser and a Bain breathing system. Anaesthesia 
was maintained using a nose cone connected to the Bain breathing system and the 
same gas/anaesthetic mixture. The depth of anaesthesia was monitored and the level 
of isoflurane (1.5-2%) adjusted to achieve a surgical plane of anaesthesia, as indicated 
by regular breathing, muscle relaxation and absence of reflexes. No procedure was 
commenced until the pedal withdrawal reflex was abolished. Body temperature was 
maintained by ensuring that surgical site preparation and surgery were performed on a 
towel over a heating pad rather than a cold surface. At the end of the procedure, the 
animals were disconnected from the anaesthetic machine and allowed to recover in 
cages on a heating pad to minimize the risk of hypothermia developing. Recovery 
cages were kept in the operating theatre so that the animals could be visually 
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inspected every 5 minutes. Animals became conscious and ambulatory within 2-5 
minutes from when anaesthetic delivery was stopped. They were visually monitored 
to ensure they were eating and fully ambulant and weight bearing on the operated leg 
as they moved about the cage, prior to returning them to their original groups and 
housing rooms. Animals did not receive any post-operative analgesia. Provisions were 
included in the ethics protocol for the humane euthanasia of any animal that displayed 
signs of significant pain or distress. However, this was not deemed necessary for any 
animal throughout the study. 
 
2.1.3 The DMM model  
Surgical instability models are designed to mimic post-traumatic OA in humans, and 
are the most common laboratory animal models used to study OA (122, 407). 
However, it is still unclear whether such models also mimic the more common 
idiopathic form of OA that is seen in humans (399). 
The DMM model was chosen because it is a well-established post-traumatic OA 
model (437) that has been used extensively to study the pathophysiology of OA. It 
mimics the disease in humans histologically and clinically, since meniscal damage 
secondary to trauma has been shown to be a high risk factor for development of OA in 
humans (436, 459, 460). This model reproduces a more slowly progressive disease 
than other surgical models in mice (437) with a time course suitable for evaluation of 
both the acute and chronic phases of OA disease.  
Following induction of anaesthesia, the right hind limb was prepared for surgery by 
shaving the skin with a double-sided flexible blade and applying 80% ethanol. 
Surgery was performed under a surgical microscope. The animal was placed on a 
sterile, heated towel and the leg draped with sterile paper drape to isolate the surgical 
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site and minimise contamination. Using micro-surgical scissors, a 3-6 mm lateral 
para-patella skin incision was made commencing at the level of the distal patella and 
extending down to the proximal tibial plateau. The femoro-tibial joint capsule was 
incised just medial to the patella ligament, using a #15 blade (Figure 2.1a). The 
incision was extended proximally into the vastus medialis muscle using micro iris 
scissors to enable lateral luxation of the patella. Visualisation of the menisco-tibial 
ligament of the medial meniscus was facilitated by joint flexion and blunt dissection 
and proximal elevation of the infra-patella fat pad (without removal of any tissue) 
(Figure 2.1b). Any subsequent bleeding from the fat pad was controlled by applying 
pressure over the site with surgical gauze swabs. Articular cartilage surfaces were 
maintained moist by applying sterile saline. The medial menisco-tibial ligament 
(MMTL) was identified traversing laterally from the cranial horn of the medial 
meniscus to the anterior tibial plateau. The MMTL was isolated by passing one arm of 
curved Dumont #7 tweezers (superfine point dumostar steel) under the ligament at its 
junction with the anterior pole of the meniscus (Figure 2.1c). The MMTL was then 
severed using the tweezers, by rotating the tip of the tweezers axial and anterior, 
which results in tearing of the osseous insertion site. Complete DMM was confirmed 
by ensuring the meniscus could be manually displaced/luxated medially and the 
articular surface of the medial tibial plateau visualised (Figure 2.1d).   
The joint was flushed with sterile saline, the meniscus and patella manually replaced 
in their normal anatomical locations, and the incision was then closed in three layers – 
joint capsule, subcutaneous tissue and skin. Sterile ophthalmic grade 8/0 absorbable 
suture material (Vicryl) was used to anatomically reconstruct the joint capsule using a 
continuous suturing pattern, followed by a single subcutaneous mattress suture 
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(Figure 2.1e). To achieve optimal apposition surgical tissue glue (VetBond, 
cyanoacrylate) was used to close the skin layer (Figure 2.1f). 
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Figure 2.1. Destabilisation of the medial meniscus 
Surgical transection of the medial tibio-mensical ligament (MMTL): (a) The femoro-
tibial joint capsule is incised just medial to the patella ligament; (b) Visualisation of 
the MMTL is facilitated by joint flexion, blunt dissection and proximal elevation of 
the infra-patella fat pad; (c) The MMTL is isolated by passing one arm of curved 
Dumont #7 tweezers under the ligament at its junction with the anterior pole of the 
meniscus; (d) Complete DMM is confirmed by ensuring the meniscus can be 
manually displaced/luxated medially and the articular surface of the medial tibial 
plateau visualised; (e) Anatomical reconstruction of the joint capsule using a 
continuous suturing pattern, followed by a single subcutaneous mattress suture; (f) 
Surgical tissue glue is used to close the skin layer and achieve optimal apposition. 
a b c
d e f
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2.1.3.1 Sham operated mice 
Sham mice were anaesthetised as described for ear notching and surgery. The joint 
capsule was opened and the MMTL visualised and isolated exactly as for DMM 
however the ligament was not transected. The joint was lavaged and closed as for 
DMM.  
2.1.3.2 Control mice 
Control mice were anaesthetised as described for ear notching but had no surgery. 
2.1.4 Antigen induced arthritis model 
The AIA model was chosen because it is an established chronic inflammatory arthritis 
model that induces a cell mediated immune response resulting in a localised single 
joint inflammatory arthritis. Established as an experimental model for studying human 
rheumatoid arthritis (448), AIA produces joint changes that are characterised by acute 
joint inflammation and progressive cartilage damage, fibrosis and bone erosion. 
In this model, mice previously immunised with an emulsion of methylated bovine 
serum albumin (mBSA) in Freund’s Complete Adjuvant received an intra articular 
injection of mBSA in the right knee joint (450). 
2.1.4.1 Immunisation: 
Antigen preparation 
Refer to Appendix B 
Antigen loading 
Using an 18-gauge needle, emulsion was drawn into a 1ml tuberculin glass syringe 
and the barrel ‘coated’ by sliding the plunger up and down, before squirting back the 
emulsion into the main stock.  Approximately 600 l of emulsion was then loaded 
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into the syringe. The needle was removed and replaced with a 30-gauge needle and all 
air expelled from the syringe prior to injection.  
Intradermal injection 
Mice were anaesthetised as described above and positioned in sternal recumbency 
with legs splayed. The skin at the base of the tail and dorsum was shaved using a 
double-sided flexible razor blade and cleaned with 80% ethanol (Figure 2.2a). The 
skin at the base of the tail was held taught with forceps and the needle was introduced 
subcutaneously about 5mm at the site where the skin was most taught. The needle was 
then redirected more superficially into the dermis, so that the tip could be seen 
through but did not penetrate the skin, and 50 µl of emulsion was slowly injected 
intradermally resulting in a tight white disc of adjuvant approximately 1cm anterior 
and 5-10mm medial or lateral to the tail base.  A 2
nd
 50 µl intradermal injection was
done adjacent the 1
st
 injection on the opposite side of the midline. (Figure 2.2b)
After 14 days the intradermal injections were repeated as described above 
approximately 1 cm cranial to the 1
st
 injection sites.
Following immunisation animals were checked daily and handled with care so as not 
to traumatise the injection sites. Any ulceration that developed at the injection site 
was treated with topical povidone iodine.  
2.1.4.2 Intra articular injection: 
7 days after the 2
nd
 intradermal injection, each mouse received an intra articular
injection of 10µl mBSA (20mg/ml in sterile 0.15M NaCl) into the right knee joint. 
This was performed under a dissection microscope.  
Mice were anaesthetised as described and positioned in dorsal recumbancy. The right 
hind limb was prepared by shaving the skin with a flexible razor blade and applying 
80% ethanol. A lateral parapatellar skin incision approximately 5mm in length, 
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extending to the level of the patella tendon, was made by tenting the skin with 
forceps.  By ensuring that the incision did not lie directly over the front of the knee 
excessive stretching of the wound was minimised when the animal was mobile, and 
this reduced any interference with wound healing. The leg was held between two 
fingers and fully extended. The incision was then manipulated to expose the patella 
tendon. A 31-gauge needle (0.3ml insulin syringe) was inserted with the bevel up just 
below and lateral to the patella in the patella ligament. The tip of the needle was then 
manipulated until it rested under the patella along the trochlear groove before 
injecting 10µl mBSA (20mg/ml). The skin incision was closed with tissue glue. 
2.1.4.3 Control mice: 
Two sets of control mice were used for the AIA model. Saline injected control mice 
were immunised as described above and received an intra articular injection of 10l 
saline into the right knee joint. Immunised control mice were immunised as described 
above but did not receive an intra articular injection. 
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Figure 2.2. Antigen induced arthritis: 
(a) skin preparation - the skin at the base of the tail and dorsum is shaved using a
double-sided flexible razor blade and cleaned with 80% ethanol; (b) intradermal
injections – two 50 µl aliquots of emulsion are slowly injected intradermally resulting
in a tight white disc of adjuvant approximately 1cm anterior and 5-10mm medial or
lateral to the tail base.
a
b
 66 
2.1.5 Euthanasia  
Euthanasia was performed using three techniques. For harvesting of dorsal root 
ganglia (DRG) for gene expression, mice were euthanised by CO2 exposure (animals 
become unconscious within seconds) followed by decapitation. For harvesting of 
DRG for immunohistochemistry mice were deeply anaesthetised with 50mg/kg 
pentobarbitone IP, followed by perfusion (see section 2.5.1) resulting in immediate 
death. In mice where only knee joints were harvested, euthanasia was performed by 
anaesthetic overdose with 4% isoflurane (animals become unconscious within 
seconds) followed by cervical dislocation.  
 
2.2 Histology 
In order to better understand the relationship between joint disease and pain, the 
progressive changes that occurred in different joint tissue structures following 
induction of OA, were mapped to specific pain related behaviours. Since histology is 
the gold standard by which to evaluate murine models of knee arthritis, a robust 
histological scoring system that evaluated both joint structural damage and joint 
inflammation was utilised for comparing the two animal models in this thesis.  
 
2.2.1 Knee joint processing  
Right and left knee joints were harvested following euthanasia (as described in section 
2.1.5). The skin and the majority of the muscle were dissected away leaving the joint 
capsule intact, before the knees (mid tibia to mid femur) were fixed in 10% (v/v) 
neutral buffered formalin (NBF) for 24 hours. The knee joints were then transferred to 
70% v/v ethanol for storage prior to further processing.  
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The knee joints were decalcified by placing in 10% (v/v) formic acid, in 5% (v/v) 
formalin for 24 hours at room temperature with gentle agitation.  The tissue was then 
washed for 15 minutes in distilled water to remove the formic acid before been stored 
in 70% (v/v) ethanol for at least 24 hours prior to processing to paraffin.  
The knee joint specimens were dehydrated for one hour each in graded solutions of 
70%, 75%, 85% and 95% (v/v) ethanol, and three washes of 1-hour duration in 100% 
(v/v) ethanol. This was followed by three washes of 2 hours duration in chloroform. 
Paraffin infiltration of mouse knee joints in cassettes in Paraplast (plain) involved the 
following: first wax (Paraplast Plain) for 2 hours with vacuum; second wax (Paraplast 
Plain) for 2 hours with vacuum; third wax (Paraplast Plain) for 2 hours with vacuum; 
and a final wax (Paraplast Plain) for 6 hours with vacuum. 
Knee joints were mounted in blocks with the medial side down for sagittal sections. 
Blocks were trimmed on the microtome until the very beginning of the articular 
cartilage was evident and then serial sagittal sections (4µ) were cut across the entire 
medial femorotibial compartment of the joint. All right knee joints were cut and 
mounted on superfrost plus slides (three sections per slide). A minimum of six knee 
joints per treatment group (DMM, Sham, Control, mBSA, Saline, Immunised-
control), per time point (day 3, week 1, 2, 4, 8, 12 and 16) were sectioned. For DMM 
and Sham knee joints where pathology is focal, every 4
th
 slide (i.e. every 36µ) across 
the width of the medial femoro-tibial joint was stained for scoring to ensure the 
maximum lesion was evaluated.  In the case of the mBSA, saline and immunised-
control knee joints where the disease is uniform throughout the joint only one slide 
containing three sections (at the level of the central load bearing region) was stained 
for scoring.  
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Slides were dried at 85°C for 30 min and then overnight at 55
o
C in an oven to adhere 
sections to slides.  
 
2.2.2 Histochemical Staining 
Slides were stained using toluidine blue and fast green to enable histological 
evaluation of the articular cartilage (including proteoglycan content), synovium, 
meniscus and subchondral bone. 
Sections were de-parafinised by placing slides in 70% (v/v) ethanol for 15 minutes 
and draining well. Sections were then stained for 10 minutes in 0.04% (w/v) 
Toluidine Blue O in 0.1M sodium acetate buffer (pH 4.0), rinsed quickly in running 
tap water and counterstained for two minutes in 0.1% (w/v) fast green FCF, then 
quickly rinsed again in running tap water. Finally sections were dehydrated in three 
changes of isopropyl alcohol and three changes of xylene, before mounting in a 
resinous mountant (Euckitt). 
 
2.2.3 Histological Scoring system 
For evaluation of articular cartilage proteoglycan loss and structural damage, 
osteophyte formation, and subchondral bone changes, knee joint sections were scored 
using a modification (461) of previously published guidelines (462).  The femur and 
tibia were scored separately, and on each slide (three sections) the worst score was 
recorded. Only the slide containing sections of the central weight-bearing region of 
the joint was evaluated as this coincided with the maximal lesion in DMM (see 
Methods Validation Chapter 3). Details of the scoring method used are outlined in 
Appendix C. 
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Synovial inflammation was evaluated using a newly developed scoring system that 
included assessment of the synovial lining, the sub-synovium, synovial exudate, 
panus formation and cortical bone erosion,(461). Again only the central weight-
bearing region of the joint was evaluated. Details of this scoring method are also 
outlined in Appendix C. 
The histological scoring was performed by two independent observers (SZ, CL) 
blinded to treatment and time, and the average of the two scores calculated and used 
for analysis (refer to Chapter 3, Figure3.7b for inter-observer variability). 
 
2.3 Pain behaviour testing 
Pain behaviour tests used in this thesis were selected based on what is currently 
known about the clinical characteristics of OA pain in human patients. People with 
chronic OA modify their physical activity, and adjust their weight distribution and 
gait (463).  Patients with OA have reduced thresholds to repeated mechanical 
stimulation (evoked temporal summation), and reduced pressure pain thresholds 
(localised mechanical hyperalgesia) compared to normal subjects (276, 284, 464). 
Human OA patients also demonstrate thermal hyperalgesia (277).  
Mice were acclimatised to all the test equipment in the week prior to baseline testing. 
Acclimatisation involved placing the mouse in the different test chambers for a short 
period of time (1-3 minute in forceplate and hotplate chambers, and 30 minutes in von 
Frey chamber) to allow them to explore the environment without any intervention. 
This was done on at least two occasions. For tests that involved manual restraint, mice 
were briefly restrained to simulate testing and then released back into their cage. 
Again this was done on at least two occasions. 
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2.3.1 Von Frey filament testing 
Von Frey filaments were used to test for mechanical allodynia (465). Baseline 
withdrawal thresholds were assessed up to 1 week prior to induction of arthritis. 
Testing was then performed at day 3, week 1, 2, 4, 8, 12 and 16, after arthritis 
induction 
Mice were placed in individual transparent plastic chambers sitting on a wire mesh 
floor (Figure 2.3a), and allowed to acclimatise for up to 30 minutes prior to each test 
period until exploratory and grooming behaviours decreased. A 3-second stimulus 
was then applied by touching the plantar surface of the hind paw with a von Frey 
filament presented perpendicularly and exerting enough force to bend the filament 
(Figure 2.3a). A positive withdrawal was defined as biting, licking, shaking and/or 
withdrawal of the paw during or immediately following the 3-second stimulus. The 
stimulus was applied twice before confirming a positive or negative response. A 
series of von Frey filaments were used for testing, starting with filament 3.61 (0.4 g 
force). The size of filament was incrementally increased or decreased following a 
positive or negative response respectively, using the “up and down method” described 
by Chaplan (465). This up-down procedure was applied 6 times to calculate the 50% 
withdrawal response threshold using the algorithm described by Dixon (466).Up to 6 
mice were tested at any one time. The contralateral (left) hind paw was tested in all 
mice followed by the ipsilateral (right) hind paw. Each paw was tested twice to obtain 
an average. If mice were displaying grooming behaviour, urinating, defecating, 
moving around the cage excessively or attempting to climb the walls of the chamber, 
they were not tested at that time point. 
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Figure 2.3a: Von Frey testing chambers and application of filament. 
(i) Mice are placed in individual transparent plastic chambers sitting on a wire mesh
floor; (ii) A 3-second stimulus is then applied by touching the plantar surface of the
hind paw with a von Frey filament presented perpendicularly and exerting enough
force to bend the filament.
ii. 
i.
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2.3.2 Hotplate test 
Thermal hyperalgesia was measured using a hotplate device. Baseline response 
latency was determined up to 1 week before induction of arthritis. Test measurements 
were taken at day 3, week 1, 2, 4, 8, 12 and 16, after arthritis induction.  
The hotplate was set at 52 degrees Celsius. The mouse was placed on the hotplate, 
inside a transparent plastic cylindrical chamber (Figure 2.3b). The response latency 
was determined by observing for shaking & licking of the left or right hind paw. Each 
mouse was tested twice and response times averaged. Mice were given a 10 to 15 
minute rest period between each test. A maximum exposure time of 60 seconds was 
set to ensure tissue trauma to the plantar surface of the paws did not occur. Testing 
was also stopped if the mouse attempted to jump out of the chamber. 
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Figure2.3b. Hotplate device 
Mice are placed on the hotplate, inside a transparent plastic cylindrical chamber with 
the plate set at 52 degrees Celsius. 
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2.3.3 Pressure Application Measurement 
Mechanical hyperalgesia of the knee was assessed using a Pressure Application 
Measurement (PAM) device. Baseline withdrawal thresholds were assessed up to one 
week prior to induction of arthritis. Testing was then performed at day 3, week 1, 2, 4, 
8, 12 and 16, after arthritis induction. 
Mice were manually restrained in the right hand and the PAM device was held in the 
left hand for testing. The device was held between the thumb and index finger, and 
used to squeeze the knee joint with increasing force until the mouse responded. Left 
and right knees were tested, and two measurements were taken for each knee, one 
with the transducer applied to the medial side and one with the transducer applied to 
the lateral side of the joint (Figure 2.3c). Two attempts were recorded for each 
measurement to obtain an average and ensure consistency in response. Mice that 
displayed large discrepancies between the two attempts were retested at the end of the 
test period. 
The rate of force applied was guided by the PAM software to ensure an increasing 
amount of force was applied at a constant rate (30g/s), up to a maximum of 450g. A 
positive response was defined as an attempt to withdraw the limb. The force at which 
the mouse withdrew was recorded as the withdrawal threshold. The maximum force 
(450g) was assigned if the mouse did not withdraw. If a mouse struggled and 
attempted withdrawal following manual restraint or when the PAM device was gently 
placed against the knee, the mouse was returned to his cage and allowed to settle for 5 
minutes before testing was attempted again. 
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Figure 2.3c. Pressure Application Measurement device 
Mouse is restrained and the transducer is applied to the medial side of the knee joint; 
(ii) followed by the lateral side of the knee joint. The device is held between the
thumb and index finger, and used to squeeze the knee joint with increasing force until
the mouse responds.
ii. i. 
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2.3.4 Forceplate 
An in-house developed electronic forceplate (National Instruments-DAQmx hardware 
driver) and LabVIEW Run-Time Engine 2009 Software (National Instruments 
Australia) were used to measure hind limb weight distribution. Baseline hind limb 
weight distribution was assessed up to 1 week prior to induction of arthritis. Weight 
distribution was then tested at day 3, week 1, 2, 4, 8, 12 and 16, after arthritis 
induction. 
This test involved placing a mouse in a small transparent plastic chamber with each 
hind paw resting on a separate transducer plate (Figure 2.3d). The mouse was allowed 
to settle in the chamber for up to 1 minute prior to recording. Continuous recordings 
were taken for a total period of 30 seconds to obtain an average force in grams for 
each hind limb. Recordings occurred when the mouse was observed to be positioned 
as follows: (1) front paws resting on the front vertical panel of the chamber; (2) the 
mouse was not leaning/resting on either of the lateral vertical panels of the chamber; 
(3) the tail was positioned outside of the test chamber and held slightly raised to
ensure testicles and tail base were not in contact with the transducer plates; and (4) the 
hind paws were each placed on the respective left and right plate. If the mouse moved 
during the 30-second test period, recording was paused and then recommenced once 
correct positioning was observed. Results were expressed as mean weight distribution 
ratio (right/left hind limb). 
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Figure 2.3d. Forceplate device 
(i) The mouse is placed in a small transparent Perspex chamber with the front paws
resting on the front vertical panel of the chamber and the hind paws were each placed
on the respective left and right plate; (ii) the tail is positioned outside of the test
chamber and held slightly raised to ensure testicles and tail base are not in contact
with the transducer plates.
i. ii. 
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2.3.5 Stride length 
Baseline measurements were taken up to 1 week before induction of arthritis. Test 
measurements were taken at day 3, week 1, 2, 4, 8, 12 and 16, after arthritis induction.  
Individual mice were physically restrained to enable dipping of their hind paws in 
non-toxic water based paint (Figure 2.3e(i)). They were then quickly released into a 
transparent plastic run (50mm x 100cm) in which the floor was lined with printing roll 
paper (Figure 2.3e(ii)). The sides and end of the run were covered to create darkness 
and encourage the mice to run to the end. Once the mouse reached the end they were 
removed from the run to ensure the trail of footprints they had created on the paper 
were not smudged or superimposed if the mouse attempted to run in the opposite 
direction. If the mouse paused to groom, defecate, urinate or explore, this was noted 
on the recording paper with an asterix (*) (Chapter 3, Figure 3.5b). 
The feet of the mouse were cleaned with moist tissues prior to returning the mouse to 
his cage. The floor of the run was lined with fresh printing paper for each mouse. 
Stride length was then determined based on the footprints created on the printing 
paper. The mean stride length when supporting the affected limb (right to left) and the 
unaffected limb (left to right) was calculated by averaging out 5 consecutive right-to-
left strides and 5 consecutive left-to-right strides respectively. The mean complete 
stride length for the left and right hind limb was also calculated by averaging out 5 
left-to-left strides and 5 right-to-right strides. Sections of the recorded footprints that 
included a pause period (*) as described above, were not used to calculate stride 
length. For each mouse, measurements were taken from the same footprint location to 
ensure consistency (Figure 2.3e(iii)). 
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Figure 2.3e. Stride length measurement 
The mouse is physically restrained to enable dipping of the hind paws in non-toxic 
water based paint; (ii) the mouse is then quickly released into a transparent plastic run 
(50mm x 100cm) in which the floor has been lined with printing roll paper; (iii) 
measurements were then taken from the same footprint location to ensure consistency. 
ii. 
iii. 
i.
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2.4 DRG gene expression using real time Reverse Transcription-Polymerase 
Chain Reaction (RT-PCR) 
Based on previous studies that used retrograde tracing techniques to label and 
characterise knee joint afferents (169, 226, 227), the cell bodies of the afferent 
neurons innervating the knee joint reside in the lumbar dorsal root ganglia (DRG) (L1 
– L5), with the majority in L3. In the rat 88% of knee joint afferents are located in L3
and L4. However, knee joint afferents make up a small proportion of the total neuron 
cell body population in these DRG (less than 15%), and only about half of these are 
small, myelinated and unmyelinated nociceptors. Knee joint afferents also comprise 
the large, low threshold mechanoreceptors that are required for normal joint 
movement. Therefore, to optimize the ability to identify changes in gene expression in 
nociceptor neurons in the innervating DRG, only L3 and L4 DRG were harvested for 
real time RT-PCR.   
A number of inflammatory neuropeptides including Substance P (Tac-1) and CGRP, 
and inflammatory cytokines such as IL-1 have been demonstrated to play a role in 
chronic pain and sensitisation (467-470). TRPV1, TRPV2, TRPV4 and TRPA1 are all 
part of the Transient Receptor Potential (TRP) family of cation channels and have 
been described in the DRG. Numerous studies suggest all 4 TRP channels play a role 
in the development of chronic pain, and in particular mechanical hypersensitivity 
(471-474). The role of both the endogenous opioid and cannabinoid systems in pain 
modulation has been studied extensively (265, 266, 291, 308, 311, 475). However, the 
exact role that they play in pain modulation in diseases such as OA is still not known. 
There is growing evidence that supports a neurogenic component to OA pain (361, 
476, 477), highlighting the importance of investigating markers of neuronal injury 
(ATF3) in OA.  
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Based on this current understanding of chronic pain and sensitisation, the following 
genes were selected for investigation using real time RT-PCR: Tac-1, CGRP, IL-1, 
Oprm1, CNR1, TRPV1, TRPV2, TRPV4, TRPA1 and ATF3 (Table 2.1).   
In an attempt to investigate potential links between the mechanisms involved in 
cartilage degradation and peripheral pain mechanisms, gene expression of the 
principle aggrecanases implicated in cartilage degradation in OA (ADAMTS-4 and 
ADAMTS-5) was also measured using real time RT-PCR. While ADAMTS-4 
expression relies on induction by pro-inflammatory cytokines, ADAMTS-5 is 
expressed constitutively in a number of adult tissues including DRG (34). ADAMTS-
4 has not previously been investigated in the DRG, but it is the most highly expressed 
ADAMTS in the central nervous system (CNS) and is thought to play a role in 
controlling synaptic plasticity during CNS development (478). It has been 
demonstrated that ADAMTS-5 knock out mice are protected from OA and do not 
develop mechanical allodynia at 8 weeks after surgical induction of OA (441). To 
date, no one has investigated regulation of ADAMTS-4 or ADAMTS-5 in the DRG 
and how it changes over the course of OA disease development. 
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Table 2.1. Genes selected for RT-PCR analysis and evidence for role in chronic pain states including OA pain 
Gene 
symbol 
Name Evidence for potential role in chronic OA pain 
Tac-1 Substance P 
Tachykinin-1 
Mechanical hyperalgesia is significantly reduced in NK1 receptor deficient mice in CFA-induced inflammatory arthritis model (479). 
Tac-1 expression in the DRG is down-regulated in the peak inflammatory phase of Collagen-induced arthritis. Systemic administration of NK1 receptor 
antagonist inhibits joint swelling but not mechanical allodynia (480). 
The density of Sub P immune-reactive nerve fibres in the hip joint is increased in humans with painful OA but not in patients with failed total hip 
arthroplasties that are non-painful (481). 
Calcitonin 
(CGRP) 
Calcitonin gene related 
peptide 
CGRP deficient mice do not develop thermal hyperalgesia in carrageen induced inflammatory arthritis (468). 
CGRP promotes mechanical hyperalgesia in MIA and meniscal transection induced OA (469). 
The density of CGRP immune-reactive nerve fibres in the hip joint is increased in humans with painful OA but not in patients with failed total hip 
arthroplasties that are non-painful (481).  
IL-1 Interleukin-1 Intra-articular induction of IL-1 contributes to joint pathology and pain (325). 
Oprm1 Mu opioid receptor Temporal induction of the endogenous opioid system delays onset of pain in the DMM model of OA (316). 
Opioid induced analgesia for neuropathic pain is achieved at higher doses than inflammatory pain. Opioid receptor expression in the DRG is down-regulated 
in neuropathic pain (chronic nerve constriction model) and unaltered in CFA-induced inflammatory pain (314). 
CNR1 Cannabinoid 
receptor 1 
Peripheral CNR1 activation results in a greater reduction in mechanosensitivity in MIA induced OA knee joints compared to controls (475). 
CNR1 inhibits NGF induced sensitisation of TRPV1 (482). 
TRPV1 Transient Receptor 
Potential Vanilloid-1 
Joint inflammation and pain are attenuated in TRPV1 deficient mice in CFA-induced inflammatory arthritis (188). 
Increased TRPV1-immunoreactivity present in human OA synovium. Intra-articular administration of TRPV1 antagonist reverses knee joint mechanical 
sensitisation in mice with MIA induced OA (190). 
Mechanical hyperalgesia observed in models of polyneuropathy develops earlier and with greater intensity in TRPV1 deficient mice (183). 
TRPV2 Transient Receptor 
Potential Vanilloid-2 
TRPV2 expression in DRG is up regulated following CFA-induced inflammation and is associated with onset of thermal hyperalgesia (211). 
TRVP4 Transient Receptor 
Potential Vanilloid-4 
Development of mechanical allodynia in a neuronal injury model of chronic pain is in part driven by TRPV4 (483). 
TRPA1 Transient Receptor 
Potential Ankyrin-1 
TRPA1 modulates low intensity mechanical stimulation following CFA induced inflammation (474).  
Activation of TRPA1 plays a role in inducing and sustaining mechanical hyperalgesia in CFA induced inflammatory arthritis (484). 
TRPA1 inhibitor reverses CFA-induced mechanical hyperalgesia in wild type mice but not in TRPA1 deficient mice (204).  
TRPA1 deficient mice display less reduction in ipsilateral hindlimb weight bearing compared to wildtypes in MIA-induced arthritis (485). 
ATF3 Activating Transcription 
Factor-3 
Lumbar DRG ATF3-immunoreactivity is increased in mice with MIA induced knee OA and reduced ipsilateral weight bearing (361). 
Intra articular injection of 2mg MIA induces expression of ATF3 in DRG innervating the knee joint and surrounding tissues (486). 
ADAMTS4 Aggrecanase 1 Mechanical strain of articular chondrocytes drives the release of inflammatory and neurotrophic factors associated with joint degeneration (ADAMTS4) and 
pain (NGF, TNFa) (487). 
ADAMTS5 Aggrecanase 2 ADAMTS5 deficient mice are resistant to OA-like joint pathology and do not develop mechanical allodynia in the DMM OA model (441). 
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2.4.1 DRG harvesting 
Lumbar 3 and 4 DRG were harvested at day 3, week 1, 2, 4, 8, 12 and 16, after 
arthritis induction, from DMM, Sham, mBSA injected, and Saline injected mice. 
DRG were also harvested at week 4, 12 and 16 from age matched control mice. 
Mice were euthanized using CO2 inhalation followed by decapitation. Decapitation 
was performed to facilitate exsanguination and minimise blood contamination during 
dissection and DRG harvest. The coat was sprayed liberally with 70% ethanol to 
minimize contamination. The skin covering the dorsum was dissected away to expose 
the underlying muscle layers and allow visualisation of the vertebral column (Figure 
2.4a). Harvesting of DRG was done under a dissection microscope and each mouse 
was completed in ~15 minutes.  A size-11 scalpel blade was used to score the muscles 
overlying the dorsal vertebral column. The muscles were then dissected off the 
vertebral column using a Friedman Rongeur (Figure 2.4b), exposing the dorsal 
spinous processes (Figure 2.4c). Laminectomy forceps (#2) were then used to remove 
the dorsal vertebral column, exposing the spinal cord (Figure 2.4d). The spinal cord 
was gently elevated to enable visualisation of the DRG using fine Dumont (#5) 
forceps and micro spring scissors to cut nerve roots and free up the cord, starting at 
the sacrum and working towards the thoracolumbar junction (Figure 2.4e). Left and 
right DRG (L3 and L4) were lifted with fine Dumont (#5) forceps and dissected out 
by cutting the attaching nerve roots with micro spring scissors. L3 and L4 DRG from 
each side were immediately transferred to separate 1.5ml polypropylene (Eppendorf) 
tubes, homogenised in 50l TRIzol® reagent using a motorized pestle, and then
placed in dry ice. Samples remained in dry ice until all DRG were harvested (up to 6 
hours), and then transferred to a freezer and stored at -80
o
C.
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Figure 2.4. DRG harvesting 
(a) Removal of the overlying skin to expose the vertebral column; (b) dissection of
the lumbar muscles using rongeurs; (c) exposure of the dorsal spinous processes; (d)
removal of dorsal spinous processes to expose the spinal cord; (e) lumbar DRG and
nerve roots following dissection of the spinal cord; (f) left and right L2 – L4 DRG in
situ (solid arrows).
a
d. c. 
b
f.e. 
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2.4.2 RNA extraction 
Total RNA was extracted from L3-4 DRG using the Qiagen RNeasy kits as described 
by the manufacturer. Previously homogenized samples were thawed at room 
temperature. Samples were done in batches due to the limitations of the centrifuge 
required for the extraction process, which held a maximum of 30 samples. Left and 
right DRG samples from the same animal were done at the same time, and each batch 
included samples from each treatment group to ensure consistency within individuals 
and between treatment groups in the extraction process. An additional 950l TRIzol® 
reagent was added to each sample, followed by Chloroform (300l). Samples were 
vigorously vortexed for 15 seconds, and incubated at room temperature for 5 minutes, 
followed by centrifugation for 15 minutes at 12,000 rpm to stratify the aqueous and 
organic phases. The aqueous phase, containing RNA, was carefully transferred to new 
micro-tubes in 100l aliquots using a 200l pipette, and then combined with an equal 
volume of 70% ethanol.  Samples were gently mixed by inversion before loading onto 
RNeasy spin-columns in 600l aliquots followed by centrifuging at 12,000 rpm for 20 
seconds. RWI buffer (350l) was then added to each spin column, incubated at room 
temperature for 5 minutes and centrifuged at 12,000 rpm for 20 seconds. The 
collection tubes were discarded and new collection tubes placed under the spin 
columns. 80l of DNase in RDD buffer was applied to each spin column, centrifuged 
for 20 seconds at 12,000 rpm, and reapplied. Samples were then incubated at 37
o
C for
1 hour. After incubation the spin columns were washed with 350l RWI, followed by 
two washes with 500l RPE buffer. Spin columns were centrifuged for 20 seconds at 
12,000 rpm after each wash. An additional 2-minute centrifugation was done to 
evaporate any traces of ethanol and dry the spin columns. Finally, RNA was eluted 
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from spin columns by loading 32l RNase free water and centrifuging for 1 minute at 
12,000 rpm.  
2.4.3 RNA quantification 
RNA was quantified using a Nanodrop spectrophotometer (ThermoScientific). DNA 
contamination was detected by running a no-RT quantitative RT-PCR on 0.3g of the 
total RNA using the Rotor-Gene 6000 (Corbett Life Science, Australia) and the 
housekeeping gene GAPDH.  
2.4.4 Reverse Transcription 
Due to the large number of samples (multiple treatment groups and multiple time 
points) reverse transcription could not be performed on all samples at once, and still 
ensure each sample received equal exposure time to the master mix and incubation.  
Instead reverse transcription was done in batches based on harvest time point. 
Variability in RNA yield from the DRG of individual mice prevented reverse 
transcription of 1g RNA for each sample. Instead, an equal amount of total RNA 
(0.5 to 1 g), based on the smallest total yield from any given sample in a batch, was 
reverse transcribed into cDNA using the Omniscript RT kit (Bioline).  
The reverse transcription (RT) master mix was made up as described in Appendix B. 
All RNA samples were denatured prior to performing RT by placing on a heating 
block, set at 70
o
C, for 5 minutes. To each calculated amount of RNA was added
enough RNase-free water to make a total volume of 30l. 10l of master mix was 
then added to the side of each tube. Samples were then spun down quickly in the 
centrifuge and incubated for 3 hours at 37
o
C, followed by 5 minutes incubation in a
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heating block set at 93
o
C. The samples were then cooled quickly by placing in ice for 
5 minutes. The cDNA samples were diluted with RNase-free water to a total volume 
of 150L per 1g of original RNA. The cDNA samples were stored at 4
o
C until used. 
 
2.4.5 Primer design  
Murine primer sets were designed using MacVector 11.1 primer design software. 
Primers were purchased from Sigma Genosys and full details are provided in 
Appendix A. Primer specificity was confirmed by performing a melt curve analysis 
and demonstrating a single amplicon of appropriate size. 
 
2.4.6 Quantitative real-time RT-PCR 
qRT-PCR was performed using the Rotor-Gene 6000 (Corbett Life Science, 
Australia) and analysis software (Corbett Research Pty Ltd, copyright 2004). cDNA 
standards were prepared by combining aliquots of multiple samples of cDNA from 
different treatment conditions (i.e control, sham, DMM, saline, AIA) and post-
induction times, and making serial 4-fold dilutions to provide four standards (1:1, 1:4, 
1:16, 1:64) that were used as “in-run standards”. Standards were run in duplicate 
along with 2 negative controls (RNase free water), with each primer pair that was 
tested. A master mix was made up comprising 1x Immomix, 10M forward and 
10M reverse primer and 1x SYBR Green 1 dye made up to a total of 20l per 
reaction, in RNase free water. 20 l of master mix was added to each reaction tube 
followed by 5l of cDNA sample or standard. The following thermal profile was used 
for each reaction: 10 minutes denaturation at 95
o
C; 45 cycles of 95
o
C for 10 seconds; 
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a primer specific (see Appendix A) annealing temperature for 15 seconds; and 
extension for 20 seconds at 72
o
C.
A melt curve analysis was performed for each reaction to confirm that a single 
product was produced for each amplicon. Quantitative analysis was then performed 
and RNA values for each gene were normalised to total RNA, and expressed as fold 
change relative to mean sham-operated and saline-injected respectively.  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was initially trialled for 
normalisation of RNA values for genes of interest, as this has previously been widely 
used as a housekeeping gene, including for studies of DRG gene expression (488, 
489). However, analysis of data revealed that GAPDH demonstrated significant 
variation in expression between sham and treatment mice DRG, at some of the 
measured time points. Unfortunately, insufficient RNA sample remained from many 
of the measured time points, to allow identification of a more suitable housekeeping 
gene that displayed stability in expression in DRG tissue, across the different 
treatment groups and the different time points. For this reason, RNA values were not 
normalized against a housekeeping gene, but instead normalised to total RNA and 
expressed as fold change relative to the respective sham-operated or saline-injected, 
control as previously recommended (490-492). 
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2.5 Immunohistochemistry 
DRG (lumbar 3-5) samples harvested for immunostaining were collected at key time 
points (day 7, week 4, 8 and 16) and stored initially as fixed-frozen blocks at -80
o
C.
To maximize the preservation of DRG tissue architecture and cell morphology, and 
allow multiple sectioning of individual DRG over the lengthy period it took to stain 
for the different antibodies, samples were subsequently embedded in paraffin for long 
term storage.  
Immunostaining of DRG was then performed in batches, the size of which was 
limited by the number of Sequenza trays (Thermo Scientific) available. Each batch 
contained sections from each treatment group and two time points. This allowed 
qualitative analysis of relative protein expression in the DRG between treatment 
groups and over time. 
2.5.1 Perfusion of mice with paraformaldehyde 
Mice were anaesthetised with an intraperitoneal injection of 50mg/kg pentobarbitone. 
Once deeply anaesthetised (loss of pedal reflex and slow breathing) mice were placed 
in a fume hood and positioned in dorsal recumbency on a tray. The limbs were held 
out in an extended position using adhesive tape. The coat was sprayed with 70% (v/v) 
ethanol and the skin overlying the ventral thorax was lifted with forceps to allow a 
large skin incision to be made with tissue scissors. The xiphoid process was then 
elevated and an incision made through the diaphragm to facilitate complete sectioning 
of the ribcage, to expose the heart. 
A small incision was made in the right auricle and a short 25-gauge needle (attached 
via minimum volume tubing to a 50ml syringe) was inserted into the left ventricle. 
90 
Flush solution (approximately 15ml) was then run through the animal until clear fluid 
was coming from the right auricle and the abdominal organs were pale. Fixative 
solution (approximately 50ml) was then run through the animal until the animal 
became rigid. Details of the composition of the flush and fixative solution are listed in 
Appendix B.  
The DRG were then dissected out as described in 2.4.1 and post fixed in 4% PFA for 
90 minutes. Isolated DRG were then placed in 30% sucrose at 4
o
C for 24 hours before
mounting into Base Molds (Tissue Path, Fischer Scientific) in a water-soluble 
specimen matrix (Tissue-Tek O.C.T). The specimen blocks were placed immediately 
in dry ice for snap freezing and then transferred to the freezer for storage at -80
o
C
until further processing. 
2.5.2 DRG Processing   
Following the harvesting of all time points, DRG stored at -80
o
C were brought to
room temperature and transferred to 70% (v/v) ethanol prior to paraffin embedding. 
Individual DRG specimens were wrapped in Kimwipes™ to ensure they were not lost 
during processing. 
All DRG specimens were dehydrated for 30 minutes each in graded solutions of 70%, 
75%, 85% and 95% (v/v) ethanol, and three washes of 30 minutes duration in 100% 
(v/v) ethanol. This was followed by three changes of 30 minutes duration in 
chloroform. DRG were then put through three 30-minute cycles in wax (Paraplast 
Plain) without vacuum. DRG were embedded in Paraplast Plain in cassettes using 
magnification to ensure a consistent orientation. DRG tissue was embedded flat along 
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their longitudinal access. In this orientation the neurons were centered with nerve 
roots extending from either side.   
Blocks were trimmed on the microtome until neurons were first visualised 
(microscopically), before serial sections (4µ) were cut and mounted onto superfrost 
plus slides (one sections per slide). The 1
st
 and 10
th
 slide were stained with
Haematoxylin and Eosin (H&E) to enable evaluation of DRG cellular morphology 
prior to immunohistochemical staining of slides 2-9.  If the number of neurons on 
these sections was sparse a further 10 sections were cut and mounted on slides, and 
the H&E staining repeated on slide 20 to evaluate the quality of the section prior to 
immunohistochemical staining of slides 11-19.  
To de-paraffinise, slides were immersed in xylene for two changes of 5 minutes 
duration each. The sections were then immersed in graded solutions of 100%, 100%, 
95% and 70% (v/v) ethanol for three minutes each. The slides were then rinsed in a 
container of running tap water and drained well before been stained for 10-12 seconds 
in Mayer’s Haematoxylin. Sections were then rinsed quickly in running tap water and 
placed in Scott’s blueing solution for one minute, and again rinsed quickly in running 
tap water. Sections were then counterstained in Eosin for 1 minute and rinsed 
immediately under running water. Finally sections were dehydrated in three changes 
of isopropyl alcohol and three changes of xylene, before mounted in a resinous 
mountant (Euckitt
®
).
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2.5.3 Antibody staining 
2.5.3.1 Deparaffinisation 
Slides were immersed in xylene for two changes of 5 minutes duration each. The 
sections were then immersed in graded solutions of 100%, 100%, 95% and 70% (v/v) 
ethanol for three minutes each. The slides were then rinsed in a container of running 
tap water and drained well. 
2.5.3.2 Primary antibody incubation 
Slides were assembled in Sequenza trays (Thermo Scientific). Wash buffer (Tris 
Buffered Saline and Tween-20) was added to the top of each slide chamber and 
incubated at room temperature for 6 minutes.  100l of Dako Protein Block (serum 
free) was then added to each slide chamber, and incubated at room temperature for 10 
minutes. 100µl of diluted primary antibody or appropriate negative control antibody 
was added to each slide chamber followed by incubation at 4
o
C overnight. Details of
antibodies are available in Appendix A. 
2.5.3.3 Detection 
Wash buffer (TBST) was added to each slide chamber and incubated at room 
temperature for 6 minutes. Three drops of Envision+ polymer (dual link) were added 
to each chamber and incubated for 30 minutes, followed by wash buffer (TBST) for 6 
minutes. Slides were then removed from the Sequenza tray and placed in a humid 
chamber. 200ml of substrate chromogen (NovaRED) was applied to each slide, 
making sure the section was covered with reagent, and incubated for 15 minutes at 
room temperature. Slides were then placed in rack and washed in running tap water 
for five minutes. 
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2.5.3.4 Counterstain 
Slides were placed into Mayer’s Haematoxylin for 10 seconds and washed until clear. 
Slides were then placed in Scott’s Blue for 1 minute and washed until clear. 
2.5.3.5 Mounting 
Slides were put through four changes of 100% (v/v) ethanol with 10-second agitation 
in each container. Slides were then put through three changes in xylene with 20-
second agitation in each container. Slides were left in xylene in preparation for 
mounting. Slides were drained, mounted in a resinous mountant (Euckitt
®
) and a
coverslip applied, and then allowed to dry in the fume hood. 
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CHAPTER 3:  Development and validation of methods 
The methods for induction of post-traumatic OA by DMM and inflammatory arthritis 
using AIA are well established in the host laboratories (439, 450, 461). In contrast, 
our laboratories had not previously evaluated pain outcomes in these mouse models. 
This chapter outlines how the pain assays were selected, and the protocol for 
conducting them was developed, modified and optimised.  
Furthermore, different histopathological scoring systems have previously been used to 
quantify arthritis progression in DMM (47) and AIA (439). Histopathological scoring 
in the DMM model is focused on quantifying articular cartilage damage (462). In 
contrast, histopathological scoring in the AIA model is aimed primarily at quantifying 
the inflammatory changes (448, 452, 493). This chapter therefore also describes 
experiments to validate the use of a single histological scoring system to enable direct 
comparison between the two arthritis models for subsequent correlation with pain 
outcomes.  
3.1 Pain assessment 
The International Association for the Study of Pain (IASP) defines pain as “An 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (494). This definition, adopted by 
pain experts to also describe pain in animals, highlights the challenge that researchers 
face when attempting to accurately and consistently quantify pain in preclinical 
studies. Nociception refers to the processing of information about the internal and 
external environment by the peripheral and central nervous system. This commences 
with the activation of peripheral nociceptors (specialised nerve endings that detect 
noxious stimuli). Transmission of nociceptive input to the cerebral cortex results in 
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the perception of pain. However, pain can also be perceived in the absence of any 
nociceptive signalling.  
Like humans, animals experience pain as a complex physiological, somatosensory, 
emotional and cognitive phenomenon, however they cannot verbally express or 
describe the emotional component that is unique to every individual. The challenge 
for researchers is to identify pain assays that accurately mimic the pain observed with 
human disease, and develop outcome measures that are consistent and can be 
validated. 
Changes in behaviour, posture and even facial expression provide valuable clues 
about an animal’s pain experience. Burrowing and nesting behaviours are also now 
recognised as an indicator of health and wellbeing in laboratory mice (495, 496), and 
has been validated as a marker of acute post-surgical pain (497, 498). However, there 
is currently no report of its validation as a marker of chronic pain, such as that which 
develops in both humans and animals with OA. Similarly, facial expression markers 
have been validated in mouse, rat and rabbit models of acute pain (499-503), but have 
proven unreliable as markers of chronic pain. 
Chronic pain assessment in humans relies principally on self-reporting assessment 
tools such as the WOMAC questionnaire (504). The use of questionnaires assists 
clinicians and researchers with quantifying the chronic pain state in an individual 
(505, 506). More recently attempts have been made to develop qualitative pain 
assessment tools that allow for the phenotyping of chronic OA pain and therefore, a 
more targeted approach to pain management (430, 507, 508).   
Chronic OA pain in human patients is characterised by movement evoked joint pain, 
locomotor restriction, spontaneous pain at rest, and poor sleep (509). Some of these 
features have also been demonstrated in preclinical models of arthritis, inflammatory 
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pain and chronic musculoskeletal pain. For example, fragmented sleep has been 
demonstrated in mice with chronic muscular pain (510).  
Somatosensory testing has also been used to characterise chronic OA pain. 
Researchers have demonstrated that patients who present with high levels of clinical 
pain, but only mild to moderate radiographic evidence of knee joint pathology, 
demonstrate reduced thermal and mechanical thresholds in quantitative sensory tests 
of central sensitisation (511). On the other hand, patients with mild knee OA pain 
experience knee joint mechanical hyperalgesia, as demonstrated by an increase in the 
pressure pain threshold (PPT), but not thermal hyperalgesia (512). In a cohort of 
patients with different degrees of knee OA, pain intensity (as reported by the patient) 
correlated significantly with knee PPT, temporal summation (TS) and conditioning 
pain modulation (CPM) (513). These three quantitative sensory tests are used to 
assess changes in central pain mechanisms, and reflect the development of central 
sensitisation. 
Chronic OA is also characterised by changes in gait. For example, patients with 
medial compartment knee OA demonstrate altered foot kinematics (514). Gait 
disturbances are also observed in pre-clinical models of OA. In the Collagen-induced 
arthritis model, mice demonstrate an increased stride frequency and shorter stride 
length (515). However, these gait modifications may reflect progression of joint 
pathology and subsequent changes in joint mechanical function and/or range of 
motion, rather than indicating joint pain severity (516). 
The pain assays selected for evaluation in this thesis can be used to assess the 
development of central sensitisation (as is observed in a sub group of chronic OA 
patients), and represent features of the pain state in pre-clinical models that reflect the 
clinical features observed in chronic OA patients. 
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Three stimulus evoked pain tests were investigated: 
1. The von Frey fibre test for tactile allodynia
2. The hotplate test for thermal hyperalgesia
3. The PAM (pressure application device) test for mechanical hyperalgesia
Three motor function based behaviour tests were also investigated: 
1. Hind-limb weight distribution using a force plate (incapacitance)
2. Gait analysis using hind-limb stride length measurements
3. Motor coordination using a rotarod
All six tests have been validated as outcome measures of pain through ablation of 
response following the administration of established analgesics such as non-steroidal 
anti-inflammatory drugs and opioids (316, 406, 423, 517, 518).  
However, despite the validation of these pain tests, it is apparent from the literature 
that there is tremendous variability in the outcome measures that define a positive 
response and subtle differences in the exact method used to measure these outcomes. 
This absence of standardisation means that outcomes do not translate across research 
laboratories, and result in many inconsistencies in the published data from apparently 
the same experiments. The interpretation of many of the behavioural outcomes, and in 
particular, what constitutes a “response” can be very subjective and operator/observer 
dependent, which leads to a significant amount of irreproducibility in the field.  
The purpose of the experiments described in this chapter, therefore, was to optimise 
the methods used and determine which pain outcome measures could detect 
pain/disability in mouse OA, and that would therefore be used in subsequent 
longitudinal studies. 
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Twelve naïve 8-week-old male C57BL/6 mice were used to evaluate the suitability of 
5 of the six pain-related behaviour tests (von Frey, Hotplate, Rotarod, Forceplate and 
Gait). A separate group of 12 naïve 8-week-old male C57BL/6 mice were used to 
evaluate the PAM device. This was done because the PAM testing required 
significant restraint of the mice (see section 3.1.3), and it was thought that imposing 
this additional stress on the mice might confound the results of the other pain tests. 
The aim of using naïve mice was to establish a repeatable method for each pain 
behaviour assay that achieved consistent baseline values. Where modifications were 
made to a particular assay, the modified method was trialled on six new mice. Once 
consistent baselines were established, the pain behaviour tests were used to 
investigate pain using the AIA model.  This model was used because it produces a 
more severe inflammatory response in the knee joint. Based on the current literature 
(420, 519, 520), an inflammatory arthritis such as AIA should provide a more robust 
model for demonstrating difference in pain behaviour between treatment mice and 
saline injected mice with no joint pathology. AIA was established in six mice, as 
described in Chapter 2 (section 2.1.4), and six mice served as immunised, saline 
injected, controls. Joint inflammation peaks early in the AIA model (521) and so for 
the experiments described in this chapter, testing was conducted day 0 (prior to 
immunisation), day 3, day 7 and day 14 (von Frey and PAM). Table 3.1 outlines the 
testing schedule and how many times individual mice were tested using the different 
pain assays.  
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Table 3.1. Testing schedule for optimisation of pain behaviour assays 
Pain test 
Baseline testing* AIA testing** 
Trial 1 Trial 2 Trial 3 Trial 4 Day 3 Day 7 Day 14 
Von Frey A (12) A (12) B (12) C (12) C (12) C (12) 
Hotplate 42 A (12) 
Hotplate 50 A (12) A (12) A (12) A (12) A (12) 
Hotplate 52 B (12) B (12) B (12) B (12) 
Hotplate 55 B (12) B (12) 
PAM D (12) E (12) E (12) E (12) E (12) 
Force plate A (12) C (12) C (12) C (12) 
Stride length A (6) A (12) A (12) A (12) 
Rotarod A (12) A (12) A (12) A (12) A (12) 
A, B C, D and E denote different mice cohorts. The number of mice tested is 
indicated in brackets. * Animals that were used to establish baselines for more than 
one pain test were rested for at least 24 hours before performing the next test. 
Baseline testing was done over a 2-week period prior to administering the first 
immunisation. ** Animals that underwent more than one pain test were rested for at 
least two hours before performing the next pain test. 
A single assessor (SZ) performed all behaviour testing described in this thesis. The 
assessor was blinded to treatment group until the completion of testing at all time 
points. Blinding is a crucial aspect of conducting pain behaviour experiments, as it 
reduces detection bias in a study. It is done because the assessor may be influenced by 
the knowledge about treatment assignment (for example, an animal with osteoarthritis 
should demonstrate a lower pain response threshold than a control animal) and this 
can induce a systematic detection bias. Overestimation of treatment effect due to 
unblinded assessors in randomised clinical trials has been estimated to range from 17 
- 50% (522, 523). There is an even greater risk of observer bias in animal model
experiments where the outcome measure is subjective, as in the case of behaviour 
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testing and scoring of histological preparations (524). Recently the impact of 
unblinded assessors in animal model experiments on observer bias was evaluated 
(525). Ten experiments (2450 animals) were included in the meta-analysis, and an 
average exaggeration of 59% of the odds ratio (OR) from non-blinded assessments, 
was calculated. This implies a considerable high risk of observer bias if an assessor is 
not adequately blinded. 
Despite the recent publication of guidelines for the reporting of in vivo animal 
experiments (ARRIVE Guidelines) (395), many publications do not include proper 
reporting, especially details of the blinding. Care must be taken when interpreting 
results from studies that simply state the experiment was blinded without clarification 
of the blinding. For example, are there any visible differences (e.g. surgical incision) 
between treatment groups that would unblind the assessor? Does the assessor remain 
blinded until the conclusion of the experiment when all data has been collected? Is the 
order that testing or scoring occurs random? Or do all animals in one treatment group 
get tested followed by the other treatment group? Are different treatment groups 
housed in mixed cages to avoid any bias associated with testing cage mates?   
For the experiments described in this Chapter, there were no visible differences 
between mice from the two treatment groups (Saline vs. AIA). Mice were housed in 
mixed treatment group cages, and tested in a random order each time. 
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3.1.1 Mechanical allodynia 
Quantitative assessment of mechanical allodynia was done using von Frey filaments 
(Stoelting Touch Test Sensory Evaluator Kit, USA) and the ‘up-down’ method 
described by Dixon (466). Details of the method used are outlined in Chapter 2 
(section 2.3.1). The use of a monofilament device to perform sensory testing was first 
reported in humans in 1922 (526) and subsequently standardised in the form of a set 
of calibrated nylon monofilaments by Semmes and Weinstein (527). These same 
monofilaments are now used by researchers to measure mechanical withdrawal 
thresholds and draw conclusions about the development of sensitisation in 
neuropathic, acute and chronic pain models. However, there is still no established 
consensus on what normal thresholds are in mice or rats. In addition there are a 
number of limitations of using nylon monofilaments to measure mechanical sensory 
thresholds in animal models of disease which require further consideration (528). 
Although the nylon monofilaments are calibrated, application parameters such as 
bend rate and the tip geometry influence the amount of vertical force generated by 
each fibre. In addition, the degree of bending can affect the non-vertical loading and 
therefore alter the total vertical force generated (528). Other confounders include, the 
application time, which can vary from less than a second to more than 10 seconds; 
and the site of application, which is difficult to accurately control. The significance of 
these application parameters is user dependent, and highlights the need for individuals 
to learn and practice the technique to ensure consistency and repeatability of results. It 
also suggests a reason for why there is such variability between individuals and 
highlights the challenge of yielding reproducible results across two or more different 
laboratories.  
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There are currently no published guidelines on how to train an experimenter to 
perform the test, and there is no standardised protocol for conducting the test, or 
method for the analysis and reporting of results. The method of analysis used in this 
thesis (465) is frequently reported, but is by no means universally accepted. 
 
The following test method was used: 
1. Six mice were placed in individual transparent plastic chambers with wire mesh 
flooring, and left undisturbed for one hour to acclimatise.  A one second stimulus 
was applied to the plantar surface of the hind paw with a von Frey filament 
presented perpendicularly and exerting enough force to bend the filament. 
2. A positive response was defined as shaking, licking, biting and/or withdrawal of 
the tested paw.  
3. A series of von Frey filaments were used, starting with filament 3.61 (0.4 g force) 
4. The left hind paw was tested in all six mice followed by the right hind paw in all 
animals. 
To establish baseline paw withdrawal threshold (PWT) using von Frey filaments, the 
same mice were tested on two separate occasions with a five-day rest period in 
between. This initial baseline data (Trial 1 and 2) collected from naïve mice was 
highly variable and inconsistent both within (right vs. left paw) and between 
individual animals (Figure 3.1a and 3.1b). To rule out the effect of stress due to over 
handling and testing, the von Frey test was repeated using the same method on a 
different group of naïve mice (n=12) (Trial 3). This group of mice demonstrated a 
similar withdrawal threshold (Figure 3.1b). 
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Figure 3.1a. Baseline 50% paw withdrawal threshold (PWT) 
Using von Frey filaments, naïve C57BL mice were tested (n=12) on the left and right 
hind paw. Graph demonstrates the observed within animal variability (left vs. right 
paw) in baseline 50% PWT. 
Figure 3.1b. Baseline 50% PWT using von Frey filaments 
Trial 1 and 2 represent the same cohort of naïve mice (n=12) tested on two occasions 
with a five-day rest period in between. Trial 3 is a second cohort of C57BL mice 
tested using the same method as trial 1 and 2. These mice demonstrated similar within 
and between animal variability in baseline 50% PWT. Trial 4 represents a third cohort 
of C57BL mice tested using a modified method. The results are presented graphically 
as a scatter plot, with mean and SEM marked. 
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A number of factors were attributed to this inconsistency: 
- Operator error in interpreting mouse response 
- The length of acclimatisation time  
- Use of a wire mesh floor surface 
In addition, these initial baseline 50% withdrawal thresholds in naïve mice were 
higher than that reported in the literature by other pain research groups (406, 441). 
As a naïve operator, I was unfamiliar with basic behaviour characteristics of mice. For 
example, mice are highly driven when it comes to basic activities such as voiding and 
grooming. This translated to a higher withdrawal threshold if mice were tested while 
they were performing these activities. The mice also displayed a quiescent state where 
they appeared unresponsive, but their eyes remained fully open. In this state, the 
response to a tactile stimulus was unpredictable. For any given stimulus, the response 
was either exaggerated or they did not respond at all. Mice that were asleep in the 
chamber at the time of testing were hypoalgesic and did not respond even when the 
largest von Frey fibres were used.  
In addition, I observed that there was variability in how quickly mice acclimatised 
after being placed in the test chambers, and that they did not remain settled 
indefinitely. In fact, following this period of reduced activity, the mice entered a state 
of heightened arousal where they demonstrated excessive grooming, excitatory 
exploratory behaviour, and attempts at escape from the chamber. In this state mice 
were very difficult to test. It was also observed that after a period of time mice began 
to shift their weight from one limb to the other. In contrast, some mice fell asleep 
after being in the chamber for only 30 minutes. 
It has been demonstrated in rats that the type of floor surface used influences the 
withdrawal threshold for the von Frey test and that wire mesh floors are associated 
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with a large variability in withdrawal threshold between control animals (529).  
Exposure to a wire mesh floor may itself induce a hyper aesthetic state resulting in an 
artificially reduced withdrawal threshold. Rodents do experience anxiety from being 
elevated (530), and so the mesh floor may act as a stressor because the mice can see 
through it. Physiological stress will influence an animal’s sensory processing. In 
addition, the mesh floor allows mice to receive visual cues as the operator’s hand 
approaches the mouse and raises the von Frey filament. This phenomenon was 
observed during testing and resulted in movement and a state of alertness before the 
filament was even applied to the paw. 
The stress of elevation because the surface is not opaque, the influence of visual 
signalling, and the effect of sensory stimulation due to standing on the mesh floor, 
could all in part explain the failure of some mice to settle in the chambers, and also 
why longer acclimatisation periods resulted in heightened activity levels. 
The state of arousal and attentiveness is an important modulator of pain sensitivity in 
humans (531, 532). The modulatory effect of equivalent behavioural states on 
mechanical and thermal nociception has also been examined in mice using a nerve 
injury model in three different mouse strains including the C57BL strain (533). 
Researchers reported six behavioural states; deep sleep, light sleep, resting, alert, 
grooming and exploring. They concluded that nociceptive sensitivity was influenced 
by activities such as grooming, alertness, light sleep and deep sleep (533). 
To address these confounding factors, the following caveats were added to the testing 
method. Mice were not tested when asleep, grooming, urinating, defecating or highly 
active and frequently rearing on their hind limbs. Mice that remained stationary in a 
hunched position, but with eyes open, for an extended period of time, were deemed to 
be asleep and therefore were lightly stimulated (light tap on Perspex wall) prior to 
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testing. Testing was not done while a mouse was observing the operator through the 
mesh floor. Mice were tested twice on each paw with a minimum 15-minute break 
between testing, and the two scores were averaged to obtain a mean 50% withdrawal 
threshold. Where the two scores differed by more than the equivalent of two von Frey 
filaments, mice were tested a third time and the three scores averaged. 
Acclimatisation time was reduced from one hour to 30 minutes. If after 30 minutes 
the mice were still very active, testing was incrementally delayed by 10 minutes until 
a point when the mice appeared settled in their cages. Acclimatisation time was 
capped at one hour because after this point, mice either became further agitated or 
started to fall asleep. Both of these states increased the variability and potentially 
reduced the accuracy of testing.  
With the adoption of these modifications to the method, subsequent von Frey testing 
achieved more consistent baseline 50% withdrawal thresholds, both within and 
between individual mice (Figure 3.1b: Trial 4). 
Following the establishment of consistent and repeatable 50% withdrawal threshold 
measurements from naïve mice, AIA was induced and testing repeated on Day 3 and 
day 14, post arthritis induction (Figure 3.1c). This demonstrated little change in left 
and right 50% PWT in saline injected mice at day 3 and 14. In AIA mice there was no 
change in the 50% PWT of the left hind limb, but a significant reduction in the 50% 
PWT of the right hind limb at day 3 (p = 0.007) that persisted to day 14 (p = 0.012). 
This confirmed the ability to detect reduction in PWT using the von Frey method 
described above, following the induction of arthritis. 
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Figure 3.1c. Development of von Frey test protocol 
50% PWT at day 0, day 3 and day 14 following induction of AIA in C57BL mice 
(n=6), in the right knee joint.  Sham group (n=6) were immunised and received an 
intra articular saline injection. At day 3 (P=0.007) and 14 (P=0.012) 50% PWT in the 
right limb was significantly reduced compared to baseline in AIA mice. The results 
are presented graphically as a line graph of the means with SEM marked. 
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3.1.2 Thermal hyperalgesia 
Quantitative assessment of thermal hyperalgesia was performed using a hotplate 
device (Ugo Basile, Italy). The hotplate assay was first reported by Woolfe and 
MacDonald in 1944 (534), and later modified by Eddy and Leimbach (535). Eddy and 
Leimbach used a 55-degree hotplate to test a number of novel new compounds for 
their analgesic properties in comparison to morphine and methadone. They tested 
2000 naïve mice and calculated a mean reaction time of 9.51 seconds +/- 1.02 
seconds.  
Pain researchers have used the hotplate assay extensively. However, there is still no 
consensus on the optimal test temperature, the effect of acclimatisation and 
habituation, or which response behaviours best correlate with pain. The literature 
suggests that a lower intensity stimulus (≤ 50 degrees Celsius) is more sensitive at 
detecting an effect, but produces greater variability in the response latency (517, 536). 
There are conflicting reports about the effect of habituation, with some researchers 
demonstrating a significant decrease in response latency (from 20 to 12 seconds) 
across trials when using a 50 degrees hotplate, but no change in sensitivity to the 
analgesic effects of morphine (517). Other researchers have demonstrated a 
significant repeated testing effect in mice tested 6 times at 30-minute intervals over a 
three-hour test period using a 59-degree hotplate, with a trend of decreasing latency 
with each test trial (537). In contrast, response latency was unaffected by repeated 
testing when a 55-degree hotplate was used with a short maximum exposure (20 
seconds) (538).  
A decrease in response latency represents an increased sensitivity to a noxious heat 
stimulus. This may be due to the influence of stress-induced anti-nociception (SIA), 
which in part is mediated via the endogenous opioid system (539). A novel test 
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environment, restraint or other physical stressors can all induce SIA (540). Repeated 
exposure to a noxious stimulus, whether during habituation or repeated test measures, 
will potentially reduce the effect of SIA and therefore result in an increase in 
sensitivity. This could be explained by the idea that different temperatures will recruit 
different populations of sensory afferents, some of which can be modulated by 
opioids (including endogenous opioids) and others that can’t. 
Prior to testing, mice were acclimatised by placing them in the Perspex cylindrical 
chamber for brief intervals of time (30 to 60 seconds), on four separate occasions over 
a one-week period. Two temperature settings, 42 degrees and 50 degrees Celsius, 
were used to optimise the test. These temperatures were selected for the following 
reasons: 
- Exposure to temperatures greater than 42 degrees Celsius represents a shift in
perception from innocuous warmth to noxious heat (541).
- There are a number of nociceptors that detect heat and have been implicated in
the development of inflammation driven thermal hyperalgesia. The role of the
TRPV1 receptor is the best characterised of these and this receptor is activated
by noxious temperatures greater than 42 degrees Celsius (541).
- The literature suggests that a low intensity stimulus (≤ 50 degrees Celsius) is
more sensitive at detecting a treatment effect.
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Initially the hotplate was set to 42 degrees Celsius. Individual mice were placed in a 
cylindrical Perspex chamber, which lay over the hotplate and prevented escape. A lap 
timer was used to record the time at which the following observations first occurred: 
- Shaking of front paw
- Licking/chewing of front paw
- Shaking of hind paw
- Licking/chewing of hind paw
- Jumping
Exposure to the hotplate did not exceed 60 seconds to avoid thermal injury to the 
ventral paw skin. Mice were then returned to their cage mates. After a 15-minute 
period of recovery the test was repeated with the hotplate temperature set at 50 
degrees Celsius. Exposure to the hotplate for the second time did not exceed 30 
seconds to avoid thermal injury to the ventral paw skin. Baseline measurements were 
taken on three separate occasions in the same 12 mice over a one-week period. 
When the hotplate was set at 42 degrees Celsius only 2 out of 12 mice responded 
before the 60-second cut off. One mouse responded on only one occasion and one 
mouse responded for two out of three baseline tests. When the hotplate was set at 50 
degrees Celsius all mice responded in less that 60 seconds, but there was significant 
within-mouse variability across the three baseline trials (Figure 3.2a), and significant 
between-mouse variability for any given baseline test [(mean ± SD (10.0 ± 3.0)]. This 
finding supported what other investigators have reported about the use of a low 
intensity stimulus (517, 536). 
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Figure 3.2a. Baseline paw withdrawal latency (PWL) 
Hotplate set at 50°C. Graph demonstrates the variability in baseline PWL in naïve 
C57BL mice (n=12) tested three times over a one-week period (trial 1 – 3). The PWL 
endpoint was defined as either front limb or hind limb response.  
Figure 3.2b. Development of Hotplate test protocol 
Baseline hind limb PWL when hotplate set at 50°C in C57BL mice (n=12). PWL 
endpoint defined as time to first attempt at shaking or licking hind paw. Testing was 
then repeated day 3 and day 7 following induction of AIA. At day 7, PWL in AIA 
was significantly increased compared to saline injected mice (P=0.02). The results are 
presented graphically as a bar graph of the means with SEM’s marked. 
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Licking behaviour of the front paws was displayed when mice were grooming as well 
as in response to the noxious heat stimulus. Therefore, in some mice the time to first 
licking their front paw was very short and did not represent a withdrawal response to 
a noxious stimulus. It was also difficult to interpret jumping behaviour. Jumping 
behaviour was observed in many mice during acclimatization when the hotplate was 
in fact not turned on (room temperature). Therefore, jumping is an escape behaviour 
and not specifically related to pain. So mice that displayed jumping behaviour may 
have been attempting escape from the confinement of the chamber, or the noxious 
heat stimulus, or both. Despite acclimatisation, some mice had an aversion to being in 
the Perspex chamber and almost immediately attempted to escape by jumping.  
Based on these observations, the following changes were made to the hotplate test 
protocol: 
- Mice whose first response was to jump were eliminated from the study.
- The paw withdrawal latency (PWL) was redefined as time to first attempt at shaking
or licking a hind limb. This avoided misinterpretation of grooming behaviour (licking 
the front paws) as a positive response to the thermal stimulus.  
This protocol was then used to compare AIA mice and immunised saline injected 
mice at day 3 and day 7 (Figure 3.2b).  
There was no significant difference in PWL between treatment groups at D0 or D3. 
At D7 there was a significant difference between treatment groups (p=0.02). 
However, this corresponded to a decrease in PWL in the saline group rather than the 
AIA group. There was no significant difference within each treatment group when 
comparing baseline (D0) to D3 or D7 post treatment (Table 3.2). 
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Table 3.2: Hotplate Test 
Plate set at 50°C. End point described as hind limb paw withdrawal latency (PWL). 
(*) Paired data analysis using Wilcoxon signed-rank test (significance p<0.05). (**) 
Unpaired data analysis using Mann-Whitney test (significance p<0.05). 
Therefore, development of thermal hyperalgesia could not be demonstrated in the 
AIA model when mice were exposed to a 50 degrees Celsius heat stimulus. Based on 
this finding the protocol for the hotplate test was revised further and tested on 12 
additional mice. The TRPV2 channel is activated following exposure to temperatures 
greater than 52 degrees Celsius (206), and may also play a role in the development of 
inflammation driven thermal hyperalgesia (211). The hotplate settings were therefore 
increased to 52 and 55 degrees Celsius and mice were exposed to the stimulus for a 
maximum of 60 seconds. Two measures were taken for each temperature setting and 
the values averaged. Mice were rested for at least 15 minutes prior to retesting. At 55 
degrees 10 out of the 12 mice displayed jumping behaviour on at least one of the 
trials. At 52 degrees only two mice displayed jumping behaviour on one of the trials, 
and the PWL was less variable within individual mice (Figure 3.2c).  
Treatment Baseline vs. D3 Baseline vs. D7 
Saline 0.35* 0.21* 
AIA 0.60* 0.60* 
Baseline Day 3 Day 7 
AIA vs. Saline 0.26** 0.26** 0.02** 
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Figure 3.2c. Development of Hotplate test protocol 
Baseline hind limb PWL when hotplate set at 52°C in C57BL mice (n=12). PWL 
endpoint defined as time to first attempt at shaking or licking hind paw. The higher 
temperature resulted in less variability in baseline PWL in mice (P = 0.42; trial 1 vs. 
trial 2) 
Figure 3.2d. Development of Hotplate test protocol 
Hind limb PWL at day 0, day 3 and day 7 following induction of AIA in C57BL mice 
(n=6), in the right knee joint. Sham group (n=6) were immunised and received an 
intra articular saline injection. At day 3 and 7 PWL was decreased compared to 
baseline in both saline and AIA mice. The results are presented graphically as a bar 
graph of the means with SEM’s marked. 
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Following the establishment of less variable hind limb withdrawal latency 
measurements from naïve mice, AIA was induced and testing repeated on Day 3 and 
day 7, post arthritis induction.  
At 52 degrees Celsius the PWL was decreased at day 7 relative to baseline in both 
AIA and Saline groups, but the decrease was not statistically significant (AIA p=0.92; 
Saline p=0.25) (Figure 3.2d). There was no significant difference between AIA and 
saline at any of the test time points (Day 3 p=0.82; Day 7 p=0.12). While this 
experiment failed to demonstrate a significant change in hotplate hind limb latency 
with AIA up to 7 days post induction, the test itself was robust and repeatable. 
3.1.3 Mechanical hyperalgesia  
Knee joint hypersensitivity is measured clinically in OA patients to assess pain. This 
is usually done by directly squeezing the joint with a pressure-measuring device such 
as a pressure dolorimeter (542). Electronic devices such as these have been shown to 
produce less between-observer variability compared to manual techniques (543). 
However, it is only moderately reliable at differentiating OA patients from healthy 
controls, and is poorly correlated with other measures of pain intensity such as the 
McGill Pain Questionnaire (544).  
The use of a commercial digital pressure application measurement (PAM) device 
(Ugo Basile, Italy) has the advantage of delivering a quantifiable force that can be 
directly applied to the knee joint. Baseline withdrawal thresholds (WT) are reported in 
rat models of inflammatory arthritis (518). The PAM device has been validated in 
both mice and rats (545), however, the majority of studies reporting the use of the 
PAM device were conducted in rats (453, 546, 547). The device’s software produces 
a graphical readout of the pressure being applied in real time and this allows the rate 
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of increase in pressure to be controlled. Increasing the pressure applied at a consistent 
rate produces greater inter-operator agreement (545). It has been demonstrated that 
the ramp speed of a stimulus increase affects the response threshold, with an 
increased steepness resulting in increased thresholds (548). An optimal increase rate 
of 30g/s is recommended for mice when using the PAM device, and this translates to 
a maximum test time of 15 seconds when the maximum applied force is set at 450g 
(Figure3.3a). 
Figure 3.3a. Pressure Application Measurement (PAM) device 
Screen shot of force/time graph with optimal rate of increase set at the recommended 
30g/sec. Maximum test time = 15 seconds and maximum force = 450g.  
Figure 3.3b. PAM protocol restraint method 
The mouse is cradled in the palm of the right hand while grasping the loose skin along 
the neck and back, with the tail secured between the palm of the hand and the last 
digit. 
117 
For mice a 5 mm circular probe is recommended to limit the size of the stimulus area. 
Unlike rats, mice require significant restraint to enable application of the circular 
probe over the area of the knee joint. Initially mice were removed from their home 
cage by grasping them at the base of the tail. They were then placed on the top of the 
wire lid, and while the left hand continued to gently hold the base of the tail, the right 
hand pinched the loose skin at the back of the neck. The tail was then released and the 
mouse cradled in the palm of the right hand while grasping the loose skin right along 
the neck and back, with the tail secured between the palm of the hand and the last 
digit (Figure 3.3b). The WT was determined for the right and left knee in naïve mice, 
by squeezing the knee between the thumb (with probe attached) and the index finger. 
There was considerable variability between the left and right limb in the majority of 
individual mice (Figure 3.3c). 
Figure 3.3c. Development of PAM device protocol 
Baseline testing of naïve C57BL mice (n=12). Trial 1 graph illustrates considerable 
variability between left and right hind limb withdrawal threshold (WT) in the majority 
of mice (P = 0.033; right vs left WT). 
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A number of observations were made during baseline testing that may have 
contributed to the variability in PAM outcome.  Some mice resisted restraint and 
vocalised when restrained prior to the application of the probe. These mice were 
released, allowed to recover and then restrained again. Other mice became very still 
and unresponsive when restrained, displaying a catalepsy-like state. Manipulation-
induced behavioural arrest in response to restraint such as pinching the skin of the 
neck has been demonstrated in a number of prey species including mice and rabbits 
(549, 550). The response to having pressure applied to the knee varied between 
individuals; some simply turned and looked at their knee, some vocalised, some 
retracted their limb and struggled in an attempted to release themselves, and some 
displayed both of these behaviours. 
The variability in baseline thresholds was attributed to the following: 
- Differences in response behaviour between mice.
- Confounding effect of distress caused by the actual restraint method
- Confounding effect of manipulation-induced behavioural arrest (catalepsy)
- Variability in the exact anatomical location where the probe made contact with
the knee, ie. medial vs. lateral joint compartment, patella-femoral vs femoro-
tibial joint compartment.
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To reduce this variability in baseline WT both within and between mice, the 
following modifications were made to the PAM protocol, and baseline testing was 
then performed on a new set of 12 mice. 
- Each mouse was tested at four sites; medial and lateral knee joints on both left
and right knees. The medial and lateral measurements from each side were
combined and averaged to obtain a single WT value for the left and right knee.
- Mice who struggled and vocalised immediately following restraint were
released and given time to recover before testing was attempted again.
- In mice that demonstrated catalepsy, mild head movement in the direction of
the knee was considered a positive response.
- In mice that did not demonstrate catalepsy, purposeful limb withdrawal,
struggling and/or vocalisation were all considered a positive response.
Mice were tested twice at each location to obtain an average withdrawal response. 
Following these adjustments and with continued practice of the technique, baseline 
testing became less variable (Figure3.3d). AIA was then induced and testing repeated 
on day 7 and day 14, post arthritis induction (Figure 3.3e). This demonstrated a small 
decrease in left and right WT in both saline injected and AIA mice at day 7. This 
decrease reverted at day 14 except in the right hind limb of AIA mice. In AIA mice 
there was a significant decrease (p = 0.035) in right hind limb WT compared to the 
left hind limb at day 14. This confirmed the ability to detect a reduction in WT using 
the PAM device as described above, following the induction of arthritis. 
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Figure 3.3d. Development of PAM device protocol 
Baseline testing of naïve C57BL mice (n=12). Trial 2 graph illustrates reduced 
variability between left and right hind limb WT in all mice, following modifications 
to the testing protocol (as described in section 3.1.3). 
Figure 3.3e. Development of PAM device protocol 
WT at day 0, day 7 and day 14 following induction of AIA in C57BL mice (n=6), in 
the right knee joint.  Sham group (n=6) were immunised and received an intra 
articular saline injection. At day 14 (P=0.035) WT in the right knee was significantly 
decreased compared to the left knee in AIA mice. The results are presented 
graphically as a line graph of the means with SEM’s marked. 
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3.1.4 Weight distribution  
Hind limb weight distribution is considered a clinically relevant measure of OA pain 
(551).  It mimics the clinical observation of pain on standing that is reported by OA 
patients.  
A purpose built incapacitance tester was used to measure hind limb weight 
distribution (Figure 3.4a). This device quantifies the force applied to two precision 
force transducers over which lie metal plates where the hind paws of the test mouse 
are placed. A special Perspex chamber was also made, to restrain the mouse and 
enable visualisation of correct positioning. The transducers were linked to LabVIEW 
Run-Time Engine 2009 software (National Instruments, Australia) and a National 
Instruments-DAQmx hardware driver that enabled continuous data acquisition and 
graphical readout (Figure 3.4b), as well as the easy conversion of data to excel format 
for later viewing and analysis. Commercially available incapacitance testers such as 
the Columbus Instruments InCap do not provide a continuous readout, but rather give 
a single readout based on the average force applied over a pre set time interval, 
usually no more than a few seconds.  
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Figure 3.4a. Incapacitance device used to measure hind limb weight distribution. 
Figure 3.4b. Hind limb weight distribution 
Graphical continuous readout of applied force of the right (series 1) and left (series 2) 
hind limb. Each 30-second test trial was preceded by 2 standard weight measurements 
(13.0g and 14.6g) to zero the instrument. 
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Mice were acclimatised prior to baseline testing by placing them in the chamber for 3-
minute intervals on alternate days, the week before testing commenced. The 
continuous graphical readout enabled a number of observations to be made during this 
acclimatisation period. 
- Even when mice appear to be still, they will shift their weight from limb to
limb periodically.
- When male mice position their forelimbs on the front vertical wall of the
Perspex chamber, their scrotum remains in contact with the force plates and
this contributes to the force applied to each plate.
- Naïve mice with no prior musculoskeletal pathology will preferentially
weight-bear on one particular hind limb and intermittently shift their weight.
- Subtle movements like turning the head to the left or right results in significant
changes in hind limb weight distribution.
Based on these observations, it was evident that a single time point measurement 
would reflect an animal’s weight distribution patterns less accurately than averaging 
the weight distribution measurements over a set time interval. A 30 second test period 
was selected. It was observed that mice become very agitated if confined in the test 
chamber for longer periods. 
After placing the mouse in the test chamber, the tail was exteriorised and supported to 
ensure the base of the tail and the testicles were elevated off the force plates. The 
mouse was then allowed to settle in the chamber and get into the correct position, 
before testing commenced. This modification reduced the variability in baseline 
weight distribution in naïve mice (Figure 3.4c: Trial 1 vs. Trial 2). AIA was then 
induced and testing repeated on day 3 and day 7, post arthritis induction (Figure 3.4d). 
This demonstrated no change in hind limb weight distribution in saline injected mice 
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at day 3 or day 7. In AIA mice there was a significant change in hind limb weight 
distribution at day 3 (p = 0.001) and day 7 (p < 0.001). In fact, the right to left weight 
distribution ratio decreased from 1 to less than 0.5. This confirmed the ability to 
detect a change in R to L hind limb weight distribution using an incapacitance device 
as described above, following the induction of arthritis. 
Figure 3.4c. Development of hind limb weight distribution test protocol 
Baseline hind limb weight distribution in naïve C57BL mice (n=12). Trial-1 
measurements are a single point in time measurement of applied force (right/left) in 
grams, recorded once the mouse was correctly positioned in the test chamber. Trial-2 
measurements are the average of a 30 second continuous measurement of applied 
force (right/left) in grams, recorded during periods when the mouse was correctly 
positioned in the test chamber. The results are presented graphically as a scatter plot 
with means and SEM’s marked. 
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Figure 3.4d. Development of hind limb weight distribution test protocol 
Hind limb weight distribution (R/L ratio) at day 0, day 3 and day 7 following 
induction of AIA in C57BL mice (n=6). Sham group (n=6) were immunised and 
received an intra articular saline injection. In AIA mice there was a significant 
decrease in the R/L weight distribution ratio at day 3 (P=0.001) and day 7 (P<0.001). 
The results are presented graphically as a line graph of the means with SEM’s 
marked. 
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3.1.5 Stride length  
The relationship between pain, disability and kinematics has been investigated 
extensively in humans with OA (552) however, the clinical significance of gait 
analysis as a tool for investigating the relationship between knee angles and moment, 
and pain and disability is still not clearly defined. It has been demonstrated that 
people with OA have a shorter stride length and walk more slowly than disease free 
adults (553). Stride length has also been measured in numerous animal models of 
arthritis using manual video recordings (554), video-based automated gait analysis 
systems (eg Catwalk™, Noldus Information Technology) (555), automated treadmills 
(556), digital imaging systems (e.g. DigiGait, Mouse Specifics, Inc.)(515), and paw 
print measurements (493). 
For this study a one-metre-long clear Perspex tunnel was used (Figure 2.3e). The base 
of the run was lined with white thermal paper Each mouse was restrained by pinching 
the dorsal skin of the neck and non-toxic paint (Crayola, Australia Pty Ltd) applied to 
the ventral surface of the hind paws (Figure 2.3e). The mouse was then released into 
the tunnel, leaving its paw prints on the paper as it made its way to the end of the 
tunnel. The paper was removed and allowed to dry. The paw prints were then used to 
measure the distance between consecutive footprints from opposite limbs (right-to-left 
and left-to-right distance) and from the same limb (left-to-left and right-to-right 
distance) (Figure 3.5a).  
After an initial test trial it was observed that many mice were hesitant to walk along 
the tunnel. In subsequent trials the sides and last third of the top of the tunnel were 
covered with black paper. This created a dark environment and encouraged mice to 
run to the end of the tunnel.  
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It was also observed that some mice stopped along the run to groom and/or 
urinate/defecate. Paw prints made during these activities were noted on the paper and 
not used to measure stride length, as this artificially reduced the average stride length 
(Figure 3.5b). Measurements were taken from a section where at least 5 consecutive, 
uninterrupted strides occurred. 
Figure 3.5a. Hind limb paw print trace for stride length measurement 
The right-to-left and left-to-right stride lengths are labelled in blue. The right-to-right 
and left-to-left stride lengths are labelled in red.  
Figure 3.5b. Development of stride length measurement protocol 
Hind limb paw print trace with urine stains marked (black dotted line). This trace 
illustrates the decrease in stride length (right-to-right) that occurs when mice stop to 
urinate or defecate. These artificially shortened strides were not used to calculate the 
average stride lengths 
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Figure 3.5c. Development of stride length measurement protocol 
Hind limb paw print traces recorded at day 0, day 3 and day 7 following induction of 
AIA in C57BL mice (n=6). Sham group (n=6) were immunised and received an intra 
articular saline injection. Both stride length (right-to-left) and complete stride length 
(right-to-right) were reduced in AIA mice at day 3 compared to baseline. The results 
are presented graphically as a line graph of the means with SEM’s marked. 
Speed was not measured in this study, but it was apparent simply through visual 
observation that mice moved at different speeds along the run. Speed alters stride 
length (557) and so in many studies walking velocity is adjusted for when 
determining changes in stride length (515). However, speed itself changes with 
disease state and pain, and so adjusting for differences in walking speed may mask 
changes in gait that are in fact due to joint disease and/or pain. For example, 
Complete Freund’s adjuvant (CFA) induced arthritis in rats results in both reduced 
velocity and a dramatic reduction in stride length (558). 
In this study relative stride length was also determined by calculating stride length 
when supporting the affected limb (right-to-left) relative to complete stride length 
(right-to-right) as previously described (493, 559). 
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Following acquisition of baseline stride length data, AIA was induced and testing 
repeated on Day 3 and day 7, post arthritis induction. This showed firstly that both 
stride length measurements (right-to-left and right-to-right) were consistent pre-
arthritis induction (Figure 3.5c day 0). Both stride length (right-to-left) and complete 
stride length (right-to-right) were reduced in the AIA mice at day 3 (Figure 3.5c) but 
then returned to baseline by day 7. This is similar to other studies that used the AIA 
model, where a decrease in stride length was only observed in the early acute phase of 
the disease (493). 
3.1.6 Rotarod  
The rotarod is an automated rotating rod that forces motor activity once a mouse or rat 
is placed on it. It has been used to test sensorimotor skills (balance and coordination) 
in a number of different animal models, including arthritis models in rats and mice 
(412, 560, 561). 
In this experiment an accelerating rotarod was used (Ugo Basile, Italy) (Figure 3.6a), 
commencing at a speed of 4 rpm and accelerating to 40 rpm over a 300 second 
interval, and continuing for a total of 6 minutes (or until the mouse fell off the rod). 
To condition mice to the rotarod four training trials were conducted the week prior to 
commencing baseline testing. These involved 2 trials with a 15-minute rest interval 
between testing. As previously reported (520), latency to fall (LTF) was defined as 
time to fall or passive rotation, with passive rotation occurring when a mouse freely 
rotated on the rod for two consecutive revolutions. 
To determine baseline and subsequent LTF values, one training trial was conducted 
followed by two test trials. The two test trials were used to determine the mean LTF. 
Mice were rested for 15 minutes between each test. 
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Despite conditioning the mice, there was considerable variability in baseline LTF 
between mice (range 198 – 400) (Figure 3.6b), with some mice displaying the ability 
to remain on the rotarod for much longer than the maximum 6 minutes. A ceiling 
value of 400 seconds did not truly reflect the LTF for those mice. During testing it 
was observed that mice developed different strategies for staying on the rod. For 
example, some mice used the side panel to lean on for support. This enabled them to 
take weight off the contralateral limb and still use the ipsilateral limb to walk and not 
fall off the rod. Other mice performed single passive revolutions at regular intervals to 
rest their hind limbs and therefore prevent falling.  
Changes in LTF have best been demonstrated in animal models where arthritis is 
induced in both hind limbs (560) or in multiple limbs (412). This may be due to the 
fact that when multiple joints are affected it is difficult to compensate by shifting 
weight distribution to an unaffected limb and minimise the work done by the affected 
limb. 
131 
Figure 3.6a. Development of rotarod test protocol 
The mouse in the first chamber is moving while the device is rotating and maintaining 
his balance. The mouse in the second chamber has lost balance and fallen off the rod. 
Figure 3.6b. Development of rotarod test protocol 
Baseline latency to fall (LTF) measurements recorded in seconds. The rotarod 
commences rotating at a speed of 4 rpm, accelerates to 40 rpm over 300 seconds and 
continues for a total of 6 minutes. The graph illustrates the variability in baseline LTF 
in naïve C57BL mice (n=12) and how the number of animals that remained on the 
rotarod after 6 minutes skews the data. The results are presented graphically as a 
scatter plot with means and SEM’s marked.  
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The decision was made not to continue with rotarod testing for the following reasons: 
- The adaptive behaviours that were observed confounded any changes (or lack
thereof) in LTF observed following induction of AIA.
- In subsequent experiments arthritis would be induced in only one knee joint,
allowing for adaptive compensatory behaviours to develop.
- The ability of individual mice to stay on the rod for times that far exceeded 6
minutes meant that a maximum LTF of 400 seconds masked the extent of
variability in LTF between individual animals.
3.1.7 Pain testing Conclusions 
After conducting these preliminary pain behaviour experiments and testing the 
modified pain behaviour test protocols in the AIA model, the following tests were 
selected to conduct subsequent experiments in this thesis.  
1. Von Frey
2. Hotplate 52°C
3. PAM – medial and lateral averaged for each knee joint
4. Forceplate – 30 second continuous reading averaged
5. Stride length – right-to-left and right-to-right stride
 These pain behaviour tests were then used to define the pain phenotype in both 
arthritis models and investigating how this changes over time, and how it maps to 
knee joint pathology. 
133 
3.2 Histology scoring  
Pathology in all joint tissues can be a feature of OA in humans. Synovitis, cartilage 
proteoglycan loss, loss of cartilage integrity and erosion, alterations in chondrocyte 
morphology, subchondral bone remodelling leading to erosion, increased 
vascularisation and thickening, and formation of marginal osteophytes and 
enthesiophytes, are features of knee joint histology changes in patients with 
symptomatic OA presenting for total knee replacement (TKR) (379). Different 
aspects of joint pathology feature in different OA phenotypes and at different stages 
of the disease; and only some have been associated with pain.  Most patients with 
knee OA have medial compartment tibio-femoral joint (TFJ) OA, femora-patella joint 
(FPJ) OA, or a combination (562, 563). In this thesis, histological evaluation of TFJ 
pathology focused on the pattern of change observed in human patients. A method of 
evaluation was required to define and quantify the knee joint histopathology that 
developed in the two distinct mouse models that were used. 
Reporting of OA joint pathology in mouse models has previously focused 
predominantly on the changes that occur in cartilage, and published recommendations 
such as The OARSI Histopathology Initiative (462) are aimed at standardising how 
histological sections are assessed. An additional challenge when it comes to assessing 
and reporting joint histopathology is that joint injury can result in both focal and 
diffuse joint pathology. In the case of the DMM model, pathology develops primarily 
in the medial compartment of the joint. Therefore, evaluating a pt-OA model requires 
scoring multiple sections of the joint in order to identify maximum and cumulative 
(total in all sections of the TFJ) pathology scores (462).  
In contrast, histological evaluation of inflammatory arthritis models such as AIA has 
previously been determined on a single 6m sagittal section corresponding to the 
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central weight-bearing region of the medial TFJ (439). This assumes inflammation is 
a global joint change. There are multiple scoring systems reported (452, 493, 521) and 
all focus on synovial changes (including cellular infiltration) and the degree of joint 
space inflammatory cell effusion.  
A detailed scoring system (Appendix C) was developed to evaluate TFJ pathology in 
the two mouse models used in this study. It combined the evaluation of joint structural 
damage (articular cartilage and subchondral bone changes) using a similar scoring 
system to that described in the OARSI Histopathology Initiative (462), and the 
evaluation of joint changes associated with inflammation (synovitis, synovial 
hypertrophy and joint cellular infiltration). To enable comparison between the two 
arthritis models, histological evaluation of knee joints was done on a single 6m 
sagittal section that corresponded to the central weight-bearing region of the medial 
TFJ.  
The following validations were performed before adopting the scoring system to 
compare the two arthritis models over time, and investigate the relationship between 
specific joint pathology features and pain outcome measures. 
1. Serial sagittal sections across the width of the medial TFJ from DMM, Sham, AIA
and Saline injected control mice at day 7 and day 28 following induction of
arthritis (n=6 mice per treatment group), were scored using the measures of joint
inflammation defined in Appendix C. Two (2) independent observers who were
blinded with regard to treatment, joint region and time performed the scoring. The
maximum score for each of the joint inflammation parameters irrespective of the
slide was recorded. The scoring system demonstrated a significant and repeatable
difference between treatment groups and within treatment group (AIA, DMM,
Sham) over time (day 7 vs. day 28) (Figure 3.7a). The differences over time for
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DMM and Sham demonstrated the sensitivity of the scoring system, as it was able 
to quantify post-surgical inflammation (evident in DMM and Sham groups at day 
7), and inflammation associated with OA disease (evident in DMM only at day 
28). The scoring system also demonstrated low inter-observer variability of 
individual scores and total scores  (Figure 3.7b). 
Figure 3.7a. Synovial inflammation 
This graph represents the maximum score for each of the joint inflammation 
parameters irrespective of the slide. Serial sagittal sections across the width of the 
medial tibio-femoral joint from DMM, Sham, AIA and saline injected mice (n=6 per 
treatment group) at day 7 and day 28 following induction of arthritis, were scored 
using the measures of inflammation defined in Appendix C. The results are presented 
graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. 
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Figure 3.7b. Inter-observer variability 
This graph represents the inter-observer variability for both individual (panus-PA, 
cortical bone erosion-CBE, synovial hyperplasia-SH, sub-synovial inflammation-SSI, 
synovial exudate-SE) and total inflammation scores of AIA mice (n=6) at day 28 
following induction of arthritis. Scoring was performed by two independent observers 
blinded with regard to treatment, joint region and time, The results are presented 
graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. 
Figure 3.7c. Serial sagittal section scores 
This graph represents the combined scores of serial sagittal sections across the width 
of the medial TFJ for tibial articular cartilage (AC) damage (mean = 0.33, SEM = 
0.33) and tibial proteoglycan (PG) loss (mean = 5.0, SEM = 0.0) for AIA mice (n=4). 
Scores were similar across all sections of the medial compartment indicating the 
central weight-bearing region is a suitable site for scoring maximum joint damage. 
The results are presented graphically as floating bars (minimum and maximum) and a 
line at the mean. 
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2. In AIA mice (n=4), serial sagittal sections of the medial TFJ were scored by two
independent observers blinded to joint region, to determine if structural joint
changes were similar across the entire medial compartment of the joint and
therefore whether the central weight-bearing section reflected the maximum
cartilage damage score. Scores were similar across all sections of the joint (Figure
3.7c), indicating that the central weight-bearing region was a site of maximum
joint damage.
3. In DMM mice, serial sagittal sections of the medial TFJ were scored by two
independent observers, blinded to joint region, to determine the maximum
cartilage damage score based on serial sections and compare with scores from the
central weight-bearing section. There was no significant difference between the
central weight-bearing region score and the maximum articular cartilage damage
score when determined by scoring serial sections (Figure 3.7d).
4. In DMM mice, sagittal sections corresponding to the site of maximum
inflammation score, the maximum articular cartilage damage score and the central
weight-bearing region of the medial compartment of the TFJ were scored (n=3) at
seven time points (day 3, week 1, 2, 4, 8, 12, 16), by two independent observers
who were blinded to joint region and time (Figure 3.7e). At all time points the
inflammation score was not significantly different between the central weight-
bearing section and the maximum articular cartilage structural damage section. At
week1, 4, 12 and 16 these two sections both reflected the maximum joint
inflammation score.
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Figure 3.7d. Maximum score vs. central weight bearing section 
This graph represents the maximum scores determined by scoring serial sagittal 
sections across the width of the medial compartment of the TFJ and the central 
weight-bearing (CW-B) section scores for each measured parameter: tibial articular 
cartilage damage (AC-D (T)); tibial proteoglycan loss (PG-L (T)); osteophyte 
maturity (OM); osteophyte size (OS) and subchondral bone sclerosis (SCB-Sc); from 
DMM mice (n=6) 28 days after induction of arthritis. The results are presented 
graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. 
Figure 3.7e. Synovial inflammation comparative scores 
This graph represents histology scores for sagittal sections corresponding to the site of 
maximum inflammation score (synovitis max.), maximum articular cartilage damage 
score (AC damage max.) and the central weight-bearing region (CWB) of the medial 
compartment of the TFJ from DMM mice (n=3) day 3, week 1, 2, 4, 8, 12 and 16 
after induction of arthritis. The results are presented graphically as box plots, with 
medians marked and whiskers depicting upper and lower limits of dataset. 
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Taken together, these findings indicated that both maximum articular cartilage 
damage and global joint inflammation can be reliably quantified, and compared 
between treatment groups, by evaluating a single histological section at the level of 
the central weight-bearing region of the medial TFJ, using the scoring system 
described in this thesis (Appendix C). 
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CHAPTER 4:  Knee joint histopathology following 
destabilization of the medial meniscus (DMM) and 
antigen-induced arthritis (AIA) in mice 
4.1 Introduction and aims 
In this current chapter, the progressive histopathological changes that occurred in 
different knee joint tissue structures, following induction of arthritis using two distinct 
arthritis models are evaluated and compared.  
The knee joint is a complex organ comprising cartilage, subchondral bone, synovium, 
capsule, ligaments, tendons and muscles; and pathology of all joint tissue structures is 
a feature of OA in humans (70). Inflammation is a major feature of animal models 
such as AIA, and inflammation also plays a significant role in the pathogenesis of OA 
in humans (70). In fact, joint inflammation (synovitis) is one of the few joint 
pathologies of OA that has been shown to correlate with disease symptoms (74, 75).  
Histopathology is the gold standard by which to measure joint pathology in animal 
models of arthritis. However, different methods and scoring systems have been 
reported for the two animal models used in this thesis (25, 26, 439, 448).  In order to 
better compare joint pathology changes over time in the two models, the same 
processing methods and scoring system were used. The scoring system used 
quantifies all aspects of OA joint pathology, allowing further investigation into 
whether different stages of disease and different disease phenotypes (inflammatory vs. 
post-traumatic) demonstrate different patterns of joint pathology. The scoring system 
also provides scope for investigating the relationship between pain and specific joint 
pathologies at different stages of OA disease. 
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The aims of chapter 4 are: 
1. To characterize the histopathology changes that develop in the knee joint
following induction of arthritis using two murine models (AIA and DMM),
including the temporal pattern of these changes.
2. To identify any associations between the different tissue pathologies that develop
over time, and compare these associations between the two murine models to
identify key features that might link the models to different human OA
phenotypes.
4.2 Methods, statistical analysis and data presentation 
Details of the methods used to induce the two models of arthritis, DMM and AIA, are 
described in chapter 2, section 2.1. The methods used for histological processing, 
sectioning and staining are described in chapter 2, section 2.2. The scoring system 
used is outlined in Appendix C. Development and validation of this scoring system is 
described in chapter 3, section 3.2. 
Comparison of histopathology scores between treatment groups and time points were 
analysed using the nonparametric ranked Kruskal-Wallis analysis for multiple groups 
and, where there was significance, the Mann Whitney U-test (for unpaired data) was 
performed for between group comparisons (StataSE software, Stata corporation, TX, 
USA). The Benjamini-Hochberg correction (564) was applied to the P values of the 
histology scores. The resulting P values for each histology score, when the alpha level 
was set at 0.05, are summarized in Table 4.1a and 4.1b. The results are presented 
graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of the 
dataset. 
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Associations between the different histology scores were determined by generating 
partial correlation coefficients, using Kendall’s tau-b (565). This nonparametric 
process uses pairwise ranked data values between the two variables under study 
(ordinal scores) and thus does not require data to be normally distributed or the 
relationship between the variables to be linear. The Benjamini-Hochberg correction 
was applied to the P values of the histology associations for each score, resulting in P 
< 0.022 being considered significant when the alpha value was set at 0.05. 
Ordinal logistic regression was used to determine whether the histology outcome 
variables changed over time; and correcting for time, whether there was a difference 
between treatments. The Benjamini-Hochberg correction was applied to the P values 
of the time and treatment effects for each score, resulting in P < 0.035 being 
considered significant when the alpha value was set at 0.05.  
Since AC damage is the hallmark of human OA and radiographic joint space 
narrowing is still used to diagnose and grade the disease; AC damage was assigned as 
the dependent variable and odds ratios were calculated to determine what factors 
increase the risk of joint disease developing in the two arthritis models. In human OA, 
synovitis is more strongly associated with pain than AC damage (74), and so in 
separate analyses synovitis was also assigned as a dependent variable and odds ratios 
were calculated to determine what factors increased the risk of synovitis developing 
in the two arthritis models. 
In the results, ‘significance’ refers to statistical significance, with P values included in 
the results tables.  
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4.3 Results 
Representative histological sections of the knees of mice day 3, week 1, 2, 4, 8, 12 
and 16 after induction of arthritis (DMM and AIA), and age matched control mouse 
joints are presented in Figures 4.1a to 4.1c. Marked differences in joint histological 
features were observed between treatment groups and many histopathological features 
demonstrated a model-specific temporal pattern of change.  These differences 
between models and with time, are readily apparent in outcomes of quantitative 
scoring of arthritis pathology. 
4.3.1 Effect of AIA and DMM on inflammation following induction of arthritis 
Joint inflammation was defined as synovitis. Synovial inflammation was evident in 
AIA, DMM and sham surgery mice from day 3 following induction of arthritis. In 
both models it peaked at week 2 and then decreased gradually until week 16 (Figures 
4.2c). Synovitis was significantly increased in AIA mice compared to saline injected 
mice at all time points (Figure 4.2a). Synovitis was significantly increased in DMM 
mice compared to sham surgery mice at day 3, week 1 and week 16, and significantly 
increased compared to age matched controls at week 4, 8, 12 and 16 (Figure 4.2b). 
Sham surgery resulted in less synovitis than DMM at all time points. After week 4, 
there was no significant difference between sham surgery mice and age match 
controls. AIA mice developed significantly greater synovitis compared to DMM mice 
at week 1, 2, 4, 8 and 12 (Figure 4.2c). 
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Table 4.1a Joint histopathology scores in AIA and DMM 
Score Time (W) DMM vs Sham DMM vs AIA AIA vs saline 
Synovitis
1
0.4 0.019 0.053 0.004 
1 0.006 0.005 0.002 
2 0.198 0.004 0.004 
4 0.053 <0.001 <0.001 
8 0.084 <0.001 <0.001 
12 0.060 <0.001 <0.001 
16 0.008 0.025 <0.001 
PG loss
2
0.4 0.794 0.048 0.026 
1 0.433 0.002 0.001 
2 0.004 0.002 0.002 
4 <0.001 0.005 <0.001 
8 <0.001 <0.001 <0.001 
12 0.004 <0.001 <0.001 
16 <0.001 <0.001 <0.001 
AC damage
3
0.4 0.800 0.040 0.140 
1 0.101 0.320 0.022 
2 0.004 0.070 0.016 
4 <0.001 0.017 <0.001 
8 <0.001 0.423 <0.001 
12 0.004 <0.001 <0.001 
16 <0.001 0.054 <0.001 
Osteophyte 
maturity
4
0.4 - - - 
1 0.058 0.009 - 
2 0.002 0.002 - 
4 <0.001 <0.001 - 
8 <0.001 0.020 0.020 
12 0.003 0.011 0.003 
16 <0.001 <0.001 <0.001 
Osteophyte 
size
5
0.4 - - - 
1 0.058 0.009 - 
2 0.002 0.002 - 
4 <0.001 <0.001 - 
8 <0.001 0.051 0.020 
12 0.003 0.003 0.003 
16 <0.001 0.291 <0.001 
SCB sclerosis
6 0.4 0.935 0.317 0.390 
1 0.342 0.008 0.003 
2 0.031 0.002 0.022 
4 0.002 <0.001 0.045 
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8 0.002 0.738 0.277 
12 0.145 0.002 <0.001 
16 0.028 <0.001 0.002 
SCB 
vascularity
7
0.4 0.794 0.005 0.065 
1 0.338 0.009 0.015 
2 0.012 0.002 0.002 
4 0.107 0.004 0.003 
8 0.459 0.858 0.299 
12 0.332 0.862 0.125 
16 0.393 0.072 0.050 
Chondrocyte 
hypertrophy 
(cell death)
8
0.4 0.002 0.326 0.002 
1 0.007 0.053 <0.001 
2 0.003 1.000 0.002 
4 <0.001 0.033 <0.001 
8 <0.001 0.004 <0.001 
12 0.007 <0.001 <0.001 
16 <0.001 <0.001 <0.001 
Knee joint histopathology scores between treatment groups (DMM vs. Sham, DMM 
vs. AIA, and AIA vs. Saline) comparisons using Kruskal-Wallis analysis followed by 
Mann-Whitney U-test. After Benjamini-Hochberg correction, 5% confidence level is 
P < 0.025
(1)
, P < 0.026
(2)
, P < 0.022
(3)
, P < 0.02
(4)
, P < 0.02
(5)
, P < 0.022
(6)
, P <
0.015
(7)
, P< 0.033
(8)
. P-values shown in bold typeface are significant below after
correcting for multiple comparisons. 
Table 4.1b Synovitis histolopathology scores in DMM and AIA 
Knee joint histopathology synovitis scores, DMM vs. AIA, comparisons using 
Kruskal-Wallis analysis followed by Mann-Whitney U-test. After Benjamini-
Hochberg correction, 5% confidence level is P < 0.013
(1)
, P < 0.023
(2)
, P < 0.005
(3)
, P
< 0.005
(4)
, P < 0.011
(5)
. P-values shown in bold typeface are significant below after
correcting for multiple comparisons. 
Time 
(weeks) 
Panus
1 Cortical 
bone 
erosion
2
Synovial 
hyperplasia
3
Sub synovial 
inflammation
4
Synovial 
exudate
5
0.4 0.371 0.089 0.224 0.053 0.150 
1 0.392 0.004 0.231 0.004 0.011 
2 0.005 0.003 0.005 0.005 0.005 
4 0.013 <0.001 0.005 <0.001 <0.001 
8 0.140 0.023 0.002 0.001 <0.001 
12 0.003 0.008 0.001 <0.001 0.002 
16 0.271 0.163 0.242 0.002 0.001 
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Figure 4.1a. OA knee joint histopathology – Acute inflammatory phase 
Representative sections of knee joint day 3, week 1 and 2 post induction of arthritis in 
DMM, Sham surgery, AIA and Saline injected mice. Images are toluidine blue stained 
saggital sections near the central weight-bearing region of the joint. X5 magnification 
Sham
Saline
Day 3 Week 1 Week 2
DMM
AIA
I. 
II. 
100µm
147 
Insert I = Synovitis at week 1 
Insert II = PG loss and SCB vascular invasion at week 2. 
I. 
25µm
II. 
25µm
148 
Figure 4.1b. = OA knee joint histopathology – Early progressive OA 
Representative sections of knee joint week 4 and 8 post induction of arthritis in DMM and AIA mice. Sham surgery and Saline injected mice 
included for comparison. Images are toluidine blue stained saggital sections near the central weight-bearing region of the joint. X5 magnification 
Insert III = osteophyte formation at week 8  
(Sham Wk8)(Saline Wk4)Week 4 Week 8  
DMM
III. 
AIA 100µm
25 µm
149 
Figure 4.1c. = OA knee joint histopathology – Late chronic OA 
Representative sections of knee joint week 12 and 16 post induction of arthritis in DMM and AIA mice. Sham surgery and Saline injected mice 
included for comparison. Images are toluidine blue stained saggital sections near the central weight-bearing region of the joint. X5 magnification 
Insert IV = SCB sclerosis at week 12; Insert V = AC damage and joint space narrowing at week 16. 
(Sham Wk16)(Saline Wk16)
Week 12 Week 16
IV. 
DMM
AIA
V. 
100µm
V
25µm
IV 25µm
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Figure 4.2. Knee joint inflammation histopathology I 
Joint inflammation (defined as synovitis) in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 
1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper 
bounds) and 5% (lower bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 
(**); and P<0.001 (***). 
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The total synovitis score depicted in Figure 4.2 was arrived at by sum of scores of five 
individual parameters: panus, cortical bone erosion associated with panus, synovial 
lining cell hyperplasia, sub-synovial inflammation and synovial exudate. Overall, the 
temporal pattern of development and the degree of severity of these five measures of 
synovitis differed between the two models.  
4.3.1.1 Panus 
The appearance of panus occurred in both models immediately following induction of 
arthritis, with severity peaking at week 2 (Figure 4.3a). Panus was significantly worse 
in the AIA compared with DMM at week 2, 4 and 12.  
4.3.1.2 Bone erosion 
The degree of cortical bone erosion associated with panus increased in the AIA model 
immediately following induction of arthritis (Figure 4.3b). This peaked at week 2 and 
did not decline substantially until week 8, although it was still significantly increased 
compared to DMM mice up until week 12. This was in contrast to the DMM model, 
which demonstrated a low and consistent level of bone erosion throughout the course 
of the disease. Cortical bone erosion was significantly greater in AIA compared with 
DMM at week 1, 2, 4, 8 and 12.  
4.3.1.3 Synovial hyperplasia 
Synovial hyperplasia occurred in both models following induction of arthritis with no 
significant difference between AIA and DMM until week 2 when synovial 
hyperplasia peaked in AIA mice (Figure 4.3c). Synovial hyperplasia remained 
significantly greater in AIA until week 16, when it declined to a level similar to 
DMM mice. 
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4.3.1.4 Sub-synovial inflammation 
Immediately following induction of arthritis sub-synovial inflammation was severe in 
the AIA model and did not start to resolve until week 8 (Figure 4.3d). In contrast sub-
synovial inflammation developed more gradually and was not as severe in the DMM 
model. Sub-synovial inflammation remained significantly more severe in AIA mice 
compared to DMM from week 1 until week 16, despite the decrease observed in AIA 
mice from week 8. 
4.3.1.5 Synovial exudate 
Synovial exudate was a consistent feature in the AIA model until week 16 when the 
proportion of mice with joint exudate declined (Figure 4.3e). In contrast, synovial 
exudate was only observed consistently in the first week following induction of 
arthritis in DMM mice and declined up until week 4. Beyond week 4 there was no 
synovial exudate observed in any DMM mice. Synovial exudate was significantly 
more severe in AIA mice compared to DMM from week 1 until week 16.
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Figure 4.3. Knee joint inflammation histopathology II 
Panus (a); Cortical bone erosion (b); Synovial hyperplasia (c); Sub-synovial inflammation (d); and Synovial exudate (e), in DMM vs AIA mice 
at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as box plots, with medians marked, 
95% (upper bounds) and 5% (lower bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 
(*); P<0.01 (**); and P<0.001 (***).  
0.4 1 2 4 8 12 16
0
2
4
6
Weeks post arthritis induction
T
o
ta
l 
s
c
o
re
 /
 6
Panus
**
*
**
0.4 1 2 4 8 12 16
0
2
4
6
Synovial Hyperplasia
Weeks post arthritis induction
T
o
ta
l 
s
c
o
re
 /
 6
****
**
**
0.4 1 2 4 8 12 16
0
1
2
Weeks post arthritis induction
T
o
ta
l 
s
c
o
re
 /
 2
Synovial Exudate
AIA
DMM
Control
* ** *** *** **
**
0.4 1 2 4 8 12 16
0
2
4
6
Weeks post arthritis induction
T
o
ta
l 
s
c
o
re
 /
 6
Bone Erosion
** **
**
***
*
0.4 1 2 4 8 12 16
0
2
4
6
Subsynovial Inflammation
Weeks post arthritis induction
T
o
ta
l 
s
c
o
re
 /
 6
**
****
***
**
***
a b c
d e
154 
4.3.2 Effect of AIA and DMM on articular cartilage degradation following 
induction of arthritis 
Articular cartilage (AC) histopathology was measured in terms of the combined score 
of maximum tibial and femoral AC proteoglycan loss, AC structural damage and 
chondrocyte hypertrophy/apoptosis.  
4.3.2.1 Proteogylcan loss 
Maximum proteoglycan loss peaked at week 1 in AIA and was significantly greater 
than saline injected mice at all time points (Figure 4.4a). Maximum proteoglycan loss 
was significantly greater in DMM mice than in sham surgery mice from week 2 
(Figure 4.4b). AIA mice had significantly greater proteoglycan loss than DMM mice 
at weeks 1 to16 (Figure 4.4c). 
4.3.2.2 AC structural damage 
In AIA mice, maximum AC structural damage was very mild up to week 4, and then 
increased dramatically from week 8 to 16 (Figure 4.5a). The difference between AIA 
and saline injected mice was significant at weeks 1 to 16. At no time point was 
structural damage in saline injected mice significantly different to age-matched 
controls. Maximum AC structural damage observed in DMM mice was mild at day 3 
post surgery, and did not become significantly greater than sham surgery or age-
matched control mice until week 2, and increased progressively until week 16 (Figure 
4.5b). Structural damage was mild and transient in sham surgery mice, and there was 
no significant difference between sham surgery and age-matched controls at any of 
the time points that were scored. There was little difference between the two arthritis 
models in AC structural damage scores over the time course of the study; DMM > 
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AIA at week 4 and AIA > DMM at week 12. By week 16 there was no significant 
difference in structural damage between DMM and AIA mice (Figure 4.5c). 
4.3.2.3 Chondrocyte hypertrophy 
Chondrocyte hypertrophy in non-calcified cartilage developed early and persisted in 
both AIA and DMM mice (Figure 4.6a and b), and was significantly greater than in 
saline injected and sham surgery, respectively. There was a significant difference 
between the two models from week 4 to 16, when chondrocyte hypertrophy was 
greater in AIA (Figure 4.6c). 
156 
Figure 4.4. Knee joint articular cartilage histopathology I 
Proteoglycan loss in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); and P<0.001 
(***). 
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Figure 4.5. Knee joint articular cartilage histopathology II 
Articular cartilage structural damage in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 
4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) 
and 5% (lower bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); 
and P<0.001 (***). 
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Figure 4.6. Knee joint articular cartilage histopathology III 
Chondrocyte hypertrophy in non-calcified cartilage in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at 
day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% 
(upper bounds) and 5% (lower bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); 
P<0.01 (**); and P<0.001 (***). 
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4.3.3 Effect of AIA and DMM on bone following induction of arthritis 
Bone histopathology changes were defined in terms of osteophyte development 
(maturation and size), and subchondral bone (SCB) vascularisation and sclerosis or 
thickening.  
4.3.3.1 Osteophytes 
Osteophytes developed in both DMM and AIA mice, but not in sham surgery or 
saline injected mice. In AIA, osteophytes only developed late (week 8) and reached 
peak size and maturity at week 16 (Figures 4.7a and 4.8a). In the DMM model in 
contrast, osteophytes developed early (week 1), initially as neo-cartilage and then 
maturing to bone through endochondral ossification, reaching peak size and maturity 
by week 4 (Figures 4.7b and 4.8b). Osteophyte size was significantly greater in DMM 
mice compared to AIA at week 1, 2, 4 and 12. Osteophyte maturity was significantly 
greater in DMM compared to AIA from week 1 to 16. By week 16 there was no 
significant difference in osteophyte size between the two models although those in the 
AIA model had not fully ossified (Figures 4.7c and 4.8c).  
Unique to the AIA model was the development of enthesophytes. These were 
observed from week 1, increasing in size and maturity up to week 16. The 
enthesophytes were observed on the anterior, medial margin of the tibia, at the level 
of the growth plate, adjacent the site of insertion of the patella ligament. This novel 
pathology has not previously been described in the AIA model. 
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4.3.3.2 Subchondral bone  
Subchondral bone sclerosis displayed two phases of change in both AIA and DMM. 
In control mice SCB sclerosis increased with age, reaching a median score of 2 by 
week 16. In the AIA model SCB sclerosis was absent at weeks 1 and 2, and was 
observed from week 4. At week 12 and 16 it was significantly increased compared to 
saline injected mice (Figure 4.9a). Saline injected mice displayed greater SCB 
sclerosis than controls in the first two weeks following injection, and then 
demonstrated a similar pattern of increase with age after week 4. Both DMM and 
sham surgery mice displayed increased SCB sclerosis compared to age matched 
controls in the first two weeks following surgery (Figure 4.9b). From week 4, sham 
surgery joints displayed a similar increase over time as age matched controls. In 
contrast, SCB sclerosis increased more rapidly in the DMM after week 2, exceeding 
the score of sham surgery and control mice. The difference between the groups was 
significant at week 4 and 8. SCB sclerosis was greater in DMM than AIA in the early 
stages of disease, and this difference was significant at weeks 1, 2 and 4. SCB 
sclerosis in AIA then exceeded DMM following week 8, and was significantly 
different again at week 12 and 16 (Figure 4.9c). 
SCB vascularisation remained similar to age matched controls at all time points in 
saline injected mice but was significantly increased in AIA compared to saline 
injected mice from week 1 to week 4 (Figure 4.10a). SCB vascularisation remained 
similar to age matched controls at all time points in DMM and sham surgery (Figure 
4.10b). SCB vascularisation was significantly increased in AIA compared to DMM in 
the early stages of disease (day 3 to week 4), and then decreased at week 8 to levels 
comparable to the other treatment groups (Figure 4.10c). 
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Figure 4.7. Knee joint osteophyte histopathology I 
Osteophyte size in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); and P<0.001 
(***). 
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Figure 4.8. Knee joint osteophyte histopathology II 
Osteophyte maturity in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); and P<0.001 
(***). 
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Figure 4.9. Knee joint subchondral bone histopathology I 
SCB sclerosis in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); and P<0.001 
(***). 
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Figure 4.10. Knee joint subchondral bone histopathology II 
SCB vascularisation in AIA vs. saline injected (a); DMM vs. sham surgery (b); and DMM vs. AIA (c) mice, at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as box plots, with medians marked, 95% (upper bounds) and 5% (lower 
bounds) percentiles hinged, and whiskers depicting upper and lower limits of dataset. Significance = P<0.05 (*); P<0.01 (**); and P<0.001 
(***). 
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4.3.4 Time and Treatment effect on joint pathology  
Logistic regression analysis was used to interrogate the pattern of change over time 
for each histology outcome variable, and also within the two arthritis models (Table 
4.2). This provides a more robust evaluation of the effect of the two arthritis induction 
methods on the different joint pathologies, by taking time into account and allowing 
all the data to be included in the analyses rather than individual time points.  
When corrected for treatment group (sham, saline, DMM, AIA), synovial 
inflammation increased over time up to week 2, and thereafter decreased significantly. 
Articular cartilage structural damage and chondrocyte hypertrophy progressively and 
significantly increased over time, however there was no significant time effect for AC 
proteoglycan loss. Osteophyte size and maturity both increased significantly with time 
post arthritis induction. Both SCB sclerosis and vascularity also demonstrated a 
significant temporal effect, SCB sclerosis increasing while SCB vascularity decreased 
over time.  
When time was corrected for, a significant treatment effect was observed for a 
number of the histology outcomes, in some cases differing between the two arthritis 
models. Synovitis was significantly increased in AIA and DMM relative to saline and 
sham respectively, and increased in AIA relative to DMM, regardless of which stage 
of the disease process. This treatment effect was also evident in four of the individual 
parameters (panus, bone erosion, synovial hypertrophy and sub-synovial 
inflammation) that combine to make up the synovitis score. Synovial exudate was 
only increased in AIA relative to saline and DMM. AC structural damage, AC 
proteoglycan loss and chondrocyte hypertrophy were all increased in AIA and DMM 
relative to their saline and sham controls. Only AC proteoglycan loss and chondrocyte 
hypertrophy were significantly increased in AIA relative to DMM. Osteophyte size 
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and maturity were increased in AIA and DMM relative to saline and sham, but 
decreased in AIA relative to DMM. SCB sclerosis was increased in DMM relative to 
sham but not in AIA relative to saline. SCB vascularity was increased in AIA and 
DMM relative to saline and sham. 
Table 4.2. Joint histopathology logistic regression analysis 
Score Period(w) Time
1
Time (P) Treatment
2
Cf tx
3
 Tx (P)
Synovitis 0 - 2 Increased 0.010 Sham Increased Saline <0.001 
AIA Increased Saline <0.001 
DMM Increased Sham   0.002 
AIA Increased DMM <0.001 
Synovitis 2 - 16 Decreased <0.001 Sham Increased Saline < 0.001 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Increased DMM <0.001 
AC damage 0 - 16 Increased <0.001 Sham Increased Saline   0.003 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA - DMM   0.330 
AC PG loss 0 - 16 - 0.110 Sham - Saline   0.820 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Increased DMM <0.001 
Chondrocyte 
hypertrophy 
0 - 16 Increased <0.001 Sham - Saline   0.370 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Increased DMM <0.001 
Osteophyte 
maturity 
0 - 16 Increased <0.001 Sham - Saline   0.910 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Decreased DMM <0.001 
Osteophyte 
size 
0 - 16 Increased <0.001 Sham - Saline   0.820 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Decreased DMM <0.001 
Subchondral 
bone  
sclerosis 
0 - 16 Increased <0.001 Sham - Saline   0.350 
AIA - Saline   0.350 
DMM Increased Sham <0.001 
AIA - DMM   0.048 
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Subchondral 
bone  
vascularity 
0 - 16 Decreased <0.001 Sham - Saline   0.960 
AIA Increased Saline   0.004 
DMM Decreased Sham   0.010 
AIA Increased DMM   <0.001 
Panus 0 -16 Decreased <0.001 Sham Increased Saline <0.001 
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Increased DMM <0.001 
Bone erosion 0 -16 Decreased <0.001 Sham Increased Saline <0.001 
AIA Increased Saline <0.001 
DMM Increased Sham 0.031 
AIA Increased DMM <0.001 
Synovial 
hypertrophy 
0 -16 Decreased <0.001 Sham - Saline 0.230
AIA Increased Saline <0.001 
DMM Increased Sham <0.001 
AIA Increased DMM <0.001 
Subsynovial 
inflammation 
0 - 16 Decreased <0.001 Sham Increased Saline <0.001 
AIA Increased Saline <0.001 
DMM Increased Sham 0.003 
AIA Increased DMM <0.001 
Synovial 
exudate 
0 -16 Decreased <0.001 Sham Increased Saline 0.008 
AIA Increased Saline <0.001 
DMM - Sham 0.370 
AIA Increased DMM <0.001 
Logistic regression on joint histology scores in AIA and DMM was used to determine 
whether histology outcome variables changed over time, and then when correcting for 
time whether there was a difference between treatments. Where the direction (i.e. 
increase vs decrease) and/or significance of the temporal change for a particular 
histological feature differed with time after arthritis induction, the periods are 
reported separately. (1) Change over time when corrected for treatment, (2) Change 
between treatments when corrected for time, (3) Comparator treatment. 
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4.3.5 Correlation between pathological change in different joint tissues in AIA and 
DMM when corrected for time 
The knee joint functions as a biomechanical organ comprising numerous tissues. 
Since OA is a failure of the entire joint organ, understanding how the pathological 
changes that occur in different joint tissues are associated provides important 
information on changes in pathophysiology in different arthritis phenotypes and with 
time. The preceding regression analysis provided information on the change in joint 
pathology measures with time, and in the two models, but not how the changes in the 
different joint tissues are interrelated. These associations were determined by 
calculating partial correlation coefficients for the various joint tissue pathologies in 
the different treatments (AIA, Saline, DMM, Sham) when corrected for time (Table 
4.3). The significant associations in the two arthritis models and those common to 
both models are also represented schematically in Figures 4.11a-c, with positive 
correlations shown in solid lines and negative correlations in dashed lines, the weight 
of the line reflecting the strength of the correlation. 
4.3.5.1 Articular cartilage histopathology partial correlations  
In AIA mice AC structural damage correlated positively with chondrocyte 
hypertrophy but not proteoglycan loss. In addition, AC structural damage in this 
model correlated with all measured bone pathologies other than vascularity 
(positively with osteophyte maturity, osteophyte size and SCB sclerosis). 
Proteoglycan loss in AIA on the other hand, only correlated with SCB vascularity and 
chondrocyte hypertrophy, all being positive associations. Chondrocyte hypertrophy 
also correlated positively with SCB sclerosis and negatively with vascularity. 
In DMM mice AC structural damage correlated with cartilage and bone related 
pathologies (positively with proteoglycan loss, chondrocyte hypertrophy, osteophyte 
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size, osteophyte maturity and SCB sclerosis; negatively with SCB vascularity). AC 
proteoglycan loss also correlated positively with chondrocyte hypertrophy, and bone 
related pathologies (osteophyte maturity and osteophyte size, and SCB sclerosis). In 
addition, chondrocyte hypertrophy positively correlated with osteophyte size and 
maturity. 
4.3.5.2 Joint inflammation partial correlations 
In AIA mice synovitis scores correlated positively with SCB vascularity, negatively 
with SCB sclerosis, as well as the previously stated positive association with AC 
structural damage. In DMM mice however, synovitis scores only correlated with SCB 
vascularity, no significant correlations found with any articular cartilage or other bone 
related pathologies.  
4.3.5.3 Bone histopathology partial correlations 
In AIA mice SCB sclerosis correlated strongly with osteophyte size and maturity, and 
there was a strong negative correlation with both synovitis and SCB vascularity. SCB 
vascularity also strongly negatively correlated with osteophyte size and maturity. In 
DMM mice SCB sclerosis was positively correlated with osteophyte maturity but not 
size, and there was a negative correlation with SCB vascularity but not synovitis. In 
both AIA and DMM mice, there was a positive correlation between osteophyte size 
and maturity, strongest in AIA. 
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Table 4.3. Cartilage pathology, bone pathology and joint inflammation partial 
correlations in AIA and DMM 
a. Articular cartilage structural damage Treatment r P 
AC PG loss AIA 
Saline 
DMM 
Sham 
0.176 
0.289 
0.561 
0.314 
0.082 
0.004 
<0.001 
0.001 
Chondrocyte hypertrophy AIA 
Saline 
DMM 
Sham 
0.414 
0.108 
0.513 
0.109 
<0.001 
 0.520 
<0.001 
0.350 
Osteophyte maturity AIA 
Saline 
DMM 
Sham 
0.343 
- 
0.325 
- 
<0.001 
- 
0.001 
- 
Osteophyte size AIA 
Saline 
DMM 
Sham 
0.313 
- 
0.393 
- 
<0.001 
- 
<0.001 
- 
SCB sclerosis AIA 
Saline 
DMM 
Sham 
0.265 
0.120 
0.387 
0.221 
0.018 
0.093 
<0.001 
0.089 
SCB vascularity AIA 
Saline 
DMM 
Sham 
-0.190
-0.028
-0.313
-0.058
0.027 
0.860 
0.004 
0.610 
Synovitis AIA 
Saline 
DMM 
Sham 
0.179 
0.151 
-0.178
0.169
0.008 
0.190 
0.077 
0.037 
b. Articular cartilage proteoglycan loss Treatment r P 
Chondrocyte hypertrophy AIA 
Saline 
DMM 
Sham 
0.369 
0.182 
0.588 
0.133 
0.001 
0.170 
<0.001 
0.230 
Osteophyte maturity AIA 
Saline 
DMM 
Sham 
 0.010 
- 
0.492 
- 
0.920 
- 
<0.001 
- 
Osteophyte size AIA 
Saline 
DMM 
Sham 
0.009 
- 
0.450 
- 
0.910 
- 
<0.001 
-
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SCB sclerosis AIA 
Saline 
DMM 
Sham 
-0.045
0.070
0.280
-0.001
0.730 
0.630 
0.007 
0.990 
SCB vascularity AIA 
Saline 
DMM 
Sham 
0.230 
-0.032
-0.178
0.020
<0.001 
0.830 
0.077 
0.860 
Synovitis AIA 
Saline 
DMM 
Sham 
0.213 
0.117 
-0.063
0.075
0.066 
0.300 
0.420 
0.370 
c. Chondrocyte hypertrophy Treatment r P 
Osteophyte maturity AIA 
Saline 
DMM 
Sham 
0.170 
- 
0.358 
- 
0.074 
- 
<0.001 
- 
Osteophyte size AIA 
Saline 
DMM 
Sham 
0.144 
- 
0.349 
- 
0.088 
- 
<0.001 
- 
SCB sclerosis AIA 
Saline 
DMM 
Sham 
0.400 
-0.246
0.242
0.042
<0.001 
0.036 
0.042 
0.770 
SCB vascularity AIA 
Saline 
DMM 
Sham 
-0.285
0.020
-0.103
-0.038
0.008 
0.900 
0.410 
0.800 
Synovitis AIA 
Saline 
DMM 
Sham 
0.086 
 0.135 
-0.057
0.095
0.400 
0.270 
0.420 
0.330 
d. Subchondral bone sclerosis Treatment r P 
Osteophyte maturity AIA 
Saline 
DMM 
Sham 
0.393 
- 
0.261 
- 
<0.001 
- 
0.012 
- 
Osteophyte size AIA 
Saline 
DMM 
Sham 
0.370 
- 
0.086 
- 
<0.001 
- 
0.460 
- 
Synovitis AIA 
Saline 
DMM 
Sham 
-0.342
-0.079
-0.168
-0.081
0.004 
0.460 
0.073 
0.390 
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Cartilage pathology, bone pathology and joint inflammation partial correlations in 
AIA and DMM when corrected for time.  P-values shown in bold typeface are 
significant below after Benjamini-Hochberg correction for multiple comparisons, 5% 
confidence level is P < 0.022. 
SCB vascularity AIA 
Saline 
DMM 
Sham 
-0.700
-0.160
-0.495
-0.406
<0.001 
0.240 
<0.001 
<0.001 
e. Osteophyte maturity Treatment r P 
Osteophyte size AIA 
Saline 
DMM 
Sham 
0.865 
- 
0.429 
- 
<0.001 
- 
<0.001 
- 
Synovitis AIA 
Saline 
DMM 
Sham 
-0.167
- 
-0.127 
- 
0.067 
- 
0.110 
- 
SCB vascularity AIA 
Saline 
DMM 
Sham 
-0.351
-
-0.167
- 
<0.001 
- 
0.038 
- 
f. Osteophyte size Treatment r P 
Synovitis AIA 
Saline 
DMM 
Sham 
-0.209
- 
 0.042 
- 
0.014 
- 
0.550 
- 
SCB vascularity AIA 
Saline 
DMM 
Sham 
-0.319
-
-0.192
- 
<0.001 
- 
0.190 
- 
g. Synovitis Treatment r P 
SCB vascularity AIA 
Saline 
DMM 
Sham 
0.305 
-0.195
0.255
0.152
<0.001 
0.140 
0.011 
0.180 
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Figure 4.11. Knee joint histopathology associations 
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Significant associations between pathological changes in different knee joint tissues 
(cartilage, bone, and joint inflammation) in AIA model (a); DMM model (b); DMM 
and AIA models combined (c); as determined by calculation of partial correlation 
coefficients when corrected for time. After Benjamini-Hochberg correction, 5% 
confidence level is P < 0.022. 
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c
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4.3.6 Comparison of joint tissue pathology relationships in AIA versus DMM  
Finally, ordinal logistic regression models were developed that described the variables 
that were significantly and independently associated with OA progression as 
measured by cartilage structural damage (Table 4.4) and OA joint inflammation as 
measured by synovitis (Table 4.5). These models were highly significant but revealed 
very different independent risk factors with significant odds ratios for the two arthritis 
models (Table 4.4 and 4.5). The risk of cartilage damage in the DMM model was 
increased 1.7 fold in association with joint injury (surgery), 2.4 fold with increased 
AC proteoglycan loss, 2.3 fold with increased osteophyte size, 2.0 fold with increased 
chondrocyte hypertrophy and 1.7 fold with increased SCB sclerosis. In contrast, the 
risk of cartilage damage in the AIA model was increased in association with time 
after disease induction (1.2 fold), increased synovitis (1.2 fold), increased 
chondrocyte hypertrophy/cell death (2.0 fold), and increased osteophyte size (13 
fold). 
The risk of joint inflammation in the DMM model was increased 3.5 fold in 
association with joint injury (surgery) and 4 fold with increased vascular invasion. 
However, in DMM the risk of joint inflammation was decreased with time post-
surgery and increased SCB sclerosis (0.77 fold and 0.63 fold, respectively). In the 
AIA model the risk of joint inflammation was increased 9.4 fold in association with 
treatment (mBSA injection) and 1.4 fold with increased AC PG loss. The risk of joint 
inflammation in AIA was decreased in association with increases in osteophyte size 
and SCB sclerosis (0.21 fold and 0.43 fold, respectively).  
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Table 4.4. Risk factors for OA (cartilage damage) 
Best ordinal logistic regression models defining the variables significantly associated 
with increased risk of OA development (defined as AC damage) in the AIA and 
DMM models. The included variables in both models are corrected for all others i.e. 
they are independently significant risk factors for cartilage erosion 
Table 4.5. Risk factors for OA (joint inflammation) 
Best ordinal logistic regression models defining the variables significantly associated 
with increased risk of joint inflammation (defined as synovitis) in the DMM and AIA 
models. The included variables in both models are corrected for all others i.e. they are 
independently significant risk factors for joint inflammation. 
Model Risk factor OR (95% CI) P 
(variable) 
P 
(model) 
DMM/Sham Surgery/joint injury 1.7 (1.0 – 2.9) 0.047 <0.001 
AC PG loss 2.4 (1.5 – 3.9) <0.001 
Chond. Hyp./cell death 2.0 (1.2 – 3.2) 0.005 
OP size 2.3 (1.3 – 4.1) 0.010 
SCB sclerosis 1.7 (1.1 – 2.7) 0.023 
AIA/Saline Time 1.2 (1.1 – 1.4) 0.003 <0.001 
Synovitis 1.2 (1.0 – 1.4) 0.019 
Chond. Hyp./cell death 2.0 (1.3 – 3.0) 0.002 
OP size 13 (3.3 – 50) <0.001 
Model Risk factor OR (95% CI) P 
(variable) 
P 
(model) 
DMM/Sham Surgery/joint injury 3.5 (2.4 – 5.1) <0.001 <0.001 
Time  0.77 (0.72 – 0.82) <0.001 
SCB vascular invasion 4.0 (1.9 – 8.3) <0.001 
SCB sclerosis 0.63 (0.43 – 0.92)  0.016 
AIA/Saline mBSA/saline 9.4 (2.4 – 36)  0.001 <0.001 
AC damage 1.2 (1.0 – 1.3)  0.003 
AC PG loss 1.4 (1.1 – 1.7)  0.008 
OP size 0.21 (0.11 – 0.40) <0.001 
SCB sclerosis 0.43 (0.29 – 0.64) <0.001 
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4.4 Discussion 
In this chapter, knee joint sections from DMM and AIA mice were histologically 
scored for the purpose of evaluating the histopathological changes that occur in the 
two models over time. Sham surgery, saline injected and age matched control knee 
joints were also scored for comparison. The focus of this chapter was to identify the 
temporal pattern of joint pathology and any associations between the different joint 
tissue changes that could distinguish the models as unique joint disease phenotypes. 
How these different histopathological changes in joint tissue relate to pain is 
investigated in subsequent chapters. 
Knee joint pathology in the DMM model was characterised by moderate early phase 
synovial inflammation that increased and peaked at week 2 and despite declining 
thereafter, low-grade inflammation persisted. Regression analysis revealed this low-
grade inflammation was greater than that of sham surgery and age matched control 
mice. Although the early phase of synovial inflammation was attributed to surgical 
trauma and tissue disruption since it also developed in sham surgery mice, it was also 
significantly greater in DMM suggesting an acute additive effect of OA-inducing joint 
injury. In contrast, the AIA model was characterised by severe synovial inflammation 
that while also peaking at week 2 persisted for longer (12 weeks) before decreasing to 
levels that were comparable to the DMM model at week 16.  
The idea that AIA is an inflammation driven model of arthritis and DMM is a post-
traumatic model of OA with trauma associated mild inflammation is not new (413, 
437, 521); however, this is the first time that an attempt has been made to not only 
quantify the degree of inflammation that occurs in the two models in terms of the 
different joint tissue changes that are involved in the inflammatory process (synovial 
hyperplasia, sub-synovial infiltration, synovial exudate, panus formation and cortical 
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bone erosion)(461), but also determine any associations between joint inflammation 
and the development of OA-like joint pathologies.  
Despite the presence of significant synovitis in both models, a direct association 
between synovitis and AC damage was only identified in AIA. In the AIA model 
there was an association between synovitis and subchondral bone pathology (both 
vascularisation and sclerosis). In contrast, synovitis was only associated with SCB 
vascularity in the DMM model. In combination with the fact that synovitis is a 
significant risk factor for development of AC damage in the AIA model but not in 
DMM, these associations suggest that inflammation, at least as measured by 
histological scoring of synovitis, is a more direct driver of joint pathology in this 
model than in the DMM.  
The correlation differences between the two models also suggests that the severity of 
inflammation and the type of inflammation, rather than its absolute presence, may 
determine the role it plays in the development of OA joint pathology. This study did 
not evaluate differences in inflammatory cell populations or the presence of specific 
cytokines in the inflammatory ‘soup’ that developed in the two models. However, 
evidence of the existence of these differences can be drawn from the type of 
histopathological inflammation observed in each model. For example, panus, sub-
synovial inflammation and synovial exudate were a feature of both early and late 
phase AIA inflammation. While panus was also present in both early and late phase 
DMM inflammation, synovial hyperplasia rather than sub-synovial inflammation was 
an early and persistent feature in this post-traumatic OA model.  
Human OA, both its presence and severity, is still defined by radiographic changes of 
joint space narrowing and the presence of osteophytes (566, 567). These radiographic 
hallmarks of human OA are reflected histologically in the DMM model as AC 
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proteoglycan loss and structural damage (joint space narrowing), and osteophyte 
maturation to calcified cartilage and bone (such that they would be detected on 
radiographs). AC proteoglycan loss and structural damage appeared early (week 1-2) 
and were both progressive thereafter. In contrast, these 2 aspects of cartilage 
pathology were not temporally associated in the AIA model where there was 
immediate and complete proteoglycan loss (day 3) that persisted, and a more delayed 
development of AC structural damage (week 8). Temporally the formation of 
mature/boney osteophytes (potentially visible radiographically) was quite distinct in 
the two models; 2-4 weeks in DMM and 12-16 weeks in AIA. Nevertheless, by 16 
weeks both arthritis models had pathology that would be consistent with the current 
radiographic diagnostic criteria for OA in patients. 
Although osteophyte formation occurred in both models, there were distinct 
differences and specific tissue pathology associations. In the DMM model there was a 
moderate association (r = 0.429) between osteophyte size and maturity, reflecting 
initial formation of cartilaginous outgrowths that then underwent endochondral 
ossification to form mature osteophytes. In AIA there was a very strong association 
between osteophyte size and maturity (r = 0.865), perhaps suggesting some subtle 
difference in pathophysiology of their formation in the two models. This may be 
further supported by the fact that osteophyte size and maturity were significantly 
correlated with AC structural damage but not AC PG loss or chondrocyte hypertrophy 
in the AIA model. In contrast, osteophyte size and maturity were significantly 
correlated with all three components of articular cartilage pathology (AC PG loss, AC 
structural damage and chondrocyte hypertrophy) in the DMM model. Yet in both 
models osteophyte size was associated with an increased risk of OA progression as 
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measured by cartilage structural damage, although in AIA the risk was much greater 
(OR = 13). 
In human OA patients, osteophyte size is also associated with a moderate increased 
risk of OA disease progression (568). However, this increased risk is largely 
accounted for when adjustments are made for the effect of joint malalignment on 
disease progression, due to the strong association between large osteophytes and joint 
malalignment. 
The factors that drive osteophyte formation are incompletely understood, but likely 
involve mechanical and soluble/growth factor signaling to activate mesenchymal stem 
cells (MSC) in the periosteum and synovial membrane, and potentially also 
macrophage-like cells [reviewed in (569)]. The relative contribution of biomechanics 
and soluble mediators to osteophyte development may differ with arthritis phenotype 
as previously demonstrated comparing the more inflammatory collagenase-induced 
OA (ciOA) with the less inflammatory DMM model of post-traumatic OA (570, 571). 
The osteophyte development in AIA may reflect a stronger role for growth factors 
such as TGF and BMPs-2 and -9 rather than biomechanics as previously reported in 
ciOA (572-576), while in DMM, joint instability may be more critical with 
osteophytes potentially acting to stabilise the joint (577). Osteophyte development in 
AIA occurred when synovitis was resolving but cartilage erosion was maximal, 
potentially implicating a role for increasing micro-instability with loss of cartilage 
volume in the late stages of this model. However, there was significant negative 
correlation between subchondral bone vascularity and both osteophyte size and 
maturation in AIA but not DMM. This is consistent with the greater joint 
inflammation and associated bone resorption in early AIA, and late osteophyte 
formation may be indicative of the need to resolve specific pro-inflammatory signals 
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to allow bone formation. This phenomenon was recently described in TNF-transgenic 
mice where blocking the key Wnt inhibitor Dikkopf-1, reversed the bone-destructive 
pattern typical of rheumatoid arthritis to one of bone formation, and particularly 
osteophyte formation, typical of osteoarthritis (578).  
In addition to osteophyte formation the AIA model also resulted in the formation of 
enthesophytes. This histopathological finding has not been reported previously in the 
AIA model. Enthesophytes differ from osteophytes with respect to anatomical 
location, tissue derivation and most likely pathogenesis. Unlike osteophytes, 
enthesophytes do not develop from the margins of the articular surface, but rather 
from the site of insertion of tendons, ligaments or articular capsule and they extend in 
the direction of pull of their tendon or ligament of origin (579). Based on location, the 
enthesophytes observed in the AIA mice most likely originated from the attachment 
site of the patella tendon/ligament. In contrast to osteophytes, which developed late in 
AIA, the enthesophytes developed early (week 1) and this would suggest that 
inflammation and not joint instability is a key factor in driving their formation in the 
AIA model.  
In humans the formation of enthesophytes and osteophytes are strongly correlated 
following correction for age and gender (580). This association has been further 
investigated in individuals with high bone mass in an attempt to identify a subset of 
OA patients with an OA phenotype that is characterised by excess bone formation 
(581). 
Our ‘tissue’ definition of OA has broadened from describing it as a disease of 
articular cartilage to a disease of multiple tissues that make up the joint organ (62, 
122). This study identified different model-specific associations between the three 
major tissue structures in the joint (articular cartilage, synovium and subchondral 
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bone). While providing further support to the clinical relevance of the “joint organ” 
definition, it also highlights how the pathological interaction between joints tissues is 
dependent on the arthritis phenotype.  The subchondral bone is one tissue that is 
reshaping our understanding of OA pathogenesis (62, 73, 582, 583). In the DMM 
model SCB sclerosis was consistently greater than sham surgery and age matched 
controls, despite the observed age-related increase in SCB thickening. The only 
decrease in SCB sclerosis that was observed in DMM occurred in week 1, when joint 
inflammation peaked and the SCB was characterised by increased vascularity. A 
similar pattern of change from SCB resorption to bone formation was observed in the 
AIA model, however, the decrease in SCB persisted for longer (week 4), reflecting 
the differences in joint inflammation severity and the degree of SCB vascularisation 
in the two models. SCB vascularisation was significantly associated with synovitis in 
AIA and DMM, indicating that it is part of the “whole joint inflammation” that occurs 
in the early stages of disease in both models.  
Despite the temporal differences described, by 16 weeks the two models were not 
significantly different with respect to inflammation (synovitis and SCB 
vascularisation), AC structural damage or osteophyte size. By all accounts at week 16 
histopathologically both models are OA-like. However, model specific tissue 
pathology associations were identified that confirm the unique disease phenotypes 
that these models represent (Figure 4.10). While it must be remembered that no causal 
relationships can be established from the data presented in this chapter, the different 
associations between joint pathologies in the two models may have implications when 
considering the potential of therapeutic intervention targeting one tissue to treat the 
global joint pathology of OA. In other words, the “OA phenotype” matters.  
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In the DMM model there was a strong positive relationship between cartilage 
structural damage and both PG loss and chondrocyte hypertrophy/apoptosis. This is 
consistent with the known role of both aggrecanolysis and the chondrocyte 
differentiation in OA cartilage degradation, and that genetic modifications targeting 
these molecular pathways can reduce OA cartilage damage in mice [reviewed in 
(407)]. Interestingly while AC structural damage in AIA was associated with 
chondrocyte hypertrophy and this with PG loss, there was no significant association 
between PG loss and cartilage erosion in this model. In the final OLR analysis of the 
two models the subtle differences in the cellular and molecular regulation of cartilage 
degradation are evident in PG loss and chondrocyte hypertrophy/apoptosis being the 
significant risk factors in DMM, while it was only chondrocyte hypertrophy/apoptosis 
in AIA. This is consistent with previous observation using genetically modified mice, 
demonstrating that the molecular regulation and/or enzymes involved in the sustained 
PG loss in AIA are distinct from those in DMM (439). However, it also confirms the 
importance of hypertrophic differentiation and chondrocyte death in cartilage 
structural damage (584-586), and that modulating this is an important therapeutic 
target that may cross different osteoarthritis phenotypes.  
That the relationships observed between different histopathological aspects of 
cartilage pathology align with current understanding of the pathophysiological 
mechanisms in this tissue provides confidence in the current analyses. We therefore 
explored the associations between different joint tissues in the two models. Consistent 
with the associations observed in human knee OA (63, 66, 570, 587) AC structural 
damage in the DMM model was significantly associated with increased SCB 
thickening and osteophyte formation (size), these two variables being significant 
independent risk factors in the logistic regression model describing AC damage in the 
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DMM model. This suggests that in the DMM induced post-traumatic OA the tissue 
specific mechanisms driving cartilage damage, SCB sclerosis and osteophyte 
formation are co-dependent. This is supported by data from genetically modified mice 
where targeting molecular mechanisms expected to specifically modulate bone 
turnover can significantly reduce cartilage damage in models of post-traumatic OA 
(407).  
In the AIA model however, despite some evidence for a correlation, SCB sclerosis did 
not remain in the final analysis as an independent risk factor for AC structural 
damage. Instead when corrected for all other variables, synovitis and osteophyte size 
were significant predictors of increasing AC structural damage in AIA. The factors 
that control association between osteophyte formation and cartilage damage as 
discussed above, appear to be acting in both arthritis models although at different 
times in disease progression. The negative correlation between synovial inflammation 
and SCB sclerosis observed in both models could in part account for the delayed AC 
structural damage observed in AIA model as synovitis persists at a greater level for 
longer, and supports the idea that the reduced SCB thickening is chondroprotective 
(583, 588).  However, the complex relationship between SCB and cartilage damage in 
OA is evident from recent therapeutic studies in mice (589, 590). Administration of 
bisphosphonates to reduce bone resorption had no effect on cartilage damage 
following meniscectomy-induced OA, however if the mice were first made 
osteopaenic or “bone-resorbers” by ovariectomy or Runx-2 overexpression, then 
bisphosphonates significantly reduced AC structural damage. This data suggests that 
excessive bone resorption may contribute to rather than protect against cartilage 
damage in OA. While no significant association was found between SCB 
vascularisation (the histological marker of bone resorption) and cartilage damage in 
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the AIA model, it would be interesting to determine if bisphosphonates had a 
chondroprotective effect in this model.  
It is perhaps also not surprising that in a model initiated by inducing an acute intra-
articular immune/inflammatory response to a foreign antigen (AIA), that synovitis 
would be a significant risk factor for cartilage damage.  Interestingly however, no 
direct association could be demonstrated between synovial inflammation and the 
development of articular cartilage pathology in the DMM model. This is somewhat 
surprising given that genetic modulation of various immune/inflammatory pathways 
has been shown to significantly inhibit cartilage degradation in mouse models of post-
traumatic OA (reviewed in (407)). This may reflect that the histopathological scoring 
method used for synovitis does not discriminate between different cellular or 
molecular phenotypes of inflammation. Thus while deficiency of complement factor 5 
(82), IL-1 (591), and IL-6 (592) for example have been shown to be 
chondroprotective in mouse post-traumatic OA, mice lacking complement regulatory 
protein 59a (82) or deficient in toll-like-receptors (TLRs)1-4 or their primary response 
gene Myd88 (593) show no change in OA cartilage damage. Thus there are specific 
inflammatory pathways and molecules that may be up-regulated and play critical roles 
in OA, and importantly in different stages and/or phenotypes of OA. This has been 
demonstrated previously for S100A9, which plays a central role in cartilage 
degradation in the more inflammatory ciOA, but not DMM (571). Whether it is 
simply the severity and prolonged time course of the synovial inflammation in AIA 
that drives the association between synovitis and AC damage in this model compared 
with DMM; or that more of the individual pathways that show association in DMM 
are up regulated in AIA; or that different, or more-potent pathways are regulated, is 
not clear.  
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Despite both models resulting in OA-like joint pathology, the different tissue 
associations observed in the two models suggest that different tissue specific 
mechanisms may be driving the joint pathology changes that ultimately lead to OA. 
The data presented in this chapter demonstrates that even when the long-term global 
joint pathology is the same, the relationship between the different tissue pathologies 
and the risk factors for developing OA, are likely determined by the initiating cause, 
and this is different for each animal model. This highlights the importance of defining 
animal model phenotypes in terms of initiating mechanisms and temporal joint tissue 
pathology, as well as end-stage joint disease characteristics. While most would agree 
that DMM is a model of post-traumatic (pt)-OA, the idea that AIA may also be an OA 
model would not be widely accepted. Acutely AIA is clearly a model of inflammatory 
arthritis, but at least from a pathological viewpoint, at some stage it “becomes OA”. 
With time long-term AIA could be considered a model of “post-inflammatory (pi)-
OA”. 
Although the two models eventually show all the hallmark pathological features of 
human OA (AC erosion, SCB sclerosis, marginal osteophytes), the time course of 
how this is arrived at and the relationship between the joint pathologies are very 
different. This suggests that even if both models are ultimately definable as different 
OA phenotypes, how one might plan to target or treat the disease has to be different. 
Furthermore, if despite ultimately similar OA pathology, the disease pathophysiology 
(tissue relationships and time course) differs between the models, does this mean the 
pathology/pain relationship and pain pathophysiology/molecular mechanisms will 
also differ? The relationship between pathology and pain in DMM versus AIA will be 
explored in the following chapters. 
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CHAPTER 5:  Pain behaviour outcomes following 
destabilization of the medial meniscus (DMM) and 
antigen-induced arthritis (AIA) in mice 
5.1 Introduction and aims 
In the previous chapter, the progressive histopathological changes that occur in 
different knee joint tissue structures following induction of arthritis using the DMM 
and the AIA models were evaluated, and different tissue pathology associations 
identified for each model. Interestingly, these joint pathology associations were not 
time dependent, and in contrast to the indistinguishable OA-like pathology observed 
in both models at week 16, were very much model-specific. 
In this chapter, activity-based and evoked pain-response behaviours were measured 
following induction of arthritis using DMM and AIA. This enabled further 
differentiation between the two models through evaluation of different pain related 
behaviours at key stages of disease development, as well as characterization of the 
temporal pattern of behaviour demonstrated in the two arthritis models. Associations 
between different pain behaviour outcomes were also investigated. 
Animal models are a useful pre-clinical research tool that are used to understand 
disease pathophysiology and facilitate the development and testing of new therapeutic 
agents (128). In the case of OA, the focus of pre-clinical research is to develop and 
test therapeutic agents that not only demonstrate efficacy with respect to halting joint 
disease progression and initiating joint pathology repair, but also that target the most 
clinically relevant disease symptom – pain (391).  
The challenge then becomes to identify animal models that mimic OA joint disease 
pathophysiology and symptomatology (399). This challenge is made even greater 
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because of the complex nature of pain as both a symptom and a disease.  Defining and 
quantifying pain in a pre-clinical setting is difficult (363). This in part explains why 
pre-clinical OA models remain unreliable predictors of disease response in humans 
and why favorable outcomes in animal models do not readily translate to effective 
human therapies (128).   
To address this current impediment to translation in OA research, pain outcomes in 
this thesis were defined (in terms that reflect what has been observed clinically in 
human OA), standardized (by developing detailed protocols on how tests are 
conducted to minimize operator variability), and then measured simultaneously in two 
animal models over a defined time period that reflected joint disease progression. The 
two models were specifically selected because; one has been used extensively to 
investigate OA specific pathophysiology (DMM) (28, 47, 407, 439) and one has been 
used to investigate arthritis pain and inflammatory pain mechanisms more broadly 
(AIA) (198, 453, 519, 594, 595).  
The aims of chapter 5 are: 
1. To characterize and compare the pain related behaviours that develop with knee
joint arthritis induced by DMM and AIA.
2. To track, in parallel, how each pain related behaviour changes temporally with
disease progression in the two models of arthritis.
3. To identify any associations between different pain-related behaviours in the two
models of arthritis.
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5.2 Methods, statistical analysis and data presentation 
Details of the methods used to induce the two models of arthritis, DMM and AIA, are 
described in chapter 2, section 2.1. The pain assays used in this chapter have 
previously been reported and validated (316, 465, 493, 517, 545), and the exact 
methods used for carrying out the pain tests were developed by the researcher 
(chapter 3, section 3.1) and described in chapter 2, section 2.3.  
Comparison of pain data between treatment groups and time points were analysed 
using the nonparametric ranked Kruskal-Wallis analysis for multiple groups and, 
where there was significance, post hoc analysis using the Mann Whitney U-test (for 
unpaired data) was performed for between group comparisons. Within treatment 
group comparisons relative to baseline were conducted using the Wilcoxon signed-
rank test (StataSE software, Stata corporation, TX, USA). The results are presented 
graphically as means with error bars depicting the standard error of each data set. 
The experiments reported in this chapter were designed to be hypothesis generating 
due to the variable nature of pain behaviour data and the fact that pain testing as 
described in this thesis (refer to Chapters 2 and 3) has not previously been conducted 
in two distinct arthritis models, tested longitudinally at the same time points over a 16 
week period of joint disease progression. For this reason, the alpha value was set at 
0.05 and the Benjamini-Hochberg correction was not applied to the P values to 
correct for repeated measures. 
Associations between the different pain related behaviours were determined by 
generating partial correlation coefficients, using Kendall’s tau-b (565). This 
nonparametric process uses pairwise ranked data values between the two variables 
under study (ordinal scores) and thus does not require data to be normally distributed 
or the relationship between the variables to be linear. Linear regression was used to 
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determine whether the pain-related behavior outcome variables changed over time; 
and when correcting for time, whether there was a difference between treatments. 
In the results, ‘significance’ refers to statistical significance, with p values included in 
the relevant results tables (Tables 5.1 – 5.7). 
5.3 Results 
Changes from baseline were observed in both AIA and DMM mice at different time 
points for the different pain related behaviours. These changes followed a similar 
trend in both animal models. However, a model-specific temporal pattern was 
observed for individual pain-related behaviours. These model-specific temporal 
changes are readily visible in figures 5.1c, 5.3c, 5.4c, 5.5c and 5.5i and are discussed 
in the following sections. 
5.3.1 Effect of AIA and DMM on tactile allodynia following induction of arthritis 
Paw withdrawal, evoked by von Frey filament stimulation was used to calculate the 
50% paw withdrawal threshold (PWT) as a measure of tactile allodynia. Following 
the establishment of a consistent method for measuring PWT evoked by von Frey 
filament stimulation, this pain assay was used to test for tactile allodynia in four 
separate experiments. The results reported in this section are the combined data from 
four cohorts of mice. Not all time points were captured for each mouse for several 
reasons. Firstly, a proportion of mice were culled at predetermined time points for the 
purpose of knee joint (see chapter 4) and DRG (see chapter 6) tissue harvesting. 
Secondly, we wished to avoid excessive testing and any confounding effect the 
associated stress of frequent testing would have on response thresholds. Any mice that 
191 
demonstrated extreme agitation and did not settle following the acclimatisation period 
were excluded from that test period, but were not excluded completely from the study. 
The decision to exclude an animal during a particular test period was made by the 
operator blinded to treatment. No particular treatment or sham group was excluded 
with any greater frequency. A total of 154 mice were used for testing. Ipsilateral 50% 
PWT’s for DMM, AIA, sham and saline groups are summarised graphically in figure 
5.1a-c and P values listed in Table 5.1. Contralateral 50% PWT’s are summarized in 
figure 5.1d-f. 
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Table 5.1. Von Frey (ipsilateral 50% PWT) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05).
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.582 
0.373 
0.022 
0.536 
0.065 
0.088 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.321 
- 
0.042 
0.013 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.527 
0.052 
0.027 
0.685 
- 
- 
Week 1 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
- 
- 
- 
<0.001 
0.011 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
<0.001 
0.003 
- 
0.028 
Week 2 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.692 
0.005 
1.000 
0.002 
0.838 
<0.001 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.065 
0.077 
0.003 
0.056 
0.249 
0.028 
Week 4 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.931 
0.001 
0.150 
0.784 
0.878 
0.003 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.017 
0.013 
<0.001 
0.008 
0.753 
0.028 
Week 8 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.593 
0.066 
0.915 
0.621 
0.655 
0.007 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.108 
0.224 
<0.001 
<0.001 
0.116 
0.028 
Week 12 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.035 
0.038 
0.654 
0.234 
0.417 
0.020 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.117 
0.272 
0.333 
0.056 
0.115 
0.046 
Week 16 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.175 
0.002 
0.305 
0.067 
0.092 
0.017 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.041 
0.783 
0.019 
0.016 
0.345 
0.028 
* T1 and T2 = 1
st
 and 2
nd
 treatment, D0 = baseline
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Baseline ipsilateral PWT in DMM and AIA mice was not significantly different from 
the respective control groups or age matched naïve mice (P = 0.582). Baseline 
contralateral PWT in DMM and AIA mice was also not significantly different from 
the respective control groups or age matched naïve mice (P = 0.355).  
Ipsilateral PWT decreased significantly compared to age matched naïve mice in both 
the AIA and DMM model. In the AIA model, both saline-injected and mBSA-injected 
mice developed early (day 3) ipsilateral tactile allodynia. However, the decrease in 
PWT was significantly greater in AIA mice compared to saline-injected mice at day 3 
(P = 0.013), week 1 (P < 0.001), and week 2 (P = 0.002). Immunised control mice that 
did not receive an intra-articular injection also developed persistent ipsilateral tactile 
allodynia (figure 5.1g). 
In the DMM model, both sham and DMM mice developed early ipsilateral tactile 
allodynia by day 3. This began to resolve in sham mice after week 8 testing, and 
returned to baseline levels by week 12. In contrast, the tactile allodynia that developed 
in DMM mice persisted over the 16-week time course.  
In the contralateral limb, significant differences in PWT between the six treatment 
and control groups were only observed at week 1 (P = 0.014) and week 16 (P = 0.034) 
following induction of arthritis. In general, there was greater variability in PWT 
within treatment groups and between treatment groups over time, on the contralateral 
side (figure 5.1f and 5.1h). 
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Figure 5.1a-c. Ipsilateral 50% Paw Withdrawal Threshold (PWT) 
Using von Frey filament stimulation of the hind paws, as a measure of tactile allodynia in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. 
AIA (c) mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the 
means with SEM’s marked. Significance for Treatment vs. sham/saline/control = P<0.05 (*); P<0.01 (**); and P<0.001 (***). Significance for 
Treatment vs. baseline (day 0) = P<0.05 (#); P<0.01 (##); and P<0.001 (###).
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Figure 5.1d-f. Contralateral 50% Paw Withdrawal Threshold (PWT) 
Using von Frey filament stimulation of the hind paws, as a measure of tactile allodynia in DMM vs. sham (d); AIA vs. saline (e); and DMM vs. 
AIA (f) mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the 
means with SEM’s marked. 
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Figure 5.1g-h. 50% PWT in immunised only mice 
Ipsilateral (g) and contralateral (h) 50% Paw Withdrawal Threshold (PWT) using von Frey filament stimulation of the hind paws, as a measure 
of tactile allodynia in immunised only (Im Control) mice and compared with AIA mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction 
of arthritis. The results are presented graphically as a line graph of the means with SEM’s marked. Significance for AIA vs. saline = P<0.05 (*); 
P<0.01 (**); and P<0.001 (***). Significance for AIA vs. baseline (day 0) = P<0.05 (#); P<0.01 (##); and P<0.001 (###). Significance 
for ImControl vs baseline (day 0) = P< 0.05 (§) 
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5.3.2 Effect of AIA and DMM on thermal hyperalgesia following induction of 
arthritis 
Paw withdrawal latency (PWL) evoked by placing individual mice on a metal 
hotplate set at 52 degrees C, was used as a measure of thermal hyperalgesia. This pain 
assay was used to test for thermal hyperalgesia in five separate experiments. The 
results reported in this section are the combined data from five cohorts of mice. Not 
all time points were captured for each mouse because a proportion of mice were 
culled at predetermined time points for the purpose of knee joint and DRG tissue 
harvesting. Not all time points were captured in each cohort because of the 
confounding issue of conditioning when mice are tested too frequently on a hotplate 
(refer to Chapter 3). 
Any mice that demonstrated extreme agitation and/or attempted to escape from the 
chamber by jumping as soon as they were placed on the hotplate even when it was set 
to room temperature, were excluded from testing. A total of 178 mice were used for 
testing. PWL’s for AIA, DMM, saline, sham and control groups are summarised 
graphically in figure 5.2a-e and P values listed in Table 5.2.  
Baseline PWL (figure 5.2a) was significantly different between the six treatment and 
control groups (P = 0.027). Post-hoc analysis identified a significant difference 
between saline injected and immunized control mice (P = 0.023). Baseline PWL for 
all other treatment and control/sham group combinations was not significantly 
different. 
In all mice there was a temporal effect in the first week of testing with a decrease in 
PWL. This was followed by an increase in PWL at week 2. This decrease in PWL 
between baseline and the first test period only reached significance in the age matched 
control group (P = 0.012).
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In AIA and saline injected mice there was a mild but significant decrease in PWL 
compared to baseline at week 8 (P = 0.041 and P = 0.017). In AIA mice this decrease 
in PWL was persistent and reached significance again at week 16 (P = 0.046). In 
saline injected mice PWL returned to above baseline levels by week 12. To 
investigate if immunisation alone had an effect on PWL, immunized non-injected 
mice were also tested (Figure 5.2e). In immunized control mice there was no 
significant difference between baseline and any of the other measured time points 
(week 1, 4 and 8). Baseline and week 1 PWLs were significantly lower in saline 
injected mice compared to immunised non-injected mice (P = 0.023 and 0.026).  
In DMM mice PWL decreased from week 4 (P = 0.028) to week 16, compared to 
baseline. PWL was decreased in DMM mice compared to Shams from week 4 to 
week 16, but the difference between the groups was not significant. PWL was also 
decreased in DMM compared to AIA, reaching significance at week 4 only (P = 
0.018). 
Figure 5.2a. Hotplate paw withdrawal latency (PWL) baseline 
Evoked by placing individual mice on a metal hotplate set at 52
0
C, was used as a
measure of thermal hyperalgesia. The baseline values are presented graphically as a 
scatter plot (mean and 95% CI). 
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Table 5.2. Hotplate (52
0
C PWL)
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment  P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.582 
0.125 
0.836 
0.179 
0.098 
0.106 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.599 
- 
0.789 
0.536 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.775 
0.493 
0.909 
0.265 
- 
- 
Week 1 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.641 
0.194 
0.500 
0.120 
0.171 
0.077 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.347 
0.454 
0.314 
0.230 
0.012 
0.465 
Week 2 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.166 
0.061 
0.564 
0.817 
- 
0.261 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.077 
0.530 
0.388 
0.060 
- 
- 
Week 4 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.140 
0.159 
0.018 
0.388 
0.580 
0.768 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.028 
0.093 
0.203 
0.241 
0.028 
0.273 
Week 8 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.108 
0.502 
0.063 
0.753 
0.040 
0.909 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.600 
0.753 
0.041 
0.017 
0.655 
0.068 
Week 12 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.465 
0.053 
0.063 
0.214 
0.077 
0.117 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.225 
0.345 
0.116 
0.292 
- 
- 
Week 16 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Im Control 
AIA vs. Control 
0.234 
0.028 
0.462 
0.137 
0.066 
0.007 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.686 
0.917 
0.046 
0.753 
-
- 
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Figure 5.2b-e. Hotplate PWL 
Evoked by placing individual mice on a metal hotplate set at 52 degrees C, was used 
as a measure of thermal hyperalgesia in DMM vs. sham (b); AIA vs. saline (c); DMM 
vs. AIA (d); and Immunised-control (e) mice at day 3, week 1, 2, 4, 8, 12 and 16 
following induction of arthritis. The results are presented graphically as a line graph 
of the means with SEM’s marked. Significance for Treatment vs. Control/ImControl 
= P<0.05 (*) and P<0.01 (**). Significance for Treatment vs. baseline (day 0) = 
P<0.05 (#); Significance for AIA vs DMM = P< 0.05 (§). 
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5.3.3 Effect of AIA and DMM on mechanical hyperalgesia following induction of 
arthritis 
Paw withdrawal, evoked by applying digital pressure across the knee joint of 
individual mice, was used as a measure of mechanical hyperalgesia. This pain assay 
was used to test for mechanical hyperalgesia in two separate experiments. The results 
reported in this section are the combined data from two cohorts of mice. Not all time 
points were captured for each mouse because a proportion of mice were culled at 
predetermined time points for the purpose of knee joint and DRG tissue harvesting. 
Not all time points were captured in each cohort to avoid excessive testing and any 
confounding affect the associated stress of frequent restraint and testing would have 
on response thresholds (refer to Chapter 3). If an individual mouse could not be 
restrained appropriately for testing without exerting excessive force the measurement 
was excluded for that time point but the mouse was not excluded from the study. A 
total of 131 mice were used for testing. PWT for AIA, DMM, saline, sham and 
control groups are summarised graphically in figure 5.3a-h and P values listed in 
Table 5.3. 
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Table 5.3. PAM device (right knee PWT) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
 
treatment, D0 = baseline. 
Time Treatments P – value 
(T1 vs. T2)* 
Treatment  P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.317 
0.317 
- 
0.289 
0.480 
0.242 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
- 
- 
- 
- 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
 
Week 1 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
- 
- 
- 
0.788 
- 
0.708 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
0.109 
0.317 
- 
0.007 
Week 2 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.091 
0.047 
0.563 
0.648 
0.026 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
- 
Week 4 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
- 
- 
- 
0.725 
- 
0.845 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
0.317 
- 
0.578 
Week 6 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.169 
0.209 
0.112 
0.565 
0.887 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.052 
0.425 
- 
- 
0.388 
- 
Week 8 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
- 
- 
- 
0.150 
- 
0.156 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
- 
Week 12 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.652 
- 
0.385 
0.107 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
- 
- 
- 
- 
- 
- 
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Week 14 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.740 
- 
- 
- 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.035 
0.087 
- 
- 
- 
- 
Week 16 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. Control 
AIA vs. Im Control 
0.149 
0.002 
0.010 
0.600 
0.221 
0.180 
DMM 
Sham 
AIA 
Saline 
Control 
Im Control 
0.028 
0.140 
- 
- 
0.317 
-
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There was no significant difference between baseline PWT for the six different 
treatment and control groups in either the right (P = 0.518) or left (P = 0.192) knee 
joint.  
In the AIA model ipsilateral PWT decreased at two weeks following induction of 
arthritis and at two weeks there was a significant difference in ipsilateral PWT 
between AIA and aged matched control mice (P = 0.026). By week 16 ipsilateral 
PWL returned to baseline levels. A similar pattern of change was observed in both 
saline-injected and immunized control mice. But, there were no significant 
differences observed in the saline injected or immunized control mice compared with 
age-matched control mice, at any of the measured time points. 
In the DMM model ipsilateral PWT also decreased at two weeks following induction 
of arthritis and remained decreased until week 16. In DMM ipsilateral PWT was 
significantly lower than age-matched controls at week 2 (P = 0.047) and week 16 (P = 
0.002). It was also significantly lower than baseline measurements in DMM mice at 
week 6 (P = 0.052), week 14 (P = 0.035) and week 16 (P = 0.028). The decrease in 
ipsilateral PWT in sham mice followed a similar temporal pattern but the decrease 
was of a much smaller magnitude and was not significantly different from baseline or 
compared to age matched controls at any measured time points.  
Contralateral PWT conformed to a similar temporal pattern of change in both AIA 
and DMM mice, however the decreases were minimal and not significant. 
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Figure 5.3a-c. Ipsilateral paw withdrawal threshold (PWT) 
Using the PAM device across the knee joint, as a measure of mechanical hyperalgesia in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. 
AIA (c) mice at day 3, week 1, 2, 4, 8, 12, 14 and 16 following induction of arthritis. The results are presented graphically as a line graph of the 
means with SEM’s marked. Significance for Treatment vs. control = P<0.05(*); and P<0.01(**). Significance for Treatment vs. baseline (day 0) 
= P<0.05(#). Significance for AIA vs. DMM =P< 0.01(§§).
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Figure 5.3d-f. Contralateral paw withdrawal threshold (PWT) 
Using the PAM device across the knee joint, as a measure of mechanical hyperalgesia in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. 
AIA (c) mice at day 3, week 1, 2, 4, 8, 12, 14 and 16 following induction of arthritis. The results are presented graphically as a line graph of the 
means with SEM’s marked. 
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Figure 5.3g-h. PWT in immunised only mice 
Ipsilateral (g) and contralateral (h) PWT using the PAM device across the knee joint, as a measure of mechanical hyperalgesia in Immunised 
only (Im-control) and compared with AIA mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented 
graphically as a line graph of the means with SEM’s marked. 
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5.3.4 Effect of AIA and DMM on hind limb weight distribution following 
induction of arthritis 
Hind limb (HL) weight distribution was measured in mice across six experiments, and 
the results reported in this section are the combined data from six cohorts of mice. 
Not all time points were captured for each mouse because a proportion of mice were 
culled at predetermined time points for the purpose of knee joint and DRG tissue 
harvesting. Not all time points were captured in each cohort to avoid excessive testing 
and any confounding affect the associated stress of frequent restraint and confinement 
in a small test chamber would have on stress induced analgesia (refer to Chapter 3). If 
an individual mouse was unable to settle in the test chamber the measurement was 
excluded for that time point but the mouse was not excluded from the study. A total of 
229 mice were used for testing.  HL weight distribution, expressed as the ratio of right 
to left HL weight bearing force in grams, for AIA, DMM, saline, sham and control 
groups are summarised graphically in figure 5.4a-d and P values listed in Table 5.4. 
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Table 5.4. Forceplate (hindlimb weight distribution) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.255 
0.086 
0.542 
0.452 
- 
0.180 
DMM 
Sham 
AIA 
Saline 
Control 
- 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.097 
- 
<0.001 
<0.001 
- 
- 
DMM 
Sham 
AIA 
Saline 
Control 
< 0.001 
< 0.001 
< 0.001 
0.116 
- 
Week 1 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.379 
- 
<0.001 
<0.001 
0.001 
- 
DMM 
Sham 
AIA 
Saline 
Control 
0.005 
0.019 
<0.001 
0.732 
- 
Week 2 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.177 
0.152 
<0.001 
<0.001 
- 
0.012 
DMM 
Sham 
AIA 
Saline 
Control 
0.040 
0.082 
<0.001 
0.254 
- 
Week 4 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.120 
0.549 
0.003 
0.008 
0.477 
0.004 
DMM 
Sham 
AIA 
Saline 
Control 
0.469 
0.026 
0.016 
0.124 
0.075 
Week 8 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.949 
0.127 
0.670 
0.942 
0.055 
0.423 
DMM 
Sham 
AIA 
Saline 
Control 
0.117 
0.148 
0.215 
0.210 
0.345 
Week 12 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.322 
0.641 
0.093 
0.784 
0.162 
0.067 
DMM 
Sham 
AIA 
Saline 
Control 
0.913 
0.011 
0.200 
0.093 
0.463 
Week 16 DMM vs. Sham 
DMM vs. Control 
DMM vs. AIA 
AIA vs. Saline 
AIA vs. ImControl 
AIA vs. Control 
0.676 
0.108 
0.615 
0.249 
0.363 
0.059 
DMM 
Sham 
AIA 
Saline 
Control 
0.018 
0.017 
0.100 
0.859 
0.116 
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Baseline hind limb weight distribution in AIA and DMM mice was not significantly 
different from the respective control groups or age matched naïve mice (P = 0.235). 
There was no significant change in HL weight distribution at any of the measured 
time points (Figure 5.4d) in control, saline injected or immunized non-injected mice. 
A similar temporal pattern of change in HL weight distribution was observed in both 
AIA and DMM mice, with a decrease in right HL weight bearing in the early stages of 
the disease (week 1 – 4) following induction of arthritis. This decrease was not 
detected consistently in the chronic phase of the disease in either arthritis models. The 
changes in HL weight distribution were greater in magnitude and lasted longer in AIA 
mice.  
In AIA mice right to left HL weight distribution decreased significantly at day 3 (P < 
0.005), week 1 (P < 0.005), week 2 (P < 0.005) and week 4 (P = 0.016), after 
induction of arthritis compared to baseline (Figure 5.4a).  
In DMM mice right to left HL weight distribution decreased significantly at day 3 (P 
< 0.005), week 1 (P = 0.005), week 2 (P = 0.040) and then again at week 16 (P = 
0.018) after induction of arthritis. In sham mice the initial decrease in HL weight 
distribution was less and was only significant at day 3 (P < 0.005) and week 1 (P = 
0.019). Interestingly, sham mice also demonstrated a second phase of reduced HL 
weight distribution, that was significantly reduced compared to baseline at week 4 (P 
= 0.026), week 12 (P = 0.011) and 16 (P = 0.017). 
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Figure 5.4a-d. Hind limb (HL) weight distribution 
Measured using a Forceplate, and expressed as right to left (R:L) HL ratio, in DMM 
vs. sham (a); AIA vs. saline (b); DMM vs. AIA (c); and Immunised-control (d) mice 
at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are 
presented graphically as a line graph of the means with SEM’s marked. Significance 
for AIA vs. Saline/ImControl = P<0.01 (**); and P<0.001 (***). Significance for 
Treatment vs. baseline (day 0) = P<0.05 (#); P<0.01 (##); and P<0.001 (###). 
Significance for AIA vs DMM = P< 0.01 (§§); and P< 0.001 (§§§). Significance for 
AIA vs. Control = P<0.05 (Φ); and P<0.01 (ΦΦ) 
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5.3.5 Effect of AIA and DMM on stride length following induction of arthritis  
Gait was characterised by measuring changes in stride length. Stride length was 
determined by measuring the distance between the right and left HL paw print (right-
to-left stride length; RLS), the left and right HL paw print (left-to-right stride length; 
LRS), and the distance from one right HL paw print to the next (full stride length 
right; FSLR), and one left HL paw print to the next (full stride length left; FSLL). 
Five consecutive measurements were averaged to determine a final value for each 
stride length parameter. Results for RLS, LRS, FSLR and FSLL are depicted 
graphically in figures 5.5a – 5.5l and P values listed in Table 5.5a – 5.5d.  
The stride measurements were also used to calculate the right relative step 
(LRS:FSLL ratio) when weight bearing on the unaffected limb, and the left relative 
step (RLS:FSLR ratio) when weight bearing on the affected limb. FSL is closely 
associated with walking speed and so normalising stride length to a complete walk 
cycle (FSL) eliminates speed (493, 557) as a confounding factor when interpreting 
changes in stride length following induction of arthritis in the two models. Results for 
right and left relative step are depicted graphically in figures 5.5m and 5.5n.  
Measurements were performed across two experiments, and the results reported in 
this section are the combined data from three cohorts of mice. Not all time points 
were captured for each mouse because a proportion of mice were culled at 
predetermined time points for the purpose of knee joint and DRG tissue harvesting. 
Also, during some test periods individual mice stopped too frequently to allow 
measurement of at least 5 consecutive uninterrupted strides. The most common 
behaviour displayed during stopping was grooming and urination. These mice were 
excluded from that single test period but were used for subsequent testing at later time 
points. A total of 84 mice were used for testing. 
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Table 5.5a. Stride length (right to left stride - RLS) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.874 
0.199 
0.180 
DMM 
Sham 
AIA 
Saline 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.505 
0.115 
0.058 
DMM 
Sham 
AIA 
Saline 
0.615 
0.258 
0.006 
0.093 
Week 1 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.773 
0.882 
0.467 
DMM 
Sham 
AIA 
Saline 
0.308 
0.638 
0.446 
0.078 
Week 2 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.326 
0.051 
0.537 
DMM 
Sham 
AIA 
Saline 
0.814 
0.875 
0.828 
0.184 
Week 4 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.749 
0.631 
1.000 
DMM 
Sham 
AIA 
Saline 
0.462 
0.173 
0.753 
0.249 
Week 8 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.873 
1.000 
0.631 
DMM 
Sham 
AIA 
Saline 
0.345 
0.028 
0.035 
0.917 
Week 12 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.100 
0.144 
0.295 
DMM 
Sham 
AIA 
Saline 
0.138 
0.293 
0.345 
0.207 
Week 16 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.715 
1.000 
1.000 
DMM 
Sham 
AIA 
Saline 
0.893 
0.075 
0.600 
0.249 
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Table 5.5b. Stride length (left to right stride - LRS) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.658 
0.374 
0.800 
DMM 
Sham 
AIA 
Saline 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.783 
0.612 
0.636 
DMM 
Sham 
AIA 
Saline 
0.754 
0.900 
0.113 
0.263 
Week 1 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.236 
0.767 
0.669 
DMM 
Sham 
AIA 
Saline 
0.433 
0.388 
0.744 
0.601 
Week 2 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.141 
0.300 
0.613 
DMM 
Sham 
AIA 
Saline 
0.158 
0.326 
0.349 
0.811 
Week 4 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.065 
0.055 
0.262 
DMM 
Sham 
AIA 
Saline 
0.075 
0.917 
0.753 
0.400 
Week 8 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.262 
0.296 
0.149 
DMM 
Sham 
AIA 
Saline 
0.600 
0.753 
0.753 
0.075 
Week 12 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
1.000 
1.000 
0.150 
DMM 
Sham 
AIA 
Saline 
0.686 
0.345 
0.917 
0.400 
Week 16 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.068 
0.582 
0.873 
DMM 
Sham 
AIA 
Saline 
0.138 
0.600 
0.028 
0.116 
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Table 5.5c. Stride length (full stride length right - FSLR) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.624 
0.237 
0.458 
DMM 
Sham 
AIA 
Saline 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.383 
0.354 
0.304 
DMM 
Sham 
AIA 
Saline 
0.875 
0.730 
0.015 
0.985 
Week 1 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.175 
0.751 
0.448 
DMM 
Sham 
AIA 
Saline 
0.100 
0.754 
0.446 
0.018 
Week 2 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.106 
0.117 
0.874 
DMM 
Sham 
AIA 
Saline 
0.209 
0.255 
0.777 
0.231 
Week 4 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.092 
0.078 
0.297 
DMM 
Sham 
AIA 
Saline 
0.046 
0.462 
0.292 
0.141 
Week 8 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.522 
0.337 
0.045 
DMM 
Sham 
AIA 
Saline 
0.116 
0.600 
0.173 
0.116 
Week 12 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.465 
0.144 
0.378 
DMM 
Sham 
AIA 
Saline 
0.080 
0.345 
0.173 
0.917 
Week 16 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.082 
0.715 
0.873 
DMM 
Sham 
AIA 
Saline 
0.225 
0.917 
0.027 
0.917 
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Table 5.5d. Stride length (full stride length left - FSLL) 
Between treatment comparisons and within treatment changes compared to baseline. 
P-values shown in bold typeface are significant (P<0.05). * T1 and T2 = 1
st
 and 2
nd
treatment, D0 = baseline.
Time Treatments P – value 
(T1 vs. T2)* 
Treatment P – value 
(vs. D0)* 
Day 0 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.887 
0.274 
0.445 
DMM 
Sham 
AIA 
Saline 
- 
- 
- 
- 
Day 3 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.581 
0.441 
0.245 
DMM 
Sham 
AIA 
Saline 
0.730 
0.551 
0.029 
0.588 
Week 1 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.237 
0.933 
0.537 
DMM 
Sham 
AIA 
Saline 
0.182 
0.530 
0.744 
0.026 
Week 2 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.248 
0.138 
0.849 
DMM 
Sham 
AIA 
Saline 
0.071 
0.410 
0.879 
0.276 
Week 4 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.109 
0.065 
0.262 
DMM 
Sham 
AIA 
Saline 
0.046 
0.463 
0.463 
0.249 
Week 8 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.337 
0.149 
0.199 
DMM 
Sham 
AIA 
Saline 
0.074 
0.345 
0.249 
0.293 
Week 12 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.201 
0.120 
0.575 
DMM 
Sham 
AIA 
Saline 
0.080 
0.173 
0.075 
0.917 
Week 16 DMM vs. Sham 
DMM vs. AIA 
AIA vs. Saline 
0.359 
0.855 
0.748 
DMM 
Sham 
AIA 
Saline 
0.174 
0.753 
0.046 
0.753 
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There was no significant difference for baseline RLS (P = 0.490), LRS (P = 0.758), 
FSLR (P = 0.567) or FSLL (P = 0.655) measurements between the four treatment 
groups. The mean baseline RLS, LRS, FSLR and FSLL were 31.6mm, 32.6mm, 
63.5mm and 63.9mm respectively.  
Changes in LRS followed a different temporal pattern in AIA and saline injected mice 
even though by week 16 LRS was the same for both groups (5.5b). In AIA mice LRS 
remained similar to baseline and only decreased significantly at week 16 (P = 0.028). 
In saline mice LRS was decreased week 4 to week 16 but this did not reach 
significance compared to day 0 or compared to AIA at any of the measured time 
points. In contrast, changes in RLS followed a similar temporal pattern in AIA and 
saline injected mice. In AIA and saline injected mice RLS was decreased at day 3 and 
week 8 but was only significant in AIA mice (P = 0.006 and P = 0.035 respectively). 
FSLR and FSLL were both significantly decreased at day 3 in AIA mice (P = 0.015 
and 0.029) and increased at week 1 in saline injected mice (P = 0.018 and 0.026). 
FSLR and FSLL decreased further week 4 to week 16 in both AIA and saline injected 
mice, reaching significance in AIA mice at week 16 (P = 0.027 and 0.046).  
The changes in stride length observed in DMM mice followed a different trend to 
AIA. LRS was decreased from week 4 to week 16 following induction of arthritis. In 
contrast RLS did not decrease until week 12. Both FSLR and FSLL increased initially 
at week 1 and then decreased, reaching significance at week 4 (P = 0.046 and 0.046). 
In sham mice RLS decreased significantly (P = 0.028) at week 8. The differences 
observed between DMM and sham mice for LRS and FSL measurements were not 
significant at any time point. 
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Figure 5.5a-c. Stride length I 
Stride length measured as hind limb right to left stride  (RLS) length, in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. AIA (c) mice at 
day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the means with SEM’s 
marked. Significance for Treatment vs. baseline (day 0) = P<0.05 (#); and P<0.01 (##). Significance for AIA vs DMM = P< 0.05 (§).
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Figure 5.5d-f. Stride length II 
Stride length measured as hind limb left to right stride  (LRS) length, in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. AIA (c) mice at 
day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the means with SEM’s 
marked. Significance for Treatment vs. baseline (day 0) = P<0.05 (#). Significance for AIA vs DMM = P< 0.05 (§).
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Figure 5.5g-i. Stride length III 
Stride length measured as hind limb right to right full stride length (FSLR), in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. AIA (c) 
mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the means with 
SEM’s marked. Significance for AIA vs. Saline = P<0.05 (*). Significance for Treatment vs. baseline (day 0) = P<0.05 (#).
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Figure 5.5j-l. Stride length IV 
Stride length measured as hind limb left to left full stride length (FSLL), in DMM vs. sham (a); AIA vs. saline (b); and DMM vs. AIA (c) mice 
at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. The results are presented graphically as a line graph of the means 
with SEM’s marked. Significance for Treatment vs. baseline (day 0) = P<0.05 (#).
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Figure 5.5m-n. Stride length V 
Stride length expressed as relative step in DMM vs. AIA mice at day 3, week 1, 2, 4, 8, 12 and 16 following induction of arthritis. Right relative 
step (m) is defined as the relative stride length when supporting weight on the unaffected limb, and calculated as the LRS:FSLL ratio. Left 
relative step (n) is defined as the relative stride length when supporting weight on the affected limb, and calculated as the RLS to FSLR ratio. 
The results are presented graphically as a line graph of the means with SEM’s marked. 
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The observed differences in LRS, RLS and FSLR between AIA and DMM 
demonstrated interesting trends although these differences were not significant. Right 
and left relative step displayed a similar pattern of change to LRS and RLS, in AIA 
mice. However, DMM displayed the reverse pattern of change to LRS and RLS, with 
an increased R relative step and decreased L relative step at week 16. So for DMM 
mice at week 16, when speed is accounted for, stride length is decreased when weight 
bearing on the affected limb and increased when weight bearing on the unaffected 
limb. The changes from baseline and the differences between treatment and sham 
groups were not significant. 
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5.3.6 Time and treatment effect on pain-related behaviours 
Linear regression analysis was used to investigate the pattern of change over time for 
each pain-related behaviour outcome variable, and also within the two arthritis 
models (Table 5.6). This provides a more robust evaluation of the effect of the two 
arthritis models on pain- outcomes, by taking time into account and allowing all the 
data to be included in the analyses rather than individual time points. 
When corrected for treatment group (sham, saline, DMM, AIA), Forceplate 
measurements decreased significantly up to day 3, before increasing significantly over 
time. Von Frey measurements decreased significantly over time up to week 4, and 
thereafter increased significantly with time. PAM measurements decreased 
significantly over time up to week 2. Hotplate and Stride length (FSLL) 
measurements progressively and significantly decreased over time. 
When time was corrected for, a significant treatment effect was observed for a 
number of the pain-related behaviour outcomes. Forceplate HL weight distribution 
was significantly decreased in AIA relative to both saline and DMM regardless of 
which stage of the disease process. Von Frey PWT was significantly decreased in 
sham relative to saline and in AIA relative to saline in the acute phase of the disease 
process (0 – 4 weeks). There were no treatment effects in the later stages of disease, 
beyond week 4. No significant treatment effect was demonstrated in PAM when time 
was corrected for. There was also no significant treatment effect when time was 
corrected for in hotplate measurements. Stride length did demonstrate a treatment 
effect: FSLL was decreased in DMM relative to sham and increased in AIA relative 
to DMM. 
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Table 5.6. Time and treatment effect on pain behaviour 
Linear regression on separate pain parameters in AIA and DMM was used to 
determine whether pain outcome variables changed over time (1), and when corrected 
for time whether there was a difference between treatment (2) and comparator 
treatments (3). Where the direction (increase vs decrease) and/or significance of the 
temporal change for a particular pain outcome differed with time after arthritis 
induction, the periods are reported separately. Forceplate, PAM and stride length data 
was normally distributed, Von Frey and Hotplate data was normalised using log 
transformation. 
Score Period 
(w) 
Time
1
Time 
(P) 
Treatment
2
Cf tx
3
 Tx (P)
Forceplate 0 – 0.4 Decreased <0.001 Sham - Saline   0.320 
AIA Decreased Saline <0.001 
DMM - Sham   0.072 
AIA Decreased DMM   0.001 
Forceplate 0.4 - 16 Increased <0.001 Sham - Saline   0.12 
AIA Decreased Saline <0.001 
DMM - Sham   0.62 
AIA Decreased DMM   0.001 
Von Frey 0 - 4 Decreased <0.001 Sham Decreased Saline   0.004 
AIA Decreased Saline <0.001 
DMM - Sham   0.63 
AIA - DMM   0.19 
Von Frey 4 - 16 Increased 0.001 Sham - Saline   0.99 
AIA - Saline   0.75 
DMM - Sham   0.21 
AIA - DMM   0.36 
PAM 0 - 2 Decreased 0.037 Sham - Saline 0.100
AIA - Saline 0.720
DMM - Sham 0.730
AIA - DMM 0.140
PAM 2 - 16 0.650 Sham - Saline 0.180 
AIA - Saline 0.340 
DMM - Sham 0.091 
AIA - DMM 0.210 
Hotplate 0 - 16 Decreased 0.007 Sham - Saline 0. 210
AIA - Saline 0.450 
DMM - Sham   0.860 
AIA - DMM 0.080 
Stride 
length 
(FSLL) 
0 - 16 Decreased <0.001 Sham - Saline   0.23 
AIA - Saline   0.86 
DMM Decreased Sham   0.019 
AIA Increased DMM   0.012 
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5.3.7 Correlation between different pain-related behaviours in AIA and DMM 
when corrected for time 
Each individual perceives the experience of pain differently, and each pain outcome 
measure may reflect a different aspect of the pain experience. Yet in pre-clinical pain 
research we attempt to define it in terms of a series of basic observations or responses 
to a specific stimulus. Understanding how the different pain-related behaviours that 
can be observed in pre-clinical studies are associated could provide important 
nuanced information about the pain phenotype of the different animal models that are 
used to study OA. The existence of any associations was investigated by calculating 
partial correlation coefficients for the different pain-related behaviours in the different 
treatments (AIA, Saline, DMM, Sham) when corrected for time (Table 5.7). 
Interestingly, when time was corrected for, there were no significant associations 
between the different pain-related behaviours in either of the arthritis models. In the 
saline group there was a weak association between PAM and hotplate, which was lost 
when correction for repeated measures was performed. 
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Table 5.7. Pain related behaviour partial ranked correlations in AIA and DMM when 
corrected for time.  
  
a. HL weight distribution Treatment r P 
Von Frey AIA 
Saline 
DMM 
Sham 
0.163 
0.123 
0.118 
0.028 
0.089 
0.440 
0.260 
0.860 
PAM AIA 
Saline 
DMM 
Sham 
0.091 
0.001 
0.277 
0.120 
0.560 
0.930 
0.250 
0.310 
Hotplate AIA 
Saline 
DMM 
Sham 
0.057 
0.017 
0.030 
0.031 
0.470 
0.790 
0.680 
0.610 
Stride length AIA 
Saline 
DMM 
Sham 
0.043 
0.065 
0.017 
0.061 
0.600 
0.320 
0.840 
0.380 
b. Von Frey     
PAM AIA 
Saline 
DMM 
Sham 
0.032 
0.123 
0.023 
0.053 
0.830 
0.460 
0.850 
0.750 
Hotplate AIA 
Saline 
DMM 
Sham 
- 
0.081 
- 
0.149 
- 
0.580 
- 
0.260 
Stride length AIA 
Saline 
DMM 
Sham 
- 
- 
- 
- 
- 
- 
- 
- 
c. PAM    
Hotplate AIA 
Saline 
DMM 
Sham 
- 
0.237 
- 
0.125 
- 
0.016 
- 
0.300 
Stride length AIA 
Saline 
DMM 
Sham 
- 
- 
- 
- 
- 
- 
- 
- 
d. Hotplate    
Stride length AIA 
Saline 
DMM 
Sham 
0.044 
0.092 
0.088 
0.118 
0.580 
0.280 
0.300 
0.160 
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5.4 Discussion 
In this chapter, pain-related behaviours were measured following induction of arthritis 
in DMM and AIA mice. Sham surgery and saline injected mice were also tested for 
comparison. The focus of this chapter was to characterise the pain that develops in 
these two distinct animal models and track how the pain-related behaviours change 
over time. Time and treatment effects were investigated, and associations between the 
different pain-related behaviours were also investigated in the two models of arthritis.  
Pain in both the DMM and AIA models was characterised by tactile allodynia, knee 
joint mechanical hyperalgesia, reduced weight bearing of the affected HL, thermal 
hyperalgesia and changes in stride length, at different points of disease progression. 
For all of the pain-related behaviours there were differences between the two models 
with respect to the degree of severity of the pain behaviour that developed and/or the 
pattern of change over time that was observed.  
There was little variability in baseline readings for the behaviour tests conducted, with 
the exception of the hotplate test. However, all pain related behaviours demonstrated 
greater variability in subsequent measurements following induction of arthritis, 
despite clearly defined endpoints and a single operator performing the testing. This 
suggests that the pain experience for each individual mouse is different, as it is for 
individual humans (596). This variability also means that many of the experiments 
conducted in this chapter were underpowered and so the conclusions that are drawn 
from these experiments are in part based on the patterns and trends that were 
observed, rather than statistically significant findings.  As stated previously these 
were hypothesis generating experiments as the methods used to conduct the behaviour 
tests were modified from what has previously been published and have not been 
previously described or tested in two distinct models of arthritis.  
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5.4.1 Tactile allodynia 
Tactile allodynia on the ipsilateral hind paw developed early in treatment and sham 
groups but not in control mice. Allodynia was observed before the time point at which 
bona fide OA like joint pathology changes start to develop in the two models (refer to 
chapter 4). This suggests that the early phase tactile allodynia is driven by the trauma 
and inflammation caused by surgery, immunisation and knee joint injection. Further 
support of this is the fact that allodynia resolved completely in sham surgery mice at 
the time when OA was well established in DMM mice.  
Interestingly in the AIA model, allodynia developed in both mBSA and saline 
injected mice. Allodynia is a hallmark sign of central sensitisation. Central 
sensitisation is a manifestation of both activity dependent (early phase) and 
independent (late phase) sensory signal plasticity that can be transient or long lasting. 
It occurs after a period of initial nociceptive transmission and is sustained beyond the 
initiating signal. Immediate changes involve alteration of the distribution and function 
(increased excitability) of ion channels and receptors in response to high-level 
nociceptor input. On going noxious input and inflammation then lead to 
transcriptional changes at the level of the DRG and spinal cord (dorsal horn) (255). 
Since it is unlikely that a minor interference (ie saline injection) could trigger the type 
of changes in the sensory nervous system that are needed for central sensitisation to 
develop (597), von Frey testing was also performed on immunised mice that had no 
knee joint intervention. As predicted, a similar degree of allodynia was observed in 
immunised-only mice. This novel finding has not been reported before in the AIA 
model and highlights the limitations of using models that have both a systemic and 
local joint effect.  
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Tactile allodynia in the contralateral hind paw could not be demonstrated consistently 
in either model. Interpretation of results from the contralateral side is difficult because 
a response to von Frey fibres requires movement of the contralateral limb, which may 
result in greater weight bearing on the ipsilateral knee joint and a worsening of the 
pain in that joint. In other words, pain in the ipsilateral knee joint may indirectly 
increase the threshold at which an animal responds to a noxious stimulus on the 
contralateral side. However, the differences between the ipsilateral and contralateral 
50% PWT in each treatment group cannot be fully explained by this, especially in the 
saline injected and immunised-only mice. For consistency, animals were tested first 
on the left hind paw and then the right hind paw. The effect of testing order cannot be 
excluded as another contributing factor to the observed difference in 50% PWT 
between the ipsilateral and contralateral limbs.  
5.4.2 Mechanical hyperalgesia 
In DMM mice development of ipsilateral knee joint mechanical hyperalgesia 
displayed an early (week 6) and late (week 16) phase, which corresponds to the acute 
and chronic stage of OA disease development and pathology in this model (refer to 
chapter 4). In contrast, AIA mice displayed greater pain pressure sensitivity earlier on 
in the disease when joint inflammation was at a peak and less sensitivity in the late 
phase when OA joint pathology was well established (refer to chapter 4). As occurred 
with tactile allodynia, a similar pattern of mechanical hyperalgesia was observed in 
saline injected and immunized-only mice. These observations again highlight the 
confounding effect of measuring pain outcomes in an animal model that induces 
systemic and local joint effects. Changes in pressure pain sensitivity in the 
contralateral knee were very mild but followed a similar temporal pattern to the 
ipsilateral knee in both AIA and DMM mice. 
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Reduced pressure-pain threshold is a clinically relevant measure of OA pain as it 
mimics what has been observed in patients with knee OA pain (268). Patients with 
mild knee pain display greater sensitivity to pressure applied to the lateral side of the 
joint. While patients with severe knee pain display greater sensitivity to pressure 
applied to the medial side of the joint (284). In addition, these patients display 
increased evoked temporal summation, in response to repeated pressure application. 
Both of these are measures of central sensitisation. Interestingly, the degree of 
localized sensitisation as measured by pressure application tests and evoked temporal 
summation correlate with clinical pain ratings reported by OA patients. This is in 
contrast to the lack of correlation between standard radiological findings and clinical 
or experimental pain measures in OA patients. It highlights the need for similar 
investigations to better define the relationships that may exist between experimental 
measures of pain and specific joint pathologies in pre-clinical animal models. 
It must be noted that the level of physical restraint required when testing mice for 
knee joint sensitivity to a mechanical stimulus made it challenging to differentiate 
between mice that were responding to the applied stimulus and those that were 
demonstrating escape behaviour due to the restraint method. In addition, the stress 
associated with restraint may also have induced activation of the endogenous opioid 
system and other mechanisms involved in stress-induced analgesia, which in turn 
would influence the response threshold in individual mice. These added complexities 
reinforce the importance of blinding and testing control and sham mice in parallel 
throughout the experiment. 
5.4.3 Hind Limb Weight distribution 
Hind limb weight distribution in DMM and AIA mice was evaluated as a measure of 
pain using a force plate. The average right to left HL weight bearing ratio pre-
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treatment ranged from 1.0 – 1.1 in AIA, DMM, sham and naïve control mice. Both 
models induce a mono-articular arthritis and so any shift in weight distribution that 
favours the non-treated HL is assumed to be an avoidance response secondary to pain. 
However, in the DMM model it can’t be ruled out that changes in weight distribution 
are also due to biomechanical changes arising from joint instability. The fact that two 
aspects of OA could be at play in the DMM model (pain and biomechanical 
instability) may in part explain the conflicting results published by researchers using 
DMM and other joint destabilisation models (316, 406, 598). 
Reduced weight bearing on the ipsilateral HL was observed early in AIA, DMM and 
sham surgery mice. Unlike the pain-related behaviour tests that indicate central 
sensitisation, changes in HL weight distribution were not observed in saline injected 
and immunized-only mice. This suggests that HL weight distribution is a measure of 
pain driven primarily by local joint pathology and not by systemic mechanisms.  
The pattern of change in HL weight distribution was similar in both models. 
However, the peak reduction in ipsilateral HL weight bearing was greater in the AIA 
mice (50% vs. 30%) and persisted for longer (4 weeks vs 2 weeks) in this early phase 
of change. This suggests that the early changes in weight bearing may reflect the 
inflammation and trauma caused by the methods used to induce arthritis and not the 
direct effect of OA on weight bearing. Interestingly, a late phase (week 16) reduction 
in ipsilateral HL weight bearing was only observed in DMM and sham mice despite 
significant OA joint pathology in AIA mice and the absence of joint pathology in 
sham mice at this stage (refer to chapter 4). This late reduction in ipsilateral HL 
weight bearing was observed more consistently in DMM mice, with decreased 
ipsilateral HL weight bearing observed in 3 of the 4 DMM cohorts that were tested at 
week 16 and in only 2 of the 4 sham cohorts. The fact that changes in HL weight 
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distribution was observed in AIA, DMM and sham surgery mice indicate that altered 
weight distribution is not simply a biomechanical phenomenon following the creation 
of joint instability. However, the reasons why reduced weight bearing in the 
ipsilateral HL persisted in some sham surgery mice long after post-surgical joint 
pathology had resolved is still not known. 
5.4.4 Stride length 
In DMM mice gait was characterised by a small increase in FSLL, FSLR, LRS and 
RLS in the immediate post-surgical period (week 1) followed by a sustained decrease 
in LRS, FSLL and FSLR from week 4, that persisted until week 16.  This is similar to 
what has been observed in patients with knee OA where both stride length and 
walking velocity (reflected in full stride data) are reduced (553); and what has been 
reported in arthritis animal model studies using digital gait analysis systems (515). 
These changes can in part be explained by the reduced range of motion and increased 
joint stiffness that also occurs in patients with chronic knee OA. Despite these known 
associations from what has been observed in patients with knee OA, changes in stride 
length have not previously been investigated in the DMM model, as a potential 
marker of disease progression or indicator of response to novel therapies.  
In AIA mice a significant decrease in LRS, FSLL and FSLR occurred immediately 
following mBSA injection into the joint (day 3). This acute response to mBSA 
injection coincided with visible swelling of the knee joint, significant synovial 
exudate, sub synovial inflammation and synovial hyperplasia (refer to chapter 4). AIA 
mice recovered partially following this initial decrease in stride length before 
displaying a more gradual 2
nd
 phase of decrease in LRS, FSLL and FSLR, reaching 
DMM values by week 16. Also important to note is the fact that Relative Step 
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followed a similar pattern to the changes in stride length, suggesting that the decrease 
in FSLL and LRS is not simply due to a slower gait speed in the AIA model. 
The temporal changes in stride length support previous study findings, which 
demonstrated a similar pattern of change in the AIA model (493). The failure to 
demonstrate an association between stride length and any other pain-related 
behaviours is also supported by this study, where it was demonstrated that stride 
length correlates with other pain related measures (mechanical and thermal 
hyperalgesia) in the acute phase, at day 3, but not in the chronic phase (after week 3) 
of arthritis development (493).  
However, it is important to note that in this thesis multiple behaviour tests were not 
conducted on the same individual mice and so the ability to make any conclusions 
about potential pain-relate behaviour associations is limited. In addition, the study 
referred to here defines three weeks post joint injection as ‘chronic’, whereas the 
histological findings in this thesis would suggest that at three weeks the joint 
pathology is still characterized by acute inflammation and significant articular 
cartilage damage has not developed at this relatively early time point. 
The differences in the temporal pattern of change in stride length between the two 
models reflect some of the differences in onset of OA specific joint pathology 
development. Combined with the histology data from chapter 4, the temporal 
differences between the two models appear to reflect the early onset of OA joint 
pathology from week 4 (AC damage, osteophytes and SCB sclerosis) observed in the 
DMM model compared to AIA mice that developed characteristic OA joint pathology 
more gradually (refer to chapter 4) with significant AC damage occurring later than in 
DMM mice. 
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Overall, DMM and AIA mice displayed different temporal patterns of change for all 
stride measurements. However, the low animal numbers in each treatment group at 
these time points and the variability within each animal group meant that these 
changes were not statistical significant.  
5.4.5 Thermal hyperalgesia 
PWL decreased over time in AIA, DMM and sham mice. Thermal hyperalgesia 
developed in DMM mice from week 4. Significant decreases in PWL were observed 
in AIA and saline-injected mice but these changes were less than what was observed 
in DMM mice. In DMM mice the decrease in PWL over time was only significant at 
week 4. This is most likely due to the small sample size of paired data at each time 
point (n ≤ 5). 
Therefore, interpreting the observed changes in PWL for the hotplate test presents 
some unique challenges. Although the hotplate is a well-established and validated 
pain assay (599), variability in baseline data makes it difficult to interpret changes 
over time between groups when the baseline PWL is significantly increased in one or 
more groups of mice.  
Like many of the pain-related behaviour tests used in mice, the hotplate involves 
exposure to two stressors, physical confinement or restraint and a noxious stimulus 
(heat). In the case of the hotplate, the relatively wider and open-ended holding space 
(see Chapter 2, figure 2.3b) may provide a greater stimulus for the flight response in 
some mice. Therefore, it is likely that in some mice the primary stimulus leading to a 
behavioural response is exposure to a noxious temperature, while in other mice the 
behaviour they display is not a pain response or an indication of thermal hyperalgesia, 
but rather a stress driven escape response. This could account for the variability in 
baseline response latency that is reported (599) and that was observed in this 
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experiment. This is despite the use of two combined endpoints to define PWL (hind 
paw lick and jump), which were selected because they have been shown to increase 
both specificity and sensitivity (600) when investigating non-analgesic drug effects.  
The variability in response latency also occurs following the administration of 
analgesics. When large numbers of mice were tested to determine baseline PWL and 
the effects of variable doses of morphine, there was great repeatability within cohorts 
but significant repeatable disagreement between cohorts (535). It is still unclear 
whether this simply represents individual variability or whether it is due to unknown 
environmental factors that only affected a given cohort at a particular test period. 
It has been suggested that matching subjects into groups based on baseline (pre-
treatment) PWL would remove the confounding effect of individual differences in 
sensitivity within different cohorts and allow data to be examined for any interactions 
between individual differences and treatments effects (517).  
The reason this strategy was not adopted is because of the evidence that exists for the 
effects of habituation leading to behavioural tolerance and a reduction in both 
baseline response latency and response to some analgesic agents. A progressive 
decrease in response time and disappearance of licking behaviour has been 
demonstrated with repeated testing (601) and prior exposure of mice to an unheated 
hotplate chamber significantly decreased response latency to a 55 degree hotplate. 
Therefore, behavioural tolerance cannot be ruled out as the cause of the decrease in 
PWL observed in treatment and sham groups at the early time points. However, it was 
unavoidable to test individual mice repeatedly over a two-week period in order to 
investigate early changes in PWL following induction of arthritis.  
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5.4.6 Summary 
Pain assessment in patients with knee OA involves numerous tests that measure many 
parameters including range of motion, weight bearing, gait analysis and mechanical 
pain thresholds, as well as self-report questionnaires such as the MPQ and the 
WOMAC (268). Using multiple tests allows more complete characterisation of OA 
pain. It also helps to clearly define the pain experience unique to an individual patient 
and facilitates tracking of its progression and evaluation of its management.  
While the use of self-report questionnaires is not an option in preclinical animal 
studies, the use of multiple pain assessment tools gives greater clarity to the type of 
pain that develops in any particular animal model (pain phenotype) and provides 
greater ability to test and quantify the efficacy of novel therapeutics.  
In this chapter I have reported on the use of a range of pain-related behaviour tests to 
characterise pain in the DMM and AIA model and described how the pain changes 
over time with disease progression. Each model demonstrates a unique pain 
phenotype despite both models displaying very similar OA-like knee joint pathology 
at week 16 (refer to chapter 4). Table 5.8 summarises the pain phenotype for each 
animal model at different phases of OA joint disease (early acute inflammatory, acute 
OA, chronic OA). 
 238 
Table 5.8. Summary of pain phenotype for AIA and DMM at different phases of OA 
Phases of OA joint disease are based on histopathology changes (early acute, acute OA, chronic OA) and phentotype is defined based on 
different pain related behaviours (allodynia, mechanical hyperalgesia, thermal hyperalgesia, hind limb weight distribution and stride length). 
Plus symbol (+) = pain-related behaviour demonstrated; minus symbol (-)  = pain-related behaviour not demonstrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OA Disease Phase Pain-related behaviour  Test  AIA DMM 
Early acute (0-2 weeks) Tactile allodynia   + 
 Thermal hyperalgesia Hotplate - - 
 Mechanical hyperalgesia PAM ++ + 
 Hind limb weight distribution Forceplate ++ + 
 Gait changes Reduced stride length + - 
     
Acute OA (4-8 weeks) Tactile allodynia  + + 
 Thermal hyperalgesia Hotplate - + 
 Mechanical hyperalgesia PAM + + 
 Hind limb weight distribution Forceplate + - 
 Gait changes Reduced stride length - + 
     
Chronic OA (12-16 weeks) Tactile allodynia  + + 
 Thermal hyperalgesia Hotplate + + 
 Mechanical hyperalgesia PAM - ++ 
 Hind limb weight distribution Forceplate - + 
 Gait changes Reduced stride length + + 
 239 
The failure to demonstrate any correlation between the different pain related 
behaviours in this study highlights the importance of not relying on one single pain 
assay when evaluating the efficacy of therapeutics that are targeting the symptoms of 
OA (pain and mobility) in pre clinical models. 
The pain experienced by patients with OA has been well characterised. Peripheral 
mechanisms such as inflammation play an important role in its development. But, 
human OA pain is also driven in part by complex mechanisms that don’t directly 
correlate with joint pathology. These mechanisms lead to sensory nervous system 
modulation and subsequent development of central sensitisation (230). This explains 
why the degree of pain does not always correlate with the degree of joint pathology or 
inflammation and why patients with knee OA display mechanical hyperalgesia and 
tactile allodynia (284). It explains why OA patients experience movement-evoked 
pain and pain at rest. It also explains why patients with low pain thresholds and 
evidence of hyperalgesia may continue to experience pain following knee joint 
arthroplasty (602). 
Evaluation of the effect of both time and treatment on different pain related behaviour 
further demonstrates the complex nature of OA pain. When time was corrected for, 
weight bearing on the affected limb significantly decreased in AIA mice relative to 
both saline injected and DMM mice, indicating that regardless of the stage of disease 
HL weight bearing changes are determined by what mechanisms trigger OA to 
develop in the first place. In contrast, no treatment effect was demonstrated for the 
development of mechanical or thermal hyperalgesia when corrected for time, 
indicating that the observed changes are more likely associated with the stage of 
disease development rather than the disease etiology or animal model used to induce 
OA. Interestingly, the opposing treatment effect observed with stride length (FSLL) 
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between DMM and AIA indicates the changes in stride are model specific because 
any change in gait reflects the combined effect of joint pathology on biomechanics, 
proprioception and pain. 
The findings in this chapter demonstrate that the DMM and AIA models lead to a 
complex pain state that is in part driven by central sensitisation and that has many of 
the hallmarks of what many human OA patients experience. What isn’t clear is which 
specific joint pathology processes trigger and maintain any given pain behaviour? The 
absence of any associations between the different pain behaviours indicates that the 
mechanisms may be different for different types of pain and at different stages of the 
disease. For example, tactile allodynia appears to persist long after the initiating 
trigger has resolved. This may be because other pathological processes take over as 
the drivers of the pain in the later stages of OA disease, or as with other neuropathic 
pain states, the allodynia is maintained by activity independent (late phase) sensory 
signal plasticity that is sustained beyond the initiating signal.  
This reinforces the need to investigate the underlying changes to sensory innervation 
that accompany the different pain-related behaviours.  The relationship between tissue 
specific joint pathology and pain, and how it changes over time can then be 
characterised and a better understanding of OA pain mechanisms arrived at. In the 
following chapter the changes in gene expression of key inflammatory mediators and 
neuropeptides in the dorsal root ganglia that innervate the knee joint are investigated. 
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CHAPTER 6:  Gene expression profile of inflammatory 
mediators and neurotransmitters in the DRG 
following destabilization of the medial meniscus 
(DMM) and antigen-induced arthritis (AIA) in mice 
6.1 Introduction and aims 
In the previous chapter, activity-based and evoked pain-response behaviours were 
measured to characterise and compare the pain that develops with knee joint arthritis 
induced by DMM and AIA. Model specific temporal patterns of change in pain 
response were identified, establishing that both the DMM and AIA models lead to a 
complex pain state that is partly driven by central sensitisation and that demonstrates 
many of the characteristics of the pain experienced by human OA patients. These 
findings highlight the need to investigate the changes in sensory neurons that 
accompany the different pain behaviours observed in each model in order to better 
understand differences in pain phenotype between the two models.  
In this chapter, gene expression of key inflammatory mediators and neuropeptides in 
the peripheral sensory neurons that innervate the knee joint were measured following 
induction of arthritis using DMM and AIA. In addition, gene expression of the major 
aggrecanases (ADAMTS-4 and ADAMTS-5) involved in articular cartilage 
degradation was also measured in an attempt to identify any biomolecular links 
between joint pathology and the mechanisms that drive OA pain. This enabled further 
characterisation of the pain phenotype in the two models through evaluation of the 
changes in sensory neurons that may be contributing to the observed pain-related 
behaviours reported in the previous chapter. 
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Studies have mapped the cell bodies of afferent neurons that innervate the knee joint 
in mice to the lumbar DRG (L1 – L5) (226). Retrograde tracing and 
immunohistochemistry methods have been used to characterise the number, 
distribution and neuropeptide content of neurons residing in the DRG that innervate 
the knee joint, with the majority (approximately 90%) residing in L3 and L4 (169). 
The knee joint sensory afferents make up a small proportion of the total cell 
population in these DRG (<1 in 15) (603) and only a subset of these are the small 
myelinated (A fibre) and unmyelinated (C fibre) nociceptors. The remainder 
comprises large, low threshold mechanoreceptors (169). This has implications for the 
ability to identify small changes in gene expression in this subset of nociceptor 
neurons using the method described in this thesis where the entire DRG is processed 
for RNA extraction and PCR. To avoid further dilution of any change in expression in 
the nociceptor neurons that specifically innervate the knee joint, only L3 and L4 DRG 
were processed. 
The proteins and neuropeptides that drive and modulate pain signaling in the OA joint 
have been investigated in a number of pre-clinical animal models (485, 604-607). 
These studies add to the huge body of knowledge that already exists about pain 
mechanisms and the role of neuronal plasticity in chronic pain states (230, 432, 596, 
608-611). It is well established that inflammatory neuropeptides such as Substance P 
and CGRP, and numerous inflammatory cytokines, including IL-1, are involved in 
the development of chronic pain and sensitisation (89, 469, 612). In addition, 
nociceptor ion channels such as members of the transient receptor potential family of 
channels, TRPV1, TRPV2, TRPV4 and TRPA1, are no longer viewed simply as 
sensory transducers that translate physical stimuli into electrical signals. Their role in 
the inflammatory and neuropathic mechanisms that contribute to the development of 
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chronic pain and sensitisation has been established through numerous investigations 
using preclinical pain models (613). The endogenous opioid and cannabinoid systems 
are also primary drivers of the inhibitory mechanisms that contribute to modulation of 
pain signaling (265, 312).  
In short, a number of local inflammatory and neurogenic mechanisms have been 
identified as potentially contributing to OA pain and could therefore lead to the 
development of suitable therapeutic targets for treating OA specific pain (reviewed in 
(271, 287)). However, the significance of these channels, neuropeptides and pro-
inflammatory cytokines in the establishment of specific sub-types of OA pain and 
their activity at different stages of disease development is still unclear. This is largely 
because previous investigations have not taken the approach that pain may be 
different for different sub types (phenotypes) of OA and at different stages of the 
disease. In fact, very few studies have investigated pain mechanisms in different 
animal models in parallel, to differentiate mechanisms that are model (phenotype) 
specific, and those that reflect more generic mechanisms associated with the 
development of chronic pain. The failure to translate the current understanding of 
acute and chronic pain mechanisms highlights the need for a more targeted approach 
to OA pain (363).  
This means that the development and testing of future OA pain therapeutics should 
target specific OA phenotypes (391). For example, it has been postulated that a more 
targeted approach that focuses on local (joint specific) and peripheral (DRG) 
mediators of OA pain is more likely to lead to the development of effective 
therapeutics that are void of unwanted systemic side effects (307). In line with this 
new way of thinking, peripheral pain mechanisms were investigated simultaneously in 
two animal models over a defined time period that corresponded to joint disease 
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progression (Chapter 4) and model specific pain-related behaviour (Chapter 5). The 
lumbar DRG were targeted as the site of investigation because it is where the cell 
bodies of the sensory neurons that innervate the knee joint reside and therefore 
arguably where OA pain starts. Chronic pain and the development of central 
sensitisation involve changes in cell signaling, membrane excitability and gene 
transcription in neurons at the level of the DRG and the spinal cord, as well as 
supporting cells (astrocytes), immune cells (microglia)(614) and peripheral 
monocytes that migrate into the DRG and spinal cord (reviewed in (255, 615-618)). 
As a first step in unraveling these complexities for OA pain, investigation of gene 
expression alterations in the DRG following induction of arthritis have been 
undertaken. 
The aims of chapter 6 are: 
1. To characterise and compare temporal changes in gene expression in the lumbar 
(L3 and L4) DRG following development of knee joint arthritis induced by DMM 
and AIA.  
2. To identify any associations between the expression of different genes in the DRG 
and compare these in the two arthritis models. 
3. To investigate differences in protein expression in the lumbar (L3-L4) DRG 
following development of knee joint arthritis induced by DMM and AIA, using 
immunohistochemistry techniques. 
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6.2 Methods, statistical analysis and data presentation 
Details of the methods used to induce the two models of arthritis, DMM and AIA, are 
described in chapter 2, section 2.1. The methods used for harvesting DRG and real 
time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) are described in 
chapter 2, section 2.4. The methods used for immunohistochemistry are described in 
chapter 2, section 2.5.  
Comparison of gene expression between treatment groups was analysed using the 
nonparametric ranked Kruskal-Wallis analysis for multiple groups and, where there 
was significance, post hoc analysis using the Mann Whitney U-test (for unpaired data) 
was performed for between group comparisons. Within treatment group comparisons 
between right and left DRG gene expression were conducted using the Wilcoxon 
signed-rank test (StataSE software, Stata corporation, TX, USA). Analysis focussed 
on gene expression in the right DRG because both arthritis models induced a mono-
articular arthritis with joint pathology in the right knee joint. However, changes in 
both ipsilateral and contralateral DRG have been reported in animal models of single 
joint arthritis (375). So for completeness changes in the right and left DRG were 
compared and the R/L DRG ratio was also compared between treatment groups. 
The gene expression results are presented as the mean fold change relative to the 
respective sham or saline control group and graphed as log of the means with error 
bars depicting the standard error of each data set (Figures 6.1a-i and 6.2a-i). Bars 
above 1 represent a relative increase in gene expression and bars below 1 represent a 
relative decrease. 
Due to the current gaps that exist in our understanding of the mechanisms that drive 
OA pain, the experiments reported in this chapter were designed to be hypothesis 
generating, with a suite of genes tested. Although, the genes investigated in this 
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chapter have been implicated in a number of pain states, including arthritis, their 
pattern of expression in the peripheral nervous system at different stages of OA 
disease development using different animal models, has not previously been 
investigated. For this reason, when testing the significance of between and within 
treatment group changes in gene expression, the alpha value was set at 0.05 and the 
Benjamini-Hochberg correction was not applied to the P values to correct for repeated 
measures.  
Linear regression on log transformed gene expression data was used to determine 
whether gene expression changed over time regardless of treatment; and when 
correcting for time, whether there was a difference between arthritis models. 
Associations between the different genes within each model (when corrected for time) 
were also determined by generating Pearson partial correlation coefficients, using 
Kendall’s tau-b (565). This nonparametric process uses pairwise ranked data values 
between the two variables under study (ordinal scores) and thus does not require data 
to be normally distributed or the relationship between the variables to be linear. The 
Benjamini-Hochberg correction was applied to the P values of the associations for 
each gene pair, resulting in P < 0.040 being considered significant when the alpha 
value was set at 0.05.  
CNR1 was excluded from both linear regression and partial correlation analysis 
because of the reduced data set available for this gene, with only 1 time point in the 
AIA and saline groups and only 3 time points in the DMM and sham groups.   
In the results, ‘significance’ refers to statistical significance, with P values included in 
the relevant tables.  
Protein expression, based on immunohistochemical staining, in each of the treatment 
groups and at different time points were not measured quantitatively due to the small 
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sample size (n=2) and the challenges of maintaining the same quality of tissue 
integrity across all DRG samples and consistent staining patterns between tissue 
samples that had been stored for different periods of time. Representative images of 
DRG sections depicting protein expression trends based on immunohistochemical 
staining are presented in figures 6.4a – 6.4h. 
6.3 Results 
6.3.1 DRG gene expression (real time RT-PCR) 
When comparing gene expression in the R versus L DRG (within animal comparison) 
for each treatment group at different time points (Table 6.1), there was no significant 
difference in the saline or sham groups at any measured time point. The genes that 
showed a significant difference in expression between the R and L DRG of AIA or 
DMM mice, are displayed in Figure 6.1(a – g). In AIA, differences in gene expression 
between the R and L DRG occurred at day 3 (R DRG decreased IL-1); week 1 (R 
DRG increased TRPV2); week 2 (R DRG decreased ATF3, and ADAMTS-5); week 4 
(R DRG decreased CGRP, Oprm1, and ADAMTS-4); week 8 (R DRG decreased 
CGRP, and TRPA1); and week 12 (R DRG decreased TRPV1). In DMM differences 
in gene expression between R and L DRG occurred at week 1 (R DRG decreased IL-
1), week 4 (R DRG increased TRPA1, CNR1); week 8 (R DRG decreased TRPV1), 
week 12 (R DRG decreased CGRP, TRPA1, TRPV1); and week 16 (R DRG 
increased CGRP, TRPA1, TRPV1, TRPV2).  
In AIA there were more differences in gene expression between R and L DRG at the 
early stages of disease progression (up to week 4). In DMM the reverse trend was 
observed, with more differences in gene expression profile between R and L DRG at 
the chronic stages of disease (weeks12-16).  
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Table 6.1. Gene expression of the right vs. left L3/L4 DRG  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRG gene expression in DMM and AIA mice at day 3, week 1, 2, 4, 8, 12 and 16 
post arthritis induction. No significant differences (n.c.) observed in saline and sham 
mice. Only genes that demonstrated a significant difference (P<0.05) are listed. 
Time  Treatment  Gene  P-value 
Day 3    
 Saline n.c. - 
 AIA IL-1b 0.046 
 Sham n.c.  
 DMM n.c.  
Week 1    
 Saline n.c.  
 AIA TRPV2 0.046 
 Sham n.c.  
 DMM IL-1b 0.028 
Week 2    
 Saline n.c.  
 AIA ATF3 0.028 
  ADAMTS-5 0.028 
 Sham n.c.  
 DMM n.c.  
Week 4    
 Saline n.c.  
 AIA CGRP 0.043 
  Oprm1 0.043 
  ADAMTS-4 0.042 
 Sham n.c.  
 DMM TRPA1 0.045 
  CNR1 0.043 
Week 8    
 Saline n.c.  
 AIA CGRP 0.028 
  TRPA1 0.046 
 Sham n.c.  
 DMM TRPV1 0.043 
Week 12    
 Saline n.c.  
 AIA TRPV1 0.028 
 Sham n.c.  
 DMM CGRP 0.003 
  TRPA1 0.026 
  TRPV1 0.013 
Week 16    
 Saline n.c.  
 AIA n.c.  
 Sham n.c.  
 DMM CGRP 0.003 
  TRPA1 0.026 
  TRPV1 0.013 
  TRPV2 0.043 
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Figure 6.1a-g. Gene expression for R vs. L L3/L4 DRG 
Presented as the mean fold change relative to the respective sham or saline control group and graphed as log of the means with error bars 
depicting the standard error of each data set. Bars above 1 represent a relative increase in gene expression and bars below 1 represent a relative 
decrease. Significance for R vs. L within treatment comparisons = P<0.05 (§); and P<0.01 (§§). 
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To investigate these observations further, gene expression in the ipsilateral R DRG 
was compared in each model against the relevant sham or saline group, as well as 
between the two models (Table 6.2 and Figures 6.2a – 6.2l). Differences in R DRG 
gene expression between AIA and saline mice were only observed at week 8: at this 
time point, both ATF3 (P=0.004) and TRPA1 (P=0.004) expression was decreased in 
AIA compared to saline. Differences in R DRG gene expression between DMM and 
sham mice were observed much earlier where at day 3 TRPA1 expression was 
increased in DMM compared to sham (P = 0.020). Differences between the two 
models (DMM vs. AIA) occurred at day 3 (IL-1, ADAMTS-5); week 1 (IL-1); 
week 4 (ATF3, CNR1, ADAMTS-4); and week 8 (ATF3, CGRP, TRPA1). 
Interestingly, when differences between the two models were observed, changes in 
gene expression were generally in the opposite direction with one model having 
increased expression and the other model having decreased expression. For example: 
ADAMTS-5 at day 3 (Figure 6.2l); IL-1 at week 1 (Figure 6.2c); ATF3 at week 4 
(Figure 6.2a); and TRPA1 at week 8 (Figure 6.2f). 
Table 6.2. Gene expression of the right L3/L4 DRG 
Treatment comparison Time Gene P-value
DMM vs Sham Day 3 TRPA1 0.020 
AIA vs Saline Week 8 ATF3 0.004 
TRPA1 0.004 
DMM vs AIA Day 3 IL1b 0.016 
ADTS5 0.005 
Week 1 IL1b 0.006 
Week 4 ATF3 0.007 
CBR1 0.004 
ADTS4 0.004 
Week 8 ATF3 0.006 
CGRP 0.029 
TRPA1 0.006 
DMM vs, sham; AIA vs. Saline; and DMM vs. AIA mice at day 3, week 1, 2, 4, 8, 12 
and 16 post arthritis induction. Only genes that demonstrated a significant difference 
(P<0.05) are listed. 
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Figure 6.2a-l. Gene expression for R L3/L4 DRG 
Presented as the mean fold change relative to the respective sham or saline control group and graphed as log of the means with error bars 
depicting the standard error of each data set. Bars above 1 represent a relative increase in gene expression and bars below 1 represent a relative 
decrease. Significance for treatment vs. Sham/Saline = P<0.05 (*); and P<0.01 (**). Significance for AIA vs. DMM = P<0.05 (#); and P<0.01 
(##). 
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To account for any masking of change in ipsilateral R DRG gene expression resulting 
from changes in the contralateral L DRG, differences in the right to left (R/L) DRG 
gene expression ratio between treatment groups was also analysed (Table 6.3 and 
Figures 6.3a-6.3l). The R/L DRG gene expression ratio was different between DMM 
and sham mice at week 8, week 12 and week 16 but not at the early time points. 
CGRP, Tac-1, Oprm1, TRPA1 and TRPV1 all displayed significant changes at one or 
more time point in DMM. In marked contrast, there was no difference in R/L gene 
expression ratio between AIA and Saline at any of the measured time points. There 
were differences between DMM and AIA at all measured time points in one or more 
of the genes tested.  Most of the differences between DMM and AIA occurred at 
week 4, with differences observed in 8 of the 12 genes tested (CGRP, Oprm1, 
TRPA1, TRPV2, TRPV4, CNR1, ADAMTS-4, ADAMTS-5). The direction of 
change differed for each gene indicating both up regulation and down regulation at 
different time points for different treatments. 
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Table 6.3. Right to left DRG (L3 and L4) gene expression ratio 
 
DMM vs, sham; AIA vs. Saline; and DMM vs. AIA mice at day 3, week 1, 2, 4, 8, 12 
and 16 post arthritis induction. Only genes that demonstrated a significant difference 
(P<0.05) are listed. n.d. = no difference; * = DMM < Sham; ** = DMM < AIA 
 
 
Treatment comparison Time Gene  P-value 
DMM vs Sham Week 8 TRPV1* 0.050 
 Week 12 CGRP* 0.006 
  SP* 0.045 
  MOR* 0.029 
  TRPA1* 0.018 
 Week 16 CGRP 0.017 
  TRPV1 0.015 
AIA vs Saline n.d. n.d. n.d. 
DMM vs AIA Day 3 IL1b 0.025 
  TRPV2** 0.015 
 Week 2 ATF3** 0.037 
 Week 4 CGRP 0.002 
  MOR 0.006 
  TRPA1 0.004 
  TRPV2 0.015 
  TRPV4 0.004 
  CBR1 0.009 
  ADTS4 0.014 
  ADTS5 0.002 
 Week 8 TRPV1** 0.006 
 Week 12 SP** 0.037 
  TRPA1** 0.010 
 Week 16 CGRP 0.035 
  TRPV1 0.016 
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Figure 6.3a-l. Right to left gene expression ratio for L3/L4 DRG 
Presented as the mean fold change relative to the respective sham or saline control group and graphed as log of the means with error bars 
depicting the standard error of each data set. Bars above 1 represent a relative increase in gene expression ration and bars below 1 represent a 
relative decrease. Significance for treatment vs. Sham/Saline = P<0.05 (*); and P<0.01 (**). Significance for AIA vs. DMM = P<0.05 (#); and 
P<0.01 (##). 
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Table 6.4 summarises the changes in gene expression profile in each model and the 
differences between the two models at key time points of disease progression. The 
different phases of OA disease were defined by the histopathology in Chapter 4. The 
acute inflammatory phase combines day 3, week 1 and week 2 where there is: 
maximal synovitis; AC proteoglycan loss but mild structural damage; early largely 
cartilaginous osteophyte development; and SCB remodelling but limited sclerosis. 
The early-progressive OA phase incorporates week 4 and 8 data and reflects the stage 
in disease development when: inflammation is decreasing; articular cartilage 
structural damage and SCB sclerosis is worsening; and osteophytes are approaching 
maximal size and ossifying. The late OA phase includes week 12 and16 when all the 
hallmarks of chronic established OA are present and stable at maximal levels in both 
models, with AC structural damage/erosion, subchondral bone sclerosis and mature 
boney osteophytes. The genes that displayed differences in R vs L DRG, in the R 
DRG of arthritic vs sham/saline, or in DMM vs AIA comparisons, at one or more of 
the time-points included in these different disease phases, have been included in Table 
6.4 and the following discussion.  
The acute inflammatory phase of disease was characterised by increased ATF3, 
increased TRPV2 and decreased ADAMTS-5 expression in AIA; increased TRPA1 
expression in DMM; and decreased IL-1 in both models (although earlier in AIA). 
During this acute phase, gene expression for IL-1 (AIA decreased and DMM 
increased at day 3, AIA increased and DMM decreased at week 1) and ADAMTS-5 
(AIA decreased and DMM increased at day 3) was significantly different between the 
two models.  
The early-progressive OA phase of disease was characterised by decreased ATF3, 
CGRP, TRPA1, Oprm1 and ADAMTS-4 expression in AIA; and increased TRPA1, 
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decreased TRPV1 and decreased CNR1 expression in DMM. During this phase of OA 
gene expression for ATF3 (increased AIA and decreased DMM at week 4, decreased 
AIA and DMM at week 8); CGRP (decrease AIA and increase DMM at week 8); 
TRPA1 (decrease AIA and increase DMM at week 8); CNR1 (decrease DMM at 
week 4); and ADAMTS-4 (increase AIA and decrease DMM at week 4) was 
significantly different between the two models. 
The late OA disease phase was characterised by decreased TRPV1 expression in AIA; 
decreased Tac-1 and Oprm1 expression in DMM; increased TRPV1, TRPV2 and 
TRPV4 expression in DMM; and interestingly, initial decrease (week 12) and then 
increase (week 16) CGRP and TRPA1 expression in DMM. During this late phase 
there were no significant differences in R DRG expression between the two models. 
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Table 6.4. A summary of changes in gene expression profile in the ipsilateral L3/L4 
DRG of DMM and AIA mice.  
The genes that displayed significant differences in R vs. L DRG or in the R DRG and 
R/L DRG ratio of arthritis vs. sham/saline and DMM vs. AIA at one or more of the 
time-points included in the different disease phases (acute inflammatory, early 
progressive OA, late chronic OA) are presented.  
1. 
R DRG and R/L ratio gene expression change compared to sham. 
2.
 R DRG and R/L
ratio gene expression change compared to saline. 
3.
 R DRG gene expression change 
DMM compared to AIA (arrow indicates direction of change for DMM relative to
AIA). Arrows indicate increase (é) and decrease (ê)
OA Disease 
Phase 
Gene DMM
1
AIA
2 DMM vs 
AIA
3
Acute ATF3 -  - 
  
TRPA1  -
TRPV2 -  - 
ADAMTS-5 -  
Early OA ATF3 -  
CGRP -  
TRPA1   
TRPV1  - -
Oprm1  -
CNR1  
ADAMTS-4  
Late OA CGRP  - 
Tac-1  - 
TRPA1  - 
TRPV1   
TRPV2  - -
TRPV4  -
Oprm1  - -
-
-
-
-
IL-1β
-
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6.3.2 Time and treatment effect on DRG gene expression (real time RT-PCR) 
Linear regression analysis was used to investigate the pattern of change over time for 
each gene outcome variable (R DRG expression), and within the two arthritis models 
(Table 6.5). This provides a more robust characterization of the gene expression 
profile of the different models, by taking time into account and allowing all data to be 
included in the analyses rather than at individual time points.  
When corrected for treatment group (sham, saline, DMM, AIA) only CGRP 
expression increased significantly with time. None of the genes evaluated displayed a 
significant decrease in expression with time. When time was corrected for, a 
significant treatment effect was observed for two genes:  both TRPA1 and ADAMTS-
5 were increased in DMM relative to AIA. There were no treatment effects for any 
other genes. 
262 
Table 6.5. Time and treatment effect on DRG gene expression 
Gene Time
1
 Time (P) Treatment
2 
Cf tx
3
Tx(P) 
CGRP Increased 0.049 Sham – Saline   0.92 
(n=187) AIA – Saline   0.74 
DMM – Sham   0.26 
AIA – DMM   0.13 
IL-1b – 0.41 Sham – Saline   0.95 
(n=173) AIA – Saline   0.78 
DMM – Sham   0.59 
AIA – DMM   0.75 
Tac-1 – 0.34 Sham – Saline   0.55 
(n=184) AIA – Saline   0.32 
DMM – Sham   0.52 
AIA – DMM   0.29 
ATF3 – 0.66 Sham – Saline   0.38 
(n=187) AIA – Saline   0.83 
DMM – Sham   0.28 
AIA – DMM   0.70 
Oprm1 – 0.99 Sham – Saline   0.61 
(n=187) AIA – Saline   0.93 
DMM – Sham   0.50 
AIA – DMM   0.83 
TRPA1 – 0.49 Sham – Saline   0.43 
(n=187) AIA – Saline   0.17 
DMM – Sham   0.13 
AIA – DMM   0.036 
TRPV1 – 0.30 Sham – Saline   0.79 
(n=187) AIA – Saline   0.94 
DMM – Sham   0.57 
AIA – DMM   0.75 
TRPV2 – 0.17 Sham – Saline   0.75 
(n=180) AIA – Saline   0.68 
DMM – Sham   0.99 
AIA – DMM   0.90 
TRPV4 – 0.22 Sham – Saline   0.96 
(n=91) AIA – Saline   0.73 
DMM – Sham   0.45 
AIA – DMM   0.71 
ADAMTS-4 – 0.92 Sham – Saline 0.50 
(n=135) AIA – Saline 0.70 
DMM – Sham 0.96 
AIA – DMM 0.76 
ADAMTS-5 – 0.12 Sham – Saline 0.94 
(n=162) AIA 
DMM 
– 
– 
Saline 
Sham 
0.17 
0.37 
AIA – DMM 0.028 
Linear regression on log transformed gene expression data of the right L3/L4 DRG in 
AIA and DMM was used to determine whether gene expression changed over time 
(1), and when corrected for time whether there was a difference between treatment (2) 
and comparator treatments (3). 
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6.3.3 Correlation between different genes in AIA and DMM when corrected for 
time 
Understanding the associations in gene expression in the lumbar DRG provides 
important information about the mechanisms that may be driving the pain phenotype 
of the different OA animal models. The existence of any associations was investigated 
by calculating partial correlation coefficients for the different genes (right DRG gene 
expression) in the different treatments (AIA, Saline, DMM, Sham) when corrected for 
time (Table 6.6).  
When time was corrected for there were significant associations between all 11 genes 
in the two control groups (Saline and Sham), with the exception of IL-1 and TRPV4 
(no association in sham or saline mice); IL-1 and ADAMTS-4 (no association in 
sham or saline mice); and TRPV4 and ADAMTS-4 (no association in sham mice). In 
both AIA and DMM mice the majority of these associations between the 11 genes 
that were investigated persisted, confirming the interdependence of the neuropeptides, 
nociceptor channels, inflammatory mediators and other protein receptors involved in 
pain modulation. These associations reflect the normal network of sensory input 
regulation at the level of the DRG that are maintained in disease. However, of 
particular interest were the associations between gene expression that were lost in the 
two arthritis models, as these indicate disease-specific dysregulation that may be 
suggesting different pain regulatory pathways in the two arthritis models. Three 
particular genes showed loss of normal expression association in the two arthritis 
models; CGRP, IL-1 and ADAMTS-4.   In the case of CGRP there were 7 
associations lost in AIA (ATF3, IL-1, Oprm1, TRPV2, TRPV4, ADAMTS-4, 
ADAMTS-5) but only 2 in DMM (TRPV2, ADAMTS-4). There were 5 associations 
lost for IL-1 in both AIA (CGRP, Oprm1, TRPV1, TRPV2, ADAMTS-4) and DMM 
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(ATF3, Oprm1, Tac-1, TRPV2, ADAMTS-5), with only 2 of these (Oprm1, TRPV2) 
being common to both models. ADAMTS-4 showed the greatest loss of co-expression 
with other DRG genes, with 6 associations lost in AIA (CGRP, ATF3, IL-1, Oprm1, 
TRPV4, ADAMTS-5) and 8 in DMM (CGRP, Oprm1, Tac-1, TRPA1, TRPV1, 
TRPV2, TRPV4, ADAMTS-5), 4 of these (CGRP, Oprm1, TRPV4, ADAMTS-5) 
being common to both models. 
Table 6.6. Gene expression correlations 
Gene comparison Treatment r (tau) P 
CGRP VS ATF3 Saline 0.374   0.003 
Sham 0.495 <0.001 
AIA 0.154 0.22 
DMM  0.320 <0.001 
CGRP VS IL-1B Saline 0.286   0.003 
Sham 0.322   0.001 
AIA 0.003 0.99 
DMM 0.379 <0.001 
CGRP VS Oprm1 Saline  0.309   0.013 
Sham  0.442  <0.001 
AIA  0.139 0.29 
DMM  0.437   <0.001 
CGRP VS Tac-1 Saline 0.407 <0.001 
Sham 0.526 <0.001 
AIA 0.257    0.041 
DMM 0.410 <0.001 
CGRP VS TRPA1 Saline 0.312   0.001 
Sham 0.510 <0.001 
AIA 0.372   0.001 
DMM 0.483  <0.001 
CGRP VS TRPV1 Saline 0.527 <0.001 
Sham 0.466 <0.001 
AIA 0.333   0.006 
DMM 0.480 <0.001 
CGRP VS TRPV2 Saline 0.303   0.003 
Sham 0.468 <0.001 
AIA 0.155 0.22 
DMM 0.227   0.058 
CGRP VS TRPV4 Saline 0.323   0.005 
Sham 0.322   0.003 
AIA 0.287   0.066 
DMM 0.265   0.036 
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CGRP VS ADAMTS-4 Saline 0.456 <0.001 
Sham 0.374 <0.001 
AIA 0.168 0.29 
DMM 0.204 0.11 
CGRP VS ADAMTS-5 Saline 0.309 0.015 
Sham 0.385 <0.001 
AIA 0.031 0.85 
DMM 0.298 0.008 
ATF3 VS IL-1B Saline 0.299 0.001 
Sham 0.417 <0.001 
AIA 0.359 0.001 
DMM 0.111 0.27 
ATF3 VS Oprm1 Saline 0.286 0.023 
Sham 0.506 <0.001 
AIA 0.295 0.026 
DMM 0.471 <0.001 
ATF3 VS Tac-1 Saline 0.399 <0.001 
Sham 0.567 <0.001 
AIA 0.275 0.021 
DMM 0.407 <0.001 
ATF3 VS TRPA1 Saline 0.236 0.040 
Sham 0.460 <0.001 
AIA 0.448 <0.001 
DMM 0.426 <0.001 
ATF3 VS TRPV1 Saline 0.414 <0.001 
Sham 0.493 <0.001 
AIA 0.347 0.004 
DMM 0.404 <0.001 
ATF3 VS TRPV2 Saline 0.372 0.001 
Sham 0.536 <0.001 
AIA 0.331 0.009 
DMM 0.301 0.003 
ATF3 VS TRPV4 Saline 0.449 <0.001 
Sham 0.315 0.004 
AIA 0.394 0.023 
DMM 0.241 0.051 
ATF3 VS ADAMTS-4 Saline 0.406 0.002 
Sham 0.375 0.001 
AIA 0.256 0.095 
DMM 0.406 <0.001 
ATF3 VS ADAMTS-5 Saline 0.401 0.001 
Sham 0.249 <0.001 
AIA 0.490 <0.001 
DMM 0.332 0.001 
IL-1B VS Oprm1 Saline 0.295 0.009 
Sham 0.290 0.002 
AIA 0.167 0.19 
DMM 0.115 0.30 
IL-1B VS Tac-1 Saline 0.357 0.001 
Sham 0.376 <0.001 
AIA 0.239 0.035 
DMM 0.178 0.067 
IL-1B VS TRPA1 Saline 0.391 <0.001 
Sham 0.378 <0.001 
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AIA 0.276 0.016 
DMM 0.286 0.007 
IL-1B VS TRPV1 Saline 0.216 0.056 
Sham 0.293 0.002 
AIA 0.147 0.23 
DMM 0.259 0.021 
IL-1B VS TRPV2 Saline 0.321 0.002 
Sham 0.328 0.002 
AIA 0.055 0.65 
DMM 0.037 0.74 
IL-1B VS TRPV4 Saline 0.202 0.076 
Sham 0.196 0.14 
AIA 0.420 0.002 
DMM 0.170 0.21 
IL-1B VS ADAMTS-4 Saline 0.237 0.14 
Sham 0.109 0.32 
AIA 0.087 0.63 
DMM 0.208 0.042 
IL-1B VS ADAMTS-5 Saline 0.373 0.001 
Sham 0.214 0.040 
AIA 0.458 <0.001 
DMM 0.108 0.32 
Oprm1 VS Tac-1 Saline 0.456 <0.001 
Sham 0.522 <0.001 
AIA 0.402 <0.001 
DMM 0.588 <0.001 
Oprm1 VS TRPA1 Saline 0.444 <0.001 
Sham 0.542 <0.001 
AIA 0.411 <0.001 
DMM 0.595 <0.001 
Oprm1 VS TRPV1 Saline 0.404 <0.001 
Sham 0.601 <0.001 
AIA 0.351 0.002 
DMM 0.569 <0.001 
Oprm1 VS TRPV2 Saline 0.505 <0.001 
Sham 0.634 <0.001 
AIA 0.419 <0.001 
DMM 0.443 <0.001 
Oprm1 VS TRPV4 Saline 0.399 0.002 
Sham 0.482 <0.001 
AIA 0.502 <0.001 
DMM 0.512 <0.001 
Oprm1 VS ADAMTS-4 Saline 0.366 0.014 
Sham 0.382 <0.001 
AIA 0.164 0.37 
DMM 0.238 0.064 
Oprm1 VS ADAMTS-5 Saline 0.483 <0.001 
Sham 0.481 <0.001 
AIA 0.415 <0.001 
DMM 0.500 <0.001 
Tac-1 VS TRPA1 Saline 0.443 <0.001 
Sham 0.641 <0.001 
AIA 0.513 <0.001 
DMM 0.578 <0.001 
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Tac-1 VS TRPV1 Saline 0.366 0.001 
Sham 0.662 <0.001 
AIA 0.490 <0.001 
DMM 0.582 <0.001 
Tac-1 VS TRPV2 Saline 0.499 <0.001 
Sham 0.641 <0.001 
AIA 0.426 <0.001 
DMM 0.533 <0.001 
Tac-1 VS TRPV4 Saline 0.494 <0.001 
Sham 0.342 0.003 
AIA 0.490 <0.001 
DMM 0.470 <0.001 
Tac-1 VS ADAMTS-4 Saline 0.480 <0.001 
Sham 0.450 <0.001 
AIA 0.323 0.037 
DMM 0.222 0.089 
Tac-1 VS ADAMTS-5 Saline 0.321 0.031 
Sham 0.385 <0.001 
AIA 0.367 <0.001 
DMM 0.371 <0.001 
TRPA1 VS TRPV1 Saline 0.368 <0.001 
Sham 0.548 <0.001 
AIA 0.484 <0.001 
DMM 0.592 <0.001 
TRPA1 VS TRPV2 Saline 0.517 <0.001 
Sham 0.529 <0.001 
AIA 0.410 <0.001 
DMM 0.496 <0.001 
TRPA1 VS TRPV4 Saline 0.433 0.001 
Sham 0.336 0.011 
AIA 0.597 <0.001 
DMM 0.455 <0.001 
TRPA1 VS ADAMTS-4 Saline 0.490 0.001 
Sham 0.333 0.002 
AIA 0.397 0.002 
DMM 0.176 0.17 
TRPA1 VS ADAMTS-5 Saline 0.587 <0.001 
Sham 0.357 <0.001 
AIA 0.460 <0.001 
DMM 0.464 <0.001 
TRPV1 VS TRPV2 Saline 0.421 <0.001 
Sham 0.587 <0.001 
AIA 0.534 <0.001 
DMM 0.515 <0.001 
TRPV1 VS TRPV4 Saline 0.526 <0.001 
Sham 0.498 <0.001 
AIA 0.563 <0.001 
DMM 0.441 <0.001 
TRPV1 VS ADAMTS-4 Saline 0.624 <0.001 
Sham 0.375 <0.001 
AIA 0.474 <0.001 
DMM 0.159 0.23 
TRPV1 VS ADAMTS-5 Saline 0.471 <0.001 
Sham 0.447 <0.001 
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AIA 0.443 <0.001 
DMM 0.431 <0.001 
TRPV2 VS TRPV4 Saline 0.598 <0.001 
Sham 0.603 <0.001 
AIA 0.528 <0.001 
DMM 0.409 0.001 
TRPV2 VS ADAMTS-4 Saline 0.496 <0.001 
Sham 0.327 0.001 
AIA 0.380 0.003 
DMM -0.003 0.98 
TRPV2 VS ADAMTS-5 Saline 0.781 <0.001 
Sham 0.586 <0.001 
AIA 0.383 0.005 
DMM 0.254 0.028 
TRPV4 VS ADAMTS-4 Saline 0.470 <0.001 
Sham 0.229 0.18 
AIA 0.215 0.21 
DMM 0.139 0.43 
TRPV4 VS ADAMTS-5 Saline 0.593 <0.001 
Sham 0.438 <0.001 
AIA 0.493 <0.001 
DMM 0.479 <0.001 
ADAMTS-4 VS 
ADAMTS-5 
Saline 0.403 0.002 
Sham 0.294 0.005 
AIA 0.216 0.15 
DMM 0.171 0.17 
Gene expression Pearson partial correlations on right L3/L4 DRG in AIA and DMM 
when corrected for time, within treatment. Note: After Benjamini-Hochberg 
correction, 5% confidence level is P < 0.040 
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6.3.4 DRG protein expression (immunohistochemistry) 
Based on the key changes in gene expression and the associations that were identified 
in the two animal models and at different stages of disease progression (Table 6.4 and 
Table 6.6), antibodies against ATF3, IL-1, CGRP, Oprm1, TRPA1, TRPV1, 
TRPV2, TRPV4, ADAMTS-4 and ADAMTS-5 were used to examine the production 
of these proteins in the lumbar DRG. Despite using antibodies that had previously 
been published by other investigators and trying several modifications to the protocol 
(including heat and enzyme extraction methods and protein blocking techniques), 
optimisation of staining above the background levels that were observed in negative 
control stained sections could only be achieved for CGRP and Oprm1. Therefore only 
these two proteins could be investigated. Figures 6.4a to 6.4h are representative 
images of the differences in staining intensity and proportion of cells staining 
positive, that were observed in the two models and at the different time points. 
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Figure 6.4a-d. CGRP immunoreactivity (IR) 
IR (NovaRED staining neurons marked with black arrow) in the right L4 DRG in DMM, Sham, AIA, and Saline-injected mice at week 1 (a), 
week 4 (b), week 8 (c), and week 16 (d) post arthritis induction. X10 magnification. Inserts represent right L4 DRG negative reagent control (i) 
and right L4 DRG negative control from naïve mouse (ii). 
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CGRP immunoreactivity (IR) was detected in the right L3 and L4 DRG in all 
treatment groups at weeks 1, 4, 8 and 16, and was above the levels observed in naïve 
mice. At week 1, there was a greater level of CGRP-IR in saline, AIA and DMM mice 
compared to sham. This was reflected in the number of positive staining cells and the 
staining intensity. In contrast, the increase in CGRP gene expression at day 3 in AIA 
and DMM was not significant and there were no significant changes in CGRP gene 
expression observed in the acute inflammatory phase of disease (up to week 2). At 
week 4, there was greater CGRP-IR in saline and AIA compared to sham and DMM 
mice (number of positive staining cells and staining intensity). Interestingly, there was 
greater CGRP-IR in saline mice compared to AIA. This again did not reflect gene 
expression at this time point. At week 8, expression in all 4 groups was reduced 
compared to week 1 and 4, but still greater than naïve mice. CGRP-IR was greater in 
DMM than both sham and AIA based on number of positive staining cells and 
staining intensity. This difference in IR matched the gene expression changes at this 
time point where CGRP expression was up regulated compared to AIA (Figure 6.2b). 
At week 16 CGRP-IR in saline and sham had decreased further to levels similar to 
naïve mice. CGRP-IR in DMM was similar to week 8 and in AIA it increased to 
levels similar to DMM. 
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Figure 6.4e-h. Opmr1 immunoreactivity (IR) 
IR (NovaRED staining neurons marked with black arrow) in the right L4 DRG in DMM, Sham, AIA, and Saline-injected mice at week 1 (e), 
week 4 (f), week 8 (g), and week 16 (h) post arthritis induction. Inserts represent right L4 DRG negative reagent control (i) and right L4 DRG 
negative control from naïve mouse (ii). 
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Oprm1-IR above that observed in naïve mice was not detected at all time points and 
treatment groups. At week 1, Oprm1-IR was detected in a few cells per HPF in all 
treatment groups and this was comparable to expression in naïve mice. This aligned 
with the gene expression data where there was no significant change in both model 
during the acute inflammatory phase (up to week 2). At week 4, Oprm1-IR in saline, 
AIA and sham mice increased based on number of positive staining cells. Oprm1-IR 
in DMM was unchanged. At week 8, Oprm1-IR in all treatment groups was similar to 
age matched naïve mice. At week 16, Oprm1-IR in saline, AIA and sham mice 
remained similar to age matched naïve. However, in DMM it increased both with 
respect to number of positive staining cells and staining intensity. This was in contrast 
to the down regulation in gene expression observed in DMM at week 12. 
6.4 Discussion 
In summary, this study demonstrated multiple changes in DRG gene expression 
between arthritic and control (sham/saline) groups as well as between the two arthritis 
models at each stage of OA disease development (Table 6.4). Differences in 
expression of IL-1ATF3, TRPA1, TRPV2 and ADAMTS-5 were observed in the 
acute inflammatory stage of disease. Down regulation of IL-1 was the only 
significant gene expression change observed in both models at this stage. In the early-
progressive stage of OA the AIA model was characterised generally by a down 
regulation in gene expression (ATF3, CGRP, TRPA1, Oprm1 and ADAMTS-4) with 
fewer changes occurring in DMM. In the late chronic stage of OA the DMM model 
was generally characterised by an up regulation in gene expression (CGRP, TRPA1, 
TRPV1, TRPV2, TRPV4) with only one change evident in AIA (TRPV1).  
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Interestingly, the greatest differences in gene expression profile between the two 
animal models occurred in the late chronic phase when histological characteristics of 
OA were well established in both models with no significant differences between the 
histology observed in AIA and DMM knee joints (Chapter 4). With respect to pain-
related behaviour, both models demonstrated ipsilateral tactile allodynia, thermal 
hyperalgesia and reduced stride length at this late phase of OA disease, with 
mechanical hyperalgesia and reduced ipsilateral hind limb weight bearing, unique to 
DMM (Chapter 5). Despite the histological and behavioural similarities between the 
two models, the DRG gene expression data suggests there are significant differences 
between the two models when it comes to the mechanisms driving pain at this late 
phase of OA disease. By week 16 we observed that CGRP, TRPA1, TRPV1, TRPV2 
and TRPV4 were all up regulated in DMM; Tac-1 and Oprm1 were down regulated in 
DMM; and TRPV2 was down regulated in AIA. When corrected for time, the 
dysregulated DRG gene-expression associations for CGRP, IL-1 and ADAMTS-4, 
suggest model specific differential effects in the expression profile of these three 
genes.  
This study was not able to clearly demonstrate how the observed changes in gene 
expression related to gene translation and therefore, changes in protein expression in 
the DRG. This was in part due to the difficulties encountered in tissue processing and 
the inability to achieve consistency in antibody immunoreactivity that was above 
background in 8 of the 10 antibodies tested. For Oprm1 and CGRP where this was 
achieved, there was no consistent association between gene and protein expression at 
the different time points. These observed temporal differences may be due to the 
transient nature of gene transcription and the complex mechanisms that regulate 
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translation (619). They may also indicate post-transcriptional control of protein levels 
mediated via proteolysis or other cellular mechanisms. 
Taken together, the data presented in this chapter implicates dysregulation of multiple 
genes including CGRP, IL-1, ADAMTS-4, ADAMTS-5, ATF3 TRPA1, TRPV1, 
TRPV2, TRPV4, Tac-1 and Oprm1 in arthritis pain. However, what specific role 
these changes in the DRG that innervate the knee joint play in the pain phenotype 
observed in each animal model is still not clear. 
A primary role for the sensory neurons of the DRG is to detect noxious mechanical 
and thermal stimuli in order to protect the body from harm (620). Nociceptive pain 
detection is clearly an adaptive process that is designed for protection and 
preservation.  However, persistent and exaggerated pain is maladaptive and is driven 
in part by the plasticity of sensory nociceptor neurons. Modulation following injury or 
exposure to inflammation starts at the nociceptor and ends with alterations in central 
nervous system processing. The result is an exaggerated pain state refered to as 
“sensitisation” that is characterised by hyperalgesia and allodynia. In the case of OA 
pain, a number of mechanisms have been investigated in an attempt to better 
understand how chronic pain in this disease develops and identify potential 
therapeutic targets (432, 604, 605, 608, 621, 622). The genes identified in this study 
as displaying model-specific alterations in expression have all been shown to play a 
role in sensitisation and the development of chronic pain (163, 310). The data 
reported in this chapter sheds further light on the likely significance of their 
contribution to the development of chronic pain that is specific to different types of 
OA. 
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Sensitisation manifests as allodynia, and mechanical and thermal hyperalgesia (230), 
and is a key component of the OA pain phenotype in humans (284, 596, 623). It 
contributes to many of the clinical symptoms that patients report such as movement-
evoked pain as well as specific tests of hypersensitivity such as mechanical temporal 
summation (TS) and reduced pressure pain thresholds (PPT) (278, 624, 625). Both 
TRPV1 and TRPA1 are involved in mediating mechanosensation and 
thermosensation. Despite TRPA1 being highly co-expressed with TRPV1 at the level 
of the DRG (626), the two TRP channels play distinct roles in mediating OA pain 
especially inflammation driven pain (627). Through the use of a TRPA1 specific 
inhibitor, the role of TRPA1 in development of mechanical hyperalgesia secondary to 
inflammation has been established (628). More recently, a role for TRPA1 in the 
development of inflammation driven knee OA sensitisation was demonstrated in 
TRPA1 KO mice using the MIA model (485). The role of TRPA1 in development of 
chronic pain in a post-traumatic OA model has not previously been investigated. The 
findings in this chapter demonstrate an up regulation of TRPA1 in DMM mice during 
both the acute inflammatory and chronic phase of OA disease, suggesting that in a 
post-injury OA phenotype, TRPA1 may play an important role in development of 
sensitisation in the early inflammatory phase of OA disease and the development of 
mechanical hyperalgesia in the late chronic phase of OA disease that, based on joint 
histopathology, is likely not driven by inflammation. These findings were not 
observed in the AIA model despite the similarities in joint pathology at this time. 
The TRPV2 channel is activated by temperatures greater than 52 degrees and is 
reported to also play a role in inflammation-induced hyperalgesia that is distinct from 
TRPV1 activity, and manifests as development of thermal hyperlagesia secondary to 
high temperature stimuli (211). The study in this chapter identified that TRPV2 was 
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only up regulated in the AIA model during the acute inflammatory phase prior to the 
development of OA specific joint pathology. In the DMM model, TRPV2 was up 
regulated during the early phase of OA disease when AC damage was developing, 
osteophytes were well established and moderate joint inflammation was still present 
(Chapter 4). Interestingly, at this time point thermal hyperalgesia was present in 
DMM but not in AIA mice (Chapter 5). This suggests the role of TRPV2 in 
development of thermal hyperalgesia is model and time specific. DRG culture studies, 
using a cannabinoid TRPV2 specific agonist, cannabidiol, have also demonstrated 
that TRPV2 mediates CGRP release (629). The findings in this chapter also 
demonstrated that CGRP was up regulated along side TRPV2 during the early phase 
of OA disease.  
TRPV4 is a polymodal receptor that is activated by many different stimuli including 
shear stress, hypotonicity and heat (> 27 degrees); and is expressed by low and high 
threshold neurons in the DRG (221). The observed increase in mechanical nociceptive 
threshold following disruption of TRPV4 in 129/Sv mice (221) and establishment of 
TRPV4 as a high threshold mechanoreceptor (219), suggests a role for TRPV4 in 
mediating mechanical hyperalgesia. This has been demonstrated with inflammatory 
mediator driven sensitisation (630) and neuropathic pain (631).  Investigators have 
also demonstrated that up regulation of TRPV4 drives mechanical hyperalgesia 
induced by DRG exposed to the pro-inflammatory cytokine, IL-17 (632). In addition, 
TRPV4 plays an important role in temperomandibular joint inflammatory pain via the 
trigeminal ganglion (633). 
TRPV4’s important role in maintaining joint homeostasis is evident by the numerous 
inherited skeletal dysplasias and arthropathies seen in humans with TRPV4 mutations 
(634-636). TRPV4 is found in bone (osteoblasts and osteoclasts) where it plays a role 
 284 
in bone remodelling activity, and articular chondrocytes where it mediates cellular 
responses to hyposmotic stress (637). More recently, it has been demonstrated that 
TRPV4 KO mice are more susceptible to obesity-induced OA when fed a high fat diet 
(638). All of this makes TRPV4 an attractive therapeutic target for OA as both a 
DMOAD (639) and for treating OA pain. Yet little is known about the role that 
TRPV4 plays in mediating chronic OA pain that is not driven primarily by 
inflammation. There are currently no studies that have reported on the role of TRPV4 
in the development of chronic pain that is induced using a joint instability model such 
as DMM to identify if it plays a role in the chronic pain of a post-injury OA 
phenotype. In this study, both the upregulation of TRPV4 and the development of 
mechanical hyperalgesia occurred in the chronic stage of OA disease and were only 
observed in the DMM model.  
CGRP is co-expressed with TRPV1 in a subset of small sized sensory neurons in the 
DRG and its receptors are located in both the dorsal horn of the spinal cord and in 
several regions of the brain. CGRP increases synaptic transmission and neuronal 
responsiveness to noxious stimuli at the level of the spinal cord (dorsal horn neurons), 
and therefore contributes to the development of central sensitisation. Specific to 
arthritis pain, it has been demonstrated in the MIA model using retrograde tracing 
techniques, that there is greater expression of both CGRP and TRPV1 in sensory 
afferents that innervate the knee joint compared to the general DRG sensory neuron 
population (192).  With the recent development of small molecule CGRP receptor 
antagonists and antibodies to treat migraine headache, and evidence of their potential 
for treating inflammation driven pain (640) as well as arthritis pain (641), a better 
understanding of the role CGRP plays in development of chronic OA pain is needed 
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in order to take advantage of these emerging novel therapeutics that may prove to be 
effective at treating some types of chronic OA pain. 
Interestingly, the study reported in this chapter identified that in the early phase of OA 
CGRP gene expression was down regulated in AIA mice, while in the late phase of 
OA CGRP gene expression was up regulated in DMM mice. Previous knee OA 
animal model studies have demonstrated an increase in CGRP gene expression in the 
sensory neurons innervating the knee joint (192, 642). Both these studies used the 
MIA model of arthritis, which results in severe joint inflammation and chondrocyte 
death. Changes in CGRP gene expression following surgically induced OA have been 
reported in one study that compared MIA induced arthritis with two post-injury OA 
models, DMM and Anterior cruciate ligament transection (ACLT) (426). In all three 
models the sensory neuronal response to the induced knee joint pathology was a down 
regulation of both CGRP and Tac-1 gene expression at the level of the lumbar DRG. 
For MIA lumbar DRG gene expression was measured 5 weeks after intra articular 
injection of 2mg MIA. PG loss was the only histological joint pathology change that 
was measured. For DMM and ACLT DRG gene expression at a single time point was 
measured, but investigators did not report what this time point was or what joint 
pathology was observed at this time point. Therefore it is difficult to compare it with 
the findings reported in this chapter, where at week 16 (late phase OA) CGRP was up 
regulated and Substance P was down regulated in the DMM model. The effects of 
CGRP receptor blockade have also been investigated in a surgically induced OA 
model (medial meniscal transection). In this study, blockade of the CGRP receptor 
resulted in reversal of OA induced pain as measured by changes in hind limb weight 
distribution (469).  
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ATF3 regulates transcription by binding to DNA sites as a homodimer to inhibit 
transcription (643), or heterodimer to activate transcription (644). ATF3 is induced by 
different stress signals from a range of tissues including the liver, heart and kidneys 
(645). ATF3 is induced following transection of sensory and motor neurons (362) and 
is considered a marker of peripheral neuronal injury. ATF3 expression in the DRG 
has also been reported in inflammatory pain models following injection of CFA (646). 
In contrast to previous studies that reported no expression of ATF3 in naïve adult 
rodents (362, 647), the study reported in this chapter demonstrates ATF3 gene 
expression in both naïve and sham/saline mice (Appendix D). In peripheral neuronal 
tissue (DRG) ATF3 promotes nerve regeneration in injured neurons (648).  
ATF3 expression in animal models of arthritis has been investigated in an effort to 
identify common nociceptive pathways between OA pain and neuropathic pain 
following nerve injury. In a study using the rat AIA model investigators were unable 
to demonstrate any ATF3-positive neurons in the lumbar DRG using IHC techniques 
at day 1,3 and 21 following induction of arthritis (452). Similarly, in a study using the 
DMM model investigators reported no ATF3-positive neurons in the L4/L5 lumbar 
DRG at any time point (316). However, a study using a collagen-induced arthritis 
model did report ATF3 expression following induction of arthritis (649).  
This chapter reports on gene expression in the innervating DRG of DMM and AIA 
induced arthritis at key stages of disease progression. Up regulation of ATF3 occurred 
in AIA mice early following knee joint injection (week 2) and during the early OA 
phase of disease (week 8). In DMM mice there was no significant change in ATF3 
expression detected early but ATF3 was increased in late-stage disease. It is difficult 
to compare these findings with previous studies because gene expression does not 
always translate to protein expression, and up regulation of gene expression can be 
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transient, only occurring at specific time points. Therefore, comparisons between 
studies can only be made if the time points investigated are equivalent with respect to 
stage of disease. Nevertheless, the current findings suggest that model specific acute 
inflammation (AIA) and chronic post-traumatic OA knee joint pathology (DMM) 
either cause peripheral neuronal injury or mimic the biomolecular alterations that 
signal the need for neuronal transcription regulation, whether it be inhibition or 
activation.  
The peripheral effects of opioids have previously been investigated in an attempt to 
identify a safer alternative to the systemic use of opioids, such as morphine, to treat 
severe pain (307). Freund’s complete adjuvant induced inflammation results in up 
regulation of Oprm1 and an increase in Oprm1 G-protein coupling in the DRG but not 
the spinal cord or hypothalamus suggesting a local adaptive change in the mu receptor 
in response to acute inflammation rather than a response to systemically released 
mediators (317). Local injection of MOR agonists in rat models of inflammatory and 
neuropathic pain result in a reduced pain response and the resolution of allodynia 
(314). The role of MOR in regulating pain in animal models of OA has also been 
investigated (316). In this study up regulation of the MOR occurred at week 8 post 
surgery when affected mice displayed no pain (as measured by forceplate) until 
treated with a peripherally active MOR antagonist (naloxone methiodide). No change 
in MOR expression was detected early at 4 weeks or late at 16 weeks after surgery. 
This differs to the findings in the current study where in the chronic phase of OA a 
down regulation in Oprm1 gene expression was detected at week 12 and an increase 
in Oprm1-IR was observed in the L3/L4 DRG at week 16. 
ADAMTS-5 is expressed in chondrocytes and fibroblasts, and is the principle 
aggrecanase in mouse cartilage and plays a key role in cartilage degradation and the 
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development of OA joint pathology (26, 27). A wider physiological role for 
ADAMTS-5 has been suggested with the establishment of its constitutive expression 
in a number of adult tissues including DRG (34). ADAMTS-5 KO mice are protected 
from development of OA joint pathology (articular cartilage damage, SCB sclerosis 
and osteophyte formation)(26). Interestingly, ADAMTS-5 KO mice have also been 
shown to not develop mechanical allodynia when subjected to DMM surgery (441). 
The investigators did not look at what changes in sensory innervation might be 
driving this protection from sensitisation. So it remains unclear whether the different 
pain phenotype observed in the ADAMTS-5 KO is primarily due to the protection 
from joint pathology or whether ADAMTS-5 plays a direct role in sensory 
modulation at the level of the DRG. Expression of ADAMTS-5 and other MMP’s in 
the DRG following induction of arthritis has not previously been reported. In the 
present study, up regulation of ADAMTS-5 expression in the DRG occurred early 
(week 2) following DMM surgery but was not present at week 4 or beyond, once OA 
specific joint pathology and mechanical allodynia were well established.   
ADAMTS-4 is the other principle aggrecanase expressed in human and mouse 
cartilage, however its role in development of OA joint pathology is less clear. Unlike 
ADAMTS-5, ADAMTS-4 is inducible by pro-inflammatory cytokines (650) and 
although ADAMTS-4 is expressed in many tissues, its role in these tissues is still 
under investigation. Characterisation of the ADAMTS-4 KO mouse identified no 
gross or histological abnormalities in any tissues and no difference in susceptibility to 
the development or severity of OA between KO and wild type mice at 4 and 8 weeks 
after DMM surgery (25). ADAMTS-4 is the most expressed ADAMTS in the central 
nervous system (CNS) (ventral horn and cortex) and is thought to play a role in 
controlling synaptic plasticity during CNS development (478). Whilst it is associated 
 289 
with neuronal repair after spinal cord injury, investigators have also demonstrated a 
neurodegenerative effect on motor neurons in a model of neurodegenerative disease 
(651). Despite its important role in the CNS, there are no previous reports of its 
expression in the DRG or the role it may play in the peripheral sensory nervous 
system and the development of OA pain. In this study, down regulation of ADAMTS-
4 expression in the DRG was observed during the early progressive OA phase in both 
models (AIA > DMM). Importantly, in the DMM model ADAMTS-4 showed the 
greatest loss of association with DRG genes involved in pain signalling (CGRP, Tac-
1, Oprm1, TRPV1, TRPV2, TRPV4, TRPA1). This loss of co-regulation of 
ADAMTS-4 gene expression may implicate this aggrecanase in having an important 
role in OA pain modulation, in particular in a post-injury OA phenotype. 
 
6.4.1 Summary 
In this chapter, the pain phenotype of the two arthritis models under investigation was 
further characterised by measuring gene expression in the DRG that innervate the 
knee joint. Some of the key protein and neuropeptide candidates that are associated 
with both inflammatory and chronic pain states were measured, and the alterations in 
expression at different phases of arthritis disease that were identified, indicate which 
of these may play a role in pain signal modulation in each model.  
Together, the findings in this chapter demonstrate two distinct peripheral sensory 
neuronal responses to OA joint pathology that change over time and are animal model 
specific. The different DRG gene expression profiles that were observed confirm that 
despite the similarities in histopathology and pain related behaviour that develops in 
both AIA and DMM in the chronic phase of OA disease, the molecular mechanisms 
that initiate and sustain the pain state are different.  
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This confirms that pain is different for different sub types (phenotypes) of OA and at 
different stages of the disease. By investigating an important aspect of sensory 
modulation in two models, it has allowed the differentiation of mechanisms that are 
model specific and therefore relevant for certain sub-types of OA. By focussing the 
investigation at the level of the DRG, peripheral mediators that may be a suitable 
therapeutic target for OA pain have been identified to allow for a more targeted 
approach to developing treatments that are devoid of systemic side effects. 
In the next chapter the relationships between the changes in sensory neurons, as 
measured by gene expression, the observed pain-related behaviour and the joint 
histopathology that develops over time, are investigated. Combining the findings on 
OA pain and OA joint pathology will provide a better understanding of what initiates 
and drives chronic OA pain, and may reveal associations between the two processes 
that will guide selection of therapeutic targets that modify joint disease and treat pain.  
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CHAPTER 7:  Associations between knee joint 
histopathology, pain behavior and peripheral sensory 
innervation following destabilization of the medial 
meniscus (DMM) and antigen-induced arthritis (AIA) 
in mice 
7.1 Introduction and aims 
The previous chapters of this thesis reported individually on the joint histopathology, 
pain-related behaviour outcomes and gene expression profiles of the innervating DRG 
in two animal models commonly used to study OA joint pathology (DMM) and 
arthritis pain (AIA) mechanisms. The two models under investigation both result in a 
consistent and reproducible chronic joint disease phenotype and ultimately lead to 
OA-like joint pathology. However, they differ in a number of ways. The DMM model 
induces altered joint biomechanics that leads to joint instability and greater loading 
strain on the medial femoro-tibial cartilage and underlying subchondral bone (SCB) 
(437). This model mimics a post-traumatic OA phenotype but has broader clinical 
relevance since meniscal tear and degeneration is also associated with non-traumatic 
age associated OA in patients (298). The AIA model on the other hand relies on an 
exogenously triggered joint immune response that leads to severe joint inflammation 
and other joint tissue pathologies. Although less directly-clinically relevant than 
DMM, this model has been used extensively to investigate the role of inflammation in 
the development of joint pain, and enabled investigators to begin to unravel the 
molecular mechanisms that drive arthritis pain (reviewed in (449, 612).  
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Histological investigation (Chapter 4) revealed that by 16 weeks both DMM and AIA 
mice display the hallmark histopathological features of human OA (AC erosion, SCB 
sclerosis, marginal osteophytes, mild synovitis), and by definition both DMM and 
AIA mice had therefore developed “knee joint OA”. However, significant temporal 
differences in joint tissue pathology progression, model specific pathology 
associations between the major tissue structures in the joint (AC, SCB and synovium), 
and different significant risk factors for development/progression of OA (as defined 
by AC damage), indicate that at the latest time points each model represents a 
different OA phenotype; “post-traumatic OA” (Pt-OA) for DMM vs. “post-
inflammatory OA” (Pi-OA) for AIA. 
When tested for pain (Chapter 5), the DMM and AIA models demonstrated distinct 
temporal patterns of pain-related behaviours, reflecting the development of a complex 
pain state that is partly driven by central sensitisation and that displays many of the 
hallmarks of human OA pain. In contrast to the joint pathology outcomes, there was 
an absence of any association between the different pain behaviours that were 
measured in either model. This highlighted the importance of using multiple pain 
assays to more accurately define the pain phenotype in a particular animal model, and 
by extrapolation, evaluate the response to any given therapy in a model.  The absence 
of any associations between the different pain behaviours likely indicates differences 
in the underlying mechanisms that drive pain at different stages of joint disease 
development, and reflects the complex nature of the relationship between tissue 
specific joint pathology and OA pain. 
Following from this, an investigation into the gene expression changes in the DRG 
(Chapter 6) identified multiple alterations in gene expression that were again model-
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specific. The gene expression profiles were also different at each phase of disease 
development (acute inflammatory, early progressive OA, late chronic OA), with the 
greatest differences paradoxically observed in the late chronic phase when 
histologically both models displayed most similarity with all the features of OA joint 
pathology. The genes investigated were highly associated in both control groups 
(sham and saline injected mice), reflecting the normal co-ordinated network of 
sensory input regulation in the DRG. For three of the genes (CGRP, IL-1 and 
ADAMTS-4), this association was lost in one or both models with different cohorts of 
other genes, and the disease-specific dysregulation suggests there are different pain 
regulatory pathways in the two arthritis phenotypes. 
Overall, these findings support the theory that OA pain, and at least the peripheral 
mechanisms that drive it, are unique for each sub-type of OA. This puts into question 
the current practice of extrapolating findings from pre-clinical investigations to 
human OA pain, without first considering which human OA phenotype the animal 
model represents, and in the case of the most commonly used model for pain research, 
MIA, perhaps any human OA phenotype at all (399). The experimental data generated 
in this thesis have demonstrated in separate analyses that joint tissue pathology, pain-
behaviour, and peripheral sensory modulation are each animal model specific. 
However, if the associations between these three disease components are the same in 
different models then, which model is selected to investigate what initiates and drives 
OA pain may ultimately not be critical to the predictive validity for human 
translation. To determine if the animal model does matter, any significant associations 
between OA disease (joint tissue histopathology), OA symptoms (pain behaviour) and 
sensory innervation (DRG gene expression) need to be characterised in different 
animal models. 
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In this chapter the relationships between joint pathology, pain behaviour and 
peripheral sensory modulation are investigated using statistical modelling to confirm 
whether the mechanisms that drive OA pain are specific to the pathophysiology of the 
disease and therefore, unique to each OA phenotype. 
The aims of chapter 7 are: 
1. To identify any associations between knee joint tissue pathology and gene 
expression in the innervating DRG of mice with knee joint arthritis induced by DMM 
and AIA. 
2. To identify any associations between pain-related behaviour and gene expression in 
the innervating DRG of mice with knee joint arthritis induced by DMM and AIA. 
3. To identify any associations between knee joint tissue pathology and pain-related 
behaviour in mice with knee joint arthritis induced by DMM and AIA. 
 
7.2 Methods, statistical analysis and data presentation 
Details of the methods used to induce the two models of arthritis, DMM and AIA, are 
described in chapter 2, section 2.1. The methods used for histological processing, 
sectioning and staining are described in chapter 2, section 2.2. The scoring system 
used is outlined in Appendix C. Development and validation of this scoring system is 
described in chapter 3, section 3.2. The pain assays used in this chapter have 
previously been reported and validated (316, 465, 493, 517, 545), and the exact 
methods used for carrying out the pain tests were developed by the researcher 
(chapter 3, section 3.1) and described in chapter 2, section 2.3. The methods used for 
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harvesting DRG and real time Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR) are described in chapter 2, section 2.4. 
Associations between the different joint tissue pathologies and gene expression in the 
right L3/L4 DRG; the different pain behaviours and gene expression in the right 
L3/L4 DRG; and the different joint tissue pathologies and pain behaviours, were 
determined for each model (when corrected for time) by generating Pearson partial 
correlation coefficients, using Kendall’s tau-b (565). This nonparametric process uses 
pairwise ranked data values between the two variables under study (ordinal scores) 
and thus does not require data to be normally distributed or the relationship between 
the variables to be linear.  
The experiments in this thesis investigating pain behavior (Chapter 5) and gene 
expression (Chapter 6) were designed to be hypothesis generating due to the lack of 
standardisation of pain behavior tests that currently exists and the fact that so little is 
known about which genes are key drivers of OA pain specifically. To this end, the 
results in this chapter are also presented without correcting for repeated measures to 
ensure identification of all significant associations between joint tissue 
histopathology, pain behavior and DRG gene expression, that may otherwise be 
overlooked once correction for repeated measures has been applied, but which may 
still be worthy of further investigation.  
Correlation analysis was conducted for AIA and DMM only, and not for the 
equivalent sham/saline data. This was done because the aim of this study was to 
characterise the relationship between joint tissue pathology, pain behavior and DRG 
gene expression changes in two models of arthritis where significant joint disease 
develops. The results in chapter 4 confirm that only mild and transient joint pathology 
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is observed in the sham surgery and saline injected mice and neither group develops 
knee joint arthritis. 
7.3 Results 
7.3.1 Correlation between joint tissues histopathology and gene expression in right 
L3/L4 DRG in DMM and AIA when corrected for time 
An interesting pattern of associations emerged from the data (Table 7.1), with more 
correlation between joint tissue histopathology and DRG gene-expression observed in 
the DMM model compared to the AIA model (14 vs. 11). In DMM the DRG-
expression correlations were primarily with bone pathology changes (SCB sclerosis, 
SCB vascular invasion, osteophyte size and osteophyte maturity). In AIA in contrast, 
the correlations were with inflammatory change and osteophyte formation (synovitis, 
osteophyte size and osteophyte maturity). The majority but not all associations in both 
models were negative – i.e. as pathology worsened the DRG gene expression 
decreased. The positive correlations suggestive of a positive association between joint 
pathology and DRG gene-expression were: IL-1 with synovitis and AC damage in 
AIA, and CGRP, TRPV1 and CBR1 with SCB sclerosis in DMM. 
The genes whose expression was significantly dysregulated in the association analysis 
in Chapter 6 (CGRP, IL-1 and ADAMTS-4) also displayed unique associations with 
joint tissue pathology: CGRP & IL-1 as noted above, and ADAMTS-4 which was 
negatively correlated with osteophyte size and maturity in DMM. There were a 
number of pathology:DRG-expression correlations that were shared in the two 
models: TRPA1 and CBR1 negatively with synovitis; and ATF3 and MOR negatively 
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with osteophyte size. IL-1 was unique in having a significant positive correlation 
with synovitis in one model (AIA) but negative in the other (DMM). All other 
pathology:DRG-expression correlations were specific to one or other of the models. 
The strongest correlations (>0.4) were with CBR1, which was negatively associated 
with synovitis in both AIA and DMM (r = -0.596 and -0.517, respectively), and with 
SCB vascular invasion in DMM (r = -0.413). 
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Table 7.1. Histopathology and gene expression correlations 
Comparison Treatment r (tau) P 
AC damage IL-1b AIA (n=35) 0.201 0.044 
AC PG loss ATF3 
TRPA1 
DMM (n=46) 
AIA (n=36) 
-0.281
-0.265
0.008 
0.014 
Synovitis Tac-1 
CNR1 
CNR1 
IL-1b 
IL-1b 
TRPA1 
TRPA1 
AIA (n=36) 
AIA (n=6) 
DMM (n=11) 
AIA (n=35) 
DMM (n=39) 
AIA (n=36) 
DMM (n=46) 
-0.365
-0.596
-0.517
0.208
-0.257
-0.324
-0.175
0.001 
0.040 
0.002 
0.004 
0.010 
0.003 
0.039 
SCB invasion CNR1 DMM (n=11) -0.413 <0.001 
SCB sclerosis CGRP 
TRPV1 
CNR1 
DMM (n=46) 
DMM (n=46) 
DMM (n=11) 
0.249 
0.233 
0.380 
0.019 
0.037 
0.033 
OP size ATF3 
ATF3 
Oprm1 
Oprm1 
TRPV4 
ADAMTS-4 
ADAMTS-5 
AIA (n=36) 
DMM (n=46) 
AIA (n=36) 
DMM (n=46) 
DMM (n=35) 
DMM (n=34) 
AIA (n=30) 
-0.228
-0.204
-0.303
-0.213
-0.245
-0.275
-0.165
0.021 
0.050 
0.008 
0.043 
0.044 
0.006 
0.038 
OP maturity Oprm1 
TRPV1 
ADAMTS-4 
ADAMTS-5 
AIA (n=36) 
DMM (n=46) 
DMM (n=34) 
AIA (n=30) 
-0.292
-0.147
-0.240
-0.157
0.003 
0.023 
0.041 
0.036 
Spearman partial correlations on joint tissue histopathology outcomes and gene 
expression in right L3/L4 DRG (corrected for time) within treatment.  Alpha value set 
at 0.05. Only significant correlations (P < 0.05) are listed. 
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7.3.2 Correlation between pain behaviour and gene expression in right L3/L4 DRG 
in DMM and AIA when corrected for time 
Even more so than with joint histopathology, there were a great number of significant 
associations between pain behavior and DRG gene expression in the DMM model 
compared to the AIA model (7 vs. 2; Table 7.2). In contrast with histopathology, for 
all behavioural outcomes, a negative correlation indicates an association with 
worsening pain/disability. This is because pain (including sensitisation) was defined 
as a decrease in the relevant pain behaviour measurement (PWT, PWL, stride length, 
R/L hind limb weight distribution).  
Only one of the significant DRG-expression:pain-behaviour correlations was negative 
(TRPV1 and PAM in AIA); suggesting that for the remaining genes, an increase in 
gene expression was associated with decreasing pain and vice versa. In DMM, stride 
length was positively correlated with 6 genes (CGRP, Tac-1, TRPV1, TRPV2, 
TRPV4, ADAMTS-5), and hotplate was positively correlated with 1 gene 
(ADAMTS-4). In AIA, PAM was positively correlated with IL-1. There were no 
significant associations between tactile allodynia (Von Frey) or hind-limb weight 
distribution (forceplate), and expression of any genes in the DRG in either model. 
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Table 7.2. Pain behavior and gene expression correlations 
Comparison Treatment r (tau) P 
Stride
1 CGRP 
Tac-1 
TRPV1 
TRPV2 
TRPV4 
ADAMTS-5 
DMM (n=11) 
DMM (n=11) 
DMM (n=11) 
DMM (n=11) 
DMM (n=11) 
DMM (n=11) 
0.406 
0.451 
0.406 
0.445 
0.570 
0.474 
0.033 
0.007 
0.025 
0.016 
<0.001 
0.034 
PAM
2 IL-1β
TRPV1 
AIA (n=5) 
AIA (n=5) 
0.527 
-0.788
0.015 
<0.001 
Hotplate
3 ADAMTS-4 DMM (n=18) 0.267 0.035 
Spearman partial correlations on pain outcomes and gene expression in right L3/L4 
DRG (corrected for time) within treatment.  Alpha value set at 0.05. Only significant 
correlations (P < 0.05) are listed. (1) Stride = full stride length (left to left hind limb) 
measurement; (2) PAM = right hind limb withdrawal threshold (average of medial 
and lateral knee joint); and (3) Hotplate = hind limb withdrawal latency with plate set 
at 52 degrees. 
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7.3.3 Correlation between joint tissue histopathology and pain behaviour in DMM 
and AIA when corrected for time 
Overall, there were fewer associations between joint tissue histopathology and pain 
behavior in the DMM model (4) than in the AIA model (7). As above, negative 
correlation with any behavioral outcome indicates a positive association between that 
pain measure and histopathologic change.  Interestingly, the AIA correlations were 
predominately (5 of the 7) in a negative direction whereas in DMM the associations 
were all positive, suggesting a lack of association between pain and worse pathology 
in this model.  
In AIA, synovitis was negatively correlated with PAM and stride length; SCB 
invasion was negatively correlated with forceplate; AC damage and chondrocyte 
hypertrophy were negatively correlated with PAM; AC damage was positively 
correlated with hotplate; and OP maturity was positively correlated with forceplate. In 
DMM, synovitis was positively correlated with forceplate and stride length; SCB 
invasion was also positively correlated with forceplate; and AC damage was 
positively correlated with von Frey. 
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Table 7.3. Histopathology and pain behaviour correlations 
Comparison Treatment r (tau) P 
Synovitis Forceplate
1
PAM
2 
Stride
3
Stride 
DMM (n=23) 
AIA (n=18) 
AIA (n=12) 
DMM (n=11) 
0.273 
-0.415
-0.464
0.415
<0.001 
0.014 
0.001 
0.003 
SCB invasion Forceplate 
Forceplate 
AIA (n=38) 
DMM (n=23) 
-0.263
0.335
0.002 
0.024 
AC damage Von Frey
4
PAM 
Hotplate
5
DMM (n=9) 
AIA (n=18) 
AIA (n=38) 
0.549 
-0.349
0.172
0.041 
0.001 
0.054 
Chondrocyte 
hypertrophy/apoptosis 
PAM AIA (n=18) -0.398 0.006 
OP maturity Forceplate AIA (n=38) 0.220 0.050 
Spearman partial correlations on joint tissue histopathology outcomes and pain 
outcomes (corrected for time) within treatment.  Alpha value set at 0.05. Only 
significant correlations (P < 0.05) are listed. (1) Forceplate = right to left hind limb 
weight bearing ratio (average over 30 seconds); (2) PAM = right hind limb 
withdrawal threshold (average of medial and lateral knee joint); (3) Stride = full stride 
length (left to left hind limb) measurement; (4) Von Frey = right hind limb 50% 
withdrawal threshold; and (5) Hotplate = hind limb withdrawal latency with plate set 
at 52 degrees. 
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7.4 Discussion 
The “cause-effect” relevance of the correlations between knee joint histopathology 
and DRG gene expression is unclear, but along with the joint tissue pathology 
associations reported in chapter 4 (figure 4.11), they further demonstrate differences 
between the two models with respect to joint disease pathophysiology and how these 
relate to pain mechanisms. Acutely, AIA is a model of inflammatory arthritis and 
since synovitis is a predominant feature of joint inflammation in this model (448), it 
would be expected to be a key driver of pain. Only 4 of the 11 significant gene 
associations in AIA were with synovitis per se, 5 being with osteophyte formation 
suggesting that osteophytes may also play an important role in driving pain in this 
model. Osteophytes in AIA were late to form and mature to bone compared to the 
DMM model, and occurred after joint inflammation started to decrease, suggesting a 
need for resolution of specific pro-inflammatory signals in AIA before bone 
formation can occur as previously reported for DKK-1 in TNF-transgenic mice (578). 
Early formation of enthesophytes observed in AIA could be driven by the initiation or 
inhibition of these same pro-inflammatory signals early in the disease. If this is the 
case, then the DRG gene correlations with osteophyte formation may in fact reflect an 
indirect mechanism by which inflammation drives pain in this model.  
The joint histopathology and DRG gene expression associations observed in AIA 
were primarily negative indicating a down regulation in expression of the associated 
genes with increasing joint tissue pathology. This is not surprising given the pattern of 
DRG gene expression reported in chapter 4 where the changes in gene expression 
observed in AIA beyond the acute inflammatory phase of disease were down 
regulations in expression. 
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The exception to this is IL-1 which was positively correlated with synovitis and AC 
damage. The role of pro-inflammatory cytokines such as IL-1 and TNF- in 
mediating AC destruction and synovial inflammation, as well as the development of 
joint pain and sensitisation has been investigated using the AIA model. Use of 
neutralising antibodies to block IL-1 and TNF- activity in the joint previously 
demonstrated their role in the early establishment of destructive joint pathology in 
AIA (652), and has led to further investigation of their role in pain modulation more 
specifically. Joint inflammation and associated mechanical hyperalgesia in the first 7 
hours following induction of AIA is attenuated in IL-1 receptor type I (IL-1RI) KO 
mice, and IL-17 induced mechanical hyperalgesia in WT mice is inhibited by 
pretreatment with an IL-1RI antagonist in the first 3 days following induction of AIA 
(653). Furthermore, development of mechanical hyperalgesia following induction of 
AIA occurs in conjunction with increased production of IL-1 and neutrophil 
infiltration into the joint, and intra-articular administration of an IL-1 antagonist 30 
minutes prior to induction of AIA, attenuates both inflammation and pain (654). 
However, during the later stages of arthritis disease, the role of IL-1 may be 
different. Investigators have demonstrated that mechanical hyperalgesia persists 
following the administration of an IL-1RI antagonist from day 0 to day 21 after 
induction of AIA, while thermal hyperalgesia is attenuated from day 7 (453). This 
demonstrates IL-1’s role in development of thermal hyperalgesia but puts into 
question the role of IL-1 in driving mechanosensitivity of joint nociceptors.  
The data presented in this thesis supports these previously reported findings on the 
role of IL-1 in development of joint inflammation (synovitis) and pain, although 
which type of pain, remains unclear. However, these previous studies only tracked the 
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acute phase of the disease and did not establish what role IL-1 plays once significant 
bone and cartilage pathology is established. The positive association between IL-1 
and both synovitis and AC damage suggests a significant role for IL-1 in the 
establishment of joint OA pathology beyond the early acute phase of disease as 
reported in previous studies. This is further supported by the fact that synovitis was 
identified as a risk factor for development of AC damage in AIA (Chapter 4). 
Unlike AIA, in the DMM model IL-1 was negatively correlated with synovitis. This 
suggests that in the DMM model synovitis contributes to OA pain via other pro-
inflammatory signaling pathways in the DRG. There is little doubt that IL-1 is a key 
cytokine in OA pathogenesis (reviewed in (88)); acting to block chondrocyte 
synthesis of extra cellular matrix components, stimulate production of ADAMTS-4 
(655), and promoting chondrocyte apoptosis (656). Yet few studies have looked at 
whether the role of inflammation and the expression of IL-1 and other inflammatory 
cytokines, changes with disease severity (reviewed in (77)). Evaluation of synovial 
tissue from OA patients undergoing arthroscopy or arthroplasty identified greater 
expression of IL-1and TNF- in the synovium of the patients with less severe OA 
disease (657, 658). Here we demonstrate a similar association with respect to 
expression of IL-1 in the DRG and OA disease severity/progression.  
In DMM, there is a co-dependent relationship between articular cartilage and 
subchondral bone pathology (49, 407, 583), and data from patients would suggest that 
subchondral bone is a key driver of OA pain (292, 294). The joint histopathology and 
DRG gene expression associations observed in DMM (10 of the 14 are with SCB and 
osteophyte formation) supports a similar association in this mouse model. 
Furthermore the only positive pathology:DRG-gene-expression correlations in DMM 
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were all with SCB sclerosis suggesting this may be a major driver of pain in this 
model.  
Logistic regression modeling (chapter 4) identified synovitis as an independent risk 
factor for pathology progression (as defined by progressive AC damage) in AIA but 
not DMM, while SCB sclerosis as an independent risk factor for OA progression in 
DMM but not in AIA. The above results confirm these same model-specific tissue 
pathology associations, but now with potential molecular drivers of pain/sensitisation 
as well as progression of cartilage erosion.  This further differentiates the uniqueness 
of each OA phenotype, and highlights the need for additional exploration of the 
mechanisms underlying these associations to understand any causal effects and how 
specific joint pathologies might drive DRG-expression changes and pain in each 
model.  
In the case of pain behavior and DRG gene expression correlations, the cause-effect 
relationship would seem clearer, particularly with differentially regulated 
neuropeptides, nociceptor cation channels and inflammatory cytokines, where 
changes might directly alter neuronal excitability. The significance of stride length as 
a marker of the changes that are occurring in the sensory neurons to initiate and drive 
DMM-induced OA pain, provides evidence that the changes in stride length are not 
simply due to the biomechanical changes that occur when a joint is surgically 
destabilized, but rather they are a reflection of a gait adjustment that is driven by pain. 
In particular, since the genes that were associated with this pain-related behavior 
include neuropeptides (CGRP and SP), and nociceptor channels implicated in 
inflammation driven sensitisation (TRPV1 and TRPV2) and the development of 
mechanical hyperalgesia (TRPV1 and TRPV4). Stride length demonstrated a 
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treatment effect only in DMM mice, when corrected for time (Chapter 5), again 
suggesting that stride length is a relevant behavior marker for studying pain 
mechanisms in the DMM model. Interestingly though, all of the correlations between 
DRG-gene-expression and stride length were positive, suggesting the decrease in 
stride length that was observed is paradoxically not associated with an increase in 
expression of these genes.  
However, this does not exclude CGRP, Tac-1or the TRP channels from playing a 
significant role in the development of chronic OA pain via mechanisms other than an 
upregulation in gene transcription. For example, the TRPV1 channel is an important 
mediator of inflammatory pain (182), yet many studies have not been able to 
demonstrate an increase in DRG TRPV1 mRNA following induction of inflammation 
(181, 194). However, an increase in the number of DRG neurons expressing TRPV1 
immunoreactivity has been demonstrated in numerous models of inflammation and 
nerve injury pain (184, 194), including the MIA model of OA (192). In vitro culture 
studies have been able to demonstrate an increase in both expression and signalling of 
TRPV1 in DRG neurons (340). Synovium from patients with OA also demonstrates 
increased TRPV1 immunoreactivity (190). Sensitisation of TRPV1 following the 
release of inflammatory mediators is reported in both inflammatory and nerve injury 
models (609) and results in increased nociceptor signalling. Combined, these findings 
highlight the need to investigate multiple mechanisms of enhanced activity when 
determining the key molecular pathways involved in development of OA pain and 
sensitisation. 
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Further investigation to enable accurate assessment of therapeutic interventions using 
the DMM model is also required into other gait characteristics and methods for 
measuring them, in order to develop pain assays that are clinically relevant, easier to 
measure and more sensitive than stride length alone. One alternative has been to view 
movement provoked pain, which stride length is an indirect measure of, more broadly 
and look at measures of other spontaneous activities using purpose built automated 
instrumentation such as the LABORAS (Metris: Laboratory animal behavior 
observation, registration and analysis system). Activity based monitoring as a 
measure of both movement provoked pain and spontaneous pain has previously been 
reported in the DMM model (316, 339, 441). However, automated instruments such 
as the LABORAS produce numerous movement-based activity and behavior 
measurements, therefore a more detailed evaluation of the most sensitive of these 
measures for detecting changes with disease progression and predicting therapeutic 
efficacy needs to be conducted in the DMM model.  
The positive correlation between ADAMTS-5 expression in the DRG and stride 
length is interesting, given that ADAMTS-5 is the principle aggrecanase in mouse 
cartilage (26, 27) and ADAMTS-5 KO mice are not only protected from cartilage 
degradation and associated SCB sclerosis but also development of allodynia in the 
DMM model (441, 659). Administration of anti-ADAMTS-5 antibodies ameliorates 
allodynia in established OA induced by DMM in wild type mice, suggesting that 
analgesic effects may occur through blocking ADAMTS-5 activity in the DRG and 
reducing macrophage activation and gliosis (660, 661). It is therefore difficult to 
reconcile how decreased ADAMTS-5 expression (and presumably activity) in the 
DRG is associated with reduced stride length (increased pain) in DMM in the current 
study. In contrast to ADAMTS-5, there was a negative correlation (i.e. positive 
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association) between DRG-expression of ADAMTS-4 and osteophyte formation 
(table 7.1). Dysregulation of ADAMTS-4 gene expression in the DRG was unique to 
the DMM model (Chapter 6). While ADAMTS-4 can cleave aggrecan and play a role 
in cartilage degradation (662) is still has an undefined role in OA development (25), 
and there has been no study of its substrates or role in the DRG. Together these 
findings suggest that both ADAMTS-4 and ADAMTS-5 may play significant but 
different roles in OA pain mechanisms in a post-traumatic OA phenotype, although 
the mechanisms remain to be established. 
The negative correlation between TRPV1 and PAM in AIA is not surprising, as this 
indicates an association with local mechanical hyperalgesia and TRPV1 is known to 
play a significant role in the development of inflammation driven mechanical 
sensitisation (187). More unexpected was the positive correlation between PAM and 
IL-1 observed in this model, which means that increased DRG expression of IL-1 
is associated with a decrease rather than an increase in sensitisation and local 
hyperalgesia (ie an increase in the paw withdrawal threshold when a mechanical force 
is applied to the knee joint). Why this association is positive is not clear, given that 
IL-1 is an important pro-inflammatory cytokine involved in both the pathogenesis of 
OA (reviewed in (88, 322)) and the development of pain and sensitisation (reviewed 
in (89, 663). However, this finding is an important reminder that there are still many 
unknown complexities in the relationship between inflammation, pain and pathology 
that still require further investigation. This is evident if we look at the role of IL-1 in 
OA pathogenesis. Here, it has been shown to promote cartilage degradation (328), yet 
development of OA has been reported to be accelerated in the IL-1 KO mouse (327), 
and there is now some evidence that IL-1 can paradoxically play a protective role in 
articular cartilage homeostasis (664). 
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The associations between pain behaviour and joint tissue histopathology in the current 
study also demonstrated interesting trends. The correlations observed in the AIA 
model were primarily negative, while in DMM they were positive. This suggests a 
greater association between specific joint pathologies and pain in AIA, with measures 
of increased joint inflammation (synovitis and SCB vascular invasion) associated with 
more joint mechanical hyperalgesia, reduced stride length and decreased hind limb 
weight bearing. PAM, stride length and forceplate may therefore be particularly 
useful markers for monitoring the degree of joint inflammation in this model. It also 
confirms that reducing joint inflammation may reduce localised knee joint pain that 
can impact mobility. 
There were fewer associations in the DMM model, and in contrast to what might be 
expected measures of increased joint inflammation (synovitis and SCB vascular 
invasion) correlated with increased rather than decreased stride length and ipsilateral 
hind limb weight bearing. A positive correlation with force plate perhaps reflects the 
low levels of inflammation that persist throughout the time course of this model and 
the lack of significant change in weight distribution (right to left hind limb ratio) 
beyond the significant decrease that occurs at day 3 and week 1 (chapter 5). The 
correlation between von Frey and AC damage was also positive, but more likely 
reflects the small data set (n=9) that included only 2 time points (week 4 and week 8), 
rather than any true reflection of the relationship between AC damage and 
development of allodynia. These incongruent findings in the DMM model highlight 
the need for further histological evaluation of knee joints from the same mice in 
which pain behavior measurements have also been collected. Some researchers have 
reported development of allodynia in the DMM model that demonstrates a similar 
temporal pattern to the one observed in this thesis (339, 441), however the 
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relationship between the observed allodynia and the knee joint pathology in any given 
animal has not previously been investigated to enable comparisons with the findings 
from this thesis. Interestingly, others investigators have reported a very different 
temporal pattern of allodynia in the DMM model (604). 
7.4.1 Summary 
In summary, the correlation analyses reported in this chapter have identified model-
specific associations that further define the complex relationship between joint 
pathology, pain and gene transcriptional changes in the DRG (an important aspect of 
peripheral sensory modulation). Not only are joint tissue pathology, pain behaviour 
and peripheral sensory modulation animal model specific; the associations between 
these three disease components are also unique to the animal model under 
investigation. This confirms the importance of mapping pre-clinical findings to the 
human disease phenotype that best fits the animal model. It would appear that the 
selection of animal model and pain assay investigators use to study OA pain 
mechanisms and test therapeutic targets, does matter. 
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CHAPTER 8:  Conclusions and future directions 
The research in this thesis investigated the mechanisms that drive osteoarthritis (OA) 
pain, and whether these change over time, and differ between different OA 
phenotypes. This was done by characterising the changes that occur in OA joint 
histopathology, OA pain behaviour and dorsal root ganglia (DRG) gene transcription, 
over the different phases of OA disease development, using two distinct animal 
models (a post traumatic model of OA and an antigen-induced inflammatory model of 
arthritis).  The relationship between OA joint tissue pathology and OA pain was 
explored further by determining if any associations existed between the various 
outcomes that were measured.  
8.1 Summary 
1. Each model demonstrated a distinct temporal pattern of joint tissue
histopathological change, model-specific associations between the three major
tissue structures in the joint (articular cartilage, synovium and subchondral
bone), and a different set of risk factors for development of OA cartilage
degradation.
a) Moderate synovial inflammation peaking at week 2 and low-grade
inflammation persisting until week 16, was observed in DMM. Severe
synovial inflammation peaking at week 2 and persisting until week 12 before
declining to levels comparable to DMM (week 16) was observed in AIA.
b) Osteophyte formation was a feature of both models, however in DMM
osteophytes formed early (week 2) and persisted, and in AIA they formed late
(week 12).
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c) Unique to the AIA model was the formation of enthesophytes. Their site of
origin and early development suggest that inflammation is a key factor in
driving their formation.
d) In DMM articular cartilage (AC) proteoglycan loss and AC damage appeared
early (week 1 and 2) and developed gradually. In AIA AC proteoglycan loss
was immediate (day 3) and complete, and AC damage was more delayed in
developing (week 8).
e) The transition from subchondral bone (SCB) vascularisation to SCB sclerosis
was different in the two models and reflected the differences in joint
inflammation severity, with SCB vascularity persisting for longer (week 4) in
AIA.
f) Despite these temporal differences, by 16 weeks both models displayed all the
hallmark features of human OA; defined radiographically as joint space
narrowing and the presence of osteophytes; and observed histologically as AC
proteoglycan loss, AC erosion, SCB sclerosis and osteophyte maturity and
ossification.
g) Risk factors for OA development/progression (defined as AC damage) in the
DMM model are surgery/joint injury, AC PG loss, chondrocyte
hypertrophy/cell death, osteophyte size and SCB sclerosis. Risk factors for
OA development/progression (defined as AC damage) in the AIA model are
time, synovitis, chondrocyte hypertrophy/cell death and osteophyte size.
These risk factors suggest that different tissue-specific mechanisms; largely 
determined by the initiating cause, drive the joint pathology changes that lead 
eventually to OA. Therefore, AIA and DMM are both models of OA based on joint 
pathology but represent different phenotypes of OA based on their pathophysiology. 
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2. Both AIA and DMM models displayed tactile allodynia, knee joint mechanical
hyperalgesia, reduced weight bearing of the ipsilateral hind limb, thermal
hyperalgesia and alterations in stride length, during different stages of disease
development. However, the severity and temporal pattern in which these pain
behaviours occurred were different in each model.
a) Ipsilateral tactile allodynia developed early in all treatment and sham/saline
injected groups (by week 2), suggesting that tissue trauma and inflammation
(caused by surgery, immunisation and knee joint injection) initiates
sensitisation in both models. Persistence of tactile allodynia in DMM mice and
resolution in the shams indicates that different mechanisms are involved in the
initiation (surgical trauma and inflammation) and maintenance (OA disease
pathology) of sensitisation. Persistence of tactile allodynia in all AIA mice
(including immunised only) indicates that sensitisation in this model is largely
driven by immunisation and highlights the confounding effect immunisation
has on the alteration of pain pathways.
b) Pressure pain sensitivity (as measured by PAM) occurred in the early (week 6)
and late phase (week 16) of OA in DMM mice, indicating that mechanical
hyperalgesia is driven by local joint pathology changes in this model.  In
contrast, AIA mice displayed greater pressure pain sensitivity in the early
phase of disease with a similar pattern of response also observed in
immunised-only mice. This suggests that inflammation (both localised and
systemic) drives the development of mechanical hyperalgesia in this model,
and again highlights the confounding effect of using a model with both
systemic and localised effects.
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c) Reduced ipsilateral hind limb weight bearing was observed in DMM, sham
and AIA mice only, indicating that this is a measure of locally driven pain
mechanisms in both models.
d) Gait changes in DMM mice manifested as a decrease in left-to-right stride and
full stride length from week 4 that persisted until week 16. AIA and saline
injected mice demonstrated the same temporal pattern of change in stride
length and this was different to DMM. At week 16 both were decreased
compared to baseline. The changes in stride that occurred after week 4 are
likely driven by joint tissue pathology that develops earlier in DMM compared
to AIA (AC damage, osteophyte formation and SCB sclerosis), rather than by
joint inflammation. However, the added effect of immunisation cannot be
overlooked given the changes observed in saline mice.
Overall, each model demonstrated a unique temporal pattern of pain behaviour and 
despite both AIA and DMM displaying the same OA histopathological changes at 
week 16, the pain behaviour observed at this time point was different in each model. 
DMM was characterised by tactile allodynia, mechanical and thermal hyperalgesia, 
reduced weight bearing on the ipsilateral hindlimb and reduced full stride length. AIA 
was characterised by tactile allodynia, thermal hyperalgesia and increased full stride 
length. However, since tactile allodynia and reduced stride length were also observed 
in immunised-only mice, it is difficult to attribute these pain behaviours solely to the 
development of knee joint OA in the AIA model. 
Importantly, there were no associations between any of the pain behaviours in either 
model. This highlights the complex nature of pain and the importance of not relying 
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on one single pain assay when evaluating the efficacy of potential therapeutics in pre-
clinical studies, no matter which disease model is used.  
Also implicit in the pain behaviour findings is the difficulty in interpreting pain 
outcomes and investigating pain mechanisms using the AIA model. Models that 
induce a systemic immune or inflammatory response such as AIA may not be suitable 
for studying pain mechanisms of arthritis phenotypes where initiation of the disease 
process is locally driven (e.g. post-traumatic OA) rather than systemically driven (e.g. 
rheumatoid arthritis), due to the confounding effect immunisation can potentially have 
on all the outcomes.  
3. Changes in gene expression in the innervating DRG were observed during
each phase of OA disease in both AIA and DMM, with the greatest
differences occurring in the late chronic phase of OA. Despite the histological
similarities between AIA and DMM during this phase of disease, the gene
expression data suggests there are different mechanisms driving OA pain in
the two models.
a) In the acute inflammatory phase of disease, DRG gene expression changes in
DMM (relative to sham) occurred for IL-1 and ADAMTS-5, and in AIA
(relative to saline) changes occurred for ATF3, IL-1, TRPV2 and ADAMTS-
5.
b) In the early progressive phase of OA, DRG gene expression changes in DMM
(relative to sham) occurred for TRPA1, TRPV1 and CNR1, and in AIA
(relative to saline) for ATF3, CGRP, TRPA1, Oprm1 and ADAMTS-4.
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c) In the late chronic phase of OA, DRG gene expression changes in DMM
(relative to sham) occurred for CGRP, Tac-1, TRPA1, TRPV1, TRPV2,
TRPV4 and Oprm1, but only for TRPV1 in AIA.
d) Consistent gene expression associations were observed in sham and saline
mice. Dysregulation of these associations was identified in both AIA and
DMM for CGRP, IL-1 and ADAMTS-4, but with loss of association with
different subsets of genes in the two models. This suggests model specific
differential effects in the expression profile of these three genes and therefore,
supports the existence of different pain regulatory pathways in the two
models.
e) The observed temporal pattern of gene expression changes in each model
could not be related directly to protein expression in the DRG using
immunohistochemistry. For the two genes where antibody immunoreactivity
above background was achieved there was no consistent association between
gene expression and protein expression at different phases of disease.
4. Correlation analysis proved to be a useful tool for understanding the complex
relationship between joint pathology, pain and gene transcriptional changes in
the DRG, and defining the differences between different animal model
phenotypes.
a) Associations between joint histopathology and DRG gene expression suggest
that the synovium may be the primary tissue that drives pain in the AIA model
and SCB may be the primary tissue that drives pain in the DMM model.
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b) Associations between pain behaviour and DRG gene expression suggest that
stride length, and perhaps gait characteristics more generally, is a suitable pain
behaviour for investigating pain mechanisms in the DMM model.
c) Associations between joint histopathology and pain behaviour suggest that
PAM, stride length and forceplate may be useful markers of joint
inflammation.
So not only are joint tissue pathology, pain behaviour and peripheral sensory 
modulation animal model specific, but the associations between these three 
components of OA disease are also unique to the animal model under investigation. 
This confirms the importance of mapping pre-clinical findings to the human disease 
phenotype that best fits the animal model. Yet currently this does not occur for OA 
pain, where much of what we know is informed by studies conducted in animal 
models that don’t correspond to a human OA phenotype.  
The findings reported in this thesis support the hypothesis that the mechanisms that 
drive osteoarthritis pain are specific to the pathophysiology and stage of the disease, 
and differ between different OA phenotypes. Which model researchers use to study 
different aspects of OA pain is important to our overall understanding of its 
mechanisms and our ability to translate pre-clinical findings to effective therapeutics. 
The findings also suggest that OA joint disease and OA pain share common pathways 
and as such, the study of OA pain and pre-clinical investigation of therapeutics should 
be carried out in animal models that are phenotypically similar to specific human OA 
conditions of interest. 
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8.2 Study limitations 
This research challenges how we currently use animal models to inform our 
understanding of OA pain and make decisions about the potential efficacy of novel 
therapeutic targets. However, there are a number of study limitations that need to be 
highlighted. 
Model specific tissue pathology associations, pathology-pain associations, and pain-
DRG gene expression associations were identified. But establishing causal 
relationships for these associations was beyond the scope of this thesis, and further 
investigation is required.  
Interpretation of any pain behavior test is complicated by the fact that in most 
instances these tests involve exposure to two stressors, physical confinement or 
restraint, and a noxious stimulus (e.g. heat, mechanical, tactile, joint 
loading). Therefore, a behavioural response that is interpreted as pain may in fact 
be a stress driven escape response. Acclimatisation aims to familiarise mice to 
a particular restraint mechanism or procedure in order to minimise the stress 
response, however, it is unlikely to ever be completely eliminated.  
A relationship between the observed changes in gene expression and changes in 
protein expression in the DRG was not demonstrated. An investigation into the 
numerous post-transcriptional mechanisms that control protein levels was not within 
the scope of this study, but would provide a clearer understanding of the significance 
of the unique pattern of gene dysregulation that was observed in the two arthritis 
models.  
Although a number of key protein and neuropeptide candidates that are associated 
with both inflammatory and chronic pain states were measured, investigation of all 
genes implicated in pain signal modulation was also not within the scope of this 
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study. Investigating gene expression in the DRG was a starting point for 
characterising the sensory modulation that gives rise to sensitisation and the 
manifestation of chronic OA pain. Further investigation into pain mechanisms at the 
level of the spinal cord and brain are required in order to gain a more complete 
understanding of the mechanisms at play, and better inform gene selection for 
therapeutic targets in the future. 
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8.3 Questions arising 
A number of key questions about the mechanisms of OA pain emerge from the 
findings of this research. 
1. How suitable is the DMM model as a pre-clinical model for investigating pain
mechanisms in a human post-traumatic OA phenotype?
2. What other genes play a role in peripheral (DRG) and central (spinal cord)
sensory modulation in OA pain?
3. How important are changes in gene transcription relative to other processes that
together account for sensory modulation in OA pain?
4. How does inflammation contribute to pain and sensitisation at different stages of
OA disease in a post-traumatic OA phenotype?
5. How useful are different measurements of gait and mobility for tracking OA joint
disease progression and testing the efficacy of potential therapeutics?
6. What is the relationship between tactile allodynia (as measured by von frey) and
joint tissue pathology at different phases of OA disease?
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8.4 Future directions 
The broad investigations into pain-related behaviours and changes in DRG gene 
transcription conducted in this thesis were designed to be hypothesis generating to 
pave a path for future studies that can build on the findings from this thesis.  
The studies reported demonstrate that the DMM model is suitable for investigating 
both the histopathology and pain behaviour of a post-traumatic OA phenotype. 
Additional experiments, utilising gene array analysis, are required to fully 
characterise the DRG gene expression profile at different stages of OA in this model. 
This will then enable the selection of target genes for investigation in KO mice 
studies to characterise the role of specific genes in the initiation and progression of 
OA pain, by utilising the suite of pain assays and the histological scoring method 
reported in this thesis. The suitability of a particular gene as a future therapeutic target 
can then be evaluated. Based on the findings reported in this thesis TRPA1, TRPV1, 
TRPV4 and ADAMTS-4 KO mice are suitable candidates for further investigation, 
however there are likely to be others. 
In addition to characterising gene transcription profiles for each phase of OA, the role 
of gene translation (protein expression) also requires further investigation. This was 
commenced in this thesis but due to technical problems with optimising antibodies, 
the scope of the experiment was very limited. Further work is required to investigate 
protein expression of the other target genes identified, using a combination of IHC 
and tissue culture methods to determine the triggers that promote or inhibit protein 
expression. An investigation into sensory neuron protein expression using DRG tissue 
culture methods was commenced and preliminary data is presented in Appendix E. 
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However, because of the time required optimising the protocols and methods for this 
technique the investigation was not completed as part of the scope of this thesis. 
The DRG were selected as a starting point for characterising the sensory modulation 
that gives rise to sensitisation and the manifestation of chronic OA pain. However, in 
addition to identifying target genes at the level of the DRG, investigations into pain 
mechanisms at the level of the spinal cord (dorsal horn) and brain (e.g. thalamas, 
prefrontal cortex, somatosensory cortex, amygdala) are also required. There are clear 
advantages to targeting OA pain at the periphery, but this does not exclude the need to 
have a full understanding of the mechanisms at play all along the pain pathway to 
better inform gene selection for therapeutic targets that are likely to be effective when 
administered into the affected joint.  
The significant role that inflammation plays in OA pain was observed in both AIA 
and DMM, but was clearly different for each model. This was evident from the 
model-specific independent risk factors for developing OA that emerged from 
regression modelling and joint tissue associations that emerged from the correlation 
data. It was also demonstrated in the different gene expression profiles for each model 
at different phases of OA, and importantly in the model-specific associations between 
joint tissue histopathology, pain behaviour and DRG gene expression. The role of 
inflammation in OA pain is currently under investigation by numerous researchers 
and this needs to continue. In particular, greater clarification of the role of 
macrophage migration and differentiation of sub sets of macrophages and how each 
may alter sensory signalling differently at different stages of OA disease is required.  
Finally, it will be important to build on the pain behaviour methods that were 
described and used in this thesis, to further investigate associations between pain 
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behaviour and joint tissue pathology, especially the relevance of tactile allodynia as a 
measure of sensitisation, its association with AC damage and SCB sclerosis, and its 
value as a measure of pain when investigating therapeutic targets. Further 
examination of gait analysis and spontaneous activity based measures to optimise the 
measures used to detect changes with disease progression and to test potential 
therapeutics is also required. 
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Appendix A: Reagents and Equipment 
1. Animal Models
1.1 Complete Freund’s adjuvant preparation 
Material/Equipment Supplier 
Incomplete Freund’s Adjuvant SIGMA (order #F5506) 
Mycobacterium tuberculosis (M.tb) DIFCO (6 x 100mg vials, order #231141) 
Mortar and pestle 
1.2 Emulsion preparation 
Material/Equipment Supplier 
Methylated Bovine Serum Albumin SIGMA (order #A1009) 
1ml glass Tb syringe with leur lock Becton Dickson (order #512027) 
10ml glass syringe with leur lock Becton Dickson (order #512027) 
18 gauge drawing needles Becton Dickson (order #300204) 
30 gauge ½ inch needles Becton Dickson (order #305106) 
Dumont tweezers (#7, curved, superfine) ProSciTech (T017D) 
Flat bottomed 5 ml tube with cap 
Double edged razor blades 
Dissection microscope 
Anaesthetic machine (Isoflurane) 
Gloves and safety goggles 
1.3 DMM Surgery 
Material/Equipment Supplier 
Westcott spring scissors 11.5 cm long with 
straight tips 
ProSciTech (order #T106) 
Dumont tweezers – number 7 (curved 
with superfine points, dumostar steel) 
ProSciTech (order #T017D) 
Dumont tweezers – number 5 (straight 
with superfine points, dumostar steel) 
ProSciTech (order #T015D) 
Castroveijo Ophthalmic needle holder, 
curved 
ProSciTech (order #TT1A03C); 
Scalpel blades (no. 11) ProSciTech 
Scalpel handle (no. 3) ProSciTech 
Suture material (8/0 Vicryl) Ethicon (order # J548G) 
Tissue adhesive (Vetbond) 3M 
0.9% NaCl sterile irrigation solution 
Double-edged razor blades Schick 
Tuberculin syringes BD Medical 
Sterile gloves 
Paper drapes and sterile gauze 
Surgical microscope 
Anaesthetic machine (Isoflurane) 
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2. Polymerase Chain Reaction Primers
Molecule Species 
Accession # 
Pos’n Oligo Bases Sequence 5’ to 3’ T °C Product (bp) 
ADAMTS4 Mus musc 
NM172845 
1549F 
1793R 
24 
24 
F – TAA CTT GAA TGG GCA GGG GGG TTC 
R – AAT GGC TTG AGT CAG GAC CGA AGG 
60 245 
ADAMTS5 Mus musc 
NM011782 
2058F 
2355R 
21 
24 
F – TCT CCA AAG GTT ACG GAT GGG 
R – TCT TCT TCA GGG CTA AGT AGG CAG 
55 298 
ATF3 Mus Musc 
AB291912 
269F 
379R 
23 
23 
F – AGG ATT TTG CTA ACC TGA CAC CC 
R – TGT TGA CGG TAA CTG ACT CCA GC 
55 111 
Calcitonin (CGRP) Mus musc 
NM007587 
716F 
853R 
24 
22 
F – CCA CAG GCT AAA AGA GAA TCA CCC 
R – CCC AAA CAA CCA ACA CTT CCA G 
55 138 
Cannabinoid receptor 1 (Cnr1) Mus musc 
NM007726.3 
987F 
1149R 
22 
23 
F – TGG AGA ACC TGC TGG TGC TAT G 
R – GGA CTA TCT TTG CGG TGG AAC AC 
57 163 
GAPDH Mus musc 
BC083149 
880F 
1079R 
20 
20 
F – TGC GAC TTC AAC AGC AAC TC 
R – CCT GCT CAG TGT CCT TGC TG 
55 200 
IL1B Mus musc 
BC011437 
127F 
243R 
24 
23 
F – ACC TGT TCT TTG AAG TTG ACG GAC 
R – TCT TGT TGA TGT GCT GCT GTG AG 
55 117 
Opioid receptor mu (Oprm1) Mus musc 
AB441736 
701F 
822R 
23 
23 
F – TCT GTG TCT TCA TCT TCG CCT TC 
R – GTT CCT GTC CTT TTC TTT GGA GC 
55 122 
Tachykinin-1 (Substance P) Mus musc 
NM009311 
754F 
859R 
22 
22 
F – CGC AGT CTC CAA AGA AAG GAC C 
R – TGA AAG CAG AAC CAG GGG TAG C 
57 106 
TRPA1 Mus musc 
BC131963 
364F 
530R 
23 
21 
F – AAG TTT CTT CTC AGC CAA GGA GC 
R –ATC AAA GCC GTG TTC CCA TTC 
55 167 
TRPV1 Mus musc 
AY445519 
105F 
283R 
20 
24 
F – AGC CAA GCC CCA CAT CTT TG 
R – TGA GAC AGG TAG GTC CAT CCA CAG 
58 179 
TRPV2 Mus musc 
NM011706 
1846F 
2014R 
24 
22 
F – TAC CTC CCC CTG TTA GTG TCA TCC 
R – CAG CAA AGC CGA AAA GGA AGA C 
56 169 
TRPV4 Mus musc 
NM022017 
1454F 
1693R 
24 
21 
F – GAG AGA CAA GTG GCG TAA GTT TGG 
R – CCA GGG CAT TTC TTC GTG AAC 
58 240 
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3. Immunohistochemistry
3.1 Materials 
Materials Details Supplier 
Slides Adhesive Slides Dako K802021 
Cover slips Menzel-Glaser 22x50mm Trajan Scientific & Medical 
CS2250100 
Mountant Euckitt mounting media Trajan Scientific & Medical 
EUCKITT 
Staining chamber Sequenza Shandon coverplates ThermoFisher 
Xylene Xylene AR POCD (Point of care diagnostics) 
XYL5 
Ethanol 100% Absolute Ethanol, non 
denatured 
POCD ETHABS5 
Ethanol 95% Dilute 100% stock in milliQ 
water 
Ethanol 70% Dilute 100% stock in milliQ 
water 
Heat retrieval 
solution 
0.01M Citrate buffer, pH 6.0 Dako S1699 
Enzymatic 
retrieval 
Proteinase K Dako S3020 
0.3% Hydrogen 
Peroxide 
Diluted 30% stock in milliQ 
water 1:100 
Trajan Scientific & Medical  
UnivarAjax 260-500ml 
TBST wash buffer 0.05M Tris, 0.15M NaCl, 0.05% 
Tween 20, pH 7.6 
Dako K800 
Blocking reagent Serum-free Protein Block Dako X0909 
Antibody diluent Antibody diluent Dako S0809 
Detection Envision + Rabbit Dako K4003 
Envision + Mouse Dako K4001 
Stain NovaREDTM VectorLabs SK4805 
Counterstain Mayer’s Haematoxylin Refer to appendix B for details 
on preparation Scott’s Blue 
3.2 Antibodies 
Antibody Details Source 
CGRP Monoclonal Anti-Calcitonin Gene-
Related Peptide (CGRP) Clone CD8, 
in mouse, purified immunoglobulin 
Sigma C 9487 
F4/80 Monoclonal Anti-F4/80 antibody, in 
rat, purified immunogobulin 
Abcam ab6640 
Opmr1 Rabbit polyclonal antibody raised 
against synthetic peptide of opioid 
mu receptor, affinity purified 
Abnova PAB18103 
PGP Polyclonal anti-PGP9.5 antibody 
raised against synthetic peptide, in 
rat, affinity purified 
Abcam ab27053 
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4. DRG Tissue Culture reagents and materials
Reagent Supplier 
HBSS buffer solution Invitrogen 14025-092 
Poly-L-Lysine Sigma p1274-25MG 
N2 Invitrogen 17502048 
Laminin Sigma L2020-1MG 
Collagenase type 4 Fisher NC9620402 
Papain Fisher NC9212788 
F12 media Invitrogen 11765-054 
Fetal bovine serum Invitrogen 
Penicillin/Streptomycin Sigma P4333-20ML 
glass coverslips Fisher 12-545-102 
glass pipettes Fisher 136786B 
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Appendix B: Reagent Preparation 
1. Antigen Induced Arthritis Model
a. Freund’s Complete Adjuvant (2mg/ml)
A mask, safety glasses and gloves are worn during preparation.  
Place 1-2ml of Incomplete Freund’s adjuvant in a mortar and add 1 vial (100mg) of 
Mycobacterium turberculosis (M.tb). This avoids aerolisation of the powder during 
preparation. Pulverize the M.tb powder in the Incomplete Freund’s for about 10 
minutes, adding a little more Freund’s as you go but keeping the volume to a 
minimum so as to give best pulverization. 
Transfer the pulverized M.tb to a glass tube with lid. Add more Freund’s Incomplete 
to the mortar and use to “wash out” more of the M.tb 
Repeat several times until all of the M.tb has been transferred to the tube. 
Make the final volume of the Freund’s Complete adjuvant to 50 ml (5 x 10 ml vials) 
to achieve a concentration of 2mg/ml 
b. Methylated Bovine Serum Albumin (mBSA) (2mg/ml)
Weigh out 20mg mBSA in 10 ml tube.  Add 10ml sterile water.  DO NOT MIX but 
place in 37°C water bath over ~1hr to allow to dissolve.  Check every 15 min and 
gently flick. 
NB mBSA is prepared as a large batch (20mg in 10 ml), stored as 1ml aliquots at -20 
degrees, then thawed on the day it is needed to make emulsion. 
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c. mBSA emulsion (100l/mouse)
Make up more than the calculated amount to compensate for the losses that occur 
during preparation. For example, for 10 mice prepare 2ml emulsion, for 20 mice 
prepare 4ml emulsion, and for 30 mice prepare 5ml emulsion. 
Safety glasses and gloves are worn during preparation. 
Transfer the required amount of Freund’s complete adjuvant (FCA) (2mg/ml), using a 
1ml Gilson tip, to a 5ml flat bottom tube. Add an equal volume of dissolved 2mg/ml 
mBSA using a drop wise technique with continual vortexing of the tube. Once all the 
mBSA has been added, use an autoclaved 10 ml glass syringe with an 18-gauge 
drawing needle to create a stable emulsion using the following technique.  
- Aspirate some of the mixture into the syringe, invert syringe and pull the plunger
back most of the way to “coat” the walls of the syringe and provide a better seal. Then 
expel this back into the tube. 
- Draw up all of the emulsion, invert the syringe and expel the air. Expel the emulsion
(with force) back into the tube with the needle above the liquid to avoid any overflow 
and production of bubbles. Repeat the procedure 2-3 times then put the tube and 10 
ml syringe on ice for a few minutes to avoid heating the emulsion. 
- Minimise handling of syringe around the barrel to avoid warming it up.
- Repeat the above process 3-5 times until a thick and stable white emulsion is
formed.  
Test the stability of the emulsion by placing one drop of emulsion onto cold water in a 
beaker. If the drop stays together and little or no oil disperses onto surface of the 
water then the emulsion is suitable for use. 
NB Emulsion is made fresh on the day of the immunization and stored on ice until 
injected. 
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d. mBSA (20mg/ml)
Weigh out 20mg mBSA into a 1.5 ml tube.  Add 1ml sterile water.  DO NOT MIX 
but place in 37°C water bath over ~1hr to allow to dissolve.  Check every 15 min and 
gently flick.   
NB A larger batch is made up (200mg in 10 ml saline) and frozen at -20 degrees, in ½ 
and 1 ml aliquots, then thawed on the day it is required. 
When required, thaw and add 50µl of a sterile 3M NaCl solution to the 1ml aliquot 
and mix immediately. This solution is prepared the morning of injection, as the 
mBSA precipitates out over time.   
2. Real Time-PCR: Reverse transcription (RT) Master mix
Total volume = 1000µl 
- 
- 
- om primers (pentadecamers) 
- 
- -free glycerol
-    50 µl RT enzyme (Qiagen Omniscript kit)
3. Immunohistochemistry: Mice perfusion protocol
a. Flush solution - 9g NaCl + 5g Na2NO4 in 1L milliQ water
Add 1500 IU/500mL heparin (1500 IU = 300µL) 
b. Fixative solution - Phosphate buffered saline (PBS) + 4 % Paraformaldehyde (PFA) 
Set pH to 7.4 by adding NaOH or HCl. (Use pH meter) 
Prepare no sooner than day before and store at 4°C 
400 µl 10x RT buffer (Qiagen Omniscript kit)
200 µl RT dNTP (Qiagen Omniscript kit)
200 µl rand
100 µl RNAse inhibitor (Bioline)
50 µl RNAse
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4. DRG Culture (All procedures carried out under a laminar flow hood)
a. Preparation of Coverslips
- Place sterilized glass coverslips in tissue culture wells (2 x 6 well plates) and coat
with Poly-L-Lysine (PLL) (2ml/well) and leave at 4°C overnight
Note: The coating of these coverslips was done ahead of time and stored at 4°C 
- Turn coverslips over. Wash coverslips three times with sterile water. Use 2 ml for
each was and suction with a glass pipette. Allow coverslips to dry.
- Before use, coat the PLL-coated coverslips with Laminin (200 µl per coverslip)
and incubate for 2 hrs in the incubator at 37°C.
- After incubation, remove excess laminin from each coverslip by suctioning with
glass pipette, and allow to air dry.
b. Solutions and Culture Mediums
Poly-L-Lysine (PLL):- Add 250 ml of sterile tissue culture grade water to 25 mg of 
PLL. Store as 50 ml aliquots (100 µg/ml) at -20°C. 
N2:- Thaw 5 mL vial and store as 1 mL aliquots at -20°C 
Laminin: - Dilute 50x with sterile water (supplied at 1mg/ml concentration). Store as 
50 µl aliquots at -20°C. Thaw at room temperature and make working dilution of 
Collagenase type 4: - Dissolve 50 mg of Collagenase 4 into 50 ml of Hank’s 
Balanced Salt solution (HBSS) (1mg/ml). Store as 1 ml aliquots at 4-8°C. Thaw in 
37°C water bath before use. 
Papain; - Dissolve 1 vial of papain in 5ml of HBSS. Store as 500 µl aliquots at 4-8°C. 
F12 DRG medium and 10% FBS: - Add 5 ml of Fetal Bovine Serum (FBS) into 45 ml 
of F12 media. Make up in small quantities as required (0.5ml in 4.5ml for total of 
5ml). 
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F12 DRG Medium - Make up 100ml at a time in filter top bottles and store @ 4°C for 
up to 4wks. 
- 98 ml F12 media (use fresh bottle of F12 every ~6 weeks)
- 0.5 ml FBS
- 1 ml N2 supplement
- 0.5 ml Penicillin/Streptomycin
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Appendix C: Histology Scoring 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. Sagittal sections.  
Only score a single slide for each animal/joint and try to score the same area of the 
joint in all animals – the slide near the central weight-bearing region of the joint.  
Table 1.  STRUCTURAL CARTILAGE DAMAGE 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA, modified from that 
of Glasson et al (Arthritis Rhem 2004). The tibial plateau and the femoral condyle are 
scored separately. Only the central weight-bearing region of the joint was evaluated.  
0 Normal cartilage 
1 Roughened surface AND/OR superficial fibrillation <10% of cartilage depth 
(any % of joint surface area), 
2 Fibrillation extending >10% of cartilage depth but not reaching the calcified 
cartilage AND/OR loss of surface lamina (any % or joint surface area) 
3 Horizontal cracks/separations between calcified and non-calcified cartilage 
OR clefts down to calcified cartilage BUT no loss of non-calcified cartilage 
4 Fibrillation to the calcified layer OR loss of non-calcified cartilage lesion for 
1-25% of the joint surface
5 Fibrillation to the calcified layer OR loss of non-calcified cartilage lesion for 
25-50% of the joint surface
6 Fibrillation to the calcified layer OR loss of non-calcified cartilage lesion for 
50-75% of the joint surface
7 Fibrillation to the calcified layer OR loss of non-calcified cartilage lesion for 
>75% of the joint surface
8. Lesion extends through the calcified cartilage (any % joint surface area)
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Table 2.  PROTEOGLYCAN LOSS 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. The tibial plateau 
and the femoral condyle are scored separately. Serial sections across the width of the 
medial tibial plateau are stained. Only the central weight-bearing region of the joint is 
evaluated. 
0 Normal cartilage 
1 Decreased but not complete loss of toluidine blue staining over any % of 
surface area 
2 Complete loss of toluidine blue staining in the non-calcified cartilage extending 
to <25% of the articular surface 
3 Complete loss of toluidine blue staining in the non-calcified cartilage extending 
to 25-50% of the articular surface 
4 Complete loss of toluidine blue staining in the non-calcified cartilage extending 
to 50-75% of the articular surface 
5 Complete loss of toluidine blue staining in the non-calcified cartilage extending 
to >75% of the articular surface 
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Table 3.  CHONDROCYTE HYPERTROPHY/APOPTOSIS/CELL DEATH – 
non-calcified articular cartilage 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. POSITIVE SCORE - 
defined as enlarged chondrocyte/lacunae in non-calcified cartilage – appears as empty 
space around collapsed chondrocyte typical of cells in calcified zone PLUS the 
nucleus of the cell is dark stained and pyknotic (shrunken).  
NOTE: If the nucleus is missing from the lacunae this is considered apoptotic. If there 
is empty space around nucleus but it is not collapsed/dark staining this is not 
considered positive (compare with hypertrophic/apoptotic cells in calcified cartilage 
as an example). Tibia and femur examined separately as below.  
0 No hypertrophy/apoptosis  
1 <1/3
rd
 of cells in non-calcified cartilage across the width of the joint are
hypertrophic/apoptotic/missing nuclei 
2 1/3
rd
 – 2/3rd of cells in non-calcified cartilage across the width of the joint are
hypertrophic/apoptotic/missing nuclei 
3 >2/3
rd
 of cells in non-calcified cartilage across the width of the joint are
hypertrophic/apoptotic/missing nuclei 
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Table 4.  OSTEOPHYTE FORMATION/MATURATION 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. Only the major 
osteophyte that forms on the anterior/medial margin of the tibia is scored. Only a 
single section is scored for each mouse.  The section that is scored is that just at the 
point when separation of the anterior and posterior meniscal elements becomes 
apparent. The osteophyte in the DMM model is invariably closer to the medial margin 
of the joint in sagittal sections and the same site is scored in each mouse. 
Osteophyte “maturity” 
0 No Osteophyte 
1 Predominantly cartilaginous - little or no active endochondral ossification 
2 Mixed cartilage and bone with active endochondral ossification – chondrocyte 
hypertophy and active vascular invasion and new bone formation 
3 Predominantly bone (often with mature trabeculae and marrow space) with 
little active endochondral ossification. 
Osteophyte size 
This is judged by an “internal” standard which is the thickness of the nearby normal 
full depth articular cartilage (i.e surface to base of calcified cartilage).  
0 No Osteophyte 
1 Small  = up to 1x (same) thickness of the adjacent normal cartilage 
2 Medium = 1-3 x the thickness of the adjacent normal cartilage 
3 Large = > 3 x the thickness of the adjacent normal cartilage 
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Table 5.  SUBCHONDRAL BONE 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. Only the tibia is 
scored. NOTE “solid” trabeculae bone or cortical-type bone is seen as predominantly 
(>90%) green stained bone with canaliculi but may contain small marrow spaces and 
extends from the articular to the growth plate cartilage.  For a score of 1-3 the changes 
must be on 2 or more consecutive sections. 
0 Normal trabecular bone with > 50% marrow space 
1 2 or more “wide” vertical trabecular struts of bone that extend from the 
cartilage to the growth plate OR “solid” bone spanning up to 1/3rd of the width
of the epiphysis 
2 “solid” bone spanning > 1/3
rd
 but < 2/3
rd
 of the width of the epiphysis
3 “solid” bone spanning > 2/3
rd
 of the width of the epiphysis.
Table 6.  SUBCHONDRAL BONE Vascular Invasion/erosion 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM. Only the tibia is scored. 
Score by evaluating the number of points at which the subchondral bone is 
“breached” such that vessels or marrow WBC touch or invade the calcified cartilage. 
0  Normal: intact SC bone layer 
1  Mild: 1 or 2 points of vascular invasion to touch but not invade the 
calcified AC in tibia 
2  Moderate: 3 or more points of vascular invasion to touch but not invade 
the calcified AC in tibia; OR any number of points that invade into the 
calcified AC but do not reach the non calcified AC 
3  Severe: any number of points that invade through the calcified AC and 
reach/invade the non calcified AC 
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Synovial Inflammation Scoring 
Scoring system used for histopathological assessment of Toluidine blue stained 
osteochondral sections of mouse knees following DMM or AIA. Sagittal sections.  
Only score a single slide for each animal/joint and try to score the same area of the 
joint in all animals – the slide near the central weight-bearing region of the joint. Only 
the synovium superior (femoral side) to the meniscal remnant is scored. Both anterior 
and posterior aspects of the joint are scored. 
PANUS 
Panus, defined as fibrous tissue/synovium/inflammatory cell out growth spreading 
OVER the bone at the osteochondral junction joint margin and ultimately over the 
surface of the cartilage at the joint margins. Score the maximum distance over which 
the panus (see definition above) has spread. Use an “internal standard” to measure the 
distance which is the full thickness depth of the articular cartilage (non-calcified plus 
calcified – i.e. tol blue positive tissue) at a point 1/4 of the way across the joint (see 
figure) from the respective adjacent/affected joint margin.   
0 No panus 
1 mild: panus (2> cells thickness) is present on the bone at the joint margin but 
has not has migrated over cartilage surface 
2 moderate: panus has migrated over cartilage surface  < 1 x cartilage depth 
3 severe: panus has migrated over cartilage surface  > 1 x cartilage depth 
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Bone Erosion By Panus Or Inflammatory Cell Inflitrate 
As well as migrating over the surface of the cartilage the panus/inflammatory cell 
infiltrate can erode into the cortical bone at the joint margin. Look at the anterior and 
posterior margin of the femur between joint capsule attachment and cartilage margin. 
Bone erosion by pannus/inflammatory cells is considered to be present when there is 
loss of any depth of the cortical bone from the outside in towards the marrow cavity 
with hyperplastic synovial cells/inflammatory cells attached to and invading into this 
area of bone loss. The depth of cortical bone loss can vary from partial thickness, 
appearing as a rough and/or scalloped bone surface with attached panus through to 
complete loss of cortical bone with panus extending into the marrow. 
BONE EROSION 
Score the maximum erosion severity at the joint margin. 
0 no cortical bone erosion at any site 
1 partial thickness loss of cortical bone only  
2 focal complete loss of cortical bone  - communication with the marrow cavity 
one small “vascular” communication site 
3 widespread complete loss of cortical bone  - communication with the marrow 
cavity multiple sites or broad area of loss of cortical bone 
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SYNOVIAL HYPERPLASIA - SEVERITY 
Do not score the cells in the area actually attached to the tibia or femur (this is 
recorded in panus) OR cells on the surface of the meniscus itself or immediately 
adjacent (synovial plica here often has multiple synovial cell thickness in normal 
joints). Score the maximum hyperplasia seen anywhere along this area even if only 
focal. 
0 1 cell thick  
1 mild = 2-3 cells thick  
2 moderate = 4-5 cells thick 
3 severe = >5 cells thick  
SUB-SYNOVIAL INFLAMMATION / WBC INFILTRATION 
The infiltration of inflammatory cells (neutrophils, macrophages and/or lymphocytes) 
is evaluated.  
0 no inflammatory cells 
1 occasional scattered inflammatory cells - perivascular 
2 FOCAL areas of dense subsynovial wbc infiltrate - but still predominantly 
normal subsynovial areolar connective tissue present 
3 WIDESPREAD dense subsynovial wbc infiltrate – markedly reduced or 
little/no normal areolar connective tissue evident OR 
LYMPHOID FOLLICLE formation – distinct accumulations of mononuclear cells 
organised into rounded masses reminiscent of lymph nodules 
SYNOVIAL EXUDATE 
The infiltration of inflammatory cells (neutrophils, macrophages and/or lymphocytes) 
is evaluated.  
0 no inflammatory cells or fibrin in the synovial cavity 
1 inflammatory cells and/or fibrin clot restricted in the synovial cavity – may be 
restricted to recesses 
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Appendix D: Melt curves for real time RT-PCR 
For real time RT-PCR, primer specificity was confirmed for each gene by performing 
a melt curve analysis and demonstrating a single amplicon of appropriate size. 
Representative melt curves for the 12 genes investigated in this study are included 
below. Each graph includes samples for DMM, AIA, sham and saline injected mice. 
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ATF3 quantitative data graph represents DMM, Sham, AIA and saline injected mice 
DRG. Expression of ATF3 was demonstrated in both treatment and control groups at 
all measured time points. The graphs below represent week 4 (a) and week 8 (b) data. 
a. 
b. 
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Appendix E: the role of macrophage infiltration and 
chemokine production by sensory neurones in 
development of OA pain - preliminary findings using 
IHC and DRG tissue culture methods. 
Introduction and aims 
Recently, macrophage infiltration has been implicated in pain and sensitisation in 
animal models of OA. Researchers have demonstrated that peripheral inflammation 
alone in the absence of peripheral nerve injury is a trigger for macrophage infiltration 
into innervating DRG, and that this macrophage infiltration correlates with OA pain 
related behaviour. MCP-1 (monocyte chemo-attractant protein-1) is a chemotactic 
cytokine that mediates increased pain signaling by attracting macrophages to the 
DRG, and has also been shown to directly mediate excitatory effects at the level of the 
DRG in nerve-injury models of pain. However, the relationship between DRG 
macrophage infiltration, pain, and progression of joint pathology has not been studied. 
To further investigate the mechanisms involved in sensitisation at the level of the 
DRG (both early and late in the development of OA), IHC and DRG tissue culture 
methods were used. Immunoreactivity for F4-80 (a macrophage marker) and 
production of MCP-1 by sensory neurons in vitro, was measured in the lumbar DRG 
of AIA and DMM mice (and their respective controls). 
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 Aims: 
1. To investigate differences in F4-80 expression in the lumbar (L3-L4) DRG
following development of knee joint arthritis induced by DMM and AIA,
using immunohistochemistry techniques.
2. To measure and compare the levels of MCP-1 protein produced in culture by
lumbar DRG from mice with knee joint arthritis induced by DMM and AIA.
Methods and data presentation 
Details of the methods used to induce the two models of arthritis, DMM and AIA, are 
described in chapter 2, section 2.1. The methods used for immunohistochemistry are 
described in chapter 2, section 2.5. The methods used for tissue culture are described 
below. Details of the composition and preparation of all solutions and culture 
mediums used in DRG culture are found in Appendix B. 
a. DRG harvesting
At week 1, 4, 8 and 16, post arthritis induction, cells were harvested and isolated from 
the innervating DRG of the knee joint (L3-L5). Due to the limited cell yield from each 
individual DRG, left and right DRG were combined, and DRG 4 mice from each 
treatment group (DMM, sham, AIA, saline, immunised-control, control) were pooled 
for each 12-plate culture.  
Mice were euthanised using CO2 inhalation. The coat was sprayed liberally with 70% 
ethanol to minimise contamination. Using a dissection microscope, the skin covering 
the dorsum was dissected away to expose the underlying muscle layers and allow 
visualisation of the vertebral column and ribs. Using iris scissors an incision was 
made through the interveterbral disc space at the level of the thoracolumbar region. 
The dorsal vertebral column was then trimmed away to expose the spinal cord. The 
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spinal cord was gently lifted starting at the thoracolumbar junction and working 
towards the sacral region, to enable visualisation of the DRG. Left and right DRG (L3 
to L5) were lifted with forceps and dissected out by cutting the attaching nerve roots.  
The DRG were placed in a collection dish containing cold Hank’s Balanced Salt 
Solution (HBSS). They sat on ice for approximately one hour, until DRG from all 4 
mice (24 DRG in total) had been harvested. 
b. DRG digest
All tissue culture procedures were done inside a laminar flow hood. Using a 1ml 
pipette, the DRGs were transferred to a 15 ml centrifuge tube (falcon tube) and 
pre-warmed Collagenase type 4 added to the DRG and incubated for 20-25 minutes at 
37
o
-warmed papain was added to the DRG, followed by
gently vortexing and incubation for 20-25 minutes at 37
o
C.
Ham’s F12 medium containing 10% Fetal Bovine Serum (FBS) (0.5ml) was then 
added and the DRG digest titurated with a glass pipette for several minutes to gently 
break up the tis
strainer to remove non-dissociated cells and remaining connective tissue. The tube 
containing the digest was ‘washed’ by adding 4.5 ml of Ham’s F12 medium with 10% 
FBS, and this also filtered through the cell strainer. The filtered cell digest was 
centrifuged at 1500 rpm for 10 minutes. 
c. DRG culture
The supernatant was removed, leaving only 0.5ml. The DRG cells were re-suspended 
in 1.2ml of serum free Ham’s F12 medium by gentle mixing, and 
suspension was plated onto the centre of sterile coverslips (previously coated with 
Poly-L-Lysine and laminin) that sat in 6 well tissue culture plates. A total of 12 wells 
100µl of cell
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were plated with cells. These were then incubated at 37oC with 5% CO2 for 1.5 hours 
to allow cells to adhere before an additional 2ml of serum free Ham’s F12 medium 
was added to each cover slip, making sure not to add directly to the cells but rather the 
side of the well. The plate was gently moved from side to side to ensure the coverslips 
were fully coated with media before placing them back in the incubator and cultured 
for two days at 37oC with 5% CO2. After two days in culture, the media was changed 
and the cells cultured for an additional two days, this media being used for subsequent 
analysis. 
d. Conditioned media harvest
Before harvesting, each well was viewed under the microscope and graded 1-3 based 
on the density and viability of the cell population. Cell culture supernatant from each 
well was transferred to an assembled 3-kDa molecular weight cut-off Millipore 
centrifugal filter tube, using a 1ml pipette. The tubes were centrifuged at 5000 rpm 
(10
o
C) for 30 minutes. The bottom of the filter tubes were discarded and the tubes
inverted, before centrifuging at 1000 rpm for an additional 2 minutes. The 
concentrated supernatant was then transferred to low binding tubes and stored at -
80
o
C.
e. Protein analysis of conditioned media
Total protein was determined using a BCA assay (Thermo Fisher Scientific). Briefly 
unknown sample replicate and a series of diluted protein standards was 
pipetted into microplate wells (Pierce 96-well plate, Thermo Scientific). To each well 
shaker for 30 seconds. The plate was then covered and incubated at 37°C for 30 
minutes. The plate was then cooled to room temperature before measuring the 
absorbance at 562nm using a plate reader. 
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Levels of MCP-1 protein were determined using an ELISA (R&D systems) following 
the manufacturer’s instructions. MCP-1 values were then expressed relative to total 
protein.   
Results 
Representative images of F4-80 IR are displayed in Figure I. Levels of MPC-1 in 
conditioned media are represented in Figure II. 
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Figure I. F4-80 Immunoreactivity 
IR (NovaRED staining) in the right L3/L4 DRG in DMM, Sham, AIA, and Saline-injected mice at week 1 (a), week 4 (b), week 8 (c), and week 
16 (d) post arthritis induction. X10 magnification 
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Figure II. MCP-1 production in conditioned media 
Levels of MCP-1, expressed relative to total protein in conditioned media, L3-L45 DRG (pooled from 4 mice) in DMM, Sham, AIA, Saline-
injected and control (untreated) mice at week 1, 4, 8 and 16 post arthritis induction. Values are presented graphically as a scatter plot (mean and 
SEM) 
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